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Figure 1.20 Scaffold design for ligament-interface-bone regeneration. Mimicking the stratified
structure (Modified Goldner’s Masson Trichrome) and composition (FTIR-I: Fourier Transform
infrared spectroscopy)89 of the native insertion, a tri-phasic scaffold (Phase A: PLGA mesh, Phase
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B: PLGA microspheres, Phase C: PLGA-BG microspheres) was designed for ACL-bone interface
regeneration.110,111 This design allowed for spatial control over cell distribution (Fb: fibroblasts
on Phase A, Ob: osteoblasts on Phase C, along with chondrocytes in a hydrogel in Phase B) enabled
the formation of compositionally distinct yet structurally continuous tissue regions In vivo
(Modified Goldner’s Masson Trichrome)
Figure 1.21. (Top) Schematic diagram showing the fabrication process of a pore size gradient in
PCL scaffolds by a centrifugation method and (bottom) SEM photographs of the top surfaces of
the PCL scaffold sections along the longitudinal direction (× 100; *, average pore size) [64]
Figure 1.22 Picture depicting tendon structure and the junctions at muscle and bone
Figure 1.23 Scaffold design for tendon-interface-bone regeneration. A biphasic scaffold
comprised of layered aligned PLGA and PLGA-HA nanofibers was fabricated by electrospinning,
which led to phase-specific mineral deposition in vivo (Von Kossa, subcutaneous athymic rat
model). The bilayer scaffold was subsequently tested in a rat rotator cuff repair model,
disorganized scar tissue was observed in the single-phased controls (PLGA, PLGA-HA only).
Interestingly, tendon-bone integration via an organized bilayer fibrocartilage interface was only
observed with the biphasic design (Picrosirius red, Alcian blue)
Figure 1.24 Immunostaining for paxillin indicating its upregulation at the MTJ of a scaffoldless
muscle construct created by co-culturing a heterogeneous muscle “sarcolemma” and tendon
“fibroblasts” isolations
Figure 1.25 Osteochondral tissue structure. Cross section of the long bone and its zonal cartilage
including (A) articular surface, (B) the superficial zone, (C) the middle zone, (D) the deep zone
(E) tidemark (the interface), (F) calcified cartilage, (G) subchondral bone, and (H) trabecular bone
Figure 1.26 In vivo repair. Photographs of an osteochondral defect site in the lateral trochlear
sulcus (A) immediately after and (B) 26 weeks after implantation of a collagen-GAG scaffold
along with the (C) H&E and (D) Safranin-O with fast green histological stains of the explants
Figure 1.27 (Ai) In vitro co-culture model to evaluate the interactions of interface-relevant cells
of fibroblasts and osteoblast permit heterotypic and homotypic cell-cell interactions [99]. (Aii) Coculture models to evaluate interaction of interface-relevant cells. (A-i) In vitro coculture model of
fibroblasts (Fb) and osteoblasts (Ob) permit heterotypic and homotypic cell-cell interactions. (Aii) Fibroblast (CFDA-SE, green) and osteoblast (CM-DiI, orange-red) distribution at day 7, bar =
100 μm
Figure.1.28. Schematic picture of the MTJ structural development from early embryonic and
neonatal to adult stages. MTJ: myotendinous junctions; Tnb: tenoblasts; Mbl: myoblasts; Ten:
tenocytes; MF: muscle fibers
Figure 1.29: Extracellular (interstitial) matrix
Figure 1.30: Schematic representation of electrospinning basic set up. a) Image of Taylor cone
forming at the spinneret during the electrospinning process. b) Image of polymeric filament
forming from Taylor cone and moving toward the collector
Figure 1.31: Porous electrospun fibers. 28 wt% polystyrene in tetrahydrofuran (15kV).
Figure 1.32. Schematic representation of coaxial electrospinning setup. [419]
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Figure 1.33. A schematic showing the three steps involved in establishing the integrated graft
system.
Figure 2.1 Chemical structure of poly(lactic-co-glycolic acid) and its monomers [6].
Figure 2.2 Fabrication process of PLGA Microsphere through the single water/oil emulsion
technique.
Figure 2.3 Schematic of coaxial electrospinning setup, and the conventional uniaxial
electrospinning setup.
Figure 2.4 PLGA-Gelatin coaxial electrospun nanofiber mat (A) a uniform deposition during
electrospinning (B) the resultant 9 x 9 cm coaxial electrospun mat, and (C) coaxial electrospun
mat thickness (400 um); and PLGA uniaxial electrospun nanofiber mat (D), uninform deposition
of nanofibers during electrospinning that can be noticed from the bigger mat area when compared
to the coaxial group (E), the resultant un-uniformly deposited mat, and (F) uniaxial electrospun
mat thickness of ~ 80 µm when electrospun for 1.5, which is the same duration used for
electrospinning PLGA-Gelatin that results in a mat with a thickness of ~ 400 um .
Figure 2.5 SEM images of PLGA-Gelatin Coaxial electrospun nanofibers showing (A) overall
morphology of the electrospun (Scale bar 100 µm), (B) morphology of nanofibers showing the
smooth fibers surface (Scale bar 5 µm), and (C) PLGA-Gelatin Coaxial electrospun nanofibers
size distribution (400 nm – 1100 nm).
Figure 2.6 SEM images of PLGA Uniaxial electrospun nanofibers showing (A) overall
morphology of the electrospun (Scale bar 100 µm), (B) morphology of nanofibers showing the
smooth fibers surface (Scale bar 5 µm), and (C) PLGA Uniaxial electrospun nanofibers size
distribution (100 nm – 1100 nm).
Figure 2.7 SEM images showing the morphological change of coaxial electrospun nanofibers
after incubation In PBS at 37 C over 8 weeks period of time. (A) weeks 0, original morphology
of nanofibers, (B) 1 week after incubation, (C) 2 weeks after incubation, (D) 3 weeks after
incubation, (E) 4 weeks after incubation, (F) 5 weeks after incubation, (G) 6 weeks after incubation
showing the beginning of sever surface degradation, (H) 7 weeks after incubation, and (I) 8 weeks
after incubation showing a significant swelling and sever surface degradation when compared to
week 0. White arrows indicate some of the pores created at the surface of the fibers.
Figure 2.8 SEM images showing the morphological change of uniaxial electrospun
nanofibers after incubation In PBS at 37 C over 8 weeks period of time. (A) weeks 0, original
morphology of nanofibers, (B) 1 week after incubation, (C) 2 weeks after incubation, (D) 3 weeks
after incubation, (E) 4 weeks after incubation, (F) 5 weeks after incubation, (G) 6 weeks after
incubation, (H) 7 weeks after incubation, and (I) 8 weeks after incubation showing a significant
swelling when compared to week 0.
Figure 2.9. TEM images. (a) PLGA-Gelatin Coaxial nanofiber with a core-sheath of ~ 781 nm, a
fiber diameter of 1000 nm and a sheath thickness of 219 nm, and (b) Uniaxial nanofiber.
Figure 2.10 SEM images of PLGA-mTG Free sintered microspheres showing (A) overall

xxii
morphology of the sintered microspheres (Scale bar 500 µm), (B) high magnification image of the
interconnectivity between microspheres (Scale bar 100 µm), and (C) PLGA-mTG Free sintered
microspheres (300 µm– 600 µm).
Figure 2.11 SEM images of PLGA-mTG sintered microspheres showing (A) overall morphology
of the sintered microspheres (Scale bar 500 µm), (B) high magnification image of the
interconnectivity between microspheres (Scale bar 100 µm), and (C) PLGA-mTG sintered
microspheres (300 µm – 600 µm).
Figure 2.12 SEM images showing the morphological change of sintered PLGA-Gelatin-mTG
Free microspheres after incubation In PBS at 37 C over 8 weeks period of time. (A) weeks 0,
original morphology of sintered microspheres, (B) 1 week after incubation, (C) 2 weeks after
incubation, (D) 3 weeks after incubation, (E) 4 weeks after incubation, (F) 5 weeks after
incubation, (G) 6 weeks after incubation, (H) 7 weeks after incubation, and (I) 8 weeks after
incubation showing a significant change in morphology at the interconnected pore comparing to
week 0. White arrows indicate cracks between the adjacent microspheres.
Figure 2.13 SEM images showing the morphological change of sintered PLGA-Gelatin-mTG
microspheres after incubation In PBS at 37 C over 8 weeks period of time. (A) weeks 0,
original morphology of sintered microspheres, (B) 1 week after incubation, (C) 2 weeks after
incubation, (D) 3 weeks after incubation, (E) 4 weeks after incubation, (F) 5 weeks after
incubation, (G) 6 weeks after incubation, (H) 7 weeks after incubation, and (I) 8 weeks after
incubation showing a significant change in morphology at the interconnected pore comparing to
week 0. White arrows indicate cracks between the adjacent microspheres, and blue arrows indicate
presence of the lyophilized gelatin
Figure 2.14 Weight loss of PLGA-Gelatin Coaxial nanofibers and PLGA Uniaxial nanofibers
curve over 8 weeks after incubation in PBS at 37C.
Figure 2.15 Swelling Rate of PLGA-Gelatin Coaxial nanofibers and PLGA Uniaxial nanofibers
curve over 8 weeks after incubation in PBS at 37C.
Figure 2.16 pH change of PLGA-Gelatin Coaxial nanofibers and PLGA Uniaxial nanofibers curve
over 8 weeks after incubation in PBS at 37C.
Figure 2.17 Weight loss of PLGA-Gelatin-mTG microsphere scaffold and PLGA-Gelatin-mTG
Free microsphere scaffold curve over 8 weeks after incubation in PBS at 37 C.
Figure 2.18 Water uptake of PLGA-Gelatin-mTG microsphere scaffold and PLGA-Gelatin-mTG
Free microsphere scaffold curve over 8 weeks after incubation in PBS at 37 C.
Figure 2.19 pH change of PLGA-Gelatin-mTG microsphere scaffold and PLGA-Gelatin-mTG
Free microsphere scaffold curve over 8 weeks after incubation in PBS at 37C.
Figure 3.1 Schematic of coaxial electrospinning setup, and the conventional uniaxial
electrospinning setup.
Figure 3.2 PDGF-BB and IGF-I release profiles from coaxial and uniaxial PLGA electrospun
nanofibers. (A) PDGF-BB release profile from coaxial nanofibers and uniaxial nanofibers, (B)
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TEM image showing PDGF-BB in the core sheath of PLGA nanofiber with a sheath thickness of
284 nm, (C) IGF-I release profile from coaxial nanofibers and uniaxial nanofibers and (D) TEM
image showing IGF-I in the core sheath of PLGA nanofiber with a sheath thickness of 137 nm.
Figure 3.3. (A) The average of the retained BMP-2 in the enzymatically cross-lined geatin-mTG
hydrogel, and (B) ALP activates
Of MC3T3 cell lines seeded on PLGA-Gelatin-mTG scaffold in the three different experimental
groups shown in the figure.
Figure 3.4 TEM images of PLGA coaxial electrospun nanofibers with growth factors
incorporated at the core-shell of the nanofiber (A) TEM image showing PDGF-BB in the core
sheath of PLGA nanofiber with a sheath thickness of 284 nm, (B) TEM image showing IGF-I in
the core sheath of PLGA nanofiber with a sheath thickness of 137 nm.
Figure 4.1 Morphological characterization of primary dermal fibroblasts (A) Primary Dermal
Fibroblasts (10X), (B) Primary Dermal Fibroblasts (40X)
Figure 4.2 Morphological characterization of primary ligament fibroblasts (A) Primary Ligament
Fibroblasts (10X), (B) Primary Ligament Fibroblasts (40X)
Figure 4.3 Morphological characterization of primary osteoblasts (A) Primary Osteoblasts (10X),
(B) Primary Osteoblasts (40X)
Figure 4.4 Detection of dermal fibroblastic markers expression by Immunofluorescence (A)
ALP stain DAPI channel, (B) ALP expression, (C) merged between DAPI and ALP expression,
(D) OCL DAPI channel, (E) OCL expression, (F) merged between DAPI and OCL, (G) SCXA
DAPI channel, (H) SCXA expression, (I) merged between DAPI and SCXA
Figure 4.5 Detection of ligament fibroblastic markers expression by Immunofluorescence (A)
SCXA stain DAPI channel, (B) SCXA expression, (C) merged between DAPI and SCXA
expression, (D) Temd DAPI channel, (E) Temd expression, (F) merged between DAPI and Temd,
(G) TE-7 DAPI channel, (H) TE-7 expression, (I) merged between DAPI and TE-7
Figure 4.6 Detection of osteoblastic markers expression by Immunofluorescence (A) ALP
stain DAPI channel, (B) ALP expression, (C) merged between DAPI and ALP expression, (D)
OCL DAPI channel, (E) OCL expression, (F) merged between DAPI and OCL, (G) SCXA DAPI
channel, (H) SCXA expression, (I) merged between DAPI and SCXA
Figure 4.7 Viability and proliferation of dermal fibroblasts on different PLGA nanofibers
scaffolds (A) Uniaxial PLGA at day 3, (B) Uniaxial PLGA at day 7, (C) Coaxial PLGA at day 3,
(D) Coaxial PLGA-Gelatin at day7, and (E) proliferation of primary dermal fibroblasts cultured
on Uniaxial PLGA, and Coaxial PLGA-Gelatin. n= 3 P < 0.05*, P < 0.0**, P< 0.001***
Figure 4.8 Viability of dermal fibroblasts on different PLGA coaxial or uniaxial elctrospun
nanofibers scaffolds (A) PLGA-Gelatin-PDGF-BB at day 3, (B) PLGA-Gelatin-PDGF-BB at day
7, (C) PLGA-Gelatin at day 3, (D) PLGA- Gelatin at day7, (E) PLGA/PDGF-BB at day 3, (F)
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PLGA/PDGF-BB at day 7, (G) PLGA at day 3, (H) PLGA at day 7.
Figure 4.9 Proliferation Assay. Primary Dermal fibroblasts were cultured on PLGA-Gelatin
PDGF-BB, PLGA-Gelatin (negative control), PLGA-PDGF-BB (positive control), PLGA
(negative control), then assayed for cell proliferation on day 3 and 7. n= 3 P < 0.05*, P < 0.0**,
P< 0.001***
Figure 4.10 Viability and proliferation of ligament fibroblasts on different PLGA nanofibers
scaffolds (A) Uniaxial PLGA at day 3, (B) Uniaxial PLGA at day 7, (C) Coaxial PLGA at day 3,
(D) Coaxial PLGA-Gelatin at day7, and (E) proliferation of primary ligament fibroblasts cultured
on Uniaxial PLGA, and Coaxial PLGA-Gelatin. n= 3 P < 0.05*, P < 0.0**, P< 0.001***
Figure 4.11 Viability of ligament fibroblasts on different PLGA coaxial or uniaxial
elctrospun nanofibers scaffolds (A) PLGA-Gelatin-IGF-I at day 3, (B) PLGA-Gelatin-IGF-I at
day 7, (C) PLGA-Gelatin at day 3, (D) PLGA- Gelatin at day7, (E) PLGA/IGF-I at day 3, (F)
PLGA/IGF-I at day 7, (G) PLGA at day 3, (H) PLGA at day 7.
Figure 4.12 Proliferation Assay. Primary ligament fibroblasts were cultured on PLGA-Gelatin
IGF-I, PLGA-Gelatin (negative control), PLGA-IGF-I (positive control), PLGA (negative
control), then assayed for cell proliferation on day 3 and 7. n= 3 P < 0.05*, P < 0.0**, P< 0.001***
Figure 4.13 Viability and proliferation of osteoblasts on different PLGA microsphere
scaffolds (A) PLGA-Gelatin-mTG free at day 3, (B) PLGA-Gelatin-mTG free at day 7, (C) PLGAGelatin-mTG at day 3, (D) PLGA-Gelatin-mTG at day7, and (E) proliferation primary osteoblasts
cultured on PLGA-Gelatin-mTG free, and PLGA-Gelatin-mTG. n= 3 P < 0.05*, P < 0.0**, P<
0.001***
Figure 4.14 Viability of osteoblasts on different PLGA microsphere scaffolds (A) PLGAGelatin-mTG/BMP-2 at day 3, (B) PLGA-Gelatin-mTG/BMP-2 at day 7, (C) PLGA-Gelatin-mTG
at day 3, (D) PLGA-Gelatin-mTG at day7, (E) PLGA/BMP-2 at day 3, (F) PLGA/BMP-2 at day
7, (G) PLGA-Gelatin-mTG Free at day 3, (H) PLGA-Gelatin-mTG Free at day 7.
Figure 4.15 Proliferation Assay. Primary osteoblasts were cultured on PLGA-GelatinmTG/BMP-2, PLGA-Gelatin-mTG (negative control), PLGA/BMP-2 (positive control), PLGAGelatin-mTG Free (negative control), then assayed for cell proliferation on day 3 and 7. n= 3 P <
0.05*, P < 0.0**, P< 0.001***
Figure 5.1. A three-dimensional representation of the mold used for the devolvement of the
tri-culture model. (A) 3D view of the mold design showing the disc inserted in the provided hole,
(B) the actual 3D printed mold and the PDMS elastomer filling the cavity within the disc, (C) the
morphology of the cured PDMS segment after incubation at 37 C, and (D) the PDMS segment
placed inside of the well of the 24-well plate and separating the well into three different cambers,
the three different phases are shown occupying the different chambers. Blue arrow indicates the
PDMS elastomer.
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Figure 5.2. Dimensions of the plate that was used as the platform for the disc. (A) 3D view
showing the dimensions of the plate from different planes, (B) top view showing the width 8 mm
and the length 13 mm of the plate, and (C) side view Showing the height of the plate 2 mm.
Figure 5.3. Dimensions of the disc. (A) 3D view showing the dimensions of the disc from
different planes, (B) top view showing the diameter of the disc 17 mm, and (C) side view Showing
the thickness of the disc 5 mm.
Figure 5.4. Three different water-based dyes were added to the different chambers to
examine the permeability of these dyes to the neighboring chambers. (A) top view of the well
showing the three different dyes, each in a different chamber at day 0, and (B) bottom view of the
same well showing no evidence for water penetration after incubation at 37 C for 7 days.
Figure 5.5. Three different cell types, dermal fibroblasts, ligament fibroblasts and osteoblasts
were seeded and cultured in the well of a 24-well plate, each in a different chamber after
placing the PDMS segment to examine cell migration to the neighboring chambers. At day 3,
the PDMS segment was removed and different wells were visualized under a normal light
microscopy to examine the cell migration, as seen in the figure, no evidence for cell migration was
observed between the neighboring chambers after Day 3. Scale bars 4X and 10 X.
Figure 5.6. Three different cell types, dermal fibroblasts, ligament fibroblasts and osteoblasts
were seeded and cultured in the well of a 24-well plate, each in a different chamber after
placing the PDMS segment to examine cell migration to the neighboring chambers. At day 7,
the PDMS segment was removed and different wells were visualized under a normal light
microscopy to examine the cell migration, as seen in the figure, no evidence for cell migration was
observed between the neighboring chambers after Day 7. Scale bars 4X and 10 X.
Figure 5.7. The three different cell types were seeded in their relevant phases and teach phase was
cultured in different medium and medium compositions in a single and tri-culture environment in
order to determine what medium would best sustain their growth in the tri-culture environment.
Numbers indicate the increase in fold between day 3 and 7.
Figure 5.8. Proliferation Assay. Dermal fibroblasts cultured in different medium and medium
compositions in a single and tri-culture environment. Numbers on top of the bars indicate the
increase in fold between day 3 and 7. n= 3 P < 0.05*, P < 0.0**, P< 0.001***
Figure 5.9. Proliferation Assay Ligament fibroblasts cultured in different medium and medium
compositions in a single and tri-culture environment. Numbers on top of the bars indicate the
increase in fold between day 3 and 7. n= 3 P < 0.05*, P < 0.0**, P< 0.001***
Figure 5.10. Proliferation Assay. Osteoblasts cultured in different medium and medium
compositions in a single and tri-culture environment. Numbers on top of the bars indicate the
increase in fold between day 3 and 7. n= 3 P < 0.05*, P < 0.0**, P< 0.001***
Figure 5.11 Viability Assay. Dermal fibroblasts, ligament fibroblasts and osteoblasts were seeded
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in phases A, B and C respectively and cultured for 2 days. 2 days post initial culture, they were
assembled in which, Phase B was placed on top of Phase C and both phases were covered by Phase
A and cultured for further 3 and 7 days. After 3 and 7 days, phases were separated and assayed for
cell Viability using LIVE/DEAD assay. n= 3 P < 0.05*, P < 0.0**, P< 0.001***
Figure 5.12 Proliferation Assay. Dermal fibroblasts, ligament fibroblasts and osteoblasts were
seeded in phases A, B and C respectively and cultured for 2 days. 2 days post initial culture, they
were assembled in which, Phase B was placed on top of Phase C and both phases were covered by
Phase A and cultured for further 3 and 7 days. After 3 and 7 days, phases were separated and
assayed for cell proliferation. n= 3 P < 0.05*, P < 0.0**, P< 0.001***
Figure 5.13 Immunofluorescence Staining. The three different phases within the IGS were
immunostained with cell-specific markers to examine the localization and phenotypic maintenance
of the cells cultured within every phase. Cell migration between the phases was examined too by
immunostaining. As seen in the figure, the three different cell types remained localized in their
relevant phases and as well as maintained their phenotype in the heterogenic cellular population
for up to 7 days. Cell migration between all phases was observed after 3 and 7 days. However, no
cell migration was observed between Phase A and B after 3 days.
Table 1: A list of in vitro Endogenously secreted growth factors by dermal fibroblasts, ligament
fibroblasts and osteoblasts and the in vitro responses of the three cell types to the secreted growth
factors.

CAHAPTER 1
1. INTRODUCTION
1.1.Biomimetic Scaffolds
Tissues within the human body are prone to injuries or trauma that can lead to tissue damage or
degeneration. These traumas require treatments to facilitate their restoration, replacement or
regeneration to enhance the overall quality of life. Currently, the use of biological grafts is
considered the only viable clinical strategy for treating damaged tissues or organs. Biological
grafts include autografts known as the transplantation of tissue within an individual from a donor
site to the injury site, or allografts known as the transplantation of a tissue or a whole organ from
another individual or a cadaver. Autografts demonstrate high biocompatibility and healing
potential compared to allografts, making them the gold standard among all the biological grafts
[9]. The poor biocompatibility and integration of allografts to the host tissues, and the limited
availability and high price demand of autograft led to the necessity of finding alternatives that
mostly focus on regenerating the damaged tissues rather than repairing or replacing them [10].
[110-113]. Hence, clinical limitations associated with the treatment of several traumatic injuries
led to the emergence of an interdisciplinary known as “tissue engineering.” Tissue engineering has
been defined as “the application of biological, chemical and engineering principles toward the
repair, restoration and regeneration of tissues using biomaterials, cells, and factors alone or in
combination” [86, 110]. Tissue engineering is proposed to repair, restore or regenerate damaged
tissues or organs by combining cells, genes, or biologically active molecules with a 3D porous
matrix known as a scaffold [17]. Scaffold serve as a structural support for tissue formation where
cells interact and behave according to the physiochemical cues embedded in the scaffold itself.
[114]. Despite the fact that enormous progress has been made in the past two decades in designing
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and engineering scaffolds, tissue engineering scaffolds lack many physiochemical cues that are
essential for tissue regeneration and do not truly mimic the in vivo cellular microenvironment of
the natural extracellular matrix (ECM) [115]. The limitations of the current biological and
engineering approaches towards effective tissue regeneration made it clear that a paradigm shift is
required to successfully create technologies that can address the grand clinical challenges [6].
Developing a new interdisciplinary approach that utilizes the most advanced technologies
currently available in different fields such as developmental biology, bioengineering, biomaterials
science, stem cell biology, and clinical medicine along with full understanding of the different
tissues specific topographies may hold the key toward effective tissue regeneration [6, 15]. The
efforts of scientists from these various fields led to the emergence of a new paradigm we term
“Regenerative Engineering”. Regenerative Engineering has been defined as “the Convergence of
Advanced Materials Sciences, Stem Cell Sciences, Physics, Developmental Biology and Clinical
Translation for the regeneration of complex tissues and organ systems”. Distinct from the tissue
engineering, regenerative engineering more focuses on the subsequent response of cells to
biomaterials through the utilization of appropriate materials that exhibit suitable properties and
surface chemistry as well as providing the appropriate topographical and physiochemical cues that
could potentially influence cell differentiation and fate towards a particular tendency for effective
tissue development and regeneration (Figure 1.1) [164]. Scaffolds with such characteristics are
referred to as “biomimetic scaffolds’’ [116]. Biomimetic scaffolds have recently emerged as a
promising strategy for effective tissue regeneration. A biomimetic scaffold represents a synthetic
ECM niche that determines cell migration, proliferation, and differentiation to ensure proper
regulation of tissue/organ formation, maintenance of tissue integrity and repair, and regeneration
[116]. Ideally, a biomimetic scaffold should provide cells with a variety of physical, chemical, and
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biological cues that are naturally inherited by the native ECM to facilitate cell growth and function
[123]. In vivo, cells are found entrapped within an ECM, in which they are provided with all the
necessary physical and chemical cues that guide their development, arrangement and regenerative
abilities by molecular interactions between specific cell membrane receptors and signaling cues
from surrounding ECM material [123] To duplicate the in vivo environment, the biomimetic
scaffold should exhibit controllable physical, chemical and mechanical properties, cell adhesion
properties and growth factor release kinetics [115]. Generally, an ideal tissue engineering scaffold
should be biocompatible that do not elicit an immune response, biodegradable to be replaced with
newly formed tissue, highly porous to facilitate cell migration, proliferation, nitration diffusion
and waste removal, and exhibits topographical mechanical and architectural properties resembling
those found at the native tissue [116]. Therefore, a basic understanding of the entire spectrum of
biomimetic scaffolds provides insight into how they can potentially be used in diverse tissue
engineering, regenerative medicine, and drug delivery applications.

Figure 1.1. Schematics of regenerative engineering approach to create complex functional tissues and
organs [164].
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1.1.1. General Scaffold Requirement
1.1.1.1.Biocompatibility
Biocompatibility is one important criteria of any tissue engineering scaffold that must be
considered as the first priority when choosing any biomaterials. Tissue engineering scaffold must
be biocompatible and allow cells to function normally, adhere, migrate throughout the scaffold,
proliferate and produce ECM [116]. In addition, tissue engineering scaffold must not elicit any
immune response upon implantation as this can result in inflammatory reaction, which in turn can
initiate fibrous encapsulation that prevents tissue formation [116].

1.1.1.2.Biodegradability
Tissue engineering scaffold should not permanently stay within the host body, as the whole
purpose of using a biodegradable construct is to allow it to be replaced with the body’s own tissues
over time as it degrades, and also to limit the chance of a secondary surgery [251]. The degradation
by-products should not be toxic and be able to be eliminated out of the body without any
interference with other tissues. Incorporation of anti-inflammatory agents within the tissue
engineering scaffold is recommended to prevent any chance of inflammatory response. In addition,
depending on the application needs, the scaffold degradation rate must be tailored by selecting the
appropriate biomaterial in order to achieve a tandem degradation with the neo-tissue formation.
Due to the increase in the number of biodegradable tissue engineering products entering clinical
practice, the number of the immunological studies examining the body response to the degradation
by-products of many materials has also increased as a result, which lies lots of promises in the
research area [118, 119].
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1.1.1.3.Porosity
Tissue engineering scaffold should be highly porous with an open porous geometry and well
interconnected channels to achieve high density cell growth within the engineered construct, as
well as high mass transport of oxygen, nutrition and metabolic waste in addition to supporting
neovascularization within the construct. All, high cell density, mass transport, and
neovascularization contribute to cell viability, proliferation, and ultimately regeneration of a
functional tissue [120]. Average pore size, pore size distributions, pore volume and pore
interconnectivity are all important parameters that have to be considered when designing the tissue
engineering scaffold. Several reports have emphasized the effect of the pore size on tissue
regeneration to determine the optimum pore size for every scenario, revealing that the optimum
pore size for neovascularization is 5 µm [244], 5-15 um for fibroblasts ingrowth [245], 20 µm for
hepatocytes ingrowth [246], 200-350 µm for osteoconduction [247], and 20-125 µm for the
regeneration of mammalian adult skin [248]. These pore sizes were found to be the optimal for
these specific tissue types, as they may differ with other tissues [249]. In general, pore volume and
size should be a few times larger than the size of the cells intended to be seeded or recruited to the
scaffolds to provide extra space for sufficient entry and exit of nutrition and waste removal,
neovascularization and thus, tissue ingrowth [250]. When designing the tissue engineering
scaffold, it has to be taken into consideration that a subsequent balance between the pore size,
volume and mechanical property is required, as increase in the pore volume leads to decrease in
the mechanical integrity of the engineered construct, whereas decreasing the porosity can have
negative effects on the cellular performance.

5

1.1.1.4.Mechanical property
Tissue engineering scaffolds should be fabricated from biomaterials that exhibits intrinsic
properties mimicking those found in the native tissue and should be mechanically compatible with
the anatomical location. The human body is composed of hard and soft tissues with different
mechanical properties and these tissues contain cells that are tuned to the specific mechanical
environments in which they reside. Therefore, scaffold with biomimetic mechanical property can
act as a cue to guide cellular behaviors and fate. Many mechanobiology studies demonstrated the
role of the construct mechanical property in guiding cellular differentiation. These studies revealed
that an appropriate scaffold stiffness and mechanical properties to guide cellular differentiation
into a specific tendency can be achieved [121]. Thus, providing the appropriate mechanical
properties is a key role for effective tissue regeneration.

1.1.1.5.Architecture
The scaffold architecture plays an active role in tissue regeneration and remolding. Scaffold
architecture mainly contributes to how a cell transduces input from the external physical
environment into biochemical signals that dictate cell response [122]. The cell response to the
surrounding architecture is a phenomenon known as “contact guidance”, which can be used to
regulate cytoskeletal organization, cell shape, migration, and differentiation [123, 125-128].
Therefore, scaffolds with defined topological patterns have been studied based on the hypothesis
that topographic patterns can be employed as instructive cues to direct cellular responses [123]. A
wealth of evidence has shown that cells grown on different architectures demonstrate altered cell
morphologies and gene expressions [122]. Thus, providing a biomimetic ECM architecture may
be used to ultimately control cell behavior and fate.
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Successful tissue regeneration is highly dependent on the aforementioned requirements. These are
the general tissue engineering scaffold requirements that have to be taken into accounts when
designing the tissue engineering scaffold. However, the choice of the biomaterials in which the
tissue engineering scaffold should be fabricated is the one important criteria that all the abovementioned criteria depend on, as different materials exhibit different surface properties,
degradation rates, mechanical strengths, biocompatibility, all in which contribute to the overall
quality and integrity of the engineered scaffold. Tissue engineering scaffolds have been produced
using a wide variety of biomaterials through well-developed processing conditions, thus; choosing
the appropriate biomaterial and fabrication technique is critical for successful regeneration of the
target tissue.

1.1.2. Biomaterials and Fabrication Techniques for Biomimetic Scaffolds
For a successful tissue regeneration, the scaffold should emulate certain advantages of the native
ECM while temporarily act as a cell template that allows for tissue ingrowth and infiltration as it
degrades [131]. Surprisingly, a biomimetic scaffold does not have to entirely duplicate the native
ECM, due to the fact that the neo-tissue genesis in tissue engineering is not exactly the same as a
developmental or a wound healing process [131]. In fact, a native ECM may not be the ideal
scaffold for tissue regeneration, because tissue regeneration is an accelerated process compared to
the native development process. Natural ECMs do not possess the basic tissue engineering scaffold
requirements such as porosity and interconnected macro- or micro pore structure, that are essential
in order to allow for quick and uniform cell population throughout. Therefore, for optimal and
accelerated tissue regeneration, some important and necessary features such as porosity, pore size
and interpore connectivity have to be provided, which can only be obtained through artificially
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designed scaffolds. However, artificially designed scaffold that mimics the structural aspects of
the native ECM with tailored porosity and interconnectivity may be the best option to achieve a
functional biomimicry tissue regeneration. Thus, providing a proper niche for cell adhesion,
migration, and proliferation will be based on the material choice.

1.1.2.1.Biomaterials
In tissue engineering applications, materials are selected based on their chemistry, molecular
weight, solubility, shape and structure, hydrophilicity/hydrophobicity, lubricity, surface energy,
water absorption degradation, and erosion mechanism [129]. All of these are essential properties
that can influence the scaffold’s overall quality and the degree of biomimicry. Biomaterials used
for tissue engineering scaffold are mainly classified into two categories, naturally derived and
synthetic biomaterials. Natural biomaterials can be further classified into proteins (silk, collagen,
gelatin, fibrinogen, elastin, keratin, actin, and myosin), polysaccharides (cellulose, amylose,
dextran, chitin, and glycosaminoglycan), or polynucleotides (DNA, RNA). Natural biomaterials
are known for their excellent biocompatibility, bioactive properties, and good interactions with
cells, owing an enhanced cellular performance in biological systems [129]. Despite all of their
advantages, natural biomaterials possess poor physical and mechanical properties, which limit
their use for load-bearing applications. Synthetic biomaterials on the other hand, are further
characterized into degradable and non-degradable synthetic polymers. Biodegradable synthetic
polymers are preferred over the non-degradable polymers due to their degradability nature, which
in turn facilitate a faster neo-tissue ingrowth and better tissue infiltration, in addition to minimizing
the chance for a secondary surgery after implantation [129]. A wide range of synthetic
biodegradable polymers such as, poly(lactic acid) (PLA), poly(glycolic acid) (PGA), poly(lactic-
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co-glycolic acid) (PLGA), poly-L-lactic acid (PLLA), and polycaprolactone PCL, have been used
for many musculoskeletal tissues and skin tissue engineering due to their intrinsic tailored
properties [129]. Although synthetic polymers have the advantages of tailoring their properties
such as, porosity, degradation rate, physical and mechanical characteristics for specific
applications and needs, they possess poor biocompatibility and lack all the ligands required for
cell attachments and proliferation, which can result in poor cell adaption to the matrix and thus,
poor tissue formation. Limitations associated with both natural and synthetic biomaterials limit
their use on their own in many tissue engineering applications where both mechanical and
biocompatibility are highly required, or as materials for a biomimetic scaffold. The native ECM
resembles some properties that are found in synthetic materials only or natural materials only,
therefore, composite scaffolds are the best solution to address the disadvantages of both natural
and synthetic scaffolds, as it helps in the mutual enhancement of the scaffold properties and thereby
allowing controlled degradation and mechanical properties as well as improving the
biocompatibility, and providing cells with all the necessary physical and chemical cues that are
naturally inherited by the natural ECM, to achieve the best possible biomimicry of the native ECM
[130].

1.1.2.2.Fabrication Techniques for Biomimetic Scaffolds
Scaffold’s fabrication techniques play key role in emulating the architecture of the natural ECM.
The degree of emulation is highly effected by which fabrication technique is applied. Generally,
the scaffold’s architecture should mimic the natural ECM in a way that it should act as an
instructive tool that instruct and guide cellular behaviors while adequately housing the cells
[131,132] Biomimetic tissue engineering scaffolds have been produced using a wide variety of
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different materials and well-developed fabrication techniques to achieve the most possible close
biomimicry to the native ECM; considering the appropriate fabrication method is critical for
successful tissue regeneration of the target tissue. Some of the most extensively used fabrication
techniques for musculoskeletal tissues and skin tissue engineering include; sintered microsphere
method, solvent casting and particle leaching, gas foaming and particle leaching, and
electrospinning.

1.1.2.2.1. Sintered Microsphere
Microspheres-based tissue engineering scaffolds have attracted a significant interest in the research
field in recent years [242]. Microsphere scaffolds demonstrate several benefits, including ease

of fabrication, control over morphology, physicochemical characteristics, and its versatility
of controlling the release kinetics of encapsulated factors [243]. The Fabrication of
microsphere scaffolds was first established in 1998 by Laurencin et al. Microspheres are fabricated
using the single emulsion technique, briefly, a solution of organic polymer in Dichloromethane
(DCM) is generally added to an aqueous polyvinyl alcohol (PVA) surfactant (Figure 1.2). The
mixture is let to stir under a certain speed inside a chemical hood to allow the solvent to evaporate.
The end product of this process is a pellet of solidified microspheres, which are collected, rinsed,
freeze or air dried and sieved to the desired diameter size range.
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Figure 1.2. Fabrication process of polymeric microsphere through the single water/oil emulsion
technique.

To construct scaffolds, microspheres with the desired particle size distribution are poured into a
mold, generally stainless-steel mold, then heated above the glass transition temperature of PLGA
(Tg ~ 58 C) until they are thermally fused into the desired three-dimensional shape and
morphology [10,11]. The advantages of using PLGA to develop 3D sintered microsphere scaffolds
with a porous interconnected structure for bone tissue engineering has been demonstrated. These
scaffolds were shown to possess mechanical properties controllable pore size and pore volume that
are relatively close to the native tissue ECM, which makes them ultimately ideal for bone
regeneration [12, 13].

1.1.2.2.2. Solvent Casting and Particle Leaching:
Solvent casting and particle leaching (SCPL) is a very simple technique that does not require
specialized equipment. The main idea behind this technique is to create a highly porous three-

11

dimensional construct that mechanically and structurally resembles the native bone ECM (Figure
1.3). Briefly, the polymer is dissolved in a solvent until a homogenous and viscus polymer solution
is obtained. The polymer solution is then casted in a mold of the desired geometry along with
porogen particles (usually NaCl). The solvent then evaporates leaving behind a solidified
polymeric scaffold with the porogen particles embedded throughout. To leach out the porogen
particles, the structure is normally submerged in water, causing all particles to dissolve, leaving
behind a highly porous structure suitable for use in tissue engineering applications. By controlling
the shape, size, orientation and the amount of porogen added, different pore volumes, sizes and
different pore gradients can be obtained. Some drawbacks associated with the use of solvent
casting is that the majority of solvents used to dissolve polymers are very toxic. In addition,
depending on the pore volume and the scaffold geometry, it is sometimes very difficult to
completely leach out all porogen particles from the core of the scaffolds. The only way to
overcome this problem is by applying the principle, where multiple porous thin sheets are glued
into a thick 3D architecture. However, this method is very time consuming [255].
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Figure 1.3. Schematic of solvent casting and particle leaching scaffold fabrication technique [256].

1.1.2.2.3. Gas Foaming and Particle Leaching:
Gas foaming and particle leaching (GFPL) is the modified version of the previously discussed
technique addressing the problem of using toxic solvents. In this method, solvents are completely
dismissed, and very high pressure is used instead to guide the fabrication process (Figure 1.4).
Briefly, polymer granules are grinded and mixed with porogen particles (usually NaCl) at the
desired ratio, and then sieved to yield particles with the desired diameter. Polymer/ porogen
particles are then loaded into a mold of the desired geometry for compression with a very high
pressure. This step allows the polymer particles and the porogon particles to fuse together under
the effect of the high pressure applied, resulting in the formation of a solid polymer/porogon
composite structure resembling the geometry of the used mold. The resultant structure is then
exposed to CO2 for some time to create surface porosity throughout the structure. Exposure
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duration with CO2 and other parameters can be tailored to achieve different surface pore volumes.
Once porosity is created, the structure is then immerged in distilled water to leach out the porogon
(NaCl). The process results in highly porous structure with enhanced interconnectivity throughout
comparing to the SCPL method. Kim et al. [147] developed PLGA/HA scaffolds by gas foaming
and particulate leaching technique and emphasized that PLGA/HA scaffolds produced with GFPL
were found to significantly enhance bone regeneration when compared to SCPL fabricated
scaffolds, owing their ability to enhance bone tissue engineering.

Figure 1.4. Schematic of gas foaming and particle leaching scaffold fabrication technique [256].

1.1.2.2.4. Electrospinning:
Electrospinning is currently one of the most extensively used technique for tissue engineering
scaffold fabrication due to its resemblance to the native ECM, and its ability to process a wide
14

range of different natural and synthetic materials with different fibers orientations and diameters
that can range from the sub-microns down to the nanometer scale depending on the applications
needs [252]. Briefly, polymer granules or powder are dissolved in the appropriate solvent until a
viscous, homogeneous and completely dissolved polymer solution is obtained. A complete
dissolution of the polymer is very important for a successful bead-free production of electrospun
fibers. The polymer solution is then loaded into a syringe, and placed in an apparatus pump for
electrospinning (Figure 1.5). During electrospinning, an electrical field of high voltage is applied
at the syringe needle tip that creates large enough forces at the surface of the polymer solution to
overcome the surface tension, resulting in the ejection of an electrically charged jet that solidifies
into electrically charged fibers. The needle tip is normally placed some distance away from the
collection unit to allow branching and drawing of the fibers to occur. Polymer solution viscosity,
flow rate, applied voltage, distance between the needle tip to the collecting unit are all important
electrospinning parameters that mainly affect the fiber diameter, mechanical properties and the
overall morphology of the electrospun fibrous scaffold [253, 254].
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Figure 1.5. Schematic of the most extensively used tissue engineering fabrication technique,
electrospinning set up.

1.1.3. Biomimetic Bone Tissue Regeneration:
1.1.3.1.Bone Structure and Function:
Bone is a mineralized connective tissue that serves to provide the structural support to the entire
body [158]. Bone total mass is occupied by 8% water, 22% protein, and 70% mineral [158]. Bone
consists of organic and inorganic portions, where the organic portion of bone is collagen type 1,
and the inorganic portion is primarily hydroxyapatite (HA) and calcium phosphate (CaP) [158].
Bone tissue is characterized according to its macroscopic structure into either trabecular (spongy)
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or cortical (compact) (Figure 1.6) [158]. Cortical bone is an extremely dense tissue that forms the
outside layer of the bone, or cortex. It is formed and organized into concentric rings of sheets or
“lamellae” of densely packed collagen fibrils [158]. Cortical bone is known for its high
mineralization content and few pores, giving it the rigidity that allows it to maintain the body’s
mechanical strength and structure [158]. Human cortical bone has compressive modulus and
compressive strength of 12 – 20 GPa, and 150 MPa, whereas trabecular bone has a compressive
modulus and compressive strength of 0.04 – 1.0 GPa, and 1.0 – 7.0 MPa, respectively [159].
Trabecular bone is found forming the inner shell of the cortex with a low mineralization content
when compared to the cortex bone. Trabecular bone exhibits a highly porous structure with
sufficient amount of vascularity, connective tissues and bone marrow [158]. Bone marrow is a
great source of pluripotent stem cells, which contribute in the replenishment of the body’s
connective tissues, including bone [158]. Three different primary cell type that make up bone and
contribute in bone remodeling are Osteoclasts, Osteoblasts and Osteocytes. Osteoclasts and
Osteoblasts are fully differentiated cells that are present at the surface of the bone, while osteocytes
permeate the mineralized interior [163]. Osteoblast work in synthesizing the bone matrix in the
bone forming surfaces in addition to regulating the matrix mineralization. Osteocytes are
terminally differentiated osteoblasts that are entrapped within the mineralized matrix and serve to
support the overall bone tissue [163]. Osteoclasts on the other side are larger than osteoblasts in
size, and are multinucleated cells that are derived from different cellular precursors. They work on
reabsorbing the synthesized bone by osteoblasts for bone remolding [163]. These cells however,
are regulated by growth factors within the bone that stimulate their proliferation, differentiation
for continuous bone remodeling and healing upon fracture.
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Figure 1.6: Cortical and Cancellous bone [220].

1.1.3.2.Materials for Biomimetic Bone Tissue Regeneration:
Materials choice for bone tissue engineering is essential, as differences in the materials properties
may largely affect the overall quality of bone formation. Bone tissue engineering (BTE) scaffold
material can be optimized to achieve the possible closest biomimicry to the natural ECM and to
develop a clinically relevant engineered bone. Regardless of the material type, the ideal BTE
scaffold should be biodegradable to be replaced with newly formed bone, as the permanent
presence of the graft substitute could potentially alter bone formation or limit the tissue ingrowth
within the substrate. Certain inorganic/ceramic materials such as hydroxyapatites (HAP) or
bioactive glasses are used for their great osteoconductivity and mineralization content; but their
use is limited due to the poor solubility and resorption profile as well as poor processability into
highly porous structures, and brittleness [133].
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Synthetic polymers such as PLA, PGA, PLGA, PLLA, and PCL have been widely used for BTE
due to their degradability nature, tuned mechanical properties and the ease processability into a
variety of different fabrication techniques such as gas foaming, porogen leaching, phase
separation, electrospinning, microsphere sintering, and 3D printing to generate a wide range of
three-dimensional scaffolds with different properties and surface characteristics [133-138].
However, the poor biocompatibility and lack of supportive cell attachment cues in the synthetic
polymers limit their use on their own for BTE. In contrast, composite materials such as inorganicorganic, synthetic-organic composition are widely used aiming to mimic the properties of the
native bone by combining toughness and bioactivity of the inorganic materials, biocompatibility
of the organic materials, and degradability of the synthetic polymers, to generate bioactive
materials with tuned mechanical and degradation profiles and surface properties.

1.1.3.3.Scaffold Requirements for Biomimetic Bone Tissue Regeneration:
In bone tissue engineering (BTE), scaffolds should possess osteoconductive, osteoinductive and
oteointegrative properties to promote bone regeneration. However, osteoconductivity is the ability
of a scaffold, or a physical matrix to provide a suitable environment for the deposition of new bone
from the surrounding bone or encourage differentiated mesenchymal cells to grow along the graft
surface, osteoinductivity is the ability of the scaffold to promote osteoblastic differentiation of
progenitor cells through growth factors induction, and osteointegrivity is the ability of the scaffold
to anchor and integrate into the surrounding bone [164]. BTE scaffolds should also be designed to
fill the structure of the defect cavity, maintain it and restore bone function. It should also mimic
the mechanical and structural properties of the native bone with a sufficient amount of porosity
throughout the construct to allow cell infiltration, proliferation, neovascularization and nutrient
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transport [164]. In addition, the scaffold should also serve as a reservoir for growth factors delivery
such as, morphogenetic proteins (BMPs), insulin-like growth factors (IGFs) and transforming
growth factors (TGFs), all of which help induce the transformation of host precursor cells into
bone matrix producing cells [165].

1.1.3.4.Biomimetic Bone Tissue Engineering Approaches:
Bone is a living tissue that undergoes constant remodeling and self-renewal to maintain its
hemostasis, comprising the ability to repair its self [116]. Due to this fact, restorative surgical
intervention, after surgery for instance, usually requires not more than alignment and stable
fixation. However, if self-repair mechanisms are overstrained, in case of non-unions or critical size
defects, bone losses the ability to repair its self, which necessities the development of biomimetic
bone grafts that mimic all the different aspects found at the native ECM for effective and functional
bone restoration. In an attempt to mimic the native bone mechanically and structurally, Borden et
al. developed a scaffold for BTE using a heat sintering technique to fabricate sintered microsphere
scaffold with sufficient porosity throughout to support cellular migration and movement within
the substrate. The microsphere scaffold was fabricated from PLGA (85:15) ratio between lacticto-glycolic acid [140, 141]. By orderly pouring and the fabricated microsphere in a predefined
mold with heat applied, the neighboring individual microspheres fuse together resulting in a highly
porous 3D structure that resembles the native human trabecular bone mechanically and
structurally. The resultant scaffold had a compressive modulus of 232 MPa, and approximately ~
35% pore volume with a median pore size of 100-300 𝜇m that allows for bone cells and tissue
ingrowth. During bone formation, the pore volume would be occupied by the newly forming bone
while the microsphere matrix slowly degraded leaving voids that will resemble the pore structure
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found in the human trabecular bone. When the polymeric scaffold completely degrades, the
regenerated bone tissue possesses approximately 65% void volume resembling that of human
trabecular bone. The author demonstrated the feasibility towards developing a mechanically and
structurally biomimetic bone tissue engineering scaffold that resembles the trabecular bone
mechanical and structural properties. However, the scaffold will need to be optimized in order to
in order to increase its biocompatibility for supportive cellular performance.

To enhance the biocompatibility and cellular performance of the sintered PLGA microsphere
scaffold having the same mechanical and structural properties as well as the pore volume, the same
group modified this technique to fabricate a composite microsphere scaffold prepared from
chitosan/PLGA [142]. Milled chitosan microparticles were mixed with PLGA solution to fabricate
the chitosan/PLGA microspheres. The resultant chitosan/PLGA microsphere were poured in
predefined mold and heat sintered to achieve bonding between adjacent microspheres. The 3D
chitosan/PLGA microsphere scaffold presented a rough surface morphology (Figure 1.7a), even
distribution of microsphere surface with excellent interconnected porous structure and appropriate
mechanical properties suitable for load-bearing applications (Figure 1.7b). The composite scaffold
was able to support MC3T3-E1 cells proliferation. In addition, the presence of chitosan contributed
to the enhancement of the differentiation and the maturation of MC3T3-E1 osteoblastic-like cells
over time when compared to the raw PLGA microspheres. Findings from this study revealed that
composite scaffolds seem to combine multiple properties and increase the scaffold
biocompatibilities, which in turn leads to enhanced cellular performance.
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Scaffold bioactivity play an important role in tissue regeneration as it largely inﬂuences, directs,
or manipulates cellular responses. To further enhance the bioactivity of the chitosan/PLGA
sintered microsphere scaffold, the scaffold was surface functionalized with the biomolecule
heparin sulfate immobilization through ionic interaction between oppositely charged chitosan and
heparin molecules resulting in a bioactive scaffold mimicking the natural bone environment
(Figure 1.7c) [144]. Treatment with heparin sulfate did not alter the mechanical properties and
pores structure. Characterization experiments revealed that the heparinized chitosan/PLGA
scaffolds possessed a compressive modulus of 403.98 ± 19.53 MPa, and a compressive strength
of 9.83+0.94 MPa, which were in the range of the human trabecular bone. Furthermore, the
scaffold resulted in a highly porous interconnected structure with a total pore volume of 30.93 ±
0.90% and a median pore size of 172.33 ± 5.89 𝜇m. MC3T3-E1 cells were pre-seeded on the
heparinized chitosan/PLGA microsphere scaffold to evaluate the effect of the immobilized
heparin. In vitro results revealed that the cell number has increased significantly over time, and
MC3T3-E1 cells showed elevated osteocalsin expression when compared to the non-heparinized
chitosan/PLGA scaffolds (Figure 1.7d, e, f). In addition to the modification that has been done in
order to enhance the biocompatibility of the mechanically and structurally biomimetic PLGA
sintered microsphere scaffold, this study also demonstrated the potential of enhancing the
bioactivities of the scaffold through the surface functionalization with heparin sulfate, resulting in
a possibly close biomimicry to the native bone mechanically, structurally and chemically.

The heparinized chitosan/PLGA sintered microsphere scaffold’s ability to support bone formation
has been evaluated in an ulnar bone critical-sized-defect model in vivo (Figure 1.7 g). In vivo
assessments revealed that Heparinized chitosan/PLGA scaffold was able to guide bone formation.
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µCT analysis demonstrated that a successful bridging between the two ends of the defects was
achieved through the heparinized chitosan/PLGA scaffold with a complete bridging and enhanced
mechanical properties when compared to the chitosan/PLGA scaffold alone (Figure 1.7h). Further
histological analysis suggested that heparinized chitosan/PLGA scaffold supported normal bone
formation via intramembranous formation (Figure 1.7i).

These studies demonstrated series of different approaches attempting to generate a possibly close
biomimetic bone tissue engineering scaffold that resembles the native bone mechanically,
structurally and chemically. Despite the multitude scaffolds that have been studied, scaffold
optimization continuous to be an active area of research to find the most optimal scaffold design
for bone tissue engineering.

Figure 1.7: (a) A chitosan/PLAGA composite microsphere; (b) a 3D chitosan/PLAGA scaffold fabricated
by heat sintering (c) Chitosan/PLAGA scaffold immobilized with heparin as evidenced by them green
fluorescence; (d)–(f) MC3T3-E1 osteoblast-like cell proliferation at days 4, 7, and 11 on the heparinized
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chitosan/PLAGA scaffolds as illustrated by dual staining of cell nuclei (blue) and cytoskeletal protein actin
(red); (g) The surgical procedure showing a 15 mm segment of ulna was removed and a sintered
microsphere scaffold was implanted into the defect site; (h) Three-dimensional microCT reconstruction of
the bone regeneration in the ulnar defect from the animals with the most amount of new bone formation
(HP-CS-PLAGA-BMP2 12 weeks); (i)A radiograph showing new bone formation bridging the criticalsized defect at 12 weeks after operation using chitosan/PLAGA scaffolds loaded with heparin and bone
morphogenetic protein—2 using a rabbit ulnar model; (j) VonKossa staining of implanted scaffold showing
newbone formation adjacent to the scaffold (M: microsphere, NB: new bone); (k) trichrome staining
showing dense connective tissue formation in the void space among microspheres (CT: connective tissue);
(i) . Parallel images of new bone formation sections stained with both Trichrome staining [144].

Hydroxyapatite is an important inorganic bone mineral that gives it its rigidity. It possesses high
compressive strength and its osteoconductivity allows for bone cell attachment, migration, and
growth [145, 146]. Several studies have revealed that the induction of hydroxyapatite increases the
scaffold’s osteoconductivity, resulting in a scaffold with a functional biomimicry to the native
matrix, making it a suitable environment for cell housing that can facilitate cellular migration,
proliferation and differentiation. In an attempt to reinforce the osteoconductivity of the matrix,
Levi et al. developed sintered microsphere scaffold prepared from PLGA/ HA nanocrystals for
matrix reinforcement and osteoconduction, and salt crystals for macroporosity and control of
matrix pore size [143]. Characterization studies revealed that the resultant PLGA/ HA scaffold had
Young’s modulus and an ultimate strength values ranged between 168-265 MPa and 6-17 MPa,
respectively, which was within the range for human trabecular bone. In addition, the microspheres
diameter size distribution was between 80 – 300 𝜇m. The scaffold was pre-seeded with human
fibroblasts to evaluate its biocompatibility for 14 days. In vitro biocompatibility studies revealed
that cells were well maintained within the matrix and cell number has significantly increased by
day 14 comparing to PLGA alone. In this work, the PLGA scaffold was reinforced with HA to
increase its osteoconductivity, resulting in an increase in cell number and enhanced
biocompatibility. Despite the advantageous of HA, introducing them in larger amounts could result
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in a poorly soluble scaffold that can alter tissue ingrowth and neovascularization during
osteogenesis.

To address the solubility issue, a recent and a novel approach was developed in order to increase
the osteoconductivity of the scaffold with less HA content by functionalizing the surface of the
scaffold with appetite for more efficient bone tissue engineering aiming to produce a biomimetic
uniform distribution of appetite on the surface of the scaffold. Soo et al. developed a PLGA/ HA
composite scaffold by gas foaming and particulate leaching (GF/PL) method without the use of
organic solvents [147]. This study not only attempted to find better alternatives in order to increase
the osteocunductivity of the scaffold, but also addressed the limitations associated with solventbased technique. Briefly, PLGA granules are grinded and mixed with Sodium Chloride particles
and sieved to yield particles with a 100-200 Pm diameter. PLGA/NaCl particles are then mixed
with HA nanoparticles in a mass ratio of 1:9:1, respectively, and loaded into a disk mold for
compression with a very high pressure. The resultant PLGA/HA/NaCl disk is then exposed to CO2
to create the porosity throughout the structure. Once porosity is created, the disk is then immerged
in distilled water to leach out the salt (NaCl). To create a uniform mineral coating of apatite on
the surface of the PLGA/hydroxyapatite scaffold, the disk is then incubated in an ion rich simulated
body fluid (SBF) solution. Incubation in an ion rich SBF helps creating a sufficient layer of apatite
on the surface of the scaffold. The novelty in this work lies behind the addition of the nano-HA
particle to the scaffold structure prior to incubation in the SBF, as the presence of the nano-HA
particles within the scaffold structure helps inducing a sufficient layer of apatite on the surface of
the scaffold compared to PLGA scaffold alone with no nano-HA particles in its structure. It was
hypothesized that functionalizing the surface with appetite would enhance the osteogenic potential
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of the biomaterial scaffold. SEM images revealed that the appetite layer was uniformly created on
the surface of the PLGA/HA scaffold when compared to the PLGA scaffold alone, which showed
very poor and not uniform deposition of appetite. In vitro characterization showed improved
human osteoblast adhesion, proliferation, alkaline phosphatase expression, and mineralized matrix
synthesis on these scaffolds, which were evidenced as compared to that on PLAGA scaffolds. In
vivo implantation of the scaffolds in a subcutaneous model for 5 and 8 weeks showed enhanced
osteogenesis, calcium deposition and extensive amount of mineralization on the PLGA/HA group
when compared to PLGA alone, confirming their potential for bone regeneration

This study demonstrated a novel way of increasing the osteoconductivity of a composite
PLGA/HA scaffold by exposing appetite on the surface of the scaffold without the interference of
any solvents. The resultant scaffold exhibited less ceramic content (HA) comparing to the previous
methods [143] and high content of uniformly distributed appetite on the surface. This biomimetic
approach of uniformly distributing the appetite on the surface enhanced osteoblasts growth and
mineralization in vitro, and osteogenesis in vivo. Findings from these studies demonstrate the
potential of biomimicking the natural bone matric by introducing HA in efficient amounts that do
not alter tissue ingrowth or effect the scaffold’s solubility, for more efficient bone tissue
engineering.

In addition to the architecture and inherit properties of a polymer based scaffold, the use growth
factors to stimulate bone formation is an established approach to treat musculoskeletal disease and
trauma. However, spatial control over the release of growth factors is essential in order to eliminate
the unwanted side effect and improve tissue repair. Bone formation has been proven to be enhanced
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in many reports under the osteoinductive influence of BMP-2. However, this portion may lose
bioactivities over a short period of time due to its short half-life, which can result in poor bone
defect repair in vivo [148]. Using very high doses of proteins to maintain the therapeutic effect is
expensive and can lead to undesirable side effects [149-151]. Dexamethasone (DEX) is a bioactive
molecule that has extensively been used in bone tissue engineering due to its ability in guiding the
differentiation of mesenchymal stem cells (MSCs) toward the osteogenic tendency [152-156]. The
direct use of DEX, however, has been limited due to its toxic side effects [157]. Therefore,
developing a system capable of exhibiting a spatial deliver over these bioactive molecules in a
controlled and sustained fashion and simultaneously is indeed required to eliminate their side
effects for effective biomimetic bone regeneration.

In an attempt to address these limitation, Li et al, introduced a biomimetic bone tissue engineering
scaffold by developing a new nanoparticles-ebmedded coaxial electrospun nanofiber scaffold for
controlled dual delivery of BMP-2 and dexamethasone (DEX) [157]. BMP-2 was encapsulated
into bovine serum albumin in order to maintain the bioactivity of BMP-2 and it was coaxially
electrospun with a blend of BSA nanoparticles, DEX and the poly(ε-caprolactone)-co-poly
(ethylene glycol) (PCE) copolymer having the BSA encapsulated BMP-2 in the core-shell of the
nanofibers (Figure 1.8). In vitro studies revealed that the bioactivities of both DEX and BMP-2
have been well maintained in the duel-drug-loaded nanofiber system, and a sequential release
pattern has been obtained in which DEX expressed a fast release and BMP-2 release lasted for up
to 35 days. In addition, further in vitro studies demonstrated the ability of the system to induce
differentiation toward osteoblastic tendency when compared to the non-loaded group. In vivo
analysis revealed that the loaded-drug groups exhibited a significantly higher degree of
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osteogenesis when compared to the non-loaded group in a rat caldaria model, confirming the
synergistic effect of BMP-2 and DEX. Thus, data show that the dual-drug-loaded nanofiber
scaffold may have the strong potential in bone tissue engineering application.

Figure 1.8. Schematic illustration of the fabrication of BMP-2-loaded BSA nanoparticles stabilized with
chitosan [157].

1.1.4. Biomimetic Ligament Tissue Regeneration:
1.1.4.1.Ligament Structure and Function:
Ligament is a dense fibrous connective tissue that connects bones together to achieve joint stability
[160]. Ligament consists of very complex hierarchically interconnected organized groups of
parallel fibers, known as bundles [160]. At the microscopic level, fibroblasts are found entrapped
in the matrix. These cells are responsible for the matrix synthesis and they are relatively low in
number representing a small percentage of the ligament total volume [161]. Ligament matrix is
composed of aligned nano-micro-fibers oriented along the axis displaying a wavy or crimp
structure [162]. This complex structure, however, plays a vital biomechanical role in transferring
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the loads along the matrix axis allowing the ligament to elongate without sustaining damage upon
movement [162]. Differences in the waviness or crimp structure can largely affect the ligament’s
mechanical properties as fibers with small crimp angle are mechanically weaker than fibers with
a wider crimp angle [166]. Biochemically, 75% of the total dry weight of ligament is occupied by
different types of collagen such as collagen type I (made up 85% of the total collagen found in the
ligament), and types III, VI, V, XI and XIV, whereas the rest is occupied by watery components
that are responsible for the viscoelastic behavior of the ligament such as, proteoglycans, and other
glycoproteins such as fibronectin and tenascin-C [162]. Proteoglycans is found in various
concentrations depending on the mechanical loading to which the ligament is exposed [167]. The
higher proteoglycans concentration is found in areas that are subjected to compression, giving the
role for proteoglycans in resisting compression loads [168, 169]. Fibronectin is found on the
surface of the collagen and it acts as an adhesive glycoprotein that supports cell attachment, in
addition to its involvement in the regeneration and the repair of the ligament [170, 171]. TenascinC is another glycoprotein that is extensively found during the early stages of the ligament
development, which mainly contributes in the ECM network formation to achieve mechanical
stability [172].

Ultrastructural studies have revealed that collagen fibers (1 – 20 µm in diameter) found within the
ligament are further composed of fibrils (20 – 150 nm in diameter). During ligament development,
ligament fibroblasts secret a molecule known as “procollagen” into the extra cellular space, which
is a primary molecule responsible for collagen synthesis. Once it is secreted, a transitional
modification takes place allowing the triple helical collagen molecule to line up and start forming
fibrils and then fibers to form the extra cellular matrix. This process is promoted by an enzyme
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known as lysyl oxide, which promotes the crosslinking between the collagen fiber molecules. The
crosslinking reaction is an essential step as it reinforces the matrix and gives collagen fibers such
incredible strength [162].

Ligament acts as a connection that connects bones together, for example, anterior cruciate ligament
(ACL) connects the femur to the tibia through collagen fibers that are anchored into the bone
structure (Figure 1.9) [173]. The change between the flexible ligament to the hard bone is mediated
by a transitional zone known as “fibrocartilage”. Fibrocartilage is further divided into two rejoins,
mineralized and nonminerlized. Nonminerlized fibrocartilage is directly anchored to ligament,
whereas the mineralized fibrocartilage is directly anchored to the bone matrix. This mediated
fibrocartilage zone with its unique gradual transition in structure and mineralization content allows
for gradual change in even distribution of stress [174].

From a mechanical point of view, human ACL is exposed to tensile forces ranging from 67 N to
630 N during normal daily activates. However, the maximum tensile load that a human’s ACL can
withstand before failure was found to be 1730 N, 182 N/mm for linear stiffness, and 12.8 N m for
energy absorbed. The Young’s modulus of human ACL was found to be 111 MPa and the ultimate
tensile stress is 38 MPa [175]. These values increase during ACL development and diminish as
the parson ages [176].

To this end, understanding the anatomy, orientation, the attachment sites of the normal ligament,
mechanical properties and the kinematics is indeed necessary not only for surgeons performing the
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reconstruction, but also for scientist in order to achieve a possibly closer biomimetic design for
successful ligament tissue engineering.

Figure 1.9: Anterior Cruciate Ligament (ACL) [396].

1.1.4.2.Materials for Biomimetic Ligament Tissue Regeneration:
One of the most important preliminary steps for designing any ACL graft is to choose the
appropriate material that would achieve the design of a mechanically, physically, chemically and
structurally biomimetic ACL graft that resembles the native ACL ECM. All materials with their
degradation by-products should be biocompatible that do not elicit any immune response upon
implantation or degradation, and should also be biodegradable to allow for collagen bundle
formation and tissue ingrowth [177]. The material degradation rate should be comparable with that
of the tissue ingrowth, in which a complete degradation to the biomaterial should take place after
several months to allow for replacement by the regenerated ligament matrix [182]. In addition, the
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materials should be capable of supporting cell adhesion, proliferation and differentiation.

The current ongoing research on ligament tissue engineering, specifically ACL, mainly uses
polymers-based materials for graft fabrication such as, natural and synthetic polymers. Natural
polymers mainly include collagen, and silk fibroin, while synthetic polymers used for ligament
tissue engineering include PLA, PGA, PLLA, and PLGA [178]. The majority of these materials
have found a great interest for use in ligament tissue engineering application due to the easy
processbility of these materials into wide variety of different structures with tailored mechanical
and degradation properties that meet the applications needs [178].

Collagen-based scaffolds have been used for ligament tissue engineering due to their
biocompatibility, ability to provide functional chemical groups for cellular binding, and due to
their prevalence. Using collagen in its simplest form as a graft for ACL reconstruction may not
meet the requirements for successful ligament tissue engineering due to its poor mechanical and
degradation properties. However, for mechanical reinforcement; collagen can be crosslinked
through one of the most common crosslinking methods such as hydroxulysinonorleucine (HLNL),
dihydroxulysinonorleucine

(DHLNL),

histidinohydroxymerodesmosine

(HHMD),

and

nordihydroguaiaretic acid (NDGA). It was reported that crosslinking collagen with NDGA method
achieved much improved mechanical properties that matched with the normal ACL, when
compared to the other crosslinking methods [179, 180]. Although collagen-based scaffolds are
biocompatible, easily modifiable, hemostatic and synergic with bioactive molecules and not toxic,
limitations are still present such as, high cost, high level of hydrophilicity, patch-to-patch variation,
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complex handling, and the potential of disease transmission, which limit their use for ligament
tissue engineering [181].

Silk fibroin is another natural polymer that has been widely used for ligament tissue engineering
due to its unique mechanical properties, biocompatibility, slow degradation rate, the ability to
genetically control it as well as the easy processbility into multiple structures such as gels, films,
braded fibers and nanofibers [182]. The elegant mechanical properties and stability of silk fibers
are due to the homogeneity of the polymeric back-bone structure, extensive hydrogen bonding, as
well as the hydrophobic nature of silk and its crystallinity [178]. The primary advantageous of silk
fibroin lies in its noteworthy tensile strength, which is unmatched for other natural polymers
[183]. It was reported that silk has an elastic modulus that ranges between 5-9 GPa, a tensile
strength of 250-400 MPa, and failure strain values of 23-26% [183]. Another remarkable property
about silk fibroin is that it displays surface amino acids, which mainly support cell attachment
[184]. Silk fibroin is barely degraded in vitro, and slowly degraded in vivo (weeks-months)
through proteolysis [185]. Silk fibroin-based scaffolds have been reported to exhibit similar
mechanical properties to the natural ECM, and biocompatibility both in vitro and in vivo [185,
186]. These unique characteristics make silk fibroin one of the best natural polymers for ligament
tissue engineering.

On the other hand, the tailored mechanical and degradation properties, the easy processbility into
a variety of different structures and morphologies as well as into specific structures for ligamentlike geometries with tuned pore frequencies has established an interest in the use of synthetic
polymers for ligament tissue engineering [187]. Several poly-α-hydroxy esters are FDA approved,
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and the most common synthetic polymers used for ligament tissue engineering include PLA, PGA,
PLLA, and PLGA, [188].

PLA is an aliphatic polyester that is more amorphous and hydrophobic than PGA [189]. PLA
usually has two isoform (L- and D-) forms because of the extra methyl group compared to PGA.
This, however, slows the degradation rate of PLA when compared to PGA. PLA degrades through
desertification, and degrades completely within 10 months to 4 years depending on the molecular
weight, crystallinity, shape of the device and implantation site [189].

PLGA is a linear copolymer that can be synthesized at different ratios between its constituent
monomers, lactic (LA) and glycolic acid (GA). Depending on the ratio of lactide to glycolide
used for the polymerization, different forms, degradation and mechanical properties of PLGA
can be obtained, where the higher the lactic content to glycolic generally exhibits prolonged
degradation rates, and higher mechanical integrity. These are usually identified in regard to the
monomers’ ratio used (i.e., PLGA 85:15 identifies a copolymer consisted of 85% lactic acid and
15% glycolic acid) [190]. PLGA undergoes degradation by hydrolysis of its ester linkages,
through bulk or surface erosion, in aqueous environments, and it completely degrades within a
period of between 6 – 9 months depending on the molecular weight, purity and the shape of the
device [191]. PLGA
It was proven that both PLGA and PLLA fibers enhance the overall cellular performance as well
as matrix formation of ligament fibroblasts comparing to other biomaterials. Braided PLLA,
PLGA and PGA three dimensional scaffolds have been fabricated by Lu et al. Scaffolds were
immersed in a solution of human recombinant fibronectin (Fn) to improve cell adhesion [192].
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After 14 days of culture with rabbit ACL fibroblasts, scanning electron microscopy (SEM) analysis
found that cells seeded on PLLA-Fn and PLGA-Fn scaffolds produced the most matrix, and that
PGA was detrimental to matrix formation, thought to be from rapidly produced acidic byproducts
(Figure 1.10).

Figure 1.10. ACL fibroblast growth and matrix formation on different synthetic braided scaffolds
visualized with SEM. Images were taken after 14 days of in vitro culture in 10% fetal bovine serum. (Left)
Culture with PGA resulted in substantial matrix degradation from acidic byproducts. (Middle) PLA and
PGA in an 82:18 mass ratio showed more sustainable matrix formation, particularly with the addition of
fibronectin (Fn). (Right) PLLA scaffolds also displayed considerable matrix formation, which again was
amplified by the addition of Fn [192].

1.1.4.3.Scaffold Requirements for Biomimetic Ligament Tissue Regeneration:
Scaffolds are important components of ligament tissue engineering strategy as they define the
ultimate shape of the construct while providing the required mechanical strength during
regeneration and proper cell attachment sites, in addition to the delivery of regulatory growth
factors that stimulate cellular behaviors [195]. Regenerative engineering aims to use scaffolds to
produce a functional tissue replacement in vitro, which can be then implanted into the body to
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induce self-regeneration in vivo [193]. Anatomical location, poor vascularity, volume of the tissue
loss, the elegant mechanical and structural properties of the natural ligament and the mediated
fibrocartilage zone, are all factors that have to be taken into consideration to achieve a successful
and a biomimetic ligament tissue engineering graft [194].

Scaffolds for ligament tissue engineering should mimic all the specific characteristics of the native
ligament such as strength, compliance, elasticity and durability without causing any side effects
[178]. In addition, they should be biocompatible that do not elicit any inflammatory response or
demonstrate any immunogenicity or cytotoxicity when implanted [196]. They should also be
biodegradable that demonstrate a compatible degradation rate with the growth rate of the neotissue, in which the scaffold is totally degraded by the time the tissue is healed [197]. Degradation
rate can be tuned by tailoring many factors such as, device structure, porosity, material
crystallinity, molecular weight [198]. The graft material should be bio-resorbable and all of its
degradation by-products should be totally eliminated out of the body through natural metabolic
pathways with no residual side effects [199]. Appropriate surface chemistry and efficient amount
of porosity are indeed important features that ligament tissue engineering grafts have to exhibit in
order to enable cellular attachment, proliferation, differentiations, and to permit the diffusion of
nutrition throughout the graft [200]. In addition, the scaffold should be capable of osteointegration
to the bone matrix to increase the degree of successful ligament tissue engineering and to achieve
knee stability.

From a mechanical point of view, ligament is a load-bearing tissue that plays a crucial role in
providing joint stability and load transfer during movement such as extension and flexion [178].
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The natural ligament inherits its incredible mechanical strength from the unique crimp structure of
its bundles, reinforcing its mechanical properties and giving it such incredible stability [162]. Due
to the complexity associated with the ligament mechanical properties, many complex biomimetic
structures have been adopted for ligament reconstruction such as woven, knitted and braided fibers
[178]. Woven and knitted fibers exhibit great porosity throughout the structure, but they are
mechanically weak. On the other hand, braided fibers are mechanically and dimensionally very
stable, but they are less extensible and porous when compared to the other structures [178].
However, pore size of the braided fibers structures can be regulated by both yarn bundle size and
braiding angles [201]. Previous studies have shown that the optimal porosity for ligament scaffolds
should be above 50% to create the optimal pore diameter of 100-300 um, which is needed for in
vivo tissue ingrowth [214]. Therefore, subsequent balance between fibers structure and porosity is
a key role for providing mechanical stability and thus, successful tissue restoration and
reconstruction

In addition to the mechanical and structural biomimicry, the scaffold should also serve as a
reservoir for local, sustained, and controlled growth factors delivery to regulate cellular activates
in order help induce neovascularity and promote ligament tissue regeneration. Several growth
factors were shown to be effective in the healing of ligament repair, including, insulin like growth
factor I (IGF-I), transforming growth factor-β (TGF-β), vascular endothelial growth factor
(VEGF), basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), and platelet
derived growth factor (PDGF). Both in vitro and in vivo data have revealed that these growth
factors have the capability to enhance ligament fibroblasts proliferation and matrix production
alone or in combine [202-210]. For example, VEGF and PDGF were shown to promote vascularity
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within the regenerating matrix [211]. IGF was shown to modify the metabolic activity of cells
during ligament healing [212]. In addition, it was shown that TGF- β1, alone or in combination
with EGF, have the potential to strengthen the ligament through increasing matrix production
during the healing process in vivo [213]. Therefore, growth factors introduction may serve as a
promising tool for regulatory ligament tissue engineering.

1.1.4.4.Biomimetic Ligament Tissue Regeneration Approaches.
One of the major challenges in ligament tissue engineering is to mimic the inherited mechanical
and the structural properties of the native ACL, which are crucial for a functional ACL repair or
regeneration. Current grafts for ACL tissue replacement do not duplicate the native tissue
structurally and lack sufficient flexibility and tensile strength. One of the earliest attempts to
engineer a mechanically and structurally biomimetic graft for ACL reconstruction was adopted by
Cooper et al. In this study, a PLLA three-dimensional braided fibrous tissue engineered anterior
cruciate ligament (ACL) graft has been developed for use in ACL reconstruction [215]. The graft
structure was based on the hierarchical complexity found in the native ligament. To construct the
graft, PLLA fibers were woven into circular and rectangular braids with different branding patters
and yarn densities to achieve mechanical properties that best resemble the native ligament. The
author has evaluated the tensile testing of different shapes and yarn configurations in order to
determine configuration that best matches the triphasic nature of the natural ligament. In addition
to evaluating the implant’s capability to maintain mechanical function, the effect of porosity and
pore interconnectivity on cell and collagen infiltration, the capability of the implant to allow for
vascularization as well as the in vivo response of the ACL cell-seeded/ unseeded graft in a rabbit
ACL model for 4 and 12 weeks have been evaluated. Mechanical evaluation of the implant resulted
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in stress/strain curves that matched the triphasic nature of the native ligament, with initial low
modulus followed by a linear region of increased modulus, and ending with plateaued curves at
failure. In vitro biocompatibility tests showed good viability of the rabbit ACL cells seeded on the
PLLA graft. In vivo evaluation revealed that both cell-seeded/ unseeded PLLA graft showed
collagen infiltration, blood vessels formation and vascularity throughout the implant, however, the
cell-seeded groups (Figure b) showed more organized collagen orientation tissue formation,
enhanced vascularity with no fibrous encapsulation when compared to the unseeded group (Figure
c). Although the in vitro biocompatibility testing showed positive results, a thin layer of fibrous
capsule in the unseeded group was evidence as compared to the cell-seeded group. Data from this
study suggest the importance of biomimicking the structural and mechanical aspects of the natural
ligament tissue, as mechanically and structurally biomimicking the native ACL resulted in
enhanced matrix production and scaffold’s mechanical integrity. In addition, scaffold’s porosity
largely contributed in the vascularity found within the engineered graft. Data suggest that a
biomimetic ACL graft may lead to promising ligament replacement technology.

In a different attempt to mimic the viscoelastic properties of the ACL graft to resemble those found
in the native tissue, Laurencin et al. developed a novel PLLA braided–twist scaffold for use in
ACL reconstruction [216]. The graft was evaluated for stress relaxation, cell viability and scanning
electron microscopy SEM. In addition, the graft’s viscoelastic properties were tested using
Maxwell and quasi-linear viscoelastic (QLV) models. Stress relaxation experiments revealed that
the braided twist graft showed similar behavior to the native ACL, with final normalized stresses
of 87% and 83% after an 8 N load when compared to the braided, twisted fiber and aligned fiber
scaffolds. Maxwell study demonstrated that the braided-twist had the most favorable viscoelastic
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proprieties. In vitro cell proliferation study showed that there was no significant difference in cell
proliferation between the braided-twist and the braided scaffolds. Data from this study suggest that
the braised-twist scaffold design may be effective in scaffolds for ACL tissue regeneration as they
not only achieved a mechanical and structural biomimicry, but also mimicked the viscoelastic
aspects of the natural ACL.

Although these studies showed great mechanical, structural and viscoelastic properties that
resemble those found in the native tissue, they do not mimic the mechanical, and structural gradual
transition found along the ligament to bone junction, which can lead to the formation of a fibrous
scar tissue at the insertion site that lacks all the mechanical and structural properties of the native
one. Therefore, mimicking the complexity found at the native tissue is a key role for functional
tissue regeneration.

More recently, there has been a serious shift towards the fabrication of gradient scaffolds aiming
to mimic the complex properties transition found along the ligament to bone junction for more
functional tissue restoration. Laurencin et al. developed a multi-region polymeric based scaffold
system for use in ACL reconstruction. The graft system is specifically designed in order to promote
ligament regeneration and proper fixation to the bone at the implantation site [217]. The threedimensional graft system consists of quickly-degrading biocompatible polymeric fiber (17%
PLLA), and slowly-degrading biocompatible polymeric fiber (83% PLLA). The middle region of
the scaffold is formed from the quickly-degrading polymeric fibber to support ligament fibroblasts
ingrowth, whereas the slowly-degrading polymeric fiber forms the two ends of the braided
scaffold, which is intended to promote bone ingrowth after being secured into drilled bone tunnels
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to serve as bony attachment ends of the scaffold. The degradation rates of the quickly-degrading
and the slowly-degrading polymeric fibers are 9 – 12 months, and 1 year respectively. The
uniqueness of the design lies on the inclusion of three different region, each with specific pore
size, in which the pore size at the bony regions is designed to allow for bone cell ingrowth, whereas
the pore size at the middle region is designed to allow for ligament cell ingrowth. This structural
gradual transition plays a vital role in supporting the formation of a fibrocartilage-like tissue at the
interface. The graft system exhibits porosity at the range of between 50 – 70 %, and pore size
between 177 µm – 250 µm. The graft system has been mechanically evaluated resulting in a peak
load strength of 500 – 3200 N, with an initial stiffness range of 200 – 700 N/mm. These values
were based on a number of 10 – 60 fibers per bundle, and a number of 36 bundles per braid. To
evaluate the graft’s ability on supporting ligament regeneration and osteointegration, the graft was
implanted in a sheep ACL reconstruction model for 12 weeks. In vivo evaluations revealed that
there was a significant tissue ingrowth within the ligament region, with a complete osteointegration
at the bone tunnels along with the presence of a fibrocartilage-like tissue at the insertion site. An
early representative version of the braided graft can be shown in (Figure 1.11).

Figure 1.11. Representative image of the three-dimensional braided scaffold developed by Laurencin et al.
with distinct fiber organizations in the bony attachment ends and central intra-articular zone. [215]
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Considering the scaffold physical properties such as cross-link density, pore size, stiffness and
material composition is a key element in guiding the cell behavior, especially musculoskeletal
cells. In another gradient study by Oh et al, a scaffold with different pore size gradient was
fabricated using PCL for ACL reconstruction following a centrifugation method (Figure 1.12)
[64]. The scaffold exhibits different pore size gradients along the three regions, starting from 405
µm at the bony region, with a gradual decrease to 186 µm at the end of the ligament region.
Osteoblasts, chondrocytes and fibroblasts were seeded in the three graft regions, respectively. Cell
counting was performed along the graft, and it was found that both osteoblasts and chondrocytes
showed increased in cell number at the regions with pore size 380-405 µm, while fibroblasts were
more localized at areas with pore size of 186-200 µm. These findings suggest that different pore
sizes can strongly affect cell behavior such as proliferation and cell fate. Thus, providing the
appropriate gradient in pore size, may act as a useful tool that can guide cell differentiation and
proliferation during complex tissue regeneration [64].
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Figure 1.12. (top) Schematic diagram showing the fabrication process of a pore size gradient in PCL
scaffolds by a centrifugation method and (bottom) SEM photographs of the top surfaces of the PCL scaffold
sections along the longitudinal direction (× 100; *, average pore size) [64]

A wealth of evidence has shown that cells grown on surfaces with different architectures and
stiffness demonstrate altered cell morphologies and gene expressions [122]. Thus, providing a
biomimicry ECM architecture may be used to ultimately control cell behavior and fate. In a study
by Thayer et al. a thin (~ 5 fiber thick) layers of aligned electrospun microfibers (0.7 µm) were
embedded within collagen hydrogels containing mesenchymal stem cells (MSCs), which were
cultured for up to 14 days [218]. Electrospun microfibers were fabricated from polycaprolactone
(PCL), poly(ester-urethane) (PEUR), or a 75/25 PEUR/PCL blend, with elastic moduli of 31, 15,
and 5.6 MPa, respectively. It was hypothesized that mimicking the mechanical and structural
aspects of the native ACL can work as a cue to guide cell fate. However, in vitro gene expression
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assay showed significantly higher expression of the specific ligament marker (scleraxis) in MSCs
seeded on the composite containing 5.6 MPa fibers along with high expression of the contractile
phenotype marker α-smooth muscle actin when compared to the stiffer fiber composites. In
addition, further structural studies revealed that cells within the 5.6 MPa microfibers composite
exhibited more organized orientation along the aligned axis of the microfibers when compared to
the 15 and 31 MPa microfiber composites.

Confirming the findings from the aforementioned study, degradable PLGA nanofibers-based
scaffold has been in vitro evaluated by Moffat et al [79]. The effect of fibroblasts attachment,
alignment, and gene expression has been tested as a function of nanofibers organization (aligned
vs randomly aligned). It was found that underlying orientation primarily guided ligament
fibroblasts morphology, alignment and gene expression. In addition, it was found that the
deposition of collagen types I and III as well as mechanical properties were directly related to the
underlying nanofibers orientation. Findings from these studies indicate that nanofibers
organization and stiffness play crucial role in guiding cell response, which clearly highlight
biomimetic potential of nanofibers to the ligament native tissue.

Growth factors have been also used to support ligament tissue engineering for their active roles in
establishing the complex structure of the enthesis, healing the tissue after injury, and maintaining
tissue homeostasis. In a study by Hannah et al. a hierarchical bioactive scaffold for ligament tissue
engineering using connective tissue growth factor (CTGF)-conjugated PCL aligned nanofiber
bundles was developed (Figure1.13 a) [219]. This study not only intend to mimic the mechanical
and the complexity found within the ACL structure, but also introduced a biochemical factor in
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order to provide a biomimetic biological environment suitable for cell housing, similarly to the
natural ECM. In this study, three different scaffold geometries were fabricated as follows; (1)
individual nanofiber bundles (Figure 1.13b), (2) scaled-up scaffolds that are composed of 20
nanofiber bundles (Figure 1.13c), and (3) small scaffolds composed of only of 4 nanofiber bundles
(Figure 1.13d). In order to introduce the growth factor to the scaffold, it was covalently bound to
the surface of the individual nanofiber bundles, or on the surface of the scaffold consisting of
multiple nanofiber bundles. Controls for these scaffolds were the same scaffolds but non-CTGFconjugated. The conjugation efficiency and the release of conjugated CTGF were assessed using
X-ray photoelectron spectroscopy, assays, and immunofluorescence staining. In addition, all
Scaffolds were pre-seeded with MSCs, and the cellular response for these constructs was evaluated
both in vitro and in vivo in a nude mouse subcutaneous model for 6 weeks. Results showed that
more than 90% of the loaded growth factor has been conjugated into the surface of all scaffolds,
indicating the efficiency in loading. In vitro release studies of the CTGF-conjugated nanofiber
scaffold showed a sustained and linear release of the biochemical factor for the first 5 days with
no burst release, and a complete release of the growth factor after 15 days of incubation at 37 C in
PBS. In addition, further results showed that all CTGF conjugation scaffold resulted in more cell
proliferation and enhanced ligament-specific tissue formation in vitro and in vivo when compared
to all the other non-CTGF conjugated groups, owing the great potential for hierarchical electrospun
nanofiber bundles conjugated with CTGF as scalable and bioactive scaffolds for ACL tissue
engineering.

Figure 1.13. Aligned nanofibers (A), nanofiber bundle (B), scaffold composed of *20 nanofiber bundles
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(C), and small scaffold composed of 4 nanofiber bundles (D) [219].

1.1.5. Biomimetic Skin Tissue Regeneration:
1.1.5.1.Skin Structure and Function:
Skin is the largest organ in the human body, covering the entire exterior of the body and forming
about 8% of the total body mass, and it is necessary for the animal survival and hemostasis [257].
Skin mainly functions as a protecting interface, physically shielding internal organs and tissues
from external insults and pathogens [258]. Functionally, the skin is responsible for maintaining
the homeostasis of the living organism, through regulating the body temperature, hydration and
Vitamin D synthesis [259]. Damages to any part of the skin will expose the individual to the risk
of other health complications. Structurally, skin is composed of many cell types that are derived
from three distinct embryonic origins: neurectoderm, mesoderm, and neural crest [259]. The skin
is comprised of two layers that cover a third fatty layer. These three layers differ in function,
thickness and strength (Figure 1.14). The outermost layer is called the epidermis, and is primarily
composed of stratified squamous epithelium of keratinocytes. Keratinocytes are derived from
neurectoderm and occupies almost 90% of the total epidermal cellular population. Further,
keratinocytes are responsible for supporting the cohesion of the epidermal structure and the barrier
function [259]. Moreover, the epidermis is comprised of other cell types such as, melanocytes of
neural crest origin (contain the skin pigment), Merkel cells of the neural origin (responsible for
pressure sensing), and Langerhans cells of mesoderm origin (responsible for processing antigen)
[259]. Epidermis is a highly regenerative layer, due to the presence of stem cells which contribute
in the process of wound healing during injury.
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The middle layer is called the dermis. The dermis is a connective tissue that is responsible for
providing the skin with the mechanical support and elasticity. The dermis layer is comprised of
dermal fibroblasts of mesoderm origin, of which found entrapped within the extracellular
specialized matrix. In this layer, collagen fibers are interwoven with proteoglycans, elastin,
fibronectin, and some other components. Dermal fibroblasts are responsible for synthesizing the
extracellular matrix that makes up the skin. The first two layers, the epidermis and the dermis, are
connected by a basement membrane that is composed of various integrins, laminins, collagen
fibers, and some other proteins that play important vital roles in regulating and maintaining
epithelial-mesenchymal cross-talk [259]. In the dermis, papillary loops with candles-like structure,
called the dermal papillae, contain the microvascular and neural networks and extends the surface
area for these epithelial mesenchymal interactions. The dermis further contains of sebaceous
glands, eccrine glands, apocrine glands and hair follicles, all of which are from a neurectoderm
origin. In addition, blood vessels and lymphatic vessels of the mesoderm origin, and sensory nerve
endings of the neural crest origin are all found in the dermis. The last layer is called the
hypodermis. This last layer is located right beneath the dermis layer and it is primarily composed
of adipose tissue of mesoderm origin, and separates the dermis from the underlying muscular fascia
[259].

Human skin is a very elastic material that can be stretched to several times its original size and still
maintain its original phenotypic [264-267]. This impressive feature return to its specialized matrix
mechanical structure [268]. When the skin is stretched beyond its physiological limit, series of
cascade of events take place to restore its hemostatic balance that include, activation of ion
channels, conjugation of integrins, growth factor receptors and G-receptors with protein reactions
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[269]. These series of events result in increased mitotic activity and collagen synthesis [269 - 271].
The same series of events are initiated when damages to the skin occur during injuries that also
result in increased mitotic activity and the synthesis of collagen in order to restore the function of
the skin damaged skin. However, massive injuries such as chronic wounds cause irreversible
deformation and damage to the skin, resulting in a loss of its mechanical properties [272, 273]

Human skin is a complex living material, composed of several heterogeneous layers: epidermis,
dermis and hypodermis, with different mechanical properties, and thickness variation depending
on the anatomical location [274, 275, 276, 277]. Despite the complexity and the mechanical
diversity found within the three different layers of the human skin, the skin is mechanically treated
as a homogenous material in all induction measurements [278]. From mechanical point of view,
the human’s skin mechanical properties are age dependent, where measurements of mechanical
parameters are normally higher in newborn children than in elderly adults. For example, the mean
ultimate skin deformation before bursting is 75% for newborns and 60% for the elderly [279]. In
addition, uniaxial loads and elasticity modulus have average values of 21 N/mm2 and 70 (MPa) in
newborn and 17 N/mm2 and 60 (MPa) in elderly adults respectively. This clearly explains why
elderly adults have much thinner, stiffer, less dense and less flexible of a skin when compared to
newborn children [280, 281].

Due to the complexity associated with the structure and function of skin, engineering skin
equivalent to the normal skin has been challenging. Current skin tissue engineering approaches
primarily focus on regenerating the dermis and the epidermis layers to restore the structural
integrity of the skin, rather than regeneration for a functional restoration. Mechanical properties
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measurements may also differ than normal in the case of diabetic and some other more factors. A
complete awareness of the skin anatomy and structure, in addition to the factors affecting the
mechanical properties is indeed required for effective biomimetic skin tissue engineering.

Figure 1.14. Anatomy of the skin. Skin is composed of three layers, starting with the outermost layer: the
epidermis, dermis, and hypodermis. Epidermis is a stratified squamous epithelium that is divided into four
layers, starting with the outermost layer: stratum corneum (SC), stratum granulosum (SG), stratum
spinosum (SS), and stratum basale (SB). Outer root sheath of the hair follicle is contiguous with the basal
epidermal layer. Stem cell niches include the basal epidermal layer, base of sebaceous gland, hair follicle
bulge, dermal papillae, and dermis [259].

1.1.5.2.Materials for Biomimetic Skin Tissue Regeneration:
Several natural, synthetic or composite biomaterials have been utilized for effective biomimetic
production of skin tissue engineering scaffolds. Composite biomaterials are used in skin tissue
engineering due to the fact that they resemble the natural ECM, and can be tailored to inherit a
wide variety of instructive cues that can be used to guide the attachment, proliferation and
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differentiation of cells for enhanced skin tissue regeneration. Natural biomaterials used for skin
tissue engineering and construction could be of protein or carbohydrate. Such materials stimulate
the healing by repair of the damaged tissue and promote effective skin regeneration through
providing biomimetic surface properties for better cell adhesion and thus wound repair [260]. On
the other hand, synthetic polymers are used for their tailored degradation properties and
architecture characteristics, all of which contribute in the process of wound repair [261-263].

In skin tissue engineering, the most commonly used natural biomaterials are protein-based such
as, collagen, gelatin, silk, and fibronectin. Collagen is the most abundant naturally occurring
protein in the body responsible for maintaining structural integrity, representing approximately
25% of the total dry weight of mammals [282]. The skin ECM is primarily composed of collagen
fibers that provide the skin with structural integrity and tensile strength to support tissue growth.
Within the skin, collagen is synthesized by the skin’s fibroblasts to stimulate faster wound healing
process [283]. Structurally, collagen inherit a helical polypeptide structure with repeating sequence
units of the amino acids glycine, proline and hydroxyproline [284, 285, 286]. Out of the 29
different collagen types that have been already identified, skin is predominantly composed of
collagen type I, where collagen type III makes up very minor portion of the skin [283]. Collagenbased skin substitutes have been reported to be effective in accelerating wound healing by
providing an appropriate environment for fibroblast and keratinocyte proliferation [284].
Moreover, it has been reported that collagen can be processed into a wide variety of dressing
formulation for wound and burn repair that include, collagen sponges for deep skin wounds [287
,288]. collagen absorbable membrane [289], collagen composite films [290], composite of type III
collagen with polysaccharides [291 ,292], drug loaded collagen hydrogels [293], microfiber
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collagen scaffolds [294], and electrospun collagen nanofibrous scaffolds. Amongst all,
electrospinning is the most extensively used technique to fabricate collagen-based scaffolds for
skin tissue engineering due to the compositional and structural resemblance to the native ECM.
Gelatin, the denatured form of collagen, is another remarkable natural biomaterial for skin tissue
engineering that offers many advantageous over collagen as it inherits all the necessary arginineglycineaspartic acid (RGD) sequences that allows for enhanced cell adhesion, and it is less
immunogenic [295, 296]. Many reports have demonstrated the advances of the differently
formulated gelatin-based scaffolds in facilitating wound healing and tissue growth such as, gelatin
electrospun nanofibers [284], gelatin-alginate sponge [297], and gelatin containing EGF [298].
Gelatin is suggested to be a great candidate for treating wound and burn skin tissue.

Silk has been utilized as a promising biomaterial for skin tissue regeneration and wound healing.
Silk is extracted from silkworms and it is found as a classical fibrous protein in nature. Silk proteins
are found in two different forms in nature, either fibroin (hydrophobic) or sericin (hydrophilic);
however, the biodegradable silk- fibroin is the preferred over the sericin for its great
biocompatibility, high permeability for nutrition, due to the fact that it has been widely used as a
skin substitute for wound repair [298 - 300]. Silk fibroin-based scaffold have been prepared in the
form of electrospun nanofibers, films and woven matrixes of microfibers. Out of these silk fibroin
scaffold fabrication methods, silk fibroin-based scaffolds prepared by electrospinning have
attracted much attention as a scaffold design and material for wound dressing as they exhibit more
surface area to volume ratio of spread collagen that promoted enhanced cell adhesion and
proliferation of dermal fibroblasts and keratinocytes when compared to the other fabrication
methods of silk fibroin based scaffolds [301]. This demonstrated a rapid re-epithelialization and
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less scar formation due to the increased proliferation of keratinocytes in the wound setting [302].
It is suggested that silk fibroin may be able to address many skin tissue engineering limitations
due to its biocompatibility [303, 304], material versatility and mechanical robustness [305,
306], controllable degradability [307 - 309] and positive impact on wound healing effect.

Fibronectin is a major multifunctional component of the extracellular matrix (ECM). Fibronectin
plays a crucial role in wound healing as it supports the migration and the proliferation during the
recovery process [310]. Fibronectin has been used in many settings either alone or with the
combination of collagen and with or without fibroblasts as a skin substitute to treat different forms
of skin losses due to burn, or diabetic ulcer [311, 312]. Because of the failure to promote
vascularization in vivo, and the sever stretching fibronectin-based scaffold exhibits, the number of
fibronectin-based material is limited in the tissue engineering filed [313]. Further studies are
indeed required in order to address limitations associated with the usage of fibronectin as a
biomaterial for skin tissue engineering

Synthetic biomaterials have been extensively used for skin tissue engineering due to their tailored
structural, mechanical and degradation properties as well as easy processability into wide variety
of different geometries which render them as great biomaterials for the development of biomimetic
skin substitutes. Most of synthetic biomaterials are either degradable or non-degradable.
Biodegradable synthetic biomaterials are preferred over the non-degradable biomaterials due to
their degradability nature, which in turn can facilitate a faster neo-tissue ingrowth and better tissue
infiltration, in addition to minimizing the chance for a secondary surgery after implantation [314].
A wide range of synthesis biodegradable polymers such as, poly(lactic acid) (PLA), poly(glycolic
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acid) (PGA),

poly(lactic-co-glycolic acid) (PLGA), poly-L-lactic acid (PLLA), and

polycaprolactone PCL, have been used for and skin tissue engineering due to their intrinsic
tailored properties, and more importantly, their non-toxic degradation [284, 315]. PLGA have been
used in the form of 3D electrospun nanofibers skin graft to treat chronic wounds in a rat model in
vivo, which resulted in a complete wound healing and re-epithelialization after 14 days [316].
Similarly, PLA and PLLA membranes as artificial skin substitute have been evaluated for their
potential to treat chronic wound (2 x 3 cm) in a rat model in vivo. Histological analysis revealed
that chronic wounds treated with PLA and PLLA membranes completely healed after 21 days with
extensive collagen production [317]. Both PCL [318] and PGA [319] have been also shown to
enhance re-epithelialization at the wound site. Although synthetic biomaterials have recently
shown advances in many tissue engineering applications including utilizing them for substitutes,
they lack all the ligands required for cell adhesion, which can result in poor cell adaption to the
matrix and thus, poor tissue formation. The native ECM resembles some properties that are found
in synthetic materials only or natural materials only, however, developing synthetic/natural
composite scaffolds is the best solution to address the disadvantages associated with synthetic
scaffolds, as it will help in the mutual enhancement of the scaffold properties and thereby allowing
controlled degradation and mechanical properties as well as improving the biocompatibility, and
providing cells with all the necessary physical and chemical cues that are naturally inherited by
the natural ECM, to achieve the best possible biomimicry to the native ECM for effective skin
regeneration [130].

The biomimicry potential of composite biomaterials to the natural ECM render them as great
candidate for skin tissue regeneration and wound healing. Composites could be a mixture of
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different natural biomaterials, different synthetic biomaterials, or the combination of both. The
mixing of materials of different classes and different intrinsic properties to obtain composite
scaffolds seems particularly promising as limitations of single material scaffolds such as poor
biocompatibility, surface properties, or poor mechanical properties are often overcome by the
composite nature. As an example, for synthetic/natural composite biomaterial, Neishaboor et al.
developed composite microsphere system containing PLGA/Chitosan conjugated with stratafin for
wound healing [320]. The scaffold served as a multifunctional product, in which chitosan provided
drug binding ability and PLGA provided protection against burst release of the drug. This work
has demonstrated the feasibility toward composite scaffolds and their potential to serve as
multifunctional products. Synthetic/synthetic composite scaffolds have been also prepared for skin
tissue engineering. Lueng et al. developed a 3D electrospun nanofiber PCL/PVA composite
scaffold as a drug carrier for wound healing [321]. To fabricate the scaffold, an initial of PCL with
a thickness of 200-400 µm was first elctrospun, followed by electrospinning a second layer of drug
loaded-PVA, and finally another layer of PCL was electropun to sandwich the drug loaded-PVA
layer. PVA crosslinking was performed by spraying sodium tetraborate solutions onto the fibers
after electrospinning. In this study, the scaffold served as a multifunctional, in which PCL provided
the mechanical and structural integrity of the scaffold, whereas the crosslinked PVA controlled the
drug release, which was evidenced by the drug release data when compared to the non-crosslinked
PVA fibers.

Findings from these studies demonstrate the potential of the composite scaffolds in enhancing
wound healing for effective tissue regeneration. Composite scaffolds allow for mixing of materials
of different classes and different intrinsic properties to enhance the scaffold’s overall performance
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and capability to support cell attachments and proliferation, while acting as a template for tissue
regeneration. These optimized composite-based scaffolds were used as modular building units for
skin tissue engineering.

1.1.5.3.Scaffold Requirements for Biomimetic Skin Tissue Engineering:
Skin undergoes serious of events after injury in order to restore its function that include, migration
of fibroblasts to the site of injury, secretion of extracellular matrix (ECM) by fibroblasts, formation
of keratinocytes followed by the differentiation of keratinocytes to form the outermost layer of
epidermis; such as stratum lucidum and stratum corneum [322]. Skin injuries are either acute
(small skin wounds) or chronic (large skin wounds). Acute wounds are minor wound that are more
likely to self-heal through simple contraction and growth of the cells inside the wound. However,
large skin wound usually take much longer to heal and are more prone to risks, such as
inflammation, infection, scar formation, which results in the formation of chronic wounds. Some
factors such as older age or disease conditions such as diabetes, and renal infection, etc., can largely
affect the normal wound healing process thus resulting in poor tissue restoration. Therefore, it is
very important to put these factors into consideration while designing skin substitutes to achieve a
successful and a biomimetic skin tissue engineering graft [322 - 325]. Ideally, scaffolds for skin
tissue engineering should serve as a 3D supporting framework or template for tissue regeneration
while simultaneously preventing scar formation during the very first early stages of wound healing
[326]. Skin tissue engineering scaffolds should be biocompatible that don not elicit any immune
response upon implantation, and biodegradable with a compatible degradation rate to the rate of
the neo-tissue formation. The scaffold should possess high pore volumes with interconnectivity
throughout to enable cell infiltration, proliferation, nutrition exchange and waste removal. The
scaffold should mechanically mimic the natural skin tissue with tailored mechanical properties and
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elasticity; however, a subsequent balance between porosity and mechanical properties is indeed
required in order to achieve mechanical stability. Architecturally, the scaffold should resemble the
native ECM and should possess the appropriate surface chemistry to provide a niche for seeded
cells for adhesion, proliferation and differentiation. The scaffold should also serve as a reservoir
for controlled and spatial delivery over growth factors to stimulate cellular recruitment,
proliferation and differentiation. It is anticipated that a biomimetic scaffold resembling the
mechanical, physical, and structural aspects of the native ECM while acting as a delivery vehicle
for cells or/and growth factors can have the potential for effective skin tissue regeneration [327 328].

1.1.5.4.Biomimetic Skin Tissue Regeneration Approaches
Mimicking the mechanical and structural aspects of the natural ECM is of extreme importance in
order to guide cellular behavior and fate. Most skin tissue engineering scaffolds can be easily
tailored in order to obtain the initially desired mechanical and structural properties. However, most
of these substitutes fail to retain their mechanical and structural integrity after in vitro culturing,
limiting their potential use in vivo. Skin tissue engineering scaffolds must have the ability to retain
their structural and mechanical integrity after in vitro culture or when exposed to external forces
during the process of implantation into the defect site in vivo. After surgery, the structure at the
implant site must provide sufficient biomechanical support during the process of tissue
regeneration and structure degradation. Synthetic biomaterials have been extensively used as
scaffold materials for skin wound healing applications for their elegant mechanical properties and
ability to be processed into fibrous structures that resemble the native ECM structure. In addition,
synthetic biomaterials have been extensively used as composite with other naturally derived
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biomaterials to provide the required mechanical reinforcement for more effective skin tissue
regeneration. Venugopal et al. developed a biocompatible PCL/collagen electropsun nanofiber
scaffold for wound healing applications that resembled the native ECM mechanically and
structurally (Figure 1.15 A, B) [329]. The study not only intend to develop a skin graft that
mechanically and structurally mimic that native ECM, but also able to retain its mechanical and
structural integrity after in vitro culture for potential clinical translation. The scaffold was
morphologically and mechanically characterized and the behavior of human dermal fibroblasts on
both PCL/collagen and PCL electrospun nanofiber scaffolds have been examined. The fabricated
scaffold had an appropriate high pore volume of 90% with pore size of 2.252 ± 0.876 µm. In vitro
evaluations revealed that human dermal fibroblasts seeded on PCL/collagen elctrospun nanofiber
scaffolds showed enhanced cell morphology and proliferation after 2, 4 and 6 days in culture when
compared to the PCL alone (Figure 1.15 C, D). In addition, the scaffold’s mechanical integrity was
evaluated after 6 days in culture to examine the ability of the scaffold retain its mechanical integrity
for its potential to be used for transplantation. Results from this test showed the mechanical
stability (8.79 MPa) of the scaffold, suggesting that it can be used as an allogenic cultured dermal
substitute for transplantation in vivo (Figure 1.15 E).

In this study, PCL/collagen was used in order to produce a mechanically, structurally, and
biologically biomimetic scaffold for sufficient wound healing. The scaffold served as a
multifunctional, in which PCL provided the mechanical and structural integrity to the scaffold,
whereas collagen exposure influenced cell adhesion directly or indirectly through binding with
other ECM molecules such as fibronectin, laminin to cell surface glycoprotein, which in turns
provided the required adhesion sites that enhanced cell attachment. This study demonstrated the
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feasibility toward synthetic/natural composite biomaterials and their positional to be used as
scaffold materials for the production of mechanically and structurally biomimetic substitutes for
wound healing.
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Figure 1.15. Electrospun nanofibers, (A) Polycaprolactone, (B) PCL/collagen nanofibers (NUS), and
scanning electron microscopy morphology of fibroblast culture on nanofibrous scaffolds. (C)
Polycaprolactone, (D) PCL/collagen nanofibers, and (C) cultured dermal substitute (Fibroblast cultured on
PCL/Collagen nanofibrous membrane) [329].

Beside the use of composite biomaterials, Stem cell-based therapies are expected to have a great
impact in medicine and are also thought to be a powerful tool for the treatment of a wide spectrum
of lesions including skin wounds [330]. Amongst all different types of stem cells, bone marrow
derived stem cells have been shown to differentiate into different tendencies including epithelial
cells of the lung and liver, and into skin fibroblasts. Many promising results have shown the
positive effect of MSCs on chronic wound healing through systematic or local transplantation of
these cells [330]. The mechanism of which MSCs contribute to the wound healing process is by
either differentiating into phenotypes of various damaged cells or by enhancing the repair process
through the secretion of endogenous growth factors or cytokines that accelerate the wound healing
process [331]. Wu et al. proofed that wounds treated with BM-MSCs exhibited significantly
accelerated wound closure with increased re-epithelization, angiogenesis, and cellularity [332].
Paunescu et al. evaluated the ability of MSCs to differentiate into epithelial-like cells by simply
culturing them in using EGF, keratinocyte growth factor (KGF), hepatocyte growth factor, and
IGF-II. It has been shown that many factors including the surface chemistry, mechanical properties
or even architecture of the underlying substrate can trigger MSCs to differentiate into the epithelial
linage [339]. Ma et al. developed a PLGA/collagen electrospun nanofibers composite scaffold that
structurally, mechanically and biologically resembled the natural ECM, for culturing BM-MSCs,
which was further transplanted into a full thickness wound bed in Sprague-Dwaley rats [340]. Four
different experimental groups were involved in the study, (1) open wound bed with no scaffold
which served as a negative control, (2) PLGA/collagen scaffold free of cells which served as a
positive control, (3) PLGA/collagen scaffold with low cell density, and (4) PLGA/collagen
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scaffolds with high cell density (Figure 1.16). Histological analysis revealed that PLGA/collagen
with high MSCs resulted in a complete wound closure within 10 days when compared with the
other groups. The author further revealed that the architecture, exposure of collagen and
resembling the natural ECM mechanically and structurally as well as transplanting it in a wound
bed environment all stimulated MSCs to differentiate into epithelial tendency, which in turn
accelerated the formation of hair follicle and subcutaneous glands as well as promoted epithelial
ingrowth through chemotactic interaction and therefore facilitated the delivery of follicle
progenitor cells toward the center of wound during re-epithelialization.

Figure 1.16. Appearances of wounds in different groups on days 0 and 10 [340].

The important role of growth factors for cell migration, proliferation, differentiation in the
wounded areas has been recognized. In vivo, growth factors are endogenously secreted within the
ECM by cells themselves in constant rates to stimulate cellular proliferation and differentiation for
tissue regeneration or remolding. Efforts in tissue engineering have focused on the incorporation
of growth factors such as fibroblast growth factor (FGF), Epidermal growth factor (EGF),
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Keratinocyte growth factor (KGF), Insulin-like growth factor-1 (IGF-1), Platelet-derived growth
factor (PDGF), Transforming growth factor-b (TGF-b), intro the matrix scaffolds [333]. Numerous
growth factors incorporation methods have been developed aiming to achieve spatial release over
growth factors to mimic the endogenous release environment for more effective tissue
regeneration. one effective way of incorporating growth factors is by introducing them coaxially
in the core shell of a polymeric nanofiber for tuned and safe delivery of the growth factor to the
target sites. This has been shown to exhibit precise control over the location of the drug within the
core or shell of the nanofibers [334]. The main advantage of coaxial electrospinning over the
conventional uniaxial electrospinning is that it generates core and sheath fibers by physical
separation between the core and the sheath through the utilization of two electrospinning tips and
two solutions (Figure 1.17) [335]. The core generally contains the growth factor solution and the
sheath contains the polymeric solution. This nanofiber structure will allow for more of a spatial
control over growth factors delivery and will hugely minimize any possibility of burst release when
compared to the conventional uniaxial nanofiber [335]. Advantages of the coaxial electrospinning
made it one area of a significant interest for many researches for more effective drug delivery and
thus, tissue regeneration.
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Figure 1.17 Schematic of coaxial electrospinning setup, and the conventional uniaxial electrospinning
setup.

Building upon the knowledge, Choi et al. Developed a PCL/PEG Coaxial electrospun nanofibers
scaffold for treatment of diabetic ulcers with binary release of multiple growth factors bFGF and EGF
[336]. Two different growth factors were physically and chemically loaded into a single
nanofibrous matrix to increase wound healing efficacy and to obtain bi-phasic release profiles of the
loaded growth factors. To prepare the coaxial nanofibrous mesh, bFGF was physically incorporated in
the core-shell of the amine-functionalized copolymer PCL/PEG by coaxial electrospinning, where the
core-shell contained the growth factor and the outer sheath of the fiber consisted of the copolymers. To
chemically load the other growth factor, the initially electrospun PCL/PEG-bFGF mesh was chemically
modified with an EGF by conjugating surface-exposed amine groups of nanofibers to carboxylate
groups of EGF. To confirm the presence of bFGF in the core-shell of the polymer and the conjugation
of EGF on the surface of the fibrous mesh, X-ray photoelectron spectroscopy analysis were
conducted, which confirmed the presence of a surface-immobilized EGF on the nanofiber by the
distinctive peaks of nitrogen atoms shown in the data set. Release studies of both growth factors
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clearly demonstrated the binary release profiles of each protein; where bFGF a high initial burst
release within the first 24 hours, followed by a sustained and controlled release for 7 days, whereas
EGF showed no negligible release in 7 days. In vitro evaluation on the effect of the binary release
of both growth factors revealed that PCL/PEG-bFGF-EGF scaffold showed a significant increase
in human keratinocytes and fibroblasts proliferation when compared to the scaffolds incorporated
with bFGF or conjugated with EGF alone. To evaluate the capability of the scaffolds in treating
wounds defects, they were in vivo administered in wound beds created at the dorsal of diabetic rats.
Histological analysis revealed that the wound closure rates of diabetic ulcers were significantly
increased in 7 days in bFGF/EGF with higher keratin 14, 5, 1 expression levels and extensive collagen
and cemented matrix of keratin production when compared to bFGF, EGF and the control group.
These data strongly suggest the positive effect of the bi-phasic release of bFGF and EGF in supporting
tissue recovery with the similar phenotypes as the original keratinized tissues, owing its promising
potential as wound dressing approach that can increase wound healing rates while reducing scar
formation.

Although much progress has been made in the previously discussed approaches, most attention
has been paid to develop methods that more focus on wound closure to prevent further dehydration
and potential infection rather than looking for integrative and functional strategies for functional
restoration. In an attempt to partially restore the function of the skin, Mahjour et al. developed a
biomimetic multilayered PCL/collagen electrospun nanofiber scaffold that aimed to regenerate the
epidermal and dermal layers of the skin as well as hair follicle [337]. The multilayered skin graft
is composed of two distinguishable layers, with different architecture and mechanical properties
mimicking those found in the native tissue, where the lower layer is engineered to support dermal
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fibroblasts culture for dermal layer regeneration, and the top layer is intended to support
keratinocytes culture for epidermal layer regeneration. In addition, dermal papilla cells aggregates
were embedded in a predetermined arrangement at the interface between the epidermal and dermal
graft for hair regeneration. These dermal papilla aggregates are thought to have the capability to
differentiate into hair follicle in vivo. To construct the graft, isolated dermal fibroblasts were
seeded on the first layer, followed by embedding dermal papilla aggregates then adding the second
layer and seeding isolated keratinocytes on the top portion of the second epidermal layer. the
multilayered graft was further in vitro cultured to differentiate the dermal papilla aggregates into
hair follicles and produce proto hairs. The graft was shown to develop hair follicle-like structures
in vitro (“proto hair”), and consequently form new hairs in vivo along with the formation of dermal
and epidermal layers after transplantation to a full-thickness skin wounds in a rat model. It was
concluded that the in vitro differentiation of the dermal papilla and the in vivo regeneration of hair
was promoted by interaction between the dermis and the epidermis layer, suggesting their
contribution in regenerating new hair. In this study, a multilayered skin graft was designed to
provide a biomimetic environment for interactions between the dermis, epidermis, hair follicles
and proto hairs for a partial restoration of the skin function.

Although the previously mentioned skin tissue engineering strategies have been shown to improve
wound healing, they do not mimic the complexity found at the native skin matrix, thus limiting
their potential for functional and integrative restoration. There has been a serious shift towards
developing multilayered scaffolds that mimic the diversity found at the native ECM mechanically
and structurally to move from survival to an improved functional as well as aesthetic outcome.
Patient with severe burns suffer from irreversible loss of the skin and underlying subcutaneous
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tissue. These patients would indeed benefit from the development of sufficient epidermal-dermalhypodermal multilayered replacement. Great effort has been made in the past few years in
developing epidermal-dermal replacement to treat skin wounds and to prevent scarring, but less
attention has been paid to the reconstruction of the deeper hypodermis layer (subcutaneous tissue).
In an attempt to regenerate the three different layers, Maike et al. developed a bovine-derived
collagen–elastin tri-layered graft to examine its ability to regenerate a full-thickness wound [338].
Human keratinocytes and preadipocytes were isolated and seeded on their relevant phases, where
preadipocytes are seeded on the deeper hypodermal layer, and keratinocytes are seeded on the
outermost layer of the epidermis (Figure 1.18). After 21 days in culture, the graft was histologically
evaluated, using hematoxylin eosin, immunohistochemical staining with collagen IV as well as
immunofluorescence labeling with anti-Ki67 antibody (proliferation marker) and DAPI (40 ,6diamidino-2-phenylindole). Histological analysis revealed that a simultaneous growth of
keratinocytes and preadipocytes could be observed on the collagen–elastin matrix with extensive
production of collagen type IV on the outermost layer as evidenced by the immunohistochemical
and immunofluorescence. In addition, it was shown that keratinocytes adhered well to the surface
of the matrix and formed a confluent epidermis-like layer. Moreover, preadipocytes adhered well
and also penetrated into the deeper layers of the matrix. These promising results suggest that the
deeper layer could serve as a subcutaneous replacement. This work presented the feasibility of a
simultaneous cultivation of keratinocytes as well as preadipocytes on a single matrix, with
respective location of the layers mimicking the actual sequence of the natural skin, and could serve
as a useful template of a three-layered skin substitute for future reconstructive surgery.
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Figure 1.18. (A) Schematic presentation of the multi-layer skin substitute, (B) Immunohistochemical
staining with antibodies against collagen IV. Extracellular matrix is produced by keratinocytes on the
scaffold surface (20-fold magnification). Scale bar: 10 𝜇m, (C) Immunofluorescence labeling with DAPI.
Cytoblasts appear blue, matrix green. Keratinocytes form epitheliallike layers on the surface of the matrix
(20-fold magnification). Confocal Laser Scan. Scale bar: 10 𝜇m, (D) Simultaneous growth of keratinocytes
(*) and preadipocytes (>). Preadipocytes penetrate into deeper layers of the scaffold whereas keratinocytes
build a confluently layered epidermis-like sheet on the surface of the matrix (20-fold magnification).
Confocal Laser Scan. Scale bar: 10 um 𝜇m and (E) Proliferation of keratinocytes. Strong staining with antiKi67 antibody (brown) was observed, indicating proliferation of the seeded cells on the matrix. Scale bar:
10 𝜇m [338].
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1.2.Complex Tissue Regeneration:
The human body is surprisingly known for its regenerative capability. Blood, for instance, is
continuously regenerated throughout the human’s life. Several tissues also have the ability to selfregenerate upon injury to a certain extent, such as skin and bone; depending on how severe the
damage is [1]. Skin injuries, for instant, can be classified into two main categories; based on the
degree of trauma. Acute or Chronic. Acute wounds referred to as “Superficial Wounds” progress
through the normal stages of wound healing “hemostasis, inflammation, proliferation, and tissue
remodeling”; and show definite signs of tissue regeneration over time without any complications.
On the other hand, Chronic wounds referred to as “Full Thickness Wounds” do not progress
normally through the stages of healing and do not show evidence of healing over time, which leads
to an unsuccessful wound healing and results in the formation of a scar tissue that lacks necessary
functional and biological properties [2, 3, 4]. Bone injuries are also classified into either small
fractures that can heal and self-regenerate undergoing the normal bone fracture healing stages
“inflammation, soft callus, hard callus, tissue remodeling” in a timely manner, or into critical size
defects or lost limbs beyond a certain critical size that fail to regenerate, which necessitates the
clinical intervention [5].

One of the primarily grand challenges in the modern medicine is the limited availability of
subsequent functional impairment to lost or damaged tissues. Historically, prosthetic devices are
used to rehabilitate individuals living with joint or limb loss as a strategy to resolve this issue [6].
Artificial limbs, knees, and hips are some examples of prosthetic devices that are used. Although
a great deal of advances has been accomplished in the past few decades in order to improve the
functions of these prosthetic devices, serious drawbacks are still present such as the low stability
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and lacking the ability to perform complex biological functions that are easily performed by the
native limb, such as sensation or normal gait cycle [3, 7]. Allogenic limbs transplantations have
also been attempted with disastrous outcomes [8].

The use of biological grafts is a well-sought approach that addressed the clinical challenges of
restoring the function of damaged organs or tissues to certain extents. Currently available
biological grafts include autografts known as the transplantation of tissue within an individual
from a donor site to the injury site, or allografts known as the transplantation of tissue or a whole
organ from another individual or a cadaver. Autografts demonstrate high biocompatibility and
healing potential comparing to allografts, making them the gold standard among all the biological
grafts [9]. The poor biocompatibility and integration of allografts to the host tissues, and the limited
availability and high price demand of autograft led to the necessity of finding alternatives that
mostly focus on regenerating the damaged tissues rather than repairing or replacing them [10].

The field of “Tissue engineering,” which was established to represent a new window that primarily
focuses on the repair, restoration, and regeneration of neo-tissues using the three triangular general
components, cells with the support of biomaterials and growth factors, evolved out of this necessity
[11]. Tissue engineering utilizes scaffold matrices to fill the tissue void, provide structural support,
and to deliver growth factors and/or cells that have the ability to form tissues within the body upon
transplantation. Significant efforts have been made in the past few decades towards regenerating
single tissues both in vitro and in vivo using the tissue engineering approaches. By utilizing the
tissue engineering approaches, tissue-specific scaffolds for almost every single tissue within the
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lower and the upper extremities such as bone, ligament, cartilage, muscle, and skin have been
created with great potential [85].

This new engineering interdisciplinary has attracted much attention as a new therapeutic means
that thought to overcome all drawbacks associated with artificial organs or organ transplantation
in order to replace severely damaged tissues or organs. Despite the fact that tissue engineering
demonstrated many approaches that led to understanding the feasibility toward repairing or
regenerating single targeted tissues, the number of clinically translated products from this field are
relatively low and do not address the grand challenges associated with engineering complex tissues
such as organ systems or an entire limb.

The limitations of the current biological and engineering approaches towards complex tissue
regeneration made it clear that a paradigm shift is required to successfully create translational
technologies that can address the grand clinical challenges [6]. Developing a new interdisciplinary
approach that utilizes the most advanced technologies currently available in different fields such
as developmental biology, bioengineering, biomaterials science, stem cell biology, and clinical
medicine along with a full understanding of the human’s self-regenerative capacity may hold the
key toward complex tissue regeneration [6, 15]. The efforts of scientists from these various fields
led to the emergence of a new paradigm we term “Regenerative Engineering,” which has been
defined as “the Convergence of Advanced Materials Sciences, Stem Cell Sciences, Physics,
Developmental Biology and Clinical Translation for the regeneration of complex tissues and
organ systems”. Regenerative Engineering has elements of regenerative medicine, tissue
engineering, and morphogenesis but is distinct from these individual disciplines in that it is less
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applicable to spot the repair of injured tissues and elements and primarily focuses on the integration
and the subsequent response of stem cells to biomaterials and regeneration of the interfaces
between different tissue types [16]. This new interdisciplinary is proposed to regenerate damaged
complex tissues, with the addressing grand challenges such as the regeneration of a total knee or a
whole limb [17].

Formation of tissues simultaneously, as well as their functional assembly into complex tissues or
organ systems, is one of the primary grand challenges in regenerative engineering. It is a wellknown fact that increasing the levels of complexity in tissues or organs targeted for repair
presuppose a concomitant increase in the complexity of the associated tissue engineering
approaches or scaffold designs [19]. For example, solid organs, such as the kidney, would require
multiple essential structures to restore its function, whereas tubular hollow organs, such as the
urethra, are more easily tissue engineered from basic cells and biomaterials [19]. Similarly,
complexity is found at the interfaces between tissues, such as the transition from cartilage to bone
in the osteochondral interface in articulating joints, ligament to bone interface, tendon to bone and
muscle to tendon interfaces, which also require complexity in the associated scaffold design and
engineering approaches. [20, 21, 22, 23, 24].

From a structure-function perspective, the organs of the body are comprised of diverse tissue types
that interface with each other and operate in synchrony to enable complex functions.
Musculoskeletal tissue units, for instance, work at a very advanced level of synchrony, where all
the physiological movements of the body are systematically performed through very wellorganized actions of bone in conjunction with all the other musculoskeletal soft tissues, such as
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ligaments, tendons, muscles, and cartilage. These tissues are well intact and integrated with each
other through tissue-tissue junctions, or referred to as interfaces. These interfaces regions
demonstrate well defined, spatial change in cellular phenotype, extracellular matrix deposition, as
well as a change in mechanical properties (Figure 1.19) [25]. The gradual mechanical properties
presented at the interface has a number of functions, starting from mediating load transfer between
two distinct types of tissue to sustaining the heterotypic cellular communications required for
interface function and homeostasis [25]. Due to the structural and compositional complex
transition found at the tissue-to-tissue interfaces, the conventional surgical methods cannot
reestablish their function upon injury, leading to high rates of re-injury due to poor integration
between tissues at the reconstruction site [26]. For example, one of the clinically used approaches
in restoring the function of the damaged ligament after an ACL injury is by using the patellar
tendon (PT) approach. The patellar tendon is used to replace the damaged ACL and is fixed within
the bone tunnel with pins and screws. Despite the fact that this approach can result in good stability
to the knee joint, it does not correlate with the functional outcomes. Additionally, PT approach
results in long-term postoperative pain as well as movement restrictions to the patients, which
makes the advantages associated relatively low [27]. Similarly, some clinical methods followed in
repairing rotator cuff tears can be associated with a high possibility of postoperative failure, which
can be as high as 94% [28].

Understanding the mechanisms that derive the formation of complex tissues such as tissue-tissue
interfaces, has provided us with insights on what it is required for a regenerative tissue-tissue
interface to regenerate. These observations have provided invaluable clues for the design of
biomimetic scaffolds for engineering the complex tissue-to-tissue interface [29]. Ideally, the
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scaffold should be multi-phased to recapture the multi-tissue organization observed at the tissueto-tissue interface. The scaffold should also exhibit phase-specific structural, compositional,
material properties to stimulate cellular response such as proliferation and differentiation and with
a gradual increase in mechanical properties across the scaffold phases, similar to those found at
the native tissue in order to eliminate the formation of stress concertation. In addition, the scaffold
should introduce a spatial control over mineral distribution across the distinct phases, which can
control the mechanical heterogeneity at the interface. To better sustain the load transfer across the
scaffold, the scaffold should be pre-integrated. The scaffold should also exhibit phase-specific
surface properties to support the phase-specific relevant cell performance. Considering all these
parameters along with employing the advanced tools that the field of regenerative engineering has
provided us with will enable the creation of biomimetic scaffolds with location-speciﬁc
topographies and physicochemical cues that will guide cells towards the formation of different
tissue types. This, however, may hold the key towards the regeneration of intact multi-components
complex tissues simultaneously [18]. Therefore, the next horizon in the field of regenerative
engineering resides in how to enable the assembly of these single-tissues systems into multi-tissue
units or facilitate the integration of these composite tissue grafts in vivo [25]. Herein, we discuss
the most relevant complex tissue regeneration approaches, particularly musculoskeletal tissue
interfaces.
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Figure 1.19 Common orthopedic tissue-tissue interfaces. Ligaments, such as the anterior cruciate
ligament (ACL) in the knee (Modified Goldner’s Masson Trichrome),126 and tendons, such as the
supraspinatus tendon in the shoulder (Toluidine blue),70 connect to bone via a fibrocartilaginous (FC)
transition, which can be further subdivided into non-mineralized (NFC) and mineralized (MFC) regions
(Von Kossa). The muscle-tendon junction (Modified Goldner’s Masson Trichrome) consists of an
interdigitating band of connective tissue.60 Articular cartilage (AC), which can be subdivided into surface
(SZC), middle (MZC), and deep (DZC) zones (Modified Goldner’s Masson Trichrome), connects to
subchondral bone via a transitional calcified cartilage (CC) region (Von Kossa) [25].
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1.2.1. The Complex Bone-Ligament-Bone Junction Regeneration:
1.2.1.1.Ligament-Interface-Bone Junction Structure and Function
Ligament is a soft tissue that connects bone to bone through a characteristic fibrocartilage
interface, with controlled spatial change in cell phenotype, extracellular matrix deposition and
mechanical properties. Three distinct regions are found along the bone-ligament interface:
ligament, fibrocartilage, and bone. The fibrocartilage region is further divided intro mineralized
and nonminerlized fibrocartilage zones [29]. Where ligament is directly connected to the
nonminerlized region of fibrocartilage and the mineralized region is directly connected to bone
[36]. Within the ligament tissue, ligament fibroblasts are found entrapped in collagen type I and
III matrix [29]. At the insertion site, more specifically, the nonminerlized region, ovoid
chondrocytes are found entrapped in collagen II proteoglycan-rich matrix. Heterotrophic
chondrocytes are found in the mineralized fibrocartilage region, found entrapped in collagen type
X calcified matrix. Within the bony region, referred to as “subchondral”, osteoblasts, osteocytes
and osteoclasts are found embedded into a mineralized collagen type I matrix. This cellular
heterogeneity found along the bone-ligament insertion area is a key role in permitting the gradual
transition of mechanical loads between soft tissues and bone, which decreases the concentration
of stress formation [37, 38]. In addition, the complexity found along the bone-interface-ligament
presuppose a concomitant increase in the complexity of the associated tissue engineering
approaches or scaffold designs. However, a structurally, compositionally, and biomimicry scaffold
that support the heterogenic cellular interaction while promoting the regeneration of the distinct
tissues is indeed required to recapitulate the composite tissue structure across the ligament-bone
junction.
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1.2.1.2.Ligament-Interface-Bone Junction Tissue Regeneration Approaches
One of the initial steps that have been taken into consideration in order to address the drawbacks
associated with the traditional clinical approaches in repairing ligament injuries, specifically ACL
was adopted by Tien et al, when he attempts to improve ligament grafts to bone fixation by filling
calcium phosphate cement at the ligament-bone-ligament junction in rabbit ACL reconstruction,
which results in improved and organized bone growth at the junctions [39]. Huangfu et al, reported
a similar study where tricalsium phosphate cement (TCP) was injected at the interface region in a
canine ACL reconstruction model, which also results in improved and organized bone growth
comparing to the control group (uncemented) [40]. A different approach was adopted by
Mutsuzaki et al, when a tendon graft was soaked in different concentrations of calcium phosphate
as an ex vivo step prior to implantation in a rabbit ACL reconstruction model. The surface coated
graft was found to enhance healing and increase cellular integration at the junction site [41]. In a
different attempt, Rodeo et al, used a different technique to improve bone tunnel osteointegration
by incorporating Bone Morphogenetic Protien-2 (BMP-2) in collagen I sponge carrier, which was
placed at the edge of a tendon grafts that interact with the bone prior to implantation in a dog ACL
reconstruction model. BMP-2 incorporated collagen sponge carrier significantly increased
osteointegration at the boon tunnel after 2 weeks comparing to the control group (collagen sponge
only) [42]. Although these approaches have improved the outcomes of the ACL reconstruction
surgeries to a certain extent by promoting osteointegration to the bone tunnel, these approaches do
not lead to the regeneration of fibrocartilage interface due to the fact that these are single-phased
grafts, which do not mimic the complexity found at the native interface. This clearly demonstrate
the need for a biomimetic multi-phased stratified scaffold that mimics the complexity found in the
native tissue, which in turn can guide the regeneration of multi—tissue interface.
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There has been a serious shift towards forming multi-tissues as an attempt to form interfaces
between musculoskeletal tissues. Cooper et al. developed a multi-phased ACL graft system
composed of braided polylactide-co-glycolide (PLGA) microfibers at the center of the graft for
ligament formation, with two denser fiber regions at either end of the graft to facilitate bone
ingrowth [43]. In vitro evaluations demonstrated the high biocompatibility of the graft [44], in
addition, in vivo evaluations showed a great healing potential, when collagenous tissue infiltration
after 12 weeks has been observed [45]. In a similar approach, Altman et al. reported an
establishment to an appropriate highly pours ACL graft system that consisted of multi-regions,
silk yarns at the middle of the implant, which densely connects the knit regions at either end for
the bony integration. The graft system was evaluated in a got ACL reconstruction model, resulting
in the formation of collagenous like structure with cell alignment after 12 months [46]. To enhance
the osteointegration at the bone tunnel, and ligament regeneration, Kimura et al. evaluated a multiphased PLA-Collagen braided scaffold with basic fibroblast growth factor (FGF), which was
incorporated at the collagen hydrogel at either ends of the implant. In vivo evaluations revealed
that the scaffold design supported the formation of ligament and bone at the tunnel, in addition to
a significant improvement in tensile mechanical properties that was observed when compared to
the single-phased controls [47]. Paxton et al. investigated the use of a poly(ethylene glycol)
diacrylate (PEGDA) hydrogel incorporated with hydroxyapatite (HA) and the cell-adhesion
peptide RGD (Arg-Gly-Asp) as a material for creating an in vitro tissue interface to engineer intact
ligaments (i.e., bone-ligament-bone). Incorporating HA into PEG hydrogel decreased the swelling
rate associated with the hydrogel, but increased the stiffness of the hydrogel as well as mechanical
strength. In addition, HA incorporation increased the cellular growth capacity and most
importantly, interface formation. On the other hand, when RGD was incorporated into the
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hydrogel, it increased the swelling rate, but reduced the gel stiffness as well as mechanical strength.
The study revealed that incorporation of both HA and RGD into the hydrogel resulted in optimal
conditions for cell attachment, when compared to PEG alone [48]. Using a cell based approach,
Ma et al. reported that it is possible to form bone–ligament–bone constructs by introducing
engineered bone segments to ligament monolayers. This was achieved through co-culturing of
mesenchymal stem cells (MSC)-derived on a bone construct with a (MSC)-derived ligament
monolayer which was rolled between the two bony regions at the middle of the construct. In vivo
evaluation 2 months after implantation in an ovine model showed a complete graft integration to
the native bone along with presence of aligned, crimped, type 1 collagen, and elastin throughout
[49, 50].

These novel approaches and scaffold designs in attempting to form the bone-ligament multi-tissue
units clearly represent the advances over the single-phased unit designs. However, none of these
advanced approaches or scaffold designs touched upon the necessity of engaging the formation the
fibrocartilage interface between bone and ligament during the regeneration process of these two
tissues. The fibrocartilage interface is optimized to withstand the tensile and compressive loading
distributions at the ligament-bone interface, and thus, it plays a critical role in transitioning
mechanical load between soft tissues and bone, which as a result protects the soft tissues from
contact deformation and damage at high strains [51, 52 ,53, 54, 55]. The next challenge will be to
incorporate the fibrocartilage interface regeneration in the graft design, which is an essential step
in order to achieve physiological joint function after ligament reconstruction. This can be achieved
by considering the gradual transition in both mechanical properties and ECM morphology along
the ligament-interface-bone in the graft design. Spalazzi et al, reported a tri-phasic scaffold design
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that was hypothesized to reestablish the formation of the ligament-to-bone interface considering
the mechanical transition, transition in ECM morphology and relevant cell heterogeneity along the
complex tissues [56]. The tri-phasic scaffold consisted of three different pre-integrated continues
phases are each engineering for the regeneration of a specific tissue type, ligament, fibrocartilage
and bone. Phase A is made from polyglactin (10:90) knitted mesh to support ligament fibroblasts
culture for the regeneration of ligament, Phase B is made from PLGA (85:15) microspheres to
support fibrocondrocytes culture for the regeneration of fibrocartilage interface, and Phase C is
made from PLGA (85:15) sintered microspheres and 45S5 bioactive glass to support osteoblasts
culture for bone regeneration [57]. The three different phases were assembled and heat sintered to
pre-integrate them (Figure 1.20) [57]. Pre-integrating the scaffold to form multi-phased graft
system was essential in order to allow for cellular interaction and to support the multiple tissues
regions observed across the native ligament-interface-bone junction [58].

For ligament and bone formation, fibroblasts and osteoblasts were seed in phases A and C
respectively. Cellular interactions in the co-cultured tri-phasic scaffold have been evaluated both
in vitro and In vivo. In vitro cell interaction evaluations revealed that the controlled cell distribution
resulted in the formation of cell type-specific matrix on each phase of scaffold. In addition, Phase
C was found to be mineralized, and an extensive deposition of type I collagen was found in both
Phase A and B [57]. In vivo evolution of the co-culture revealed that the tri-phasic scaffold
supported multilineage cellular interactions as well as tissue Inﬁltration with abundant specificmatrix production in Phase A and C. In addition, cell migration from both phases to phase B was
observed with vascularity and matrix production [58].
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Figure 1.20 Scaffold design for ligament-interface-bone regeneration. Mimicking the stratified
structure (Modified Goldner’s Masson Trichrome) and composition (FTIR-I: Fourier Transform infrared
spectroscopy)89 of the native insertion, a tri-phasic scaffold (Phase A: PLGA mesh, Phase B: PLGA
microspheres, Phase C: PLGA-BG microspheres) was designed for ACL-bone interface
regeneration.110,111 This design allowed for spatial control over cell distribution (Fb: fibroblasts on Phase
A, Ob: osteoblasts on Phase C, along with chondrocytes in a hydrogel in Phase B) enabled the formation
of compositionally distinct yet structurally continuous tissue regions In vivo (Modified Goldner’s Masson
Trichrome) [57].

The tri-phasic scaffold system was further In vivo evaluated for the formation of fibrocartilagelike tissue at the interface region. This was done by tri-culturing the three different cell types,
fibroblasts, chondrocytes and osteoblasts respectively along the three different phases and compare
the findings to the co-culturing system. Specifically, fibroblasts were seeded on Phase A,
chondrocytes were seeded on phase B and osteoblasts were seeded on phase C, respectively. Triculturing the three different cell types resulted in an extensive collagen rich matric production at
the three different phases comparing to the co-culture system. In addition, formation of
fibrocartilage-like tissue at the interface rejoin containing type I and II collagen as well as
glycosaminoglycans was observed. Mechanical properties of the tri-phasic scaffold were evaluated
In vivo both after the co-culture and tri-culture experiments resulting in improved mechanical
gradient with the highest elastic modulus and yield strength at the bone phase, mimicking that at
the native ligament-interface-bone junction [57].
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These encouraging findings demonstrate that a biomimetic stratified mutli-phased scaffold system
that exhibits spatial control over the phase-relevant cell heterogeneity can lead to the regeneration
of complex tissues as well as a fibrocartilage-like interface In vivo, which highlighted the
possibilities in regenerating complex tissues on a single scaffold.

Building upon the previous observations, Subramony et al. developed a five-phased boneinterface-ligament-interface-bone caprolactone (PCL) nanofibers gradient scaffold for ACL
reconstructions [59]. To form a continuous five phases construct, mechanoactive collar were
applied at wither ends of the graft. MSCs were seeded in every junction along the graft and cultured
for both in vitro and In vivo evaluations. In vitro evaluations revealed that MSCs upregulated into
fibroblasts, fibrocondrocytes and osteoblasts specific markers on the ligament, interface and bone
phases, respectively. In vivo evaluation showed more tissue regeneration in the multi-phased graft
comparting to the single-phased graft. In another study, stem cells differentiation into fibroblasts
and osteoblasts was guided by introducing a gradient scaffold that consisted of a region of aligned
PCL fibers for ligament regeneration, contiguous with regions of unaligned PLGA nanofibers at
either ends for bone regeneration [60]. These findings suggest that the gradient multi-phased
scaffolds can be used to promote complex tissue regeneration for ACL reconstructions.

Moving forwards, by taking the mineral gradient distribution across the calcified fibrocartilage
interface into accounts. Different groups have utilized the concept of introducing a gradient of
minerals or chemical cues, such as growth factors, to induce the formation of graded calcified
matrix, mimicking that found in the native ligament-interface-bone junction. In a study that was
done by Samavedi et al. osteogenic differentiation of stem cells seeded on polymeric composition
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and mineral content graded coaxial electrospun PCL fibrous scaffold was guided in a gradientdependent manner [61, 62]. Another study that was done by Phillips et al, fibroblasts seeded on
collagen fabricated scaffold with a compositional gradient of retroviral coating for osteogenic
transcription factor (RUNX2) were induced to produce a gradient of mineralized matrix both in
vitro and In vivo [63].

Considering the scaffold physical properties such as cross-link density, pore size, stiffness and
material composition is a key element in guiding the cell behavior, especially musculoskeletal
cells. In a study by Oh et al. a scaffold with different pore size gradient was fabricated using PCL
for ACL reconstruction following a centrifugation method (Figure 1.21) [64]. The scaffold exhibits
different pore size gradients along the three rejoins, starting from 405 µm at the bony region, with
a gradual decrease to 186 µm at the end of the ligament region. Osteoblasts, chondrocytes and
fibroblasts were seeded in the three graft regions, respectively. Cell counting was performed along
the graft, and it was found that both osteoblasts and chondrocytes showed increased in cell number
at the regions with pore size 380-405 µm, while fibroblasts were more localized at areas with pore
size of 186-200 µm. These findings suggest that different pore sizes can strongly affect cell
behavior such as proliferation and cell fate. Thus, providing the appropriate gradient in pore size,
may act as a useful tool that can guide cell differentiation and proliferation during complex tissue
regeneration [64].
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Figure 1.21. (Top) Schematic diagram showing the fabrication process of a pore size gradient in PCL
scaffolds by a centrifugation method and (bottom) SEM photographs of the top surfaces of the PCL scaffold
sections along the longitudinal direction (× 100; *, average pore size) [64]

These results demonstrate the high potential of tissue engineering interfaces by utilizing gradient
multi-phased scaffold. Gradient scaffolds exhibit continuity in the structure, which in turns can
lead to improved gradual, continuous mechanical transition, cellular interactions, and gradient in
mineralization across the ligament-interface-bone junction. The physical and chemical gradual
transitions demonstrated in the gradient scaffold can stimulate stem cells to differentiate [64]. For
example, it was shown that the fate of MSC is highly sensitive to the matrix physical properties,
and they can differentiate into muscle, fibroblasts, or bone simply by changing the stiffness of the
substrate [67]. In addition, pore size gradual distribution has been shown to have a large effect on
guiding cell differentiation and proliferation during complex tissue regeneration [64]. Gradient
scaffolds are challenging to fabricate, due to the gradual transition in properties found along the
82

single scaffold, which may limit gradation in fabrication from the nano-scale to the micro-scale
found in the native ligament-bone junction respectively. Although both stratified and gradient
scaffold designs seemed to overcome most drawbacks associated with complex ligamentinterface-bone regeneration, it is strenuous to conclude which strategy is best for this application.
Further studies are needed that systematical investigate and compare between stratified and
gradient scaffolds in order to determine whether both or either once is optimal for complex tissue
regeneration.

In summary, different approaches towards complex tissue regeneration have been attempted
seeking to recapitulate the graded structural, mechanical, and biochemical properties of native
interface tissue. Growth factors as well as biochemical and biomechanical stimulation can be
incorporated into the scaffold design to promote the maintenance of heterotypic cell populations
relevant to tissue interfaces.

1.2.2. The Complex Muscle-Interface-Tendon and Tendon-Interface-Bone Junctions
Regeneration:
1.2.2.1.Muscle-Interface-Tendon Junction Structure and Function.
Tendon is a highly organized connective tissue that connects muscles to bone through a
characteristic fibrocartilage interface at either end, which plays an important role in gradually
transmitting force between muscle and bone [68]. Three specialized rejoins are characterized along
the muscle-tendon-bone junction, which are, the myotendinous junction (MTJ), the tendon proper
with the region where tendons change direction by wrapping around bony pulleys, and the bone–
tendon junction (BTJ), (Figure 1.22) [69]. The MTJ is divided into muscle and tendon rejoins
83

overlapping through an interface in between. At the muscle rejoin, myoblasts found, which are
entrapped in collagen type IV. At the interface, muscle and tendon meet, creating a network of
overlapping muscles and tendon tissues with a greater surface area for adhesion between them. At
the tendon tissue, tendon fibroblasts are found entrapped in collagen type I matrix [70].

Further, four separate ultrastructural domains are found in the MTJ connecting the actin filaments
of the terminal sarcomere with the collagen fibers of the tendon. (1) ‘the internal lamina’,
composed of actin filaments and associated crosslinking structures; (2) ‘the connecting domain’,
which connects the internal lamina to the external lamina; (3) ‘the lamina densa of the external
lamina’, with a structure similar to other laminae densa; and (4) ‘the matrix’, found in the space
between lamina densa and the collagen fibers [97].

1.2.2.2.Tendon-Interface-Bone Junction Structure and Function.
Tendon is found transitioning into bone through a fibrocartilage interface at the BTJ. This
fibrocartilage region is further divided intro mineralized and nonminerlized fibrocartilage zones
[29]. At the nonmenrlized fibrocartilage ovoid chondrocytes are found entrapped in collagen II
proteoglycan-rich matrix. Heterotrophic chondrocytes are found in the mineralized fibrocartilage
region, found entrapped in collagen type X calcified matrix. The bony region, referred to as
“subchondral”, osteoblasts, osteocytes and osteoclasts are found embedded into a mineralized
collagen type I matrix. From a mechanical point of view, nonminerlized and mineralized
fibrocartilage rejoins are half as stiff as the tendon, while bone is two orders in magnitude stiffer
than tendon. Under applied compression, a gradual decrease at the interface site takes place
progressing from the nonminerized to mineralized fibrocartilage rejoins and then to the bone
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rejoin, resulting in an increase in Young modulus at the interface site. This mechanical synchrony
presented at the tendon-interface-bone junction minimize the formation high stress concentration
and support gradual load transfer from soft to hard tissues. However, an intense load transfer
between tendon and bone can lead to increase in stress concentrations, which as a result would
increase the risk of failure at the interfaces. Thus, the cellular heterogeneity found along the
muscle-tendon-bone junction is a key role in permitting gradual transition of mechanical load
between muscle and bone, which decreased the concentration of stress formation at the insertion
site [37, 38].

Figure 1.22 Picture depicting tendon structure and the junctions at muscle and bone [69].

Similar to the bone-ligament-bone, complexity is also found in the muscle-tendon-bone junction,
which presuppose a concomitant increase in the complexity of the associated tissue engineering
approach or scaffold design. Currently, scientific literature on tendon tissue engineering (TTE)
shows that much work has focused on engineering the tendon proper; however, the structural
complexity of the bone– tendon (BTJ) and muscle– tendon (MTJ) makes their reproduction for
tissue engineering applications very difficult. Relatively few studies have investigated the
characteristics of these regions from a tissue engineering point of view. In this section, BTJ and
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MTJ tissue engineering will be reviewed, giving indications about the most promising approaches
in this field.

1.2.2.3.Current Clinical Treatment for Tendon-Interface-Bone Junction Injuries
Rotator cuff tears is considered as one of the most common tendon injuries that an immediate
require medical interveinal upon injury due to the poor self-healing potential. However, distinct
from treatment strategies followed for ligament restoration, which mainly fuscous on the
restoration of the ligament, tendon injuries are clinically managed by reattaching the tendon to
bone via mechanical means. However, restoration of the native tendon-bone function is
challenging and tendon post-operative detachment remains a primary reason for surgical failure.
Although tendon-based grafts can to certain extents restore the physiological range of motion and
joint function through the mechanical fixation methods, they do not result in adequate graft
integration, which in turns result in the formation of a scare tissue at the insertion site that lacks
all biological and mechanical functions of the native fibrocartilage tissue.

1.2.2.4.Tendon-Interface-Bone Junction Tissue Regeneration Approaches
In order to address this challenge, the feasibility of integrating tendon graft to bone has been
evaluated by several groups. Fujioka et al. reported that cellular reorganization has been observed
at the reattachment site, along with the formation of non-mineralized and mineralized
fibrocartilage-like regions by surgically reattaching the Achilles tendon to its original attachment
site [71]. Inoue et al. also reported that a supraspinatus tendon integration was successfully
promoted with a metallic implant using a bone marrow-infused bone graft [72]. In an attempt to
improve tendon fixation to bone, Chang et al, revealed that by surgically separating periosteum
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tissue or demineralized bone matrix found between the native insertion and bone, osteointegration
and the development of fibrocartilage-like matrix can be facilitated with improvement in
mechanical function [73, 74]. This has been further examined by Kyung et al. when the periosteum
was found to improve the integration of the tendon at the bone tunnel [96]. In this study,
histological evaluation showed extensive bone growth around the tendon at the bone tunnel in the
periosteum-wrapped limb than in the control limb. Kyung et al. concluded that the periosteum is
able to generate all types of connective tissue and has osteogenic capacity that can support bone
formation. These promising results suggest that osteointegration can be facilitated with the
formation of fibrocartilage-like tissue and emphasize the need for functional grafting solutions that
can promote biological fixation and true regeneration of the three distinct tissues along tendoninterface-bone junction.

Nanofibers scaffold is considered as a promising strategy that has recently been explored for
tendon and tendon-bone interface tissue engineering applications [77]. The biomimicry potential
of these fibrous nanofibers scaffolds makes them ideal for orthopedic tissue engineering. Porosity,
permeability and fibers diameter as well as morphology can be easily modulated during fabrication
process to resemble the native tendon ECM [78]. In addition, both randomly aligned and aligned
nanofibers scaffold can be easily achieved during fabrication and used to guide cellular response.
Moreover, structure, mineral as well as protein/growth factors content continuous gradation can
be achieved on nanofibers substrates using a variety of approaches. It is anticipated that gradient
nanofibers graft will enable integrative and functional repair of tendon-bone injuries due to the
relatively close biomimicry to the native tissue.
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Recently, degradable PLGA nanofibers-based scaffold has been in vitro evaluated for rotator cuff
repair by Moffat et al. [79]. The effect of fibroblasts attachment, alignment, and gene expression
has been tested as a function of nanofibers organization (aligned vs randomly aligned). It was
found that underlying orientation primarily guided tendon fibroblasts morphology, alignment and
gene expression. In addition, it was found that the deposition of collagen types I and III as well as
mechanical properties were directly related to the underlying nanofibers orientation. These
findings indicate that nanofibers organization play a crucial role in guiding cell response, which
clearly highlight biomimetic potential of nanofibers to the tendon native tissue.

Building upon these successful based-nanofibers observations, and taking into accounts the
formation of fibrocartilage tendon-bone interface, Moffat et al. also reported the development of a
biomimetic biphasic electrospun nanofibers scaffold with contiguous nonmineralized (Phase A)
and mineralized (Phase B) regions that are designed to facilitate the regeneration of the tendonbone insertion. Phase A, however, is composed of aligned PLGA nanofibers, and Phase B consists
of aligned PLGA-HA composite nanofibers (Figure 1.23). In vivo evaluations in rat [75] and sheep
[76] rotator cuff models revealed the formation of fibrocartilage-like matrix at the insertion site of
the graft. In addition, it was observed that minerlization distributions was highly maintained, in
which calcified fibrocartilage formed only at the HA-containing phase. Further, fibrocartilage
matrix maturation and enhanced collagen organization at the tendon-bone junction was promoted
by pre-seeding the biphasic scaffold with bone marrow-derived cells. When comparing the
findings with the single-phased PLGA or PLGA-HA, it was found that the regeneration of an
organized fibrocartilage interface was not achieved. These observations indicate that
biomimicking the alignment and mineral distribution found in the native tendon-bone insertion
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play a crucial role in guiding cells to form a fibrocartilage-like matrix at the insertion site with
promoting its integration to the tendon, and supporting calcified fibrocartilage formation and
osteointegration.

Moving forwards, by taking the mineral gradient distribution across the calcified fibrocartilage
interface into accounts to enhance fibrocartilage formation, different groups have utilized the
concept of introducing a gradation in minerals and protein content, to induce the formation of
graded calcified matrix, mimicking that found in the native tendon-interface-bone junction. Li et
al. demonstrated a coating-based method to generate a linear gradation of calcium phosphate on a
nonwoven mat of a polymeric electrospun nanofibers by varying the incubation time of the
scaffolds in a concentrated simulated body fluid (SBF). The gradation in mineral distribution
resulted in gradation in mechanical properties along the tendon-interface-bone junction [80]. To
further improve the mechanical properties, the soaking solution has been optimized by increasing
the concentration of bicarbonate ions, which resulted in an increase in mineral content that has
improved mechanical properties along the tendon-interface-bone junction [81]. In order to evaluate
the ability of the pre-coated scaffold to induce graded osteogenesis, adipose-derived MSCs were
seeded along the scaffold resulting in more extensive staining of osteogenic markers that was
observed on areas with higher mineral content [82]. In a similar approach, another group has
evaluated the effect of fibronectin protein gradation on a polymeric electrospun nanofibers scaffold
for the formation of fibrocartilage interface, which found to exhibit control over density and
morphology of cultured fibroblasts [83]. These findings indicate that gradation in mineral or/and
protein content along the tendon-interface-bone graft may result in spatial control over
osteogenesis and may promote the formation of fibrocartilage interface.
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In a separate study, both BMP-2 and IGF-I were used by absorbing different concentrations of
BMP-2 and IGF-I along the tendon-bone silk construct. This was achieved by increasing BMP-2
content from the center of the scaffold towards the direction of the bone, while simultaneously
decreasing IGF-I content in a gradation fashion, where the highest BMP-2 and IGF-I content were
added at the boney and the interface rejoins respectively. Culturing MSCs on the growth factors
graded substrate in a subchondral medium resulted in graded increases in calcium and GAG
deposition and increases in collagen type I, II, and X gene transcription at the bony and interface
rejoins respectively. Further results revealed that the gradations achieved closely resembled the
transition from unmineralized fibrocartilage to mineralized fibrocartilage to bone, similarity
resembling those found at the native tissue.

Figure 1.23 Scaffold design for tendon-interface-bone regeneration. A biphasic scaffold comprised of
layered aligned PLGA and PLGA-HA nanofibers was fabricated by electrospinning, which led to phase-
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specific mineral deposition in vivo (Von Kossa, subcutaneous athymic rat model). The bilayer scaffold was
subsequently tested in a rat rotator cuff repair model, disorganized scar tissue was observed in the singlephased controls (PLGA, PLGA-HA only). Interestingly, tendon-bone integration via an organized bilayer
fibrocartilage interface was only observed with the biphasic design (Picrosirius red, Alcian blue) [75].

To evaluate the potential of dual growth factors delivery in restoring the native tendon-interfacebone junction In vivo, a study by Lee et al. estimated the feasibility of the gradually immobilizing
both PDGF-BB and BMP-2 in an asymmetrically porous PCL membrane as a potential strategy
for effective regeneration of tendon-interface-bone junction. Both growth factors were
immobilized using “heparin-intermediated interactions”, which resulted in a minimal burst release
in addition to a sustained and controlled release with up to 80% of the total content has been
released after 5 weeks. In vivo evaluation in rat patellar tendon avulsion model revealed that both
PDGF-BB/BMP-2 dual release from the PCL membrane accelerated the regeneration of tendoninterface-bone respectively due to the continuous release of both factors [89]. These results
demonstrate the feasibility and the potential of gradual immobilization for dual growth factor
delivery from tendon-interface-bone grafts for the regeneration and the restoration of these
complex tissues.

1.2.2.5.Current Clinical Treatment for Muscle-Interface-Tendon Junction Injuries
Muscle-tendon interface is another critical research area in addition to tendon-bone interface, for
integrative tendon repair. As tendon connects muscle to bone, the MTJ, which connects muscle to
tendon acts as a bridge to distribute mechanical load between muscles and bones [91]. However,
any injury at the muscle-tendon junction will result in failure in mechanical load distribution. This
will result in movement restrictions and low quality of life to the injured individual due to the
extreme pain associated with the injury [91]. Current clinical treatments include conservation or
surgical. In conservation treatment, the patient is normally asked to rest to relief the pain, or is
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given injections of a variety of drugs, including corticosteroids and physiotherapy. However, due
to the limited self-healing capacity of tendons, these types of treatments can result in prolonged
treatments times, recurrent injure, weakness in the affected site, and thus partial loss of function,
which can require extensive and intensive future rehabilitation [236, 237].

Surgical intervention includes the use of autografts and allograft to treat tendons injuries. However,
the high price demand, pain and the donor site morbidity associated with harvesting autograft, as
well as the limited availability and poor biocompatibility of allografts, in addition to the poor
integration of these grafts with the surrounding tissues, are some of the drawbacks associated with
the use of autografts and allografts [238].

Alternatively, the ability of cells to sense the mechanical signals can be used as another treatment
option, which is referred to as Mechanotransduction. In this treatment, mechanical stimuli are
applied at the injured site guiding cells to convert the mechanical stimuli into biochemical signals
that can be used to aid the healing process [239]. However, many factors can either positively or
negatively affect the overall outcome of tendon healing such as the duration, frequency, magnitude
and type of mechanical stimulation applied to a tendon [240]. Therefore, the specific parameters
of the Mechanotransduction treatment necessary to improve or accelerate the healing process
without causing any damage to the tendon remains unclear [241]. Limitation associated with the
current clinical treatment clearly highlight the need for more functional and integrative methods
that mostly focus on effectively regenerating these tissues rather than repairing them
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1.2.2.6.Muscle-Interface-Tendon Junction Tissue Regeneration Approaches
Tissue engineering approaches for muscle-tendon interface repair may include the use of scaffoldsbased techniques or may be associated with scaffoldless fabrication methods. Scaffold-based
approaches include the use of composite, stratified and gradient scaffolds, in which the native
tissue can effectively be stimulated and mimicked. On the other hand, scaffoldless approaches
largely rely on the concept of cellular self-assembly or self-organization for tissue formation or
repair without the use of an exogenous substrate [90]. To date, relatively very few studies have
explored the feasibility to muscle-tendon interface regeneration comparing to the tendon-bone
interface. This may be due to the fact that the majority of tendon injuries occur in either the tendon
proper or the tendon-bone insertion, which limits the number of trails in this area. In addition, it
has been reported that no single biological scaffold has been ideal for muscle and tendon
regeneration, which marks them as inappropriate for developing a functional tissue engineered
muscle-tendon interface [94]. However, limitations associated with the clinically applied methods
for the treatment of muscle-tendon interface injuries have established an unmet clinical need for
the development of new strategies to restore the function of the native muscle-interface-tendon
junction.

An ideal scaffold design for muscle-tendon interface repair should mimic every single aspect in
the native tissue for successful restoration of the muscle-tendon-bone junction. The engineered
scaffold should consist of distinct multiple phases with different mechanical properties with the
ability to withstand mechanical loads values near that undergone by the native tissue junction. In
addition, the scaffold should structurally and compositionally mimic the native muscle-interfacetendon junction.
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The first successful fabrication of multiphasic muscle-tendon graft with functional MTJ was
adopted by Larkin et al. from a heterogeneous muscle “sarcolemma” and tendon “fibroblasts”
isolations, a scaffoldless substrate has been fabricated by co-culturing both cell types. Specifically,
cylindrical scaffoldless multiphasic tissue construct was created with robust interfaces. The
contractile and structural characteristics of the muscle constructs co-cultured with (1) engineered
self-organized tendon constructs, or (2) segments of adult or (3) fetal rat-tail tendon have been
evaluated in vitro. In addition, the construct diameter (l m) and maximum isometric force (microN)
were measured, and specific force (kPa) was determined. In vitro evaluations revealed that the
neo-interface region exhibited upregulated expression of muscle-tendon junction-specific paxillin
(Figure 1.24), and was able to maintain tensile loading at super-physiologic strain rates [92].
However, when extended to the point of rupture, they failed at the mid substance of the engineered
muscle, with the muscle-tendon interface intact. When implanted In vivo, it resulted in complete
maturation and integration to the native tissue [93]. This, however, resulted in increased in force
production, which in turns strengthened the MTJ. This successful initial step towards the
regeneration of the muscle-interface-tendon junction clearly outlines the feasibility of the
engineering MTJ.
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Figure 1.24 Immunostaining for paxillin indicating its upregulation at the MTJ of a scaffoldless muscle
construct created by co-culturing a heterogeneous muscle “sarcolemma” and tendon “fibroblasts”
isolations [92].

Larkin et al. has further investigated another possibility of restoring the MTJ by developing an in
vitro model of three-dimensional (3-D) skeletal muscle-tendon constructs to address mechanisms
of the MTJs development. In this study, it was hypothesized that engineered in vitro 3-D skeletal
muscle-tendon constructs would develop MTJs ultrastructurally resembling those found during
fetal development In vivo [100]. MTJs structures In vivo has been compared to those developed in
3-D skeletal muscle constructs co-cultured with engineered self-organized tendon constructs
(SOT), or segments of adult (ART) or fetal rat tail (FRT) by means of electron microscopy. In
vitro evaluations revealed that some of the myofibers of the engineered 3-D skeletal muscle-FRT
and -SOT constructs only displayed emerging finger-like sarcolemma projections surrounded by
collagen fibers, which structurally resemble fetal MTJs In vivo. In addition, a complete muscleinterface-tendon junction was developed on the muscle-FRT constructs. These findings suggest
that the muscle-FRT constructs model could be used for studies of developmental mechanisms
involved in the establishment of interfaces among all four muscular-skeletal tissues: muscle,
tendon and cartilage/bone.

Recently, Ladd et al. developed a tri-phasic PC-collagen and PLA-collagen co-electrospun
nanofibers scaffold onto opposite ends of a mandrel to create a scaffold with three regions for
engineering muscle-interface-tendon junction [95]. In vitro evaluation demonstrated that the
scaffold exhibited regional variations in mechanical properties with moduli from 4.49027.62 MPa, similar to the native muscle-tendon junction and generally withstood cyclic testing. In
addition, further results revealed that the scaffold facilitated both myoblasts and fibroblasts
attachment at the relevant-cell rejoins.
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To this end, different approaches has been demonstrated for the regeneration of the complex
muscle-interface-tendon and tendon-interface-bone junctions starting by using biological grafts to
the use of gradient scaffolds that exhibited continuity in the structure, which in turns led to
improved gradual, continuous mechanical transition, cellular interactions, and gradient in
mineralization across the muscle-tendon-bone junction in addition to supporting the formation of
fibrocartilage interface. Muscle-tendon interface regeneration is a critical research area for
integrative tendon repair that has not been explored enough yet. Further studies in this area are
indeed required in order to overcome many limitations associated with muscle-tendon
regeneration.

In summary, the aforementioned studies demonstrate the promise of the complex gradient scaffold
system for tendon- to-bone interface tissue engineering as well as the potential of utilizing cellular
interaction for engineering both tendon to-bone and muscle-to-tendon interface and ultimately,
functional and integrative tendon repair.

1.2.3. The Complex Cartilage-Interface-Bone Regeneration:
1.2.3.1.Cartilage-Interface-Bone Junction Complex Structure
1.2.3.1.1. Cartilage Zones Structure and Function
Osteochondral (OC) is a uniquely structured tissue that is comprised of articular cartilage, the
subchondral bone and the central cartilage-bone interface (Figure 1.25) [102]. This unique
hierarchical structure plays an important role in maintaining the tissue homeostasis as well as
providing the synchrony in physiological movement. The articular cartilage is further divided into
three distinguishable well-organized articular cartilage zones from top to bottom [103]. The first
top is the superficial or tangential zone, which occupies 10-20% of the articular cartilage [124].
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The next is the middle zone, which occupies the following 40-60% of the articular cartilage, and
the remaining thickness is occupied by the deep zone and the calcified cartilage which is believed
to be 30% of the total articular cartilage thickness.

Cells within the superficial zone or “articulating surface” are known to secrete special types of
proteins that facilitate the wear and frictional properties of the tissue during movement [106]. The
middle zone, the largest zone, has the most abundant content of proteoglycans (GAC) with the
least number of cells. This zone is known for its arch shaped, and obliquely oriented collagen
fibrils, which inherits its high compressive modulus that allows recovery from impacts undergone
by the articular surface [107, 125]. In the deep zone, where the fibrils are anchored in the
underlying subchondral bone, cells and the collagen fibrils are oriented perpendicularly to the
articular cartilage’s surface [108]. This zone is known for its high compressive modulus, less
proteoglycans content comparing to the middle zone, and less cellular content comparing to the
previous two zones [109]. However, the GAC nature of the two last layers enables the extracellular
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Figure 1.25 Osteochondral tissue structure. Cross section of the long bone and its zonal cartilage
including (A) articular surface, (B) the superficial zone, (C) the middle zone, (D) the deep zone (E)
tidemark (the interface), (F) calcified cartilage, (G) subchondral bone, and (H) trabecular bone [102].

matrix to withstand high compressive forces. At the bottom of the deep zone, a thin layer known
as “tidemark”, marks the interface between the last calcified cartilage zone to the subchondral
bone. This layer is known to minimize the stiffness gradient between the cartilage and subchondral
bone. The cell content and the collagen fibrils are very minimal in this last layer [110].

The articular cartilage is a rich collagen tissue that is mainly composed of collagen type II,
however, other collagen types V, VI, IX, and XI are also present throughout the zonal cartilage,
which play a role in the intermolecular interactions and the modulation of type II collagen [104].
In addition, type X collagen is known to assist in the mineralization between the cartilage and
underlying bone [105].

1.2.3.1.2. Subchondral Bone Structure and Function:
The subchondral bone is the last components of the osteochondral tissue, which is located just
below the interface between the zonal cartilage and the subchondral bone. It is composed two bony
zones, lamella and trabeculae. The lamella however, contains a large mass of bone with thicknesses
variations between 0.2 – 0.4 mm in humans [111]. The trabecular of the subchondral bone supplies
both the lamella and the adjacent articular cartilage with nutrition due to the high vasculature
nature [112]. However, the three main functions of the subchondral bone are absorption,
maintaining joint shape as well as providing the strength to the adjacent articular cartilage due to
its large area and low modulus of elasticity [113].
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1.2.3.2.Osteochondral Defect:
Articular cartilage is a connective tissue that acts as a shock absorber and facilitates joint’s motion
in low friction [101]. Like any other tissue, the articular cartilage is prone to lesions for many
reasons, such as traumatic events, chronic repetitive microtrauma, and aging [114]. Distinct from
bone, the avascular nature of articular cartilage makes it irreparable due to the consequent lack of
supplementation of potentially reparative cells/bioactive factors, which makes the possibility of
the cartilage to self-regenerate below minimal [115]. Thus, as the cartilage lesion progresses, it
extends to the underlying subchondral bone and the osteochondral defect (OCD) appears. Not only
diseases orienting from cartilage will result in OCD, in fact, other disease originating from the
subchondral bone can also induce OCD when reached the cartilage layer, such as osteochondritis
dissecans and osteonecrosis [116].
As a result of the OCD, the formation of fibrocartilage tissue at the defect site takes place, which
only provides very poor protection to the subchondral bone [117] However, the continuous
movement of the individual can cause a subsequent degradation to the formed fibrocartilage tissue
following by degradation to the adjacent tissues as well, resulting in impaired joint mobility, severe
pain, and low quality of life, which necessitate the clinical intervention [118, 119].
1.2.3.3.Current Clinical Treatment for Osteochondral Defects
Current clinical treatments to OCD are limited by arthroscopic debridement, bone marrow
stimulation techniques, the use of osteochondral allografts, autologous chondrocyte implantation
(ACI), or matrix-assisted chondrocyte implantation (MACI) [120, 221]. while debridement and
marrow stimulation techniques have shown same positive results in treating OCD, these techniques
are palliative, but not curative and has no significant benefits for larger OCD [121]. In addition,
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the poor biocompatibility and integration of allografts to the host tissues led to the necessity of
finding alternative therapies that mostly focus on regenerating the damaged tissues rather than
repairing or replacing the tissues.
ACI and MACI are two clinical reparative techniques that to a certain extent have overcome most
of the drawbacks associated with the discussed conventional clinical treatments. However, ACI
generally involve an arthroscopic evaluation of the defect site, following by a biopsy collection
from the same patient. The biopsy is then used to isolate autologous chondrocytes, expand them
in culture and finally seed them back onto the affected area [223]. A similar approach is followed
for the MACI with a slight difference, where the chondrocytes are first seeded on a biodegradable
matrix and then implanted at the affected area [223]. Although these two approaches are
considered the gold standard among all the alternative clinical treatments in the modern medicine,
limitations are still presented which include; the creation of a seconder OCD during the biopsy,
the multiple number of surgeries required, the relatively long recovery time as well as the slow
regeneration of the defect [224].
The aforementioned clinical treatments are more focused on either palliating the pain associated
with the OCD or repairing the damaged cartilage only. It was shown in many reports that without
the support from the subchondral bone, any treatment to reestablish the cartilage layer is likely to
fail [122]. Thus, the cartilage and subchondral bone should be taken into account as one unit during
OC regeneration, instead of being considered separately. This comes after the fact that both the
zonal cartilage and the subchondral bone are tightly connected, and no matter where the disease is
orienting from, the connected tissue will always be affected, which will result in the negative
contributions to the mechanical homeostasis of the whole joint [123].

100

In another word, OCD leads to the degeneration in bone, cartilage and the bone–cartilage interface.
However, in order for OCD defect repair to be possible it is essential that each of these components
be taken into account as one complex synchronized unit during OC regeneration, instead of being
considered separately, as the main goal for OC regeneration is to restore its biomechanical
properties, besides the regeneration of the defect.

This end, Complexity associated with the unique structure of Osteochondral tissue requires the
development of a complex multi-phased biomimetic matrix that not only support regeneration of
the zonal structure but also helps to establish a proper cartilage-bone interface.

1.2.3.4.Cartilage-Interface-Bone Tissue Regeneration Approaches:
One of the very early tissue engineering attempts to regenerate an osteochondral defect was
adopted by Chu et al. In this study, commercially available PLLA cubes were used to fabricate a
single-phased osteochondral scaffold. Peri-chondrocytes were derived from the cartilage of New
Zealand white rabbits and used to pre-seed the scaffolds prior to in vitro and In vivo evaluations
[225]. Both in vitro and In vivo evaluations showed an extensive production of collagen type I as
high as 81 ± 4 %, with very minimal production of collagen type II. Although the single-phased
scaffold did not show evidence for sufficient production of collagen type II, it supported the
proliferation, attachment and survival of the pre-seeded peri-chondrocytes cells.

In a different attempt, Malda et al. evaluated the effect of the scaffold’s fabrication techniques on
the osteochondral regeneration based on the hypothesis that the scaffold design can highly affect
the regeneration of the osteochondral tissue [226]. In this study, two different fabrications
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techniques, compression molding, and 3D fiber deposition were used in order to fabricate a singlephased scaffold using the biodegradable poly(ethylene glycol) terephthalate/poly(butylene
terephthalate) (PEGT/PBT). Pore size analysis revealed that there was a significant pore size
variation between the two scaffold designs, where the compression molding scaffolds had an
average pore size of 182 𝜇m, while the 3D fiber deposition scaffolds had an average pore size of
525 𝜇m. To further validate the hypothesis, both scaffolds were pre-seeded with chondrocytes and
in vitro and In vivo evaluations were conducted. In vitro evaluations showed a slight increase in
the DNA content of the compression scaffold after 3 days of culture in comparison with the other
scaffold, but no difference was noticed after 14 days.

In vitro GAC production was also

determined resulting in no difference between the scaffolds at all-time points. In vivo evaluations
in a nude mice subcutaneous model showed that there was an increase in the GAC production in
the 3D fiber deposition scaffolds in comparison with the compression scaffold along with a better
mechanical integrity. This study suggests that porosity as well as the scaffold architecture may
play a crucial key role in the osteochondral tissue regeneration.

Following a different approach, Coburn et al. developed a single-phased poly(vinyl alcohol)methacrylate and chondroitin sulfatemethacrylate low density electrospun nanofibers scaffold that
was used to aid chondrogenesis of goat MSCs in vitro [227]. In vitro results showed that the
scaffold exhibited an elastic-like mechanical properties similar to that found in the hyaline
cartilage. In addition, further tests showed an increase in cell proliferation and an extensive
accumulation of GAC and lacunae formation. To evaluate the in vitro production of both collagen
types I and II, Immunohistochemical assay was conducted resulting an increase in collagen type
II production, with no evidence of collagen type I production. This indicated that the addition of
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chondroitin sulfatemethacrylate facilitated the production of collagen type II and had no effects on
collagen type I production. In vivo evolutions for the scaffold in a rat osteochondral model revealed
that the nanofiber scaffold defect had a higher proteoglycan deposition than the empty defects but
less proteoglycan deposition than normal articular cartilage. Similar to the in vitro study, collagen
type II was observed with no evidence to collagen type I in the nanofiber scaffold. Results from
this study demonstrate the potential of chondroitin sulfatemethacrylate in supporting cartilage
regeneration, in addition to the potential of nanofibers matric to serve as suitable scaffold for
cartilage regeneration for osteochondral defect applications.

Although these observations suggest that the single-phased scaffolds may support the proliferation,
attachments of both bone and cartilage cells as well as the production of collagen type II and GAC
In vivo, they do not mimic the complexity found at the native osteochondral tissue. This clearly
demonstrates the need for a biomimetic multi-phased scaffold that mimics the complexity found
in the native tissue, which in turn can guide the regeneration of multi—tissue interface.

Based on these findings from the single-phased scaffolds, there has been a serious shift towards
the production of bi-phasic and multiphasic scaffolds to facilitate the regeneration of the different
components found in the native osteochondral tissue including the interface. Getgood et al.
developed two bi-phasic scaffolds to evaluate their performance at healing medial femoral condyle
and lateral trochlear sulcus osteochondral defects in a caprine model [228]. The first scaffold was
composed of collagen–GAG phosphate, while the second scaffold composed of PLGA/PGA. Both
scaffolds were implanted on the defects made either in the medial femoral condyle or the lateral
trochlear sulcus. In vivo evolutions revealed that the collagen-GAC scaffold became stiffer and
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provided radical mechanical reinforcement after 12 weeks in comparison with the other scaffold.
After 26 weeks, defects treated with collagen-GAC had a significantly higher content of hyaline
cartilage in comparison with defects treated with PLGA/PGA scaffolds, 75% - 50% respectively.
In addition, the Stellar's histological score in the lateral trochlear sulcus was significantly higher
when treated with the collagen-GAC scaffold than PLGA/PGA scaffolds (Figure 1.26) [228].

Figure 1.26 In vivo repair. Photographs of an osteochondral defect site in the lateral trochlear sulcus (A)
immediately after and (B) 26 weeks after implantation of a collagen-GAG scaffold along with the (C)
H&E and (D) Safranin-O with fast green histological stains of the explants [228].

Another bi-phasic but stratified scaffold for osteochondral regeneration was devolved by Chen et
al. [229]. The upper layer of the scaffold for cartilage regeneration was made from collagen
sponge, while the lower layer for bone regeneration was made from PLGA 75:25 and naturally
derived collagen. To fabricate the porous PLGA-collagen base layer, a particulate-leaching
technique was used. Briefly the scaffold was immersed in a type I collagen solution following by
the addition of collagen acidic solution to one side of the scaffold until solidified. The
collagen/PLGA-collagen scaffold was pre-seeded with BMSCs and cultured for 1week in vitro as
an ex vivo step prior to an In vivo implantation in femoral condyle beagle model. Four months
after implantation, it was found that cartilage and a bone-like tissues were formed in the respective
layers. Additional In vivo data revealed that the implant well integrated with the surrounding host
tissues suggesting that collagen/PLGA-collagen bi-phasic scaffold is useful for osteochondral
tissue engineering.
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Growth factors have been also used along with scaffolds as a strategy for osteochondral tissue
engineering to enhance chondrocytes proliferation and to cue cells to form the specific tissues
found in the native OC. Huang et al. devolved a poly(L -lactic acid)/ amorphous calcium phosphate
(ACP/PLLA) hybrid scaffold incorporated with basic Fibroblasts Growth Factor (bFGF) for
osteochondral regeneration [230]. The scaffold was implanted in a femoral condyle osteochondral
defect in a rabbit model for 4 and 12 weeks. Untreated defects and PLLA scaffolds incorporated
with bFGF were used as controls. In vivo assessments revealed that the PLLA-bFGF treated defects
presented better defect regeneration when compared to the untreated group in all time points.
Although PLLA-bFGF group showed a good defect regeneration, only low amount of collagen
type II was observed with a completely negative expression to aggrecan. On the other hand,
ACP/PLLA treated defect was completely filled with well-established cartilage tissue and
cartilaginous ECM after 12 weeks. In addition, an extensive collagen type II production was
observed and high levels of aggrecan gene expression were detected.

Growth factors have been also incorporated in a gradient fashion to establish a scaffold for
osteochondral interface regeneration. Mohan et al. devolved a growth factor gradient scaffold that
consisted of TGF-B1 and BMP-2 in combination with PLGA microspheres for osteochondral
repair [231]. TGF-B1 was used to establish chondrogensis at the upper portion of the scaffold,
while BMP-2 was used to establish osteogenesis at the lower portion of the scaffold. Combining
both factors in a gradient fashion in a single scaffold was based on the hypothesis that the
combination of both factors can facilitated the formation of the zonal cartilage, subchondral bone
as well as the interface in between. However, the scaffold was composed of a chondrogenic layer
of TGF-B1-loaded PLGA microspheres, the osteogenic layer was composed of BMP-2 or BMP-
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2/HA-loaded PLGA microspheres with a gradient transition between both factors in the middle.
Blank PLGA scaffold or blank gradient PLGA and PLGA/HA scaffolds were used as controls.
Scaffold were implanted in a medial condyle osteochondral defect in a rabbit model for 6 and 12
weeks. It was observed that after 6 and 12 weeks, a great extent of cartilage and subchondral bone
similar to that found in the native tissue were achieved in the growth factors loaded groups
comparing to the controls based on the gross morphology, MRI and histological data. In addition,
TGF-B/BMP-2/HA-loaded PLGA microspheres group showed well edge integration with the host
bone comparing to all the other groups. These data suggest that incorporating both BMP-2 and HA
can facilitate better bone ingrowth and integration to the host bone. In addition, the results suggest
that TGF-B1 may also enhance cartilage regeneration and the combination between both factors
may facilitate the interface regeneration.

Integrating cell based approaches along with growth factors has been also considered in the
creation of an osteochondral repair scaffold. Various cell types have been used to aid in the
regeneration of osteochondral defect such as progenitor cells and tissue specific cells such as
chondrocytes for cartilage regeneration and osteoblasts for bone regeneration [232]. Due to the
very small number of chondrocytes found in the cartilage, as well as the difficulties associated
with maintaining their phenotype in culture, they may not be transitional [233]. In fact, the
thorough digestion required to the cartilage matrix by collagenase in order to isolate chondrocytes
may be harmful to the cells. Furthermore, chondrocytes lose their proliferation capabilities as well
as their capability to produce collagen type II and I as soon as the fourth passage is reached by
29,000 folds when compared to the freshly isolated chondrocytes [234].

Due to the

aforementioned limitations associated with chondrocytes isolation, maintenance and usage, many

106

researches shifted to the use of progenitor cells such as stem cells due to their source availability
in various body parts, rapid proliferation, and their potential to undergo chondrogenic and
osteogenic differentiation, which marks them as ultimately useful for osteochondral tissue
engineering [235].

Cell aggregation at the osteochondral defect has been shown to be crucial for extra cellular matric
synthesis and proteins production to support OC tissue regeneration [109]. In a study by et al, a
novel cell-based approach that mostly focused on supporting the aggregation of bone marrow
mesenchymal stem cells (rBMSC) for osteochondral regeneration has been devolved [109]. In this
study, Different densities of isolated rat rBMSC aggregates were encapsulated in fibrin hydrogel
and injected in a rat osteochondral defect model. Four experimental groups have been involved for
the In vivo study as follows, fibrin gel encapsulated with high density of rBMSC aggregates, low
of rBMSC aggregates, sham and fibrin hydrogel alone filling the defect. 8 weeks post implantation,
various post-vivo evolutions have been conducted in order to evaluate the tissue regeneration
including; gross morphology observations, H&E, Safranin O for GAGs, collagen I, II, and
aggrecan immunostaining. Gross morphology analysis showed that fibrin gel encapsulated with
high density of rBMSC aggregates demonstrated a complete repaired to the defect, with much
smoother texture surrounding the defect area and color similar to the native cartilage in comparison
with the other groups including the sham. Immunohistochemistry showed an extensive GAC and
collagen type II production with a moderate staining of Safranin O in the high-density aggregates
group comparing to the low density and fibrin alone. In addition, Collagen type I was evident in
all groups and stained deeper in the defect filled with high density aggregates. These recent
findings demonstrate the potential of employing cell-based approaches, more specifically, high
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cellular aggregates densities in facilitating osteochondral tissue regeneration. In this study, fibrin
gel encapsulated with high densities of cell aggregates facilitated deep bone formation and full
thickness cartilage formation, which suggest that it can be used as a candidate for osteochondral
tissue regeneration.

In summary, both stratified and gradient scaffolds in conjunction with growth alone or in
combination with cells have been suggested to be great candidate for cartilage-interface-bone
regeneration. Results from the literature highlighted the limitations towards osteochondral
regeneration as well as demonstrated all the possible strategist that can be applied in order to
facilitate OC regeneration. Further studies are indeed required in order to prove the capabilities of
stratified and gradient scaffold for osteochondral regeneration to accelerate clinical translation.

1.2.4. Cell-Cell Interaction to Form Interfaces in Ligament/Tendon-to-Bone Junctions.
It is well established that tendon-to-bone healing following an ACL reconstruction does not result
in adequate graft integration at the bone tunnel; rather it results in the formation of a fibrovascular
or fibrocartilaginous tissue that lacks all biological and mechanical functions of the native
fibrocartilage tissue [71]. The formation of a nonminerlized fibrovascular within the bone tunnel
results in a weak link at the grsaft-to0bone fixation site. However, developing a fibrocartilage zone
at the insertion side (outside the bone tunnel) will physiologically be more relevant to promote
biological fixation.

The formation of fibrocartilage zone upon attaching tendon directly to bone in some cases led to
the hypothesis that the interactions between cells derived from tendon (e.g., fibroblasts) and bone
(e.g., osteoblasts) play a crucial role in the regeneration of the fibrocartilage interface at the
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insertion site [98]. The previously discussed study adopted by Fujioka et al. [71] revealed that
cellular organization at the native insertion site was observed over time after an Achilles tendon
has been sutured to the original attachment site. This study demonstrated the feasibility to
fibroblasts-to-osteoblasts interactions at the insertion site which may result in the formation of
fibrocartilage matrix similar to that found at the native tissue junction. Based on these findings, it
was hypothesized that fibroblasts-to-osteoblasts interaction interpose interface regeneration
through two mechanisms: (1) osteoblasts, fibroblasts, or both undergo transdifferentiation or
phenotypic changes, and (2) progenitor stem cells or MSCs recruit to the graft-bone interface,
where they differentiate into fibrochondrocytes and form the fibrocartilage interface [98].

To further examine the aforementioned hypothesis and observations, one of the studies made an
attempt to mimic the In vivo interactions between fibroblasts and osteoblasts during ACL
recantations by creating a co-culture system in vitro. In this system, a hydrogel divider was added
in the middle of the culture well that separated the well into two equal champers. Fibroblasts were
seeded in one camper, and osteoblasts were seeded in the other chamber (Figure 1.27) [99]. When
both cells reached confluency, the divider hydrogel was removed allowing the cells to migrate and
interact at the interface region, which resulted in the formation fibrocartilage-like rejoin. These
findings demonstrate the potential of fibrocartilage interface regeneration as a result of the
interactions between fibroblasts and osteoblasts at the insertion site.
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Figure 1.27 (Ai) In vitro co-culture model to evaluate the interactions of interface-relevant cells of
fibroblasts and osteoblast permit heterotypic and homotypic cell-cell interactions [99]. (Aii) Co-culture
models to evaluate interaction of interface-relevant cells. (A-i) In vitro coculture model of fibroblasts (Fb)
and osteoblasts (Ob) permit heterotypic and homotypic cell-cell interactions. (A-ii) Fibroblast (CFDA-SE,
green) and osteoblast (CM-DiI, orange-red) distribution at day 7, bar = 100 μm [99].

1.2.5. Cell-Cell Interaction to Form Interfaces in Muscle-Tendon Junction.
Although the exact mechanism of MTJ development is not well understood, very limited number
of studies revealed that the interaction between tenocytes and myotubes is an essential process that
leads to the formation of specialized muscle-tendon interface (MTJ) [93]. In fact, the development
of MTJ is influenced by some factors that are essential to establish a functional muscle-tendon
interface including; interactions within muscle and tendon cells, interactions between the future
forming muscle and tendon tissues in addition to some functional and structural interactions
between tenocytes and mayotubes at the site of future MTJ [93]. These interactions take place
gradually until a complete and functional MTJ is formed. First, cells within tendon interact forming
a rich collagen matrix. Muscle cells interaction results in the formation of well devolved muscle
tissue that consists of mayfibers. Mayfibers then, apply a lateral force to the tendon by the muscle
contraction, and in response to this contractile force applied to the tendon, tenocytes and the
tendon’s ECM components such as collagen fibers align themselves in the direction of the applied
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force. This allows for a direct contact between tendon and muscle through long cytoplasmic
processes. This direct contact enables the tapered ends of the muscle mayofibers to embed into the
ECM of the tendon, forming a well-developed MTJ through the creation of a network of
overlapping muscles and tendon tissues with a greater surface area for adhesion (Figure 1.28) [70,
93].

Figure.1.28. Schematic picture of the MTJ structural development from early embryonic and neonatal to
adult stages. MTJ: myotendinous junctions; Tnb: tenoblasts; Mbl: myoblasts; Ten: tenocytes; MF: muscle
fibers [93].

In an attempt to address the mechanism of the MTJ’s development, Larkin et al. developed an in
vitro model of three-dimensional (3-D) skeletal muscle-tendon constructs based on the hypothesis
that engineered in vitro 3-D skeletal muscle-tendon constructs would develop MTJs resemble
those found during fetal development In vivo [92]. To validate the hypothesis, MTJs structures In
vivo has been compared to those developed in 3-D skeletal muscle constructs co-cultured with
engineered self-organized tendon constructs (SOT), or segments of adult (ART) or fetal rat tail
(FRT) by means of electron microscopy [92]. In vitro evaluations revealed that some of the
myofibers of the engineered 3-D skeletal muscle-FRT and -SOT constructs only displayed
emerging finger-like sarcolemmal projections surrounded by collagen fibers, which structurally
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resemble fetal MTJs In vivo. In addition, a complete muscle-interface-tendon junction was
developed on the muscle-FRT constructs. These findings suggest that the muscle-FRT constructs
model could be used for studies of developmental mechanisms involved in the establishment of
interfaces among all four muscular-skeletal tissues: muscle, tendon and cartilage/bone.

1.2.6. Cell-Cell Interaction to Form Interfaces in Cartilage-Bone Junction.
Cell-cell interactions is important for the formation of a tissue interface. The interactions between
many cells types have been examined to evaluate their contributions in the formation of cartilagebone interface in the osteochondral tissue by co-culturing cells relevant to tissue types like
fibroblasts, osteoblasts and chondrocytes, or stem cells such as mesenchymal stem cells (MSCs)
in a biomimetic 3D microenvironment [392 ,393].

Jiang et al. studied whether relevant tissues cells such as chondrocytes and osteoblasts can
contribute and interact to form the interface found at the cartilage-bone junction [394]. In this
study, a stratified agarose hydrogel and composite microspheres of polylactide-co-glycolide
(PLGA) and 45S5 bioactive glass (BG) scaffold mimicking the three distinct yet continuous
regions of cartilage, calcified cartilage and bone has been developed. The scaffold was developed
in order to evaluate the potential of osteochondral interface formation by coculturing chondrocytes
at the agarose hydrogel phase, and osteoblast at the PLGA-BG phase. In vitro analysis showed
extensive chondrogenesis and improved graft mechanical property over time. In addition, it was
shown that PLGA-BG phase promoted chondrocyte mineralization, which in turns aided the
formation of the interface region and bone. These results demonstrate the potential of co-culturing
relevant tissue cells such as chondrocytes and osteoblasts in the formation of osteochondral
interface.
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In a similar approach, Chen et al. created a stem cell-derived osteochondral interface using an
interface-specific microenvironment in 3D configuration via multilayered co-culturing [395]. In
this study, MSCs were encapsulated in collagen microspheres, which guided their differentiation
into chondrogenic and osteogenic functional units that enabled the formation of the mediated
interface. The pre-differentiated functional microspheres layers were combined to form a trilayered scaffold with the chondrogenic microspheres on top, osteogenic microspheres at the
bottom, intermediating with an undifferentiated layer of MSCs encapsulated in collagen
microspheres. Culturing the tri-layered construct in a chondrogenic medium generated a
continuous calcified interface with hypertrophic chondrocytes and extensive production of
collagen type X. In addition, intermediating the undifferentiated MSC with the two differentiated
layers in the coculture system resulted in enhanced integration of the three distinct phases enabling
the formation of an osteochondral -like interface. These data suggest the potential of coculture
differentiated and undifferentiated MSCs in an appropriate 3D microenvironment for the
regeneration of osteochondral interface.

Findings from these two studies suggest that both, tissue-relevant cells as well as stem cells have
the potential to interact when co-cultured in biomimetic 3D microenvironments and form an
interface-like tissue. Further studies are indeed required in order to study the interactions of these
cells in more complex heterogenic environment for prolonged times to examine their potential to
sustain the formation of the interface-like tissue.
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1.3.Coaxial and Uniaxial Electrospinning
There are four major tissues in the human body: connective, epithelial, nervous, and muscles [341].
Regardless the tissue type and function, the extracellular matrix (ECM) of these tissues is
composed of an intricate network of interconnected macromolecules such as proteins and
polysaccharides [342]. During the tissue development, these macromolecules are secreted and
adequately organized by cells, once secreted and organized, they can then be seen as non-woven
network of bundle structured fibers known as the (ECM). The ECM as whole functions as
scaffolding for tissues within the body, providing the appropriate three-dimensional framework
for proper cell attachment, proliferation and multitude of signaling pathways (Figure 1.29) [343345].

Figure 1.29: Extracellular (interstitial) matrix. [346].

Macromolecules are found in different densities and organization depending on the function each
tissue is intended to do. For example, connective tissues such as bone, ligament and skin have
denser and more highly organized ECM structure than other tissues such as brain and adipose due
to the increased demand for mechanical support, structure and protection [342-345, 347-358].
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However, like any other tissue, these tissues are prone to injuries or trauma that can lead to tissue
damage or degeneration. In some cases, damaged tissues can restore their function and structural
integrity after injuries by following the normal body’s self-repair mechanics, however, if selfrepair mechanisms are overstrained, in the case of a complete ECM damage such as full thickness
wounds, or third-degree burns, the need for tissue repair is indeed required in order to restore the
structure and the function of these damaged tissues. Due to the fact that the microenvironment of
the healing site is complex and involves a large number of molecules, which require a cascade of
events for wound closure to occur, a well tissue engineered scaffold with an accurate structural,
and physiochemical representation of the natural ECM will be required in order to restore the
functional and structural integrity of the damaged tissues [359].

Scaffold is an essential component in tissue engineering because it physically supports cells and
provides conditions for cell attachment, proliferation, migration, and differentiation, in addition to
its ability to act as a reservoir for growth factor and other biomolecules are known to encourage
the healing process. If the general and tissue-specific scaffold requirement are not met, tissue
restoration and regeneration will not be accomplished [360]. Ideally, a scaffold should provide
cells with a variety of physical, chemical, and biological cues that are naturally inherited by the
native ECM to facilitate cell growth and function [361]. In vivo, cells are found entrapped within
an ECM, in which they are provided with all the necessary physical and chemical cues that guide
their development, arrangement and regenerative abilities by molecular interactions between
specific cell membrane receptors and signaling cues from surrounding ECM material [361]. To
duplicate the in vivo environment, the scaffold should exhibit controllable physical, chemical and
mechanical properties, cell adhesion properties and growth factor release kinetics [362]. An ideal
tissue engineering scaffold should be biocompatible that maintains cell viability in vitro and do
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not elicit any immune response upon implantation in vivo. Also, the scaffold should be
biodegradable with a degradation rate compatible to the rate of the neo-tissue formation to fully
be replaced with newly formed tissue. The scaffold should also be highly porous to facilitate cell
migration, proliferation, nitration diffusion and waste removal, and should also exhibit biomimetic
mechanical and architectural properties resembling those found at the native tissue [363]. Besides,
the scaffold should serve as a reservoir for local, sustained, and controlled growth factors delivery
to regulate cellular activates in order to help induce neovascularity and promote tissue
regeneration.

Several technologies have been employed in the past few years aiming to produce scaffolds with
location-speciﬁc topographies for functional and integrative tissue regeneration. Amongst all,
nanotechnology is one of the very promising technologies that have shown many advances in the
field of tissue engineering and regenerative medicine. Nanotechnology encompasses materials
and structures on the nanometer scale, i.e., in the range from several micrometers down to few
nanometers [364]. Compared to conventional macro-sized and bulk materials, nanostructures
exhibit much unique advantageous that include an extraordinarily high surface area per volume
ratio, tunable optical emission as well as super paramagnetic behavior, which can be successfully
exploited for a variety of health care applications such as biosensors and drug delivery [364].
Several nano-sized materials or structures such as nanotubes, nanocrystals, nanowires,
nanocomposites, nanorods, nanospheres, and nanofibers have been employed for various high
technology applications [364]. Nanofibers, for instance, have received a great deal of interest and
are being explored for a wide variety of applications. In tissue engineering, nanofibers are being
used as drug agent delivery, wound dressing materials, and as porous three-dimensional scaffolds

116

for engineering various tissues such as skin, blood vessels, nerve, tendon, bone, and cartilage
[364]. The intrinsic properties of nanofibers such as high surface to mass ratio, low density, high
pore volume, variable pore size and exceptional mechanical properties and more importantly the
structural resemblance to the native ECM, have encouraged scientists to develop several
fabrication methods for the synthesis of nanofibers. Some of these methods are phase separation,
self-assembly and electrospinning. Of these, electrospinning is the most frequently chosen
technique for the production of nanofibers because it is a simple, cost-effective, versatile process
and is the only technique that can produce at a large scale continuous nanofiber for industrial
applications [365]. Very limited number of studies have reported the production of nanofibers
using self-assembly and phase separation [365].

1.3.1. The Electrospinning Technique
Electrospinning is a relatively old technique that was first patented in the early 1900 by Cooley.
as an apparatus to prepare threads for the textile production [366]. The first apparatus setup
consisted on grounded rotors that operated at a voltage of 10kv to collect fibers as strands for
making fabric [367, 368]. Although this is a relatively old technique, it has been only used in the
medical field over the past 10 years, in particular for the fabrication of tissue engineering scaffolds
for growth factors delivery, cell based approaches or combined to stimulate the regeneration or
regrowth [369-373]. Electrospinning is currently one of the most extensively used technique for
tissue engineering scaffold fabrication due to the resemblance to the native ECM exhibited by
electrospun scaffolds, and its ability to process a wide range of different natural and synthetic
materials with different fibers orientations and diameters that can go to the sub-microns or
nanometer scale depending on the applications needs. In addition, electrospun scaffolds possess
biomimicry fibrous structure with high pore volume ranging between 60-90%, which is important
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for cell infiltration and motility [252]. The general component for the normal electrospinning setup
consist of a syringe to hold the polymer solution, two electrodes (positive and negative), a
collector, and a high DC voltage supply (Figure 1.30) [374].

Figure 1.30: Schematic representation of electrospinning basic set up. a) Image of Taylor cone
forming at the spinneret during the electrospinning process. [390]. b) Image of polymeric filament
forming from Taylor cone and moving toward the collector. [391]

Briefly, polymer granules or powder are dissolved in the appropriate solvent until a viscous,
homogeneous and completely dissolved polymer solution is obtained. A complete dissolution of
the polymer is very important for a successful bead-free production of electrospun fibers. The
polymer solution is then loaded into a syringe, and placed in an apparatus pump for
electrospinning. During electrospinning, an electrical filed of high voltage is applied at the syringe
needle tip that creates large enough forces at the surface of the polymer solution to overcome the
surface tension, resulting in the ejection of an electrically charged jet that solidifies into an
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electrically charged fibers. The needle tip is normally placed some distance away from the
collection unit to allow branching and drawing of the fibers to occur. [253, 254]. During
electrospinning, if the droplet that appears at the tip of the needled was shaped into a Taylor cone
geometry, this indicates that the electrospinning parameter and the setup as whole is producing
quality of nanofiber. This is considered as the ideal case in electrospinning. On the other hand, if
the droplet was shaped into a forked cone, this is an indication that there is an edge effect in the
electrical filed applied to the polymer solution. This is usually due to the high voltage magnitude
applied during electrospinning and it can be overcome by reducing the voltage applied [375-377].
Taylor cone geometry can be seen in (Figure 1.30).

1.3.2. General Electrospinning Parameters
Polymer concentration, polymer solution viscosity, polymer molecular weight, chosen solvent,
surface tension, vapor pressure, flow rate, applied voltage, distance between the needle tip to the
collecting unit are all non-independent important electrospinning parameters that mainly affect the
fiber diameter, mechanical properties and the overall morphology of the electrospun fibrous
scaffold [378-380]. The polymer concentration and molecular weight can directly affect the overall
viscosity of the polymer solution. Chain entanglements also have a direct effect on both the
polymer solution concentration and the molecular weight, in which the fiber-producing jet can be
prevented from breaking, allowing for a longer and continuous fiber deposition. However, if the
chain entanglements are increased, the polymer solution viscosity increases as a result, leading to
increase in the surface tension that creates a forked cone shaped droplet during electrospinning.
This however, can be manipulated by reducing the voltage applied to maintain the Taylor shaped
droplet during the process [379]. If the polymer solution concentration was high, this will result in
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a smaller deposition area and instability in fiber deposition that can be seen as breaking in the fiber
producing jet [382]. In addition, the polymer solution concentration and viscosity can directly
affect the overall surface morphology of the deposited fibers, by either creating a smooth nanofiber
surface or nanofibers beads-containing [383]. The choice of the solvent is another important
electrospinning parameter that can hugely affect the overall quality of the fibers. Solvents are used
to dissolve polymer and prepare them for electrospinning, however, a wide range of organic and
non-organic solvents can be utilized to dissolve polymers with various conductivities that can be
tuned to a specific polymer and the application need in order to achieve the best desirable fiber
morphology [382, 384, 835]. Interactions between the polymer molecules and solvent, the
resultant polymer solution viscosity as well as the fiber morphology are all dependent on the
solvent choice [384, 386]. The utilization of the un-appropriate solvent can sometimes lead to
undesirable effects such as the creation of large number of pores at the surface of the fibers, which
can negatively affect the overall quality of the fibrous scaffold (Figure 1.31). The presence of these
pores however, can lead to burst release effects in case of drug deliver and can also accelerate the
drug release and/or the device degradation. The pores are caused because of the uncomplete
evaporation of the solvent upon deposition, creating void spaces in the resultant fibers due to the
long contact of the remaining unevaporated solvent with the fiber surface [387, 388]. One last
important consideration is that during electrospinning, most fibers tend to get collected at the
grounded target, however, due to the fact that the surface of these fibers is highly charged, they
have also the possibility of getting deposited on almost every surface in the vicinity [389]. To
overcome this issue, the area of the grounded target should be specific to the desired fibrous mat
area. This will allow for a complete collection of the elctrospun fibers without losing any. All the
aforementioned are important electrospinning parameters that need to be considered during the
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process in order to achieve a controlled system that increases the accuracy of the resultant fibers
geometry.

Figure 1.31: Porous electrospun fibers. 28 wt% polystyrene in tetrahydrofuran (15kV) [387].

1.3.3. Electrospinning Strategies for Drug Delivery
One of the most interesting features of the nanofibers is the ability to couple them with regenerative
agents such as growth factors or biomolecules that are known to encourage the healing processes.
The high ratio of surface to volume of produced nanofibers can increase drug loading and cell
attachment attributes [297]. Different electrospinning strategies such as “uniaxial” and “coaxial”
electrospinning have been employed in order to achieve steady release rates of the encapsulated
agents over a period of time [297]. In both strategies, the choice of the biomaterial represents a
key component in the development of sustained and controlled release electrospun nanofibers
[297]. a wide variety of different non-biodegradable and biodegradable synthetic and naturally
derived biomaterials have been used for the synthesis of electrospun nanofibers [297]. Amongst
all, the most relevant biomaterials used for sustained and controlled released are biodegradable
polyesters such as PLA, PGA, PLGA, and PCL [398]. Common but rarely used non-biodegradable
synthetic biomaterials for sustained growth factor and biomolecules release include polyurethane
(PU), polycarbonate, and nylon-6 [399]. Naturally derived biomaterials such as collagen, silk,
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gelatin, alginate and chitosan have also been investigated for sustained growth factors and
biomolecules delivery from nanofibers [400]. Natural biomaterials are generally used to bypass
the biocompatibility limitations associated with synthetic biomaterials. Although natural
biomaterials possess enhanced biocompatibility properties, they are un-electrospunable, unless
they are blended with another synthetic biomaterial, which limit their use by their one as drug
delivery vehicles [401]. Regardless the type of the material, one important factor that largely effect
the release profile of the encapsulated agents from nanofibers is the method of encapsulation.

1.3.3.1.Uniaxial Electrospinning for Drug Delivery
Uniaxial electrospun nanofibers demonstrate a relatively simple, and scalable strategy to achieve
rapid and sustained release of the encapsulated bioactive agents. The uniaxial electrospinning setup
is relatively similar to the previously discussed setup (Figure 1.30), where a syringe to hold the
polymer solution is required, in addition to two electrodes (positive and negative), a collector, and
a high DC voltage. The same exact methodology as previously described is applied during the
uniaxial electrospinning technique, and the addition of the bioactive agent during the polymer
solution preparation before electrospinning would be the only difference. When applying the
uniaxial electrospinning methods, drug encapsulation is achieved through a single step, because
the drug is dissolved or dispersed in the polymeric solution [398]. Drug encapsulation efficiency,
drug dispersion into the fibers as well as the release rate are all characteristics factors determined
by the interactions between the polymer solution and the drug, which is further affected by the
physiochemical properties of the polymer [398]. However, to obtain a uniform drug release
kinetics from uniaxially produced nanofibers, bioactive agents have to completely be homogenized
with the polymer solution prior to electrospinning. This, can be achieved through the appropriate
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selection of the polymer to protein. For example, hydrophobic polymers such as PLA, PGA, and
PLGA can easily be homogenized with hydrophobic proteins such as BMP-2 or PDGF-BB [402].
On the other hand, hydrophilic drugs are not miscible with hydrophobic polymers but are easily
homogenized with hydrophilic polymers such as gelatin, PEG, and PVA [402]. In cases where the
protein and the polymer of interest are immiscible, they can be forced to be homogenized by
emulsifying using ultra-sonication method [403]. This however, can improve the suspension of the
bioactive agent in the organic solvent [403]. Therefore, homogenization between the polymer and
the proteins as well as the formulation properties are all important parameters that can potentially
affect the drug release kinetics.

Although uniaxial electrospinning is thought to be relatively simple and easy to perform, bioactive
agents may lose their bioactivity due to conformational changes in the organic solution
environment [402]. In another word, the process of emulsifying the protein, which involves
physical stirring, homogenization or ultra-sonication can potentially damage the proteins’
bioactivity [402]. Several methods have been developed in order to improve the stability of
proteins as well as to protect them from the harsh environment they undergo prior to
electrospinning. One strategy is to use salt complexation instead of ultra-sonication in order to
improve the proteins’ solubility in organic solvents [404]. This method resulted in retention of
almost 90% of Lysozyme oleate bioactivity after it has been incorporated by Li et al. into uniaxially
elelctrospun scaffold [404]. Another strategy is to minimize the hydrophobic interaction of the
bioactive agent and the organic solvent during electrospinning by using hydrophilic additives
[405]. In one study, it has been reported that the addition of hydrophilic polymers such as PEG
and gelatin in aqueous protein solution can be beneficial for improving the protein solubility. In
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addition, it has been reported that the addition of hydroxyapatite (HAp) in PLGA solution could
preserve the bioactivates of the loaded BMP-2, as the protein could potentially attach to the
hydrophilic particles, escaping from the harsh electrospinning process [406].

It is very well known from the literature that uniaxially elelctrospun scaffold incorporated
bioactive agent exhibit high initial burst release followed by sustain release close to linear mode
depending on the polymer choice [407-409]. Regardless the polymer type, the burst release usually
take place within the first 12 – 24 h [410]. The high initial burst release is possibly attributed to
the localization of certain fractions of the protein molecules near the surface of the fibers [410].
After the first high burst release phase, the protein release kinetics are mainly driven by the
degradation rate of the polymer as well as protein diffusion [410]. For example, proteins loaded
into the slowly degraded PCL will exhibit a steady and prolonged release profiles when compared
to the release of proteins loaded into the relatively fast degraded PLGA, where a sustained release
mode is displayed first, followed by increased release rate upon the degradation of the polymer
[411].

In order to examine the release kinetics and the effectiveness of the uniaxial elelctrospun
nanofibers encapsulated bioactive agents, Nie et al. developed a three-dimensional uniaxially
elelctrospun PLGA/HA composite nanofiber scaffold for protein delivery and bone regeneration
[412]. in this study, BMP-2 was physically blended with the polymer solution prior to
electrospinning and in vitro release profile of the encapsulated protein was reported. Although data
revealed that the protein release lasted for up to 2 weeks, a very high initial burst release was
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observed at the first few hours. This high burst release can cause undesirable side effect and
interfere with the surrounding tissues when the device is implanted in vivo.

It was expected that fibers with larger diameter would overcome drawbacks associated with the
initial burst release observed in the uniaxially elelctropun nanofibers and would also create a longer
path length for drug to diffuse. This hypothesis however, has been examined by Chen et al. In this
study, PLA uniaxial elelctrospun nanofiber scaffolds have been fabricated with two different fibers
diameters, ~ 1550 nm and ~ 200 nm [413]. Chlortetracycline, an anti-inflammatory drug agent,
was uniaxially encapsulated in both fibrous scaffold and the release behavior of the drugs from
both scaffolds has been investigated in vitro. In vitro drug release results showed that both scaffold
could not avoid the initial burst release as both showed very high initial burst release of the drug.
Further investigations showed that the larger-diameter fibers could sustained the release for a
longer time when compared to the smaller-dimeter fibers, which released all the encapsulated
protein in a shorter time. Findings from this study show that the initial high burst release issue of
the uniaxial elelctrospun nanofiber could not be resolved through the manipulation of the nanofiber
dimeter, but suggest that uniaxial encapsulation of the drug in larger-diameter fibers can be
beneficial for a long-term release.

Drawback associated with delivering growth factors from uniaxially produced nanofibers such as
the initial high burst release as well as the fast release of the encapsulated bioactive agent
encouraged scientists to try another approach aiming to bypass this issue. In an attempt to
overcome the fast release of growth factors form uniaxial electrospun nanofiber, Okuda et al.
developed a poly-L-lactide-co-e-caprolactone (PLCL) uniaxial elelctrospun nanofiber mat using
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sequential electrospinning to generate a multilayered scaffold [414]. The scaffold design consisted
of three different layers, in which the drug is incorporated in the middle layer and being
sandwiched by the other two layers to delay the release of the bioactive agent from the middle
layer. This design however resulted in minimal burst release followed by a sustained close to linear
release of the agent. Although this approach seems to address the limitations of the burst and fast
release associated with the uniaxially produced nanofibers, multilayered fibrous scaffold could
prove to be problematic in tissue engineering applications [414]. Cells seeded on multilayered
scaffold were shown to accelerate the degradation rate of the scaffold due to the cell infiltration
through the multiple layers, resulting in a complete release of the encapsulated drug at the middle
layer.

Drawbacks associated with the uniaxial electrospinning technique such as the high initial burst
release, fast release of the incapsulated bioactive agent as well as the harsh environment that the
bioactive agent has to undergo during the encapsulation process mark the need for finding more
functional and integrative alternatives that bypass the issue of the burst and fast release as well as
protect the bioactive agents from harsh loading environment.

1.3.3.2.Coaxial Electrospinning for Drug Delivery
Coaxial electrospinning, also referred to as co-electrospinning, was first patented in the early 2000
by Sun et al. to overcome the burst release limitations associated the conventional uniaxial
electrospinning methods [ 415,416]. Incorporation of growth factors coaxially in the core shell of
the polymeric nanofiber has been shown to exhibit precise control over the location of the drug
within the core-shell of the nanofibers [417]. The main advantage of coaxial electrospinning over
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the uniaxial is that it generates core and sheath fibers by physical separation between the core and
the sheath through the utilization of two electrospinning tips and two solutions (Figure 1.32) [418].
The core generally contains the growth factor solution and the sheath contains the polymeric
solution. This nanofiber structure will allow for more of a spatial control over growth factors
delivery and will hugely minimize any possibility of burst release when compared to the
conventional uniaxial nanofiber [418]. In addition, this process is used to load a wide variety of
agents into nanofibers that could potentially lose their bioactivity and functionality unless they are
in fluid or non-denaturing environment [418]. The setup for coaxial electrospinning is relatively
similar to the uniaxial electrospinning, expect for the nozzle configuration [360]. The coaxial
nozzle consists of two separate inner and outer concentric nozzles, in which the outer nozzle is
normally fed by the polymer solution, while the inner nozzle is fed by bioactive agent’s solution
[360]. Each nozzle is controlled by a separate syringe pump to allow for controlling the flow rate
of every nozzle [360].

Figure 1.32. Schematic representation of coaxial electrospinning setup. [419]
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Although this technique has been developed more than 15 years ago [420], tissue engineers has
recently started to consider the application of coaxial electrospinning to deliver growth factors and/
or biomolecules 10 years ago. When compared to the uniaxial electrospinning, this technique has
gained [421]. Coaxial electrospinning has received tremendous interest by researchers because the
produced core-shell fibers that have a great potential in preserving the protein during the
electrospinning process, resulting in retention to its bioactivity [360]. It has been reported that
another factor attribute to the preservation if the loaded protein bioactivity in the core-shell of the
coaxial nanofibers is that during the coaxial electrospinning process, only the outer fiber surface
gets exposed to the electric charge, whereas the protein at the inner core is not charger at all [422].
This however plays a significant role in the preservation of the bioactivity of the loaded in the
core-shell of the coaxial nanofibers when compared to the uniaxial nanofibers. This has been
further investigated by Ji et al. where the activities of the loaded ALP protein have been compared
both in the uniaxially and coaxially electrospun fibers [423]. Low ALP activities were observed in
the uniaxial nanofibers in comparison to the coaxial nanofibers, suggesting that high voltage and
contact with the organic solvents are harmful to the loaded bioactive agent.

An important parameter that can largely affect the integrity of the final core-shell architecture is
the miscibility between the two solutions, the polymer solution and the bioactive agent’s solution
used in the core-shell. Another considerable variable is the flow rate of both solutions, the polymer
and the core, which can be tuned in order to set the thickness of the shell and the diameter of the
core. Increasing the flow rate of the polymer solution and decreasing the flow rate of the core
solution normally results in a thicker shell and a narrower core, this however, would results in very
sustained and prolonged release over time with minimal to no initial burst release [424]. In a study
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by Wang et al. dimethyloxalylglycine (DMOG) was coaxially loaded into the hydrophobic PLA
[424]. Two scaffolds with different fiber diameter have been produced, where one scaffold had
fiber dimeters of ~ (120 nm) and the other scaffold had fiber dimeter of ~ (230nm). In vitro release
data revealed that both groups had a similar minimal initial burst release. However further
investigations revealed that the thin shell scaffolds showed almost 70% cumulative drug release
within 11 days, whereas the thick shell showed the same cumulative release after 30 days in
culture. These observations strongly indicated that the sustained release depends on the polymer
shell thickness.

The distribution of the bioactive agent within the core structure as well as the final morphology of
the overall fiber can highly affect the release behavior of the drug from the core [425]. However,
to obtain a uniform drug distribution within the core structure as well as a regular core-shell fiber
morphology, a compatible solvent with known evaporation rate has to be used. For example, if
core solvent evaporates faster than the shell solvent, a hollow fiber is obtained. This hollow fiber
structure can cause insufficient interfacial compatibility between the core and the shell, resulting
in delamination at the interface. Also, if the shell solvent evaporates faster than the core solvent,
the core solvent will be entrapped within the core-shell of the fiber, causing some portions of the
shell polymer to be dissolved and thus, producing a porous structure of a fiber that can result in
higher rates of burst release [425]. Therefore, choosing the appropriate solvent for the core and the
shell polymer is of importance to achieve desirable release outcome.

1.3.3.3.Coaxial and Uniaxial Electrospinning for Drug Delivery
A wealth number of studies has compared the release prolife of the coaxially elelctrospun
nanofiber scaffolds to the uniaxially electrospun nanofiber scaffolds. In a study by Sahoo et al.
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bFGF was coaxially and uniaxially incorporated in PLGA elelctrospun nanofiber scaffold [426].
The encapsulation efficacy of the bFGF in both groups was shown to be similar. In vitro release
data showed that the growth factor from the uniaxial nanofibers showed higher burst release when
compared to the coaxial. In addition, while the uniaxial nanofibers released all of the encapsulated
protein within 7 days, the coaxial nanofibers could sustain the release for up to 14 days. Both
scaffolds were further seeded with mesenchymal stem cells and the effect of the different growth
factor incorporation methods on the proliferation and differentiation of MSCs has been
investigated. At predetermined time points, cells showed a rapid increase in cell proliferation,
collagen production as well as gene expression in the uniaxial electrospun nanofiber group when
compared to the coaxial. This however, is attributed to the effect of the burst and fast release of
the growth factor, which stimulated the rapid proliferation and differentiation of the cultured cells
when compared to the coaxial group, which showed sustained release of the loaded protein over
time. Findings from this study demonstrate the effect of the different growth factor incorporation
methods on the cell behavior such as cell proliferation and differentiation. Although the initial high
burst release, followed by fast release of the growth factor from the uniaxial nanofibers resulted in
a significant increase in cell proliferation and differentiation in vitro when compared to the coaxial
nanofibers, this is undesirable in an in vivo setting, where the high initial burst release can cause
interference and damage to the other surrounding tissues, thus, resulting in increased in
complications rather than eliminating an existed one.

To examine the effect of the coaxial electrospun nanofibers in vivo, Wei et al. developed a very
unique, elegant and novel coaxial electrospun polycaprolactone (PCL)/polyvinyl alcohol (PVA)
core-sheath nanofiber (NF) blended with both hydroxyapatite nanorods (HA) and type I collagen
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(Col) (PCLCol/PVAHA) for the treatment of osseointegration [427]. Doxycycline (Doxy) and
dexamethasone (Dex) were successfully incorporated into the PCLCol/PVAHA NFs for controlled
release. In vitro evaluation revealed that the PCLCol/PVAHA NFs are biocompatible and enhanced
the adhesion and proliferation of murine pre-osteoblasts MC3T3 cells. In addition, the release of
Doxy and Dex from coaxial PCLCol/PVAHA NFs showed more controlled release when compared
to the uniaxial NFs. Furthermore, using an ex vivo porcine bone implantation model they found
that the PCLCol/PVAHA NFs bind firmly on the titanium rod surface and the NFs coating remained
intact on the surface of titanium rods after pullout. No disruption or delamination was observed
after the pullout test. To examine the scaffold’s capability to enhance osseointegration in vivo, the
scaffold was directly deposited on a titanium (Ti) implant surface during electrospinning. the
implant was further implanted an infected tibia rat model. In vivo evaluations revealed that the
coting the implant with PCLCol/PVAHA NFs enhanced bone osseointegration at the implant site at
2,4 and 8 weeks when compared to the implant coated with the uniaxial scaffold or un-coated.
These findings indicate that coaxial PCL/PVA NF coating doped with Doxy and/or other drugs
have great potential in enhancing implant osseointegration and preventing infection.

1.3.4. Techniques and Potential Applications for Coaxial Electrospinning:
More complex drug delivery systems can be created through the utilization of coaxial
electrospinning for more integrative tissue regeneration [428]. For example, the inner core of the
electrospun fiber could be composed the slowly biodegradable polymer PCL, loaded with an
osteogenic protein such as BMP-2, whereas the outer shell could be composed of a blend of PLGAgelatin-VEGF. BMP-2 has been shown to promote the differentiation of osteoblasts and induce
bone formation [429], while VEGF has been shown to promote vascularization [430]. By theory,
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VEGF loaded at the outer shell of the nanofiber would be released into the tissue enticement before
BMP-2 encapsulated at the inner core of the fiber upon implantation in vivo. Thus, the scaffold is
design to promote the delivery of the loaded protein in two stages, the first for promoting
vascularization throughout the implant, while the precise and the steady release of the loaded
BMP-2 at the core-shell of the nanofiber should promote the differentiation of the local precursor
cells as well as induce the formation of bone over time. PCL has been chosen to be at the core
shell of the nanofiber and loaded with BMP-2 due to its slow degradation, which will result in
releasing BMP-2 in a steady fashion over a prolonged period of time [431]. The fast release of
VEGF was shown to enhance the regeneration process in dual delivery systems with BMP-2, thus
it was chosen to be blended at the outer shell for this reason [432]. In addition, blending gelatin
along with PLGA would enhance the surface properties of the device, which in turns can increase
the biocompatibility of the scaffold and enhance cell adhesion, proliferation, therapy tissue
regeneration [433]. The thickness of the outer shell and the diameter of the core shell have to be
adjust so that an optimal delivery ratio of both growth factors is archived. Such an approach would
be beneficial in wide verity of tissue engineering applications where multiple release of growth
factors is required in a sequential manner.

132

1.4.Research Objectives and Specific Aims
The objective of this work is to develop an integrated graft system composed of three different
continues phases, each engineered to support the culture of a particular cell type, (1) dermal
fibroblasts, (2) ligament fibroblasts and (3) osteoblasts. Specifically, the in vitro capability of the
integrated graft system to sustain the biological properties of the three different cell types such as
cell viability, proliferation and phenotype in the heterogenic cellular environment will be
investigated. The major research goals are organized intro four specific aims:

Specific Aim I: Fabricate and characterize the three different phases within the integrated graft to
determine the morphological and physical properties for use in vitro, specially related to the
morphological integrity.

Specific Aim II: Evaluate the capability of the three different phases within the integrated graft
system to serve as suitable drug carriers for sustained and controlled release over growth factors.

Specific Aim III: Isolate and phenotypic characterize the three different cell types: dermal
fibroblasts, ligament fibroblasts and osteoblasts; in addition to in vitro evaluating the capability of
the three different phases within the integrated graft system to support their viability and
proliferation over time.

Specific Aim IV: Evaluate the in vitro capability of the integrated graft system to sustain the
biological properties of the three different cell types such as cell viability, proliferation and
phenotype in the heterogenic cellular environment.
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Figure 1.33. A schematic showing the three steps involved in establishing the integrated graft system.
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CHAPTER 2
SYNTHESIS, CHARACTERIZATION AND IN VITRO DEGRADATION OF THE
DIFFERENT PHASES WITHIN THE INTEGRATED GRAFT SYSTEM
2.1.Introduction
An ideal tissue engineering scaffold should possess a number of essential properties. The scaffold
should be biocompatible that maintains cell viability in vitro and do not elicit any immune response
upon implantation in vivo. In addition, the scaffold should be highly porous to facilitate cell
migration, proliferation, nutrition diffusion and waste removal. The scaffold should also exhibit
biomimetic architectural properties resembling those found at the native tissue, and more
importantly, the scaffold should be biodegradable with a degradation rate compatible to the rate of
the neo-tissue formation to be fully replaced with newly formed tissue. Moreover, the degradation
by-products should not be toxic and should be mediated by the body’s biological system. However,
the desired scaffold’s parameters can be tailored based on the material choice [1, 35]

A number of biodegradable natural and synthetic biomaterials including polymers have been
developed for tissue engineering applications [1]. Amongst all the biodegradable polymers, PLGA
or poly lactic-co-glycolic acid is considered as one of the most extensively studied and used
biomaterials as a drug carrier and a scaffold material for tissue engineering applications. PLGA
has received a tremendous amount of interest due to its biocompatibility, tunable biodegradability
and mechanical properties as well as controlled and sustained release of growth factors; and most
importantly it is an FDA approved polymer for certain applications [2, 3]. One considerable
drawback about PLGA is that it lacks all the ligands required for cell attachments and proliferation,
which can result in poor cell adaption to the matrix and thus, poor tissue formation [33]. Gelatin
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is a remarkable natural biomaterial that also has been widely investigated as a promising
implantable biomaterial for a number of tissue engineering applications. [34] The most intriguing
properties that attract research interests are its cell/tissue compatibility, biodegradability, and
functionality. In addition, gelatin inherits all the necessary arginine-glycineaspartic acid (RGD)
sequences that allow for enhanced cell adhesion, and it is less immunogenic. A great deal of studies
has focused on the development of composites biomaterials that combined gelatin and other
materials, mainly syntactic polymers for achieving tissue engineering scaffolds that exhibit the
biocompatibility of the natural polymers, and the tuned biodegradability and mechanical properties
of the synthetic polymers for functional and integrative tissue regeneration. PLGA/gelatin
composite was shown to support cellular attachment, proliferation, as well as to support the
regeneration of a variety of tissues In vivo such as bone, skin, and ligament. The unique properties
of PLGA/gelatin made it one of the favorable composite biomaterial for most researchers [4, 5,
25, 26].
PLGA is a linear copolymer that can be synthesized at different ratios between its constituent
monomers, lactic (LA) and glycolic acid (GA) (Figure 2.1).

Figure 2.1 Chemical structure of poly(lactic-co-glycolic acid) and its monomers [6].
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Depending on the ratio of lactide to glycolide used for the polymerization, different forms,
degradation and mechanical properties of PLGA can be obtained, where the higher the lactic
content to glycolic generally exhibits prolonged degradation rates, and higher mechanical integrity.
These are usually identified in regard to the monomers’ ratio used (i.e., PLGA 85:15 identifies a
copolymer consisted of 85% lactic acid and 15% glycolic acid) [6].
PLGA undergoes degradation by hydrolysis of its ester linkages, through bulk or surface erosion,
in aqueous environments. Briefly, the degradation process can be described in four main steps: (i)
hydration: water penetrates into the amorphous region, which disturbs the van der Waals forces
and hydrogen bonds, resulting in a decrease in the glass transition temperature (Tg); (ii) initial
degradation: cleavage of covalent bonds, with a decrease in the molecular weight; (iii) constant
degradation: carboxylic end groups auto-catalyze the degradation process, resulting in loss in
mass and integrity by massive cleavage of the backbone covalent bonds; (iv) solubilization: the
fragments are further cleaved to molecules that are soluble in the aqueous environment [7]. As
described previously [6], there are certain parameters that influence the degradation behavior of
PLGA such as, (i) molecular weight: where PLGA with high MW (60 – 200 kDa) exhibits longer
degradation rates; (ii) the ratio between lactide acid to glycolide acid: PLGA with higher content
of LA are less hydrophilic and thus, absorb less water resulting in slow degradation rates, as a
consequence of the presence of methyl side groups in poly-lactide acid making it more
hydrophobic than poly-glycolide acid. (iii) Stereochemistry: during the fabrication process of
PLGA a mixture of D and L lactic acid monomers are most commonly used, as the rate of water
penetration is higher in amorphous D, L regions, leading to accelerated PLGA degradation; and
(iv) end-group functionalization: polymers that are end-capped with esters generally demonstrate
longer degradation half-lives [8, 9, 6]. One more important aspect that is strongly related to the
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parameters influencing PLGA degradation is the shape of the device, depending on the water
accessibility within it. In addition, the acidic surrounding medium can also play a role in
accelerating the degradation process in PLGA due to the autocatalysis [6].
Another considerable property about PLGA is that it can be easily processed into a wide variety
of different structures depending on the application needs through well-developed fabrication
techniques. Some of the most extensively used fabrication techniques to process PLGA are (1)
double emulsion solvent evaporation for the production of PLGA microspheres, and (2) uniaxial
electrospinning technique for the production of uniaxial PLGA nanofibers, and (3) coaxial
electrospinning technique for the production of PLGA coaxial electropun nanofibers.

2.1.1. Microsphere Fabrication Technique
The fabrication of microsphere scaffolds was first established in 1998 by Laurencin et al.
Microspheres are fabricated using the single emulsion technique, briefly, a solution of organic
PLGA in Dichloromethane (DCM) is generally added to an aqueous polyvinyl alcohol (PVA)
surfactant (Figure 2.2). The mixture is let to stir under a certain speed inside of a chemical hood
to allow the solvent to evaporate. The end product of this process is a pellet of solidified
microspheres, which are collected, rinsed, freeze or air dried and sieved to the desired diameter
size range.
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Figure 2.2 Fabrication process of PLGA Microsphere through the single water/oil emulsion technique.

To construct scaffolds, microspheres with the desired particle size distribution are poured into a
mold, generally stainless-steel mold, then heated above the glass transition temperature of PLGA
(Tg ~ 58 °C) until they are thermally fused into the desired three-dimensional shape and
morphology [10,11]. The advantages of using PLGA to develop 3D sintered microsphere scaffolds
with a porous interconnected structure for bone tissue engineering has been demonstrated. These
scaffolds were shown to possess mechanical properties controllable pore size and pore volume that
are relatively close to the native tissue ECM, which makes them ultimately ideal for bone
regeneration [12, 13].

2.1.2. Uniaxial Electrospinning Technique:
Electrospinning is an easy and low-cost approach to fabricate fibrous matrices. Briefly, the
polymer is dissolved in an organic solvent, generally Hexafluoro-2-propanol (HFIP) to make the
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polymer solution. Polymer solution is then loaded in a capillary tube and confined by its surface
tension, and the ejection of polymer solution is accomplished when it is exposed to an electric field
such that the electrostatic repulsion overcomes the surface tension. During the process of
electrospinning, the solvent evaporates when the solution-jet travels in air, leaving behind
polymeric fibers which gets deposited on the collector [14–15]. Thus, continuous fibers are
collected to form a non-woven fabric that mimics the fibrous network of native ECM, with fiber
sizes similar to ECM fibrils [16, 17].

2.1.3. Coaxial Electrospinning Technique:
Coaxial electrospinning was mainly developed to overcome the burst release limitations associated
the conventional methods of blending the growth factor directly with the polymer solution and
uniaxially electrospin them [10]. This can be done by incorporating the growth factors coaxially
in the core-hell of the polymeric nanofiber during electrospinning [11]. The main advantage of
coaxial electrospinning over the uniaxial is that it generates core and sheath fibers by physical
separation between the core and the sheath through the utilization of two electrospinning tips and
two solutions (Figure 2.3) [12]. The core generally contains the growth factor solution and the
sheath contains the polymeric solution. This nanofiber structure will allow for more of a spatial
control over growth factors delivery and will hugely minimize any possibility of burst release when
compared to the conventional uniaxial nanofiber [12]. Advantages of the coaxial electrospinning
made it an area of a significant interest for many researches for more effective drug delivery and
thus, tissue regeneration.
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Figure 2.3 Schematic of coaxial electrospinning setup, and the conventional uniaxial electrospinning setup.

These artificial extracellular matrices were shown to possess mechanical properties, controllable
pore size and nanofibers diameter that are relatively close to the native tissues, which render them
ultimately ideal for tissue engineering applications. Thus, maintaining the mechanical, physical
and morphological integrity of the scaffold for the appropriate timeframe is a key element for
successful tissue regeneration [18 - 21].
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In this aim, PLGA was mainly used as a scaffold biomaterial to fabricate the three different phases
within integrated graft system and gelatin was introduced to serve as a drug carrier as well as to
enhance the biocompatibility of the overall scaffold. Scaffold fabrication was either through
electrospinning for the production of coaxial and uniaxial PLGA nanofibers, or through single
emulsion technique for the production of PLGA microspheres. Post-fabrication, the three different
phases were morphologically evaluated using SEM to examine the exterior surface and the overall
morphology as well as to assist in the particle size analysis. TEM analysis have also been conduct
in order to verify the core-shell in the coaxial nanofibers. In addition, in vitro degradation
characteristics of both PLGA coaxial and uniaxial electrospun nanofibers and microsphere
scaffolds were examined to evaluate the morphological and physical integrity, specifically weight
loss, swelling rate, water uptake and pH changes over time. These characteristics were essential to
observe in order to evaluate the capability of the three different phases to maintain their
morphological integrity over time. This helped us examining their suitability for further analysis
throughout the study.
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2.2. Materials and Methods:
85:15 Poly(lactide-co-glycolide) (PLGA) (MW ~ 94,000 kDa) was purchased from (Absorbable
Polymers, Birmingham, AL, USA), Hexafluoro-2-propanol (HFIP) was purchased from (Acros
Organics, USA), Gelatin Type A from Pork (Porcine skin) was purchased from (MP Biomedical,
OH, USA), Microbial Transglutaminase (mTG) was Purchased from (Ajinomoto, Japan),
Dulbecco’s Phosphate-Buffered Saline (PBS) of pH 7.4 wash purchased from Gibco (Grand
Island, NY), Dichloromethane (DCM) was purchased from (Fisher Scientific, USA).

2.2.1. Fabrication of PLGA-Gelatin Coaxial Electrospun Nanofibers Scaffolds
PLGA (85:15) granules were dissolved in HFIP at 16 % wt and stirred overnight at room
temperature to prepare the (shell solution) of nanofibers. To prepare the core solution, gelatin
powder type A was dissolved in HFIP at 4% wt and stirred overnight at room temperature. An
electrospinning pump (NE 300 SYRINGE pumps, USA) was used in order to fabricate the coaxial
PLGA-Gelatin nanofibers. The setting to prepare the coaxial scaffolds consisted of two coaxial
syringe pumps with different flow rates. In this study, the PLGA solution was used to form the
outer shell and the gelatin solution was used to form the inner core. These two solutions were
loaded into two separate 10 ml syringes and connected to the coaxial needles, a 16 G (ID = 1.6 mm)
outer needle and a 22 G (ID = 0.7 mm) inner needle, respectively, and then concentrically placed.
The electrospinning parameters were as follows: (applied voltage: 10 kV; 1.5 mL/h for the sheath
flow rate and 0.75 mL/h for the core flow rate). The tip of the needle was placed 10 cm away from
the collector. The electrospinning process lasted for 1.5 h. Coaxial electrospun nanofibers were
peeled from the collector and stored under vacuumed desiccator until use.
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2.2.2. Fabrication of PLGA Uniaxial Electrospun Nanofibers Scaffolds
PLGA (85:18) granules were dissolved at 16% wt in HFIP with stirring to form clear,
homogeneous, and viscous solution. PLGA solution was loaded into 10 ml plastic syringe and
electrospun at flow rate of 0.75 mL/h through a 20-gauge blunt needle with the electrospinning
pump (NE 300 SYRINGE pumps, USA) at an applied voltage of 10 kv. The tip of the needle was
placed 10 cm away from the collector. The electrospinning process lasted for 3.5 h. Uniaxial
electrospun nanofibers were peeled from the collector and stored under vacuumed desiccator until
use.

2.2.3. Fabrication of PLGA Microspheres
Single emulsion solvent evaporation technique was used to fabricate PLGA microspheres. PLGA
granules were dissolved at 12.5% wt in Dichloromethane (DCM) in glass vials. Vials were
vortexed for 1 h at a speed of 550 RPM until clear, homogeneous, and viscous solution was
obtained. Next, PLGA solution was added via a thin stream into 1% PVA solution in a 1000 ml
beaker and it was let to stir at (300 RPM) overnight to allow the solvent to evaporate. After that,
microspheres were collected, filtered, air dried and then they were stored in -20 °C for 24 h to
freeze any residual water particle inside of the microspheres. Next, microspheres were freeze dried
for 48 h and were then sieved to obtain the desired particle size range 300-600 µm.

2.2.4. Fabrication of Gelatin-mTG Hydrogel
Gelatin gel formation was initiated by mTG addition. For hydrogel preparation, 3% wt gelatin
powder type A was dissolved in preheated phosphate-buffered saline (PBS) at 50 °C and it was let
to stir on a stirrer plate for 15 minutes at 500 RPM to completely dissolve the powder. The mTG
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solution was prepared by dissolving 10% wt mTG in preheated PBS at 50 °C, then it was let to stir
on a stirrer plate for 15 minutes at 500 RPM. As soon as both gelatin and mTG completely
dissolved in PBS, the temperature of the stirrer plate was adjusted to 37 °C and they were let to
stir for another 15 minutes to allow for the temperature drop. Next, to initiate the crosslinking
reaction between gelatin and mTG for the hydrogel preparation, mTG solution was mixed with the
3% wt gelatin solution at a ratio of 1:11.5 under stirrer speed of 500 RPM at 37 °C. The mixture
was let to stir for 5 minutes until a semi-viscus solution is fabricated and ready to be injected.

2.2.5. Fabrication of PLGA-Gelatin-mTG Microsphere Scaffolds
To fabricate the three-dimensional scaffolds and incorporate it with gelatin-mTG hydrogel, PLGA
microspheres were poured into a 10 mm x 10 mm stainless steel mold and heated for 90°C for 90
minutes. These parameters allowed the microspheres to fuse together forming the 3D scaffolds.
After 90 minutes, the stainless-steel mold was removed from the oven and allowed to cool to room
temperature for 2 hours. Next, scaffolds were removed and the semi-viscus gelatin-mTG hydrogel
was injected inside of the microsphere scaffold using an insulin syringe until all pores were filled
and it was allowed to gel at 37 °C.

2.2.6. Scanning Electron Microscopy (SEM)

Both electrospun nanofibers scaffolds, and microsphere scaffolds were morphologically evaluated
under scanning electron microscopy after fabrication, and over the 8 weeks period of time during
the degradation study to evaluate the morphological changes over time. Samples were assessed
using FEI Nova NanoSEM 450 (FEI Ltd., Tokyo, Japan) at a working distance of 5 mm and an
acceleration voltage of 18 kV. Scaffolds were mounted on 15 mm stubs and were gold sputter
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coated using (Polaron E5100) for 3 minutes to eliminate surface charging. Finally, the coated
samples were loaded into the SEM and high magnification images of each experimental group
were taken and analyzed.

2.2.7. Particle Size Distribution and Pore Size Analysis
Three different images from every samples were obtained and analyzed for particle size
distribution and pore using Image J software. Briefly, 200 particles were selected from every image
of the three images of the single sample. Data from the three different images of the single sample
were used to determine the size and average size distribution as well as the pore size for every
scaffold type. The same analysis was carried out on both electrospun nanofibers scaffolds.

2.2.8. Transmission Electron Microscopy (TEM)
TEM analysis were conducted on both the Coaxial and the uniaxial electrospun nanofibers to
confirm the coaxial structure. Observations were prepared by directly depositing the spun fibers
onto copper grids of 300 mesh. The samples for TEM images were analyzed using (FEI Tecnai 12
G2 Spirit BioTWIN) transmission electron microscope and all images were recorded in GATAN
ESW 500 camera.

2.2.9. Degradation of PLGA Coaxial, Uniaxial Electrospun Nanofibers Scaffolds and
Sintered Microsphere Scaffolds
An 8 weeks’ degradation study was conducted on the coaxial and the uniaxial elctrospun
nanofibers, as well as PLGA-Gelatin-mTG and PLGA-Gelatin-mTG Free microsphere scaffolds.
However, both uniaxial electrospun nanofibers and PLGA-Gelatin-mTG Free served as controls.
Briefly, the initial weights of all samples were recorded. Next, uniaxial and the coaxial elctrospun
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nanofibers groups were cut into (1 cm X 1 cm) squares and placed individually in the wells of 24well plates with the addition of 2 ml of PBS per well. PLGA-Gelatin-mTG and PLGA-GelatinmTG Free microsphere scaffolds were also placed individually in the wells of 24-well plates and
2 ml of PBS was added per well with an N=3 per time point for every group. PBS was completely
collected for pH measurements and replaced with fresh PBS every three days from all groups
throughout the 8 weeks. Three samples from every groups were harvested every week to assess
for weight loss, swelling rate and water uptake analysis. For weight loss analysis, the harvested
samples were air dried, and then stored at – 20 for 24 h. Samples were then freeze dried for 48 h
to insure complete removal of water. The lyophilized scaffolds were weighed and the change of
scaffold mass was recorded as a percentage of mass loss using the following formula:

𝑊𝑒𝑖𝑔ℎ𝑡 𝐿𝑜𝑠𝑠 𝑅𝑎𝑡𝑒 =

𝑊𝑖 − 𝑊𝑑
𝑋 100
𝑊𝑖

Where Wi is the initial weight, and Wd is the dry weight.
For swelling rate and water uptake analysis, samples were harvested, and the wet weight was
recorded directly. Next, samples were air dried, and then stored at – 20 °C for 24 h. Next samples
were freeze dried for 48 h to insure complete removal of water. The Swelling rate and water uptake
analysis were conducted using the following formula:

𝑆𝑤𝑒𝑙𝑙𝑖𝑛𝑔 𝑅𝑎𝑡𝑒 =

𝑊𝑤 − 𝑊𝑑
𝑋 100
𝑊𝑑

Where Ww is the wet weight, and Wd is the dry weight.
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Weight loss, swelling rates, water uptake and pH measurements were plotted against time in
weeks.

2.2.10. Statistical Analysis
Data are presented as mean ± standard deviation (SD). All statistical analyses were performed
using the Statistical Software Prism GraphPad (Version 5) using two-way Analysis of Variance
(ANOVA) with a Tukey test for Post Hoc parameter comparisons. Statistical significance was set
at p < 0.05.

2.3.Results
2.3.1. PLGA-Gelatin Coaxial and PLGA Uniaxial Electrospun Nanofibers Scaffolds
2.3.1.1. Scanning Electron Microscopy (SEM)
Both PLGA-Gelatin coaxial nanofibers and PLGA uniaxial nanofibers have been successfully
fabricated. Electrospinning PLGA-Gelatin resulted in a 9 cm X 9 cm fibrous mat with a thickness
of ~ 350 – 400 µm, whereas electrospinning PLGA alone resulted in ununiformed deposition of
nanofibers on the collector with less mat thickness when electrospun for the same duration of ~ 80
µm (Figure 2.4). Size distribution analysis on Image J revealed that the nanofiber size distribution
in both the coaxial and the uniaxial electrospun mats range between 400 nm - 1100 µm with an
average size diameter of 800 ± 155 nm in the coaxial case and 752 ± 175 nm in the uniaxial case
(Figure 2.5, Figure 2.6). PLGA coaxial and uniaxial electrospun nanofiber scaffolds had pore sizes
of 50 ± 41 µm and 53 ± 32 µm respectively. SEM images demonstrate the smooth surface of the
nanofibers in both groups. In addition, both coaxial and uniaxial seem to mimic the native tissue
ECM morphologically with high porosity throughout. The 8 weeks morphology analysis showed
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a slight change in morphology compared to the initial morphology in both groups (Figure 2.7,
Figure 2.8). However, after 5 weeks of incubation at 37 °C the coaxial group started swelling
significantly and showed change in morphology when compared to the uniaxial group. The change
in morphology was noticed due to the small pores created at the surface of the nanofibers.

Figure 2.4 PLGA-Gelatin coaxial electrospun nanofiber mat (A) a uniform deposition during
electrospinning (B) the resultant 9 x 9 cm coaxial electrospun mat, and (C) coaxial electrospun mat
thickness (400 um); and PLGA uniaxial electrospun nanofiber mat (D), uninform deposition of nanofibers
during electrospinning that can be noticed from the bigger mat area when compared to the coaxial group
(E), the resultant un-uniformly deposited mat, and (F) uniaxial electrospun mat thickness of ~ 80 µm when
electrospun for 1.5h, which is the same duration used for electrospinning PLGA-Gelatin that results in a
mat with a thickness of ~ 400 𝜇m.
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2.3.1.2. Transmission Electron Microscopy (TEM)
The interior structure of the composite fibers was investigated by TEM to confirm the presence of
the coaxial structure (Figure 2.9). As expected, the core-shell nanofibers had a clear core-sheath
structure with a core-sheath of ~ 781 nm, a fiber diameter of 1000 nm and a sheath thickness of
219 nm, while the uniaxial electrospun nanofiber, which served as control; did not have similar
interior morphology.

Figure 2.9. TEM images. (a) PLGA-Gelatin Coaxial nanofiber with a core-sheath of ~ 781 nm, a fiber
diameter of 1000 nm and a sheath thickness of 219 nm, and (b) Uniaxial nanofiber.
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2.3.2. PLGA-Gelatin-mTG and PLGA-Gelatin-mTG Free Sintered Microspheres
Scaffolds
2.3.2.1. Scanning Electron Microscopy (SEM)
PLGA Microspheres were successfully fabricated and sintered forming a highly porous and
interconnected 3D scaffold with pore size of 175 ± 87 µm and average microsphere size diameter
of (460 ± 95 µm). Sintered PLGA microsphere scaffolds incorporated with Gelatin-mTG and
sintered PLGA Gelatin-mTG Free scaffolds, which served as controls were visualized under SEM
for particle size and morphological analysis. SEM images showed the smooth surface and high
porosity throughout the 3D structure in both groups (Figure 2.10, Figure 2.11). Particle size
analysis revealed that the micro-particle size distribution was within the target diameter range of
300 - 600 μm. The incorporated gelatin in the PLGA-Gelatin-mTG group was also observed filling
the porosity within the microsphere structure, which indicates the complete penetration of the
hydrogel within the scaffold. Over the 8 weeks, microspheres in both groups did not show a
significant change in surface morphology (Figure 2.12, Figure 2.13). Only a slight increase in
surface erosion was gradually observed from the SEM images over time in both groups. However,
scaffolds in both groups started to loss structural integrity and brake down over the 8 weeks, which
was evidenced by the appearance of cracks between the adjacent microspheres. Cracks between
the adjacent microspheres started to appear starting from the 3rd week in the PLGA-Gelatin-mTG
free group, and from the 5th week in the PLGA-Gelatin-mTG group.
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2.3.3. PLGA Coaxial-Gelatin and PLGA Uniaxial Electrospun Nanofibers Scaffolds
Degradation Behavior
A comprehensive degradation study on PLGA-Coaxial and Uniaxial (control) nanofibers was
carried out. Weight loss, swelling rates and pH change of all scaffolds were evaluated over 8 weeks
period of time including the controls after incubation in PBS at 37C.
2.3.3.1.Weight loss: PLGA-Gelatin Coaxial nanofibers showed significant increase in weight loss
over time comparing to PLGA Uniaxial Nanofibers (Figure 2.14). Initially, PLGA-Gelatin
Coaxial group expressed higher weight loss comparing to the other group at weeks 1, 2, 3
and 4; but no significant difference was noted. The Coaxial group started significantly
losing weight at week four to the end of the experiment. This indicates that most of the
PLGA covering the outer shell of the coaxial structure have severely degraded over time
(Figure 2.8). This curve indicates that the structure is stable for the first 4 weeks, and then
it starts to lose its stability when it rapidly starts degrading starting at week 5.

Figure 2.14 Weight loss of PLGA-Gelatin coaxial nanofibers and PLGA uniaxial nanofibers curve over 8
weeks after incubation in PBS at 37 °C.
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2.3.3.2.Swelling: PLGA-Gelatin coaxial nanofibers showed significant increase in swelling rate
over time comparing to PLGA Uniaxial Nanofibers (Figure 2.15). Even though, PLGAGelatin Coaxial group expressed higher weight loss comparing to the other group at weeks
1, 2, 3 and 4; no significant difference was noted. Due to the sever degradation taking place
to the outer shell structure at week 5, water started to rapidly diffuse to the core structure
causing a significant increase in swelling rate over time in the PLGA-Gelatin coaxial group
comparing to the other group. These findings indicate that the structure is stable over the 8
weeks with more stability from week 1 – 4.

Figure 2.15 Swelling Rate of PLGA-Gelatin coaxial nanofibers and PLGA uniaxial nanofibers curve over
8 weeks after incubation in PBS at 37 °C.
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2.3.3.3.pH change: The pH curve clearly indicates the difference in the medium acidity between
the groups over time (Figure 2.16). PLGA-Gelatin coaxial Nanofiber showed a severe drop
in pH over time comparing to the other group. The drop in the pH indicates how the coaxial
structure accelerates the degradation rate of the nanofibers, by allowing water to rapidly
diffuse to the core structure causing the inner portion of PLGA shell to degrade too. Even
though the pH drop in the PLGA-Gelatin coaxial group was severe compared to the other
group, it was still within the neutral range ~ 6.9.

Figure 2.16 pH change of PLGA-Gelatin coaxial nanofibers and PLGA uniaxial nanofibers curve over 8
weeks after incubation in PBS at 37 °C.
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2.3.4. PLGA-Gelatin-mTG and PLGA-Gelatin-mTG Free Sintered Microsphere Scaffolds
Degradation Behaviors
A comprehensive degradation study on PLGA-Gelatin-mTG and PLGA-Gelatin-mTG Free
(control) scaffolds was carried out. Weight loss, water uptake rates and pH change of all scaffolds
were evaluated over 8 weeks period of time including the controls after incubation in PBS at 37C.
2.3.4.1.Weight loss: PLGA-Gelatin-mTG Free scaffolds showed higher weight loss over after 8
weeks compared to PLGA-Gelatin-mTG scaffolds (Figure 2.17). Both scaffolds expressed
almost similar weight loss rates in the first 6 weeks. PLGA-Gelatin-mTG Free started to
rapidly loss weight after week 7 compared to the other group. Weight loss was significantly
higher in PLGA-Gelatin-mTG Free compared to PLGA-Gelatin-mTG after 8 weeks of
incubation at 37 C which indicates that water diffusion is restricted from penetration
towards the core of the scaffold in the PLGA-Gelatin-mTG group due to the incorporation
of the Gelatin-mTG hydrogel within the scaffold.

Figure 2.17 Weight loss of PLGA-Gelatin-mTG microsphere scaffold and PLGA-Gelatin-mTG Free
microsphere scaffold curve over 8 weeks after incubation in PBS at 37 °C.
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2.3.4.2.Water uptake: Water uptake in PLGA-Gelatin-mTG scaffolds was higher compared to
the other group starting from the second week of the experiment (Figure 2.18). In the first
four weeks, water uptake was almost similar between the groups and no significant
differences was noticed. After week 4, water uptake started to rapidly increase in the
PLGA-mTG group comparing to the other group. At week 8, both groups had similar water
uptake rates, which indicate the complete degradation of gelatin within the PLGA
microsphere scaffold; which in turns decreased the water uptake rate in the PLGA-GelatinmTG group and brought both group to the same level of water uptake.

Figure 2.18 Water uptake of PLGA-Gelatin-mTG microsphere scaffold and PLGA-Gelatin-mTG Free
microsphere scaffold curve over 8 weeks after incubation in PBS at 37 °C.
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2.3.4.3.pH change: pH change behaviors was significantly different between the groups over the
8 weeks (Figure 2.19). PLGA-Gelatin-mTG group had a lower pH drop over time
comparing to the other group. This indicates that the embedded hydrogel within the
substrate is restricting water diffusion to the core of the scaffold, which in turn causes the
pH to slowly drop down due to the minimal degradation of the scaffold taking place at the
core of the scaffold, which in turns resulted in minimal acidic degradation byproducts
releasing to the surrounding medium. Even though large amount of water was restricted
from penetrating to the core of the scaffold, water still could penetrate easily through the
pores within the hydrogel based on the water uptake analysis; which would not negatively
affect cells performance.

Figure 2.19 pH change of PLGA-Gelatin-mTG microsphere scaffold and PLGA-Gelatin-mTG Free
microsphere scaffold curve over 8 weeks after incubation in PBS at 37 °C.
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2.4. Discussion:
Poly(lactide-co-glycolide) (PLGA) is one of the most extensively investigated biodegradable
synthetic polymer for a wide variety of tissue engineering applications such as bone, and soft tissue
engineering [1]. PLGA exhibits a wide variety of unique properties that made it the favorable
material for most researchers which include, excellent biocompatibility, tunable biodegradability,
mechanical properties, spatial delivery over growth factors and most importantly it is an FDA
approved polymer [1, 33].

PLGA undergoes degradation via non-enzymatic hydrolysis [35]. Its degradation by-products,
lactic acid and glycolic acid are natural metabolites and non-toxic. In addition, they can easily be
eliminated out of the body in the form of carbon dioxide and water through the normal body
metabolism process. One limitation associated with PLGA is that is lacks all the ligands required
for cell attachments and proliferation, which can result in poor cell adaption to the matrix and thus,
poor tissue formation [35]. Gelatin is a remarkable natural biomaterial that also has been widely
investigated as a promising implantable biomaterial for a number of tissue engineering
applications. [34] The most intriguing properties that attract research interests are its cell/tissue
compatibility, biodegradability, and functionality. In addition, gelatin inherits all the necessary
arginine-glycineaspartic acid (RGD) sequences that allow for enhanced cell adhesion, and it is less
immunogenic. The only limitation associated with gelatin is that it possesses very poor mechanical
properties that limit its use for load-bearing applications. The native ECM resembles some
properties that are found in synthetic materials only or natural materials only, therefore, composite
scaffolds are the best solution to address the disadvantages of both natural and synthetic scaffolds,
as it helps in the mutual enhancement of the scaffold properties and thereby allowing controlled
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degradation and mechanical properties as well as improving the biocompatibility, and providing
cells with all the necessary physical and chemical cues that are naturally inherited by the natural
ECM, to achieve the best possible biomimicry of the native ECM [36].

Scaffolds represent important components for tissue engineering. They act as temporary templates
for tissue regeneration and construction. However, the degradation properties, as well as the
morphological integrity of the scaffold, is of importance for effective tissue regeneration [35].

In this study, the three different phases were successfully fabricated and characterized. The
fabrication techniques in the synthesis of the three different phases varied, due to the fact that every
tissue type has its own specific ECM morphology, which had to be mimicked during the fabrication
process of these scaffolds. Phase A&B were fabricated from PLGA-gelatin coaxial electrospun
nanofibers to support fibroblast culture for soft tissue regeneration, and Phase C was fabricated
from gelatin embedded PLGA microspheres to support osteoblasts culture for bone regeneration.
The different phases were evaluated using SEM to determine the exterior surface morphology as
well as to assist in the particle size analysis. In addition, degradation behaviors of the three phases
were also evaluated over 8 weeks period of time, which included weight loss, swelling rate, water
uptake, and pH change analysis.

SEM images of the electrospun mats showed a highly porous fibrous structure in both groups the
coaxial and the uniaxial, which mimics the native tissue ECM morphology. Nanofiber size
distribution and average diameter have been found to be within the appropriate range for ligament
and skin tissue regeneration with nanofiber size diameter ranging between 400 nm – 1100 µm with
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an average size diameter of 800 ± 155 nm in the coaxial case and 752 ± 175 nm in the uniaxial
case [29]. The 8 weeks morphology analysis showed a slight change in morphology with noticed
fiber swelling over time. After 5 weeks of incubation at 37 C, the coaxial fibers started to
significantly swell and morphologically change when compared to the uniaxial group based on
SEM and the swelling analysis. Pores were created at the surface of the coaxial nanofibers starting
from the 5th week, increase the permeability of water and thus, causing rapid swelling to the
nanofibers.

TEM analysis were conducted on both the coaxial nanofibers and the uniaxial nanofibers, which
confirmed the coaxial structure in our nanofibers system. The difference between the core-sheath
to the sheath of the nanofiber was calculated to be ~ 219 nm, which suggest promising results for
a sustained and a controlled release of growth factors from the coaxial nanofibers.

Our results showed that over 8 weeks, PLGA-Gelatin coaxial nanofibers showed significant weight
loss and swelling rates (45%, 29%) when compared to the other group (18%, 9%), respectively,
after incubation in PBS at 37 °C. The results also revealed that PLGA-Gelatin Coaxial nanofibers
are stable for the first 4 – 5 weeks, which is considered to be enough time for healthy fibroblasts
to produce good amount of ECM in which they can attach after the severe degradation of PLGA
nanofibers [29]. Although our results showed a significant difference in pH drop over the 8 weeks
period of time in the coaxial group comparing to the Uniaxial group, the pH was still within the
neutral range (pH 6.9). PLGA nanofibers are known for their in vitro and in vivo stability and
morphological integrity for prolonged period of time, however, due to the fact that the coaxial
nanofibers possess a hollow structure at the core of their fibers, they are prone to swell more rapidly
when compared to the uniaxial nanofiber. The coaxial nanofibers display a smaller sheath
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thickness when compared to the uniaxial, this however, by its turn causes water to diffuse to the
core of the fiber more rapidly than the uniaxial, filling the core and causing a rapid swelling to the
fiber. The significant weight loss of the coaxial nanofibers when compared to the uniaxial
nanofibers is attributed to the polymer volume within the fiber. In the coaxial nanofibers, PLGA
occupies only ~ 21% of the total volume of the fiber, whereas the other 79% is occupied by the
gelatin located at the core-shell of the fiber. On the other hand, PLGA occupies 100% of the total
volume of the fibers in the uniaxial nanofibers. However, due to the less PLGA content in the
coaxial nanofibers, they exhibited a significant weight loss over time when compared to the
uniaxial.

Gelatin hydrogel incorporated within the microsphere scaffold was cross-linked with microbial
transglutaminase or mTG. Both gelatin and mTG are biocompatible and have no diverse effects
upon degradation [30]. Gelatin was incorporated within the microsphere matrix to serve as a drug
carrier for growth factor delivery. We chose gelatin because it has been demonstrated in several
reports that gelatin exhibits sustained and controlled local delivery with minimal burst release of
incorporated growth factors [32]. In addition, gelatin-mTG hydrogels have been shown to be good
candidate for cell-based approaches [31].

The degradation behavior of PLGA-Gelatin-mTG microsphere scaffold and PLGA-Gelatin-mTG
Free scaffold was also evaluated over 8 weeks period of time after incubation in PBS at 37 °C.
The incorporated gelatin hydrogel in the PLGA-Gelatin-mTG group restricted water from freely
penetrating throughout the structure resulting in a minimal weight loss over time comparing to the
PLGA-Gelatin-mTG Free group. In the gelatin group, degradation only occurred to the outer
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surface of the scaffold due to the presence of the gelatin in the other areas within the scaffold,
whereas in the other group, degradation took place throughout the entire structure equally (Figure
2.12, Figure 2.13).

Water uptake in the PLGA-Gelatin-mTG group was higher compared to the PLGA-Gelatin-mTG
Free in the first four weeks with no significant difference. At week 5 through week 7, water uptake
started to significantly increase in the gelatin group comparing to the PLGA-Gelatin-mTG Free
group. This indicates that small amount of water is penetrating through the gelatin hydrogel during
the incubation time. Although water was restricted from freely penetrating through the matrix, it
was able to penetrate through the hydrogel its self in small amounts, which can be good for cells
that migrate inside the hydrogel in culture. Since only the outer surface of the microsphere scaffold
in the PLGA-Gelatin-mTG is degrading over time, the surrounding medium should contain less
degradation by-products when compared to the other group. This has been further proven in the
pH change analysis where the pH in the PLGA-Gelatin-mTG Free group significantly dropped
over the 8 weeks when compared to the gelatin group. Although the change in pH was significant
in the PLGA-Gelatin-mTG free group, it was still within the neutral range.

Over the 8 weeks, microspheres in both groups did not show a significant change in surface
morphology, only a slight increase in surface erosion was gradually observed from the SEM
images over time in both groups. However, scaffolds in both groups started to loos structural
integrity and break down over the 8 weeks, which was evidenced due to the appearance of cracks
between the adjacent microspheres, with fewer cracks in the gelatin incorporated group. This is
how sintered PLGA microsphere scaffolds normally loss their mechanical and structural integrity
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over time when cultured at 37 C, cracks between the adjacent microsphere take place until all
microspheres are unfused, in addition to the surface erosion taking place at the surface of the
microspheres, simultaneously.

2.5 Conclusion
The different phases within the IGS have been successfully fabricated with a morphology
resembling those found at the native tissue and with the appropriate particle size. We were able to
verify the core-shell structure using TEM analysis. Degradation studies revealed that the water
uptake in PLGA-Gelatin-mTG was increasing over time, implying that water is penetrating
through the hydrogel, which indicates the suitability of the substrate for further cell-based studies.
Our results indicated that PLGA coaxial nanofibers are stable for up to 5 weeks, which is
considered to be enough time for fibroblasts to produce a sufficient amount of ECM in which they
can attach to upon the sever degradation of the substrate. Also, pH analysis showed that pH was
still within the neutral range after 8 weeks in all groups. These findings demonstrate the potential
of utilizing these scaffolds for further drug release and cell-based studies to investigate their
capability of supporting spatial release over growth factors, as well as enhancing cellular
performance such as cell attachment and proliferation.
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CHAPTER 3
IN VITRO EVALUATION OF PDGF-BB AND IGF-I RELEASE FROM COAXIALGELATIN, UNIAXIAL NANOFIBER SCAFFOLDS, AND BMP-2 FROM PLGAGELATIN-MTG INCROPORATED MICROPSERE SCAFFOLD
3.1.Introduction
Growth factors are soluble-secreted signaling polypeptides capable of instructing specific cellular
responses in a biological environment [1]. The specific cellular response trigged by growth factor
signaling can result in a very wide range of cell actions, including cell survival, and control over
migration, differentiation or proliferation of a specific subset of cells. Several growth factors have
extensively been used for tissue engineering applications such as BMP-2, for bone tissue
regeneration [5], PDGF-BB and IGF-I for mostly skin, and ligament tissue regeneration
applications respectively [6, 7]. These Growth factors are endogenously secreted in the body by
cells themselves, but in very minimal amounts that cannot aid in tissue regeneration in the case of
large trauma. This led to the importance of finding optimal methods to exogenously deliver these
molecules for tissue engineering applications. For therapeutic and regenerative effects, tissue
should be exposed to these exogenous growth factors with adequate doses for relatively long
timeframe, which can range from days to weeks. The use of high dosage, however, can results in
limited efficiency due to the short half-life most growth factors and undesirable side-effects, such
as neovascularization, or non-targeted tissue or growth of tumors in the context of delivery of
antigenic growth factors [2, 3]. The need of finding effective methods in delivering exogenous
factors has established much enthusiasm and numerous clinical trials, but the results of many of
these trials have been largely disappointing. Interestingly, the trials that have shown benefit all
contain a common denominator, the presence of a material carrier, suggesting strongly that spatial
and temporal control over the location and bioactivity of factors after introduction into the body is
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crucial to achieve tangible therapeutic and regenerative effect [4].

Polymeric materials have been extensively used to allow controlled, sustained, and local delivery
of growth factors, providing the necessary spatial and temporal gradients to regulate the extent and
pattern of tissue formation [4]. In addition, they can also allow to control the kinetics and dose of
protein release while also protecting the protein from degradation until released [4].

Growth factors can be incorporated into these polymeric delivery devices in a variety of different
ways in which the release rate can be tuned and controlled. A variety of processing techniques
have been developed to bypass issues of burst release such as incorporation of growth factors
coaxially in the core-shell of the fiber during electrospinning, or incorporating of factors in
hydrogels [4].

Electrospinning has been widely used as a drug delivery method for tissue engineering applications
[8, 9]. However, to overcome the burst release limitations associated with the conventional
uniaxial electrospinning methods, the introduction of the coaxial structure has come along the way,
which has been shown to overcome the problem of burst release [10]. Incorporation of growth
factors coaxially in the core shell of the polymeric nanofiber has been shown to exhibit precise
control over the location of the drug within the core-shell of the nanofibers [11] the main advantage
of coaxial electrospinning over the uniaxial is that it generates core and sheath fibers by physical
separation between the core and the sheath through the utilization of two electrospinning tips and
two solutions (Figure 3.1) [12]. The core generally contains the growth factor solution and the
sheath contains the polymeric solution. This nanofiber structure will allow for more of a spatial
control over growth factor delivery and will hugely minimize any possibility of burst release when
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compared to the conventional uniaxial nanofiber [12]. In addition, this process is used to load a
wide variety of agents into nanofibers that could potentially lose their bioactivity and functionality
unless they are in fluid or non-denaturing environment [12]. Advantages of the coaxial
electrospinning made it one area of a significant interest for many researches for more effective
drug delivery and thus, tissue regeneration.

Figure 3.1 Schematic of coaxial electrospinning setup, and the conventional uniaxial electrospinning setup.

Hydrogels have been also widely used as prolonged, sustained, and controlled release systems for
growth factors and other molecules [13]. Some of the most extensively used hydrogels include
alginate, chitosan, collagen and gelatin hydrogels [14]. Gelatin for instance, is well-known for its
prolonged growth factor delivery, characterized by a small initial burst release and showing no
tissue damaging residual material upon degradation [15]. Many ways can be employed in order to
crosslink gelatin such as physical, chemical or enzymatic crosslinking. However, physically
crosslinking gelatin generally results in mechanically weak construct due to the low degree of
crosslinking, which only occurs at the surface of the material and does not crosslink the gelatin all
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the way through. The chemical crosslinking of gelatin can result in cytotoxic side-effects or/and
immunological responses from the host upon implantation in vivo due to the toxicity of most of
the utilized chemicals. Compared to the previous two methods, enzymatically crosslinked gelatin
is considered the gold standard among all the crosslinking methods for crosslinking gelatin because
it results in strong mechanical properties due to the excellent crosslinking extent throughout the
hydrogel, and most enzymes are biocompatible and do not elicit any immunological responses
with the host after implantation. Despite the advantageous associated with the enzymatic
crosslinking of gelatin, most enzymes are very expensive [32]. Recently, studies have reported the
use of an enzyme named “Microbial Transglutaminase” or (mTG) for enzymatically crosslinking
gelatin [32]. Distinct from all the other enzymes, this enzyme is very cheap and it is widely
available. This enzyme has been proven to be biocompatible and noncytotoxic in crosslinking
gelatin and collagen-based scaffolds [33, 34]. Gelatin crosslinking can be initiated by mixing
various amounts of mTG with gelatin under certain conditions. The addition of mTG to gelatin
catalyzes the formation of an amide bond between the carboxylic acid groups of glutamic acid and
the ε-amino group of lysine, causing a complete crosslink to gelatin throughout [35]. Gelatin-mTG
hydrogel has been used as a drug delivery system and it was shown to cause retention to the
incorporated growth factor due to the covalent binding of the factor to gelatin initiated by mTG.
Retention of the growth factor, however, does not eliminate its bioactivates as shown in previous
reports [33].

The in vitro release profile of the covalently bound growth factors from enzymatically crosslinked
gelatin hydrogels undergoes two phases. In the first phase, a very minimal burst release of about
7-8% of the total loaded growth factor can be observed [15, 16]. The second phase, which shows
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the sustained and the controlled release of the remaining loaded factor is suggested to be based on
enzymatic degradation of the crosslinked gelatin through either exogenous degrative enzymes such
as collagenase type I or endogenous secreted enzymes such as cell-associated enzymatic activity,
therapy releasing the bound growth factor [13]. This implies that if the degrading enzymes are not
presented as part of the releasing medium, rapid release of the loaded growth factor will be hard
to be accomplished, resulting in very minimal release of the loaded growth factor over time [16].

In this aim, PDGF-BB and IGF-I were coaxially incorporated in the core-shell of PLGA nanofibers
and in vitro release studies were carried out over 30 days to examine the release profiles of these
two factors from the core-shell of PLGA nanofibers. In addition, BMP-2 was incorporated in an
enzymatically cross-linked gelatin hydrogel for a sustained and controlled release. The gelatin
hydrogel was used as a releasing carrier that was further injected within PLGA microsphere
scaffold to examine the release of BMP-2 from the incorporated PLGA microsphere scaffold with
gelatin-mTG/BMP-2. These evaluations are indeed essential to conduct in order to test the
aforementioned devices’ abilities in supporting spatial release over the incorporated growth
factors.
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3.2. Materials and Methods:
85:15 Poly(lactide-co-glycolide) (PLAGA) (MW ~ 94,000 kDa) was purchased from (Absorbable
Polymers, Birmingham, AL, USA), Hexafluoro-2-propanol (HFIP) was purchased from (Acros
Organics, USA), Gelatin Type A from Pork (Porcine skin) was purchased from (MP Biomedical,
OH, USA), Microbial Transglutaminase (mTG) was Purchased from (Ajinomoto, Japan),
Dichloromethane (DCM) was purchased from (Fisher Scientific, USA), PDGF-BB, IGF-I and
BMP-2 growth factors were purchased from (Fisher Scientific, USA), all ELISA kits were also
purchased from (Fisher Scientific, USA), collagenase type I powder was purchased from
(ThermoFisher Scientific, IL, USA), Alkaline Phosphatase Substrate Kit was purchased from
(BIO-RAD, CA, USA), Pierce BCA Protien Assay kit was purchased from (Thermo Scientific, IL,
USA), Dulbecco’s Phosphate-Buffered Saline (PBS) of pH 7.4, MEM Alpha (1X) Minimum
Essential Medium, Trypsin-EDTA (0.25%) phenol red, Penicillin-Streptomycin (10,000 U/mL),
and Fetal Bovine Serum (FBS) were purchased from Gibco (Grand Island, NY).

3.2.1. Fabrication of PLGA-Gelatin-PDGF and IGF-1 Coaxial Nanofiber Scaffolds
PLGA (85:15) granules were dissolved in HFIP at 16 % wt and stirred overnight at room
temperature to prepare the (shell solution) of nanofibers. To prepare the core solution, gelatin
powder type A was dissolved in HFIP at 4% wt and stirred overnight at room temperature. At the
day of electrospinning, both growth factors were reconstituted at a concentration of 1 mg/ml, and
81 µl of the reconstitution of either PDGF-BB and IGF-I were added to 1.5 ml of gelatin solutions
and stirred for 15 minutes to allow the growth factor to homogenize with the gelatin solution. An
electrospinning pump (NE 300 SYRINGE pumps, USA) was used in order to fabricate the coaxial
PLGA-Gelatin nanofibers. The setting to prepare the coaxial scaffolds consisted of two coaxial
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syringe pumps with different flow rates. In this study, the PLGA solution was used to form the
outer shell and the gelatin-growth factors solution was used to form the inner core. These two
solutions were loaded into two separate 10 ml syringes and connected to the coaxial needles, a
16 G (ID = 1.6 mm) outer needle and a 22 G (ID = 0.7 mm) inner needle, respectively, and then
concentrically placed. The electrospinning parameters were as follows: (applied voltage: 10 kV;
1.5 mL/h for the sheath flow rate and 0.75 mL/h for the core flow rate). The tip of the needle was
placed 10 cm away from the collector. The electrospinning process lasted for 1.5 h. Coaxial
electrospun nanofibers were peeled from the collector and stored under vacuumed desiccator for
24 hours to insure complete evaporation of solvent.

3.2.2. Transmission Electron Microscopy (TEM)
TEM analysis were conducted on both the coaxial and the uniaxial electrospun nanofibers
incorporated with PDGF-BB and IGF-I to evaluate the core structure efficiency. Observations
were prepared by directly depositing the spun fibers onto copper grids of 300 mesh. The samples
for TEM images were analyzed using (FEI Tecnai 12 G2 Spirit BioTWIN) transmission electron
microscopy and all images were recorded in GATAN ESW 500 camera.

3.2.3. Fabrication of PLGA-PDGF-BB and IGF-I Uniaxial Nanofiber Scaffolds
PLGA (85:18) granules were dissolved at 16% wt in HFIP with stirring to form clear,
homogeneous, and viscous solution. From the same patch used for the coaxial nanofibers
fabrication, reconstitution of both PDGF-BB and IGF-I were directly added to 3.5 ml of PLGA
solution and stirred for 30 minutes to allow the growth factor to homogenize with the polymer
solution. PLGA-growth factors solution was loaded into 10 ml plastic syringe and electrospun at
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flow rate of 0.75 mL/h through a 20-gauge blunt needle with the electrospinning pump NANON01A (MECC, Fukuoka, Japan) at an applied voltage of 10 kv. The tip of the needle was placed 10
cm away from the collector. The electrospinning process lasted for 1.5 h. Uniaxial electrospun
nanofibers were peeled from the collector and stored under vacuumed desiccator for 24 hours to
insure complete evaporation of solvent.

3.2.4. Fabrication of PLGA Microspheres
Single emulsion solvent evaporation technique was used to fabricate PLGA microspheres. PLGA
granules were dissolved at 12.5% wt in Dichloromethane (DCM) in glassy vials. Vials were
vortexed for 1 h at a speed of 550 RPM until clear, homogeneous, and viscous solution was
obtained. Next, PLGA solution was added via a thin stream into 1% PVA solution in a 1000 ml
beaker and it was let to stir at (300 RPM) overnight to allow the solvent to evaporate. After that,
microspheres were collected, filtered, air dried and then they were stored in -20 for 24 h to freeze
any residual water particle inside of the microspheres. Next, microspheres were freeze dried for
48 h and were then sieved to obtain the desired particle size range 300 – 600 µm.

3.2.5. Incorporation of BMP-2 in Gelatin-mTG Hydrogel
Gelatin gel formation was initiated by mTG addition. For hydrogel preparation, 3% wt gelatin
powder type A was dissolved in preheated phosphate-buffered saline (PBS) at 50 °C and it was let
to stir on a stirrer plate for 15 minutes at 500 RPM to completely dissolve the powder. The mTG
solution was prepared by dissolving 10% wt mTG in preheated PBS at 50 °C, then it was let to stir
on a stirrer plate for 15 minutes at 500 RPM. As soon as both gelatin and mTG completely
dissolved in PBS, the temperature of the stirrer plate was adjusted to 37 °C and they were let to
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stir for another 15 minutes to allow for the temperature drop. Next, to initiate the cross-linking
reaction between gelatin and mTG for the hydrogel preparation, mTG solution was mixed with the
3% wt gelatin solution at a ratio of 1:11.5 under stirrer speed of 500 RPM at 37 °C. The mixture
was let to stir for 5 minutes until a semi-viscus solution is fabricated and ready to be injected.
BMP-2 incorporation was done by adding 1 µg of BMP-2 in 100 µl of gelatin-mTG solution and
mix them gently.

3.2.6. Fabrications of PLGA Microspheres Scaffold Incorporated Gelatin/BMP-2-mTG
To fabricate the three-dimensional scaffolds and use it to incorporate gelatin-mTG/BMP-2
hydrogel within it, PLGA microspheres were poured into a (10 mm x 10 mm) stainless steel mold
and heated for 90°C for 90 minutes. These parameters allowed the microspheres to fuse together
forming the 3D scaffolds. After 90 minutes, the stainless-steel mold was removed from the oven
and allowed to cool to room temperature for 2 hours. Next, scaffolds were removed and the semiviscus gelatin-mTG/BMP-2 hydrogel was injected inside of the microsphere scaffold using an
insulin syringe until all porosity were filled and it was allowed to gel at 37 °C for 1 hours.

3.2.7. In vitro PDGF-BB and IGF-I Release from Coaxial and Uniaxial PLGA Electrospun
Nanofiber Scaffolds
The resultant coaxial electrospun nanofibers scaffolds (N=5) were cut into (1 cm X 1 cm) squares,
and the uniaxial electrospun nanofibers scaffolds (N=5) were cut into (1.5 cm X 1.5 cm) squares
were loaded into 5 ml glassy vials after. The glassy vials were filled with 2 ml of PBS with pH 7.4
and were then placed on an orbital shaker at 37 °C. At predetermined time points (0, 1, 4, 6, 8 h
and then every day for 2 weeks, and then every week for 2 weeks), 125 µl from each sample were
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collected and replaced with 125 µl fresh PBS. Collected samples were stored at – 20 °C for later
analysis. The release profiles of PDGF-BB and IGF-I were analyzed using ELISA-kit following
the manufacturer’s instructions. Cumulative release over a period of 30 days was performed on all
samples. The protein content in the nanoﬁbers for the two electrospinning methods (coaxial and
uniaxial) was determined by base-surfactant method [24]. Briefly, Scaffolds of each group (N =
5) were subjected to hydrolysis in 0.1N NaOH, 5M Urea, 0.08% SDS in 50 mM Tris extraction
medium at 37 °C for 3 h. After neutralization with 0.1N HCL and centrifugation, the protein
concentration in the supernatant was measured using ELISA kits.

3.2.8. In vitro BMP-2 Release from PLGA-Gelatin-mTG Scaffolds
PLGA-Gelatin-mTG Microsphere scaffolds were loaded into 5 ml glassy vials and filled with 5
ml of PBS with pH 7.4 and they were then placed on an orbital shaker at 37 °C. At predetermined
time points (0, 1 4, 6, 8 h and then every day for 2 weeks), 250 µl from every sample were collected
and replaced with 250 µl fresh PBS. Collected samples were stored at – 20 °C for later analysis.
The release profiles of BMP-2 was analyzed using ELISA following the manufacturer’s
instructions.

3.2.9. Extraction of BMP-2 from Gelatin-mTG Hydrogel
The same scaffolds from the release experiment were harvested and used for the extraction step to
examine the amount of BMP-2 left, and to ensure that the protein is remained and it wasn’t digested
or lost during the preparation or the injection step. In order to extract the protein, the gelatin
hydrogel had to be digested first. First, every scaffold was placed in a new 5 ml vial and was filled
with 5 ml of 0.1% collagenase type I solution in PBS. Vials were placed in an orbital shaker and
were left to agitate for overnight at 37 °C at a maximum speed to insure a complete digestion of
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the gelatin hydrogel within the microsphere scaffold. The next day, the solution content from every
vial was collected and assayed using ELISA-kit for BMP-2 content after neutralization with 0.1N
HCL and centrifugation. Results were plotted as a function of remaining BMP-2 content and were
compared to the control, which underwent the same digestion procedure. The control in this case
was PLGA microsphere scaffold incorporated with gelatin-mTG hydrogel without BMP-2.

3.2.10. Alkaline Phosphate Activity Assay
To examine the bioactivities of the retained BMP-2, MC3T3 cells were seeded on PLGA-GelatinmTG incorporated microsphere scaffolds and ALP activities were measured on days 7 and 14.
Briefly, PLGA-Gelatin-mTG scaffolds were placed in triplicates/ group in low-binding 24-well
plates, and MC3T3 cells were seeded on every scaffold at a density of 5 X 104 cells/scaffold. Three
experimental groups were included in the study, PLGA-Gelatin- mTG/BMP-2 (100 ng/scaffold),
PLGA-Gelatin-mTG with BMP-2 physically adsorbed on the surface (100 ng/ scaffold) (positive
control), and PLGA-Gelatin-mTG without BMP-2 (negative control). 1 mL of αMEM culture
medium supplemented with 10% Fetal bovine serum (FBS), and 1% Penicillin Streptomycin (p/s)
was added to every well and medium was change every 3 days during the experiment length. At
the predetermined time points, culture medium was removed, scaffolds were watched twice with
PBS, and then 500 µl of 0.25 trypsin solution was added to every well to detach the cells from
every scaffold. The detached cells were then collected, and centrifuged at 1500 RPM for 5 minutes
to get a pellet. Pellet was disturbed with PBS and the centrifugation step was repeated twice to
insure the complete removal of any trypsin or medium residual. Cells were then lysed in 0.1 %
Triton X-100 through a freeze-thaw cycle. Cells were then centrifuged and the cell layer
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supernatant was collected for every sample to be assayed for total protein (BCA) and ALP content.
ALP results were then normalized to BCA data for more accurate results.
3.2.11. Statistical Analysis
Data are presented as mean ± standard deviation (SD). All statistical analyses were performed
using the Statistical Software Prism GraphPad (Version 5) using two-way Analysis of Variance
(ANOVA) with a Tukey test for Post Hoc parameter comparisons. Statistical significance was set
at p < 0.05.

3.3.Results:
3.3.1. PDGF-BB and IGF-I Release from Coaxial and Uniaxial Electrospun Nanofiber
Scaffolds
Coaxial and uniaxial nanofibers for each growth factors had almost similar average protein content
of 1000 ± 201 ng for coaxial PLGA-Gelatin-PDGF and 994 ± 189 for uniaxial PLGA-PDGF,
where the coaxial PLGA-Gelatin-IGF-I had an average protein content of 989 ± 190 ng and 991
± 181 for the uniaxial PLGA-IGF-I. Both PDGF-BB and IGF-I demonstrated a sustained and a
controlled release kinetics over the 30 days period of time from the coaxial nanofibers in
comparison with the uniaxial nanofibers (Figure 3.2). A notable high burst release of both growth
factors from the uniaxial nanofibers was detected in comparison with the coaxial, which showed a
very minimal burst release at the beginning and continued on releasing both growth factors in a
sustained and controlled fashion. Compared to the uniaxial nanofibers of both growth factors,
which released all the encapsulated PDGF-BB and IGF-I in ~ 14 days, the coaxial nanofibers could
sustain the release till 21 days. Overall, PDGF-BB showed a slower release in both cases the
coaxial and the uniaxial in comparison with the release of IGF-I from both the coaxial and the
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uniaxial.

Figure 3.2 PDGF-BB and IGF-I release profiles from coaxial and uniaxial PLGA electrospun
nanofibers. (A) PDGF-BB release profile from coaxial nanofibers and uniaxial nanofibers, (B) TEM image
showing PDGF-BB in the core sheath of PLGA nanofiber with a sheath thickness of 284 nm, (C) IGF-I
release profile from coaxial nanofibers and uniaxial nanofibers and (D) TEM image showing IGF-I in the
core sheath of PLGA nanofiber with a sheath thickness of 137 nm.

3.3.2. BMP-2 Release from Gelatin-mTG Incorporated Microsphere Scaffolds
The potential of the injectable Gelatin-mTG gel to serve as a protein delivery vehicle was evaluated
in vitro by following the release of BMP-2 from the gels as a function of time. After the collection
of all the samples during the 14 days release study, they were used to conduct ELISA assay in
order to determine the amount of protein released at every collected time point. No significant
release was detected during the 14 days indicating that BMP-2 was retained within the hydrogel.
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In order to validate this, we digested cross-linked gelatin within the microsphere scaffolds using
0.1% collagenase solution in order to release the protein to the medium, and the supernatant was
collected and used to assay the protein content. We found that in all the 5 samples the protein was
retained inside of the hydrogel and has not been released during the 14 days release study (Figure
3.3). The average retained protein from the 5 samples was calculated to be 967.5 ± 205 ng.

3.3.3. Alkaline Phosphate Activity of MC3T3 Seeded on PLGA-Gelatin-mTG/ BMP-2
Microsphere Scaffolds
In order to evaluate the osteoinductivity of the retained protein and its ability to stimulate cellular
behaviors when retained has been evaluated by conducting an ALP experiment for 14 days. At day
7, the physically adsorped-BMP-2 group had a higher ALP content when compared to the retained
BMP-2 group, and significantly high when compared to the negative control group (Figure 3.3).
At day 14, ALP content was the highest in the retained BMP-2 group when compared to the addedBMP-2 group, and significantly higher when compared to the negative control. These data
demonstrate that the retention of BMP-2 did not negatively affect the osteoinductivty and thus,
resulted in enhancing ALP activities in MC3T3 cells over time.
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3.4.Discussion:
Growth factors can be incorporated into these polymeric delivery devices in a variety of different
ways in which the release rate can be tuned and controlled. A variety of processing techniques
have been developed to bypass issues of burst release such as incorporation of growth factors
coaxially at the core-shell of the nanofiber during electrospinning, or incorporating of factors in
hydrogels.

The beauty of the electrospinning technique is that it offers a possibility of incorporating protein
growth factors within polymer nanoﬁbers, which could then serve as a source of continued and
controlled release of the growth factor [18, 19, 20, 21, 22]. Coaxial electrospinning is a modified
version of the conventional uniaxial technique, which allows for more of a prolonged, sustained
and controlled release rates of the incorporated protein [23]. During coaxial electrospinning, the
growth factor solution, which intended to be at the core-shell of the nanofiber, is physically
separated from the polymer solution, which acts as the sheath for the core. They are then
electrospun simultaneously with varying electrospinning parameters through two overlapping
needles and then collected. This results in a very organized structure of a nanofiber that consist of
a growth factor incorporated at the core-shell, and a polymeric sheath that covers the core.
Depending on the degradation rate of the polymeric sheath, the release rate can be tuned [4].

Such a method, not only offers the possibility of exhibiting a controlled and sustained release, but
also protects the protein from the organic solvent used to dissolve the outer polymeric coat, and
also enables electrospinning of a protein solution that is otherwise not ‘‘electro-spinnable” [18,
21].
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Another considerable method of growth factor delivery is through incorporating the protein within
hydrogels, such as gelatin. Enzymatically crosslinked gelatin hydrogels possess great
characteristics in providing a sustained and controlled release of growth factors [25]. As discussed
previously, growth factors incorporated within enzymatically crosslinked gelatin hydrogels
undergo two release profile phases, as the first exhibits a very minimal burst release, while the
second phase exhibits a prolonged and sustained release of incorporated growth factor over time
[13, 15, 16]. Therefore, these observations suggest that gelatin is a great candidate for drug
delivery-based approaches.

In this aim, PDGF-BB and IGF-I were either coaxially incorporated in the core shell of PLGA
nanofibers or directly blended with the polymer solution and in vitro release studies were
conducted over 30 days to examine the release profiles of these two factors from the core-shell of
PLGA nanofibers and from PLGA nanofibers. In addition, BMP-2 was incorporated in an
enzymatically cross-linked gelatin hydrogel for a sustained and controlled release. The gelatin
hydrogel was used as a drug carrier that was then injected within PLGA microsphere scaffold to
examine the release of BMP-2 from the incorporated PLGA microsphere scaffold gelatin-BMP-2.

The protein content has been evaluated in both coaxial and uniaxial nanofibers of both growth
factors. This was done by cutting the resultant coaxial electrospun scaffolds into 1 cm X 1 cm and
the uniaxial electrospun scaffolds into 1.5 X 1.5 cm with an N= 5 each, and measuring the protein
content in all samples using ELISA kits. However, it was found that coaxial and uniaxial
nanofibers for each growth factors had almost similar average protein content of 1000 ± 201 ng
for coaxial PLGA-Gelatin-PDGF and 994 ± 189 for uniaxial PLGA-PDGF, where the coaxial
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PLGA-Gelatin-IGF-I had an average protein content of 989 ± 190 ng and 991 ± 181 for the
uniaxial PLGA-IGF-I. Based on these data, we were able to determine the protein content as a
function of scaffold dimension for every growth factor in every case. Where all coaxial electrospun
nanofiber scaffold had a protein content of ~ 1 µg/ 1cm x 1cm, and all uniaxial electrospun
nanofiber scaffolds had protein content of ~ 1 µg / 1.5 cm x 1.5 cm for both factors.

The release data revealed that both PDGF-BB and IGF-I demonstrated a sustained and a controlled
release kinetics over the 30 days period of time from the coaxial nanofibers in comparison with
the uniaxial nanofibers as shown in the previous (figure 3.2). This demonstrate the spatial control
offered by the coaxial nanofibers over the uniaxial. A high notable burst release of both growth
factors from the uniaxial nanofibers was detected in comparison with the coaxial, which showed a
very minimal burst release at the beginning and continued on releasing both growth factors in a
sustained and controlled fashion. The initial burst release from the uniaxial nanofibers was due to
the facts that some of the growth factors was present at the surface of the nanofibers, which caused
the burst release as soon as the scaffold was submerged in the releasing medium. Distinct from the
uniaxial, growth factors in the coaxial nanofibers are all contained at core-shell of the nanofiber,
which minimized the chance of a burst release as shown in a previous work [26].

Compared to the uniaxial nanofibers of both growth factors, which released all the encapsulated
PDGF-BB and IGF-I in ~ 14 days, the coaxial nanofibers could sustain the release till 21 days.
Overall, PDGF-BB showed a slower release in both cases (the coaxial and the uniaxial) in
comparison to the release of IGF-I from both the coaxial and the uniaxial. This may be due to the
fact that the difference in thickness between the core-shell and the sheath in the coaxial-PDGF-BB

244

nanofiber was larger than in the coaxial-IGF-I, which in turns delayed the release of PDGF-BB
when compared to IGF-I (Figure 3.4). Another reason may be attributed to the molecular mass of
each protein, where the mass of PDGF-BB is 12.3 kDa and IGF-I is 7.6 kDa. It is well-known
based on the literature that the release kinetics from any device is dependent on the protein
molecular mass, in which the smaller the protein molecular mass the faster it releases, and the
larger the protein molecular mass, the slower and more sustained it releases. This implies that if
small and large molecular mass proteins were incorporated in the same exact device, the release
profiles will vary due to the variation in the protein molecular mass [17].

(A)

(B)

Figure 3.4 TEM images of PLGA coaxial electrospun nanofibers with growth factors incorporated
at the core-shell of the nanofiber (A) TEM image showing PDGF-BB in the core sheath of PLGA
nanofiber with a sheath thickness of 284 nm, (B) TEM image showing IGF-I in the core sheath of PLGA
nanofiber with a sheath thickness of 137 nm.

The potential of the injectable gelatin-mTG gel to serve as a protein delivery vehicle was evaluated
in vitro by following the release of BMP-2 from the gels embedded in PLGA microsphere scaffolds
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as a function of time. After the collection of all the samples during the 14 days release study, they
were used to conduct ELISA assay in order to determine the amount of protein released at every
collected time point. No significant release was detected during the 14 days suggesting that BMP2 was retained within the hydrogel. In order to validate this, we digested the cross-linked gelatin
embedded within the microsphere scaffolds using 0.1% collagenase solution in order to enable the
release of the bound protein to the medium, and the supernatant was collected and used to assay
the protein content. We found that in all the five samples the protein was retained inside of the
hydrogel and has not been released during the 14 days release study (Figure 3.3). The average
retained protein from the five samples was calculated to be 967.5 ± 205 ng. This implies that the
low protein release from the enzymatically crosslinked gelatin hydrogel was attributed to the
covalent bonding initiated between BMP-2 and gelatin as a result of the enzymatic crosslinking
with mTG, which resulted in a complete retention to the protein [33]. In fact, a previous study has
shown that the release of BMP-2 from the enzymatically crosslinked gelatin hydrogel is very hard
to be accomplished in vitro with the absence of a degrative enzyme. In this study, they revealed
that the incubation of gelatin-mTG hydrogels in collagenase containing medium could accelerate
the degradation of hydrogel when compared to incubation in normal medium, therapy enabling the
bound protein to be released [33]. In our current study, gelatin-mTG was incubated in normal PBS
that did not contain any degrative enzymes. This, however, explains the reason for the complete
retention of BMP-2 in gelatin-mTG in our case.

Because collagenase was found to be selective toward digesting both gelatin crosslinked with mTG
and non-crosslinked gelatin and had no effect on BMP-2, it was chosen as a digestion agent in the
current study to free the immobilized BMP-2. Although the binding sites where gelatin attaches
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onto BMP-2 still need to be elucidated, they do not seem to be covalently binding to the active
sites of BMP-2. When gelatin-mTG/BMP-2 is exposed to collagenase, these covalent bonds
between gelatin and non-active sites of BMP-2 get digested by the added collagenase, however, if
the bonds occurred at the BMP-2 active site, the residual gelatin fragment after digestion would
have blocked the BMP-2 active site permanently [33].

To further examine the osteoinductivity of the retained protein and its ability to stimulate cellular
behaviors when retained, ALP experiment has been conducted for 14 days. At day 7, the physically
adsorbed-BMP-2 group had a higher ALP content when compared to the retained BMP-2 group,
and significantly high when compared to the negative control group. This is because cells in the
physically adsorbed BMP-2 were in a direct contact with the protein, which was bound to their
BMP receptors upon seeding, stimulating them to achieve higher ALP levels in the first 7 days
when compared to the cells in the retain BMP-2 group, which had to invade inside of the
microsphere scaffold to come in a direct contact with gelatin-mTG/BMP-2 and start secreting cellassociated enzymes in order to degrade the crosslinked gelatin to free the bound BMP-2. At day
14, ALP content was the highest in the retained BMP-2 group when compared to the physically
adsorbed-BMP-2 group, and significantly higher when compared to the negative control. This is
due to the fact that in the retained BMP-2 groups, the protein was releasing in a sustained and
controlled manner upon the enzymatic degradation of the crosslinked gelatin by the cell-associated
enzymes activity, whereas in the physically adsorbed BMP-2, the entire protein was removed
during the medium change at day 7, which caused the ALP activities to drop over time. These data
demonstrate that the retention of BMP-2 did not negatively affect the osteoinductivity of the
retained factor and thus, resulted in enhancing ALP activities in MC3T3 cells over time.
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Previous reports have shown positive correlation between the retention of BMP-2 within the matrix
upon implantation and the osteoinductive activity, owing to its significantly short in vivo half-life
[30, 31]. On the other hand, several other studies have shown that direct injection of BMP-2 does
not result in bone formation in the absence of a suitable carrier [27]. Clinical delivery of BMP-2,
thus involves adsorption on a collagen sponge, which shows a burst release due to weak matrix–
protein interactions [28, 29]. The burst release along with the supraphysiological doses used
however, leads to side effects such as inflammation and ectopic bone formation. These findings
demonstrate the potential of retaining BMP-2 within the gelatin matrix in maintaining the levels
of osteoinductive activities of BMP-2 in vitro and in vivo.

3.5.Conclusion:
In conclusion, incorporation of growth factor coaxially at the core-shell of coaxial PLGA
nanofibers resulted in a prolonged, sustained and controlled release of both growth factors PDGFBB and IGF-I. Although both factors were incorporated within the same carrier, PDGF-BB
expressed a slower release profile when compared to IGF-I. This might have been due to the
thickness variations between the core-shell and the sheath in both growth factor carriers, or due to
the fact that PDGF-BB has a larger molecular mass of 12.3 kDa when compared to IGF-I, which
has a molecular mass of 7.6 kDa. Incorporation of BMP-2 within gelatin resulted in the retention
of the protein. The retained proteins’ bioactivities and osteoinductivites were examined through
the ALP study conducted, resulting in an increase of ALP induction of the seeded MC3T3 cells
over time for 14 days. This suggest that retention of the protein doesn’t affect its bioactivities nor
osteoinductivites. Our data suggest that both the coaxial nanofibers and gelatin-mTG are two
promising drug carriers for effective tissue regeneration.
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CHAPTER 4
PRIMARY CELL ISOLATION, AND IN VITRO BIOCOMPATIBILITY AND
CHARACTERIZATION OF THE THREE DIFFERENT CELLS CULTURED WITH
THE RELEVANT PHASES
4.1.Introduction

The goal of regenerative engineering is to design a system capable of facilitating the regeneration
of lost or damaged tissues. This may be accomplished by combining various species from the three
primary components of tissue engineering: cells, growth factors and scaffolds.

4.1.1. Cells
Cells are the building blocks of the of tissues in the living organism, it is believed that cells present
in the grafted tissue play a crucial role in effective and promising tissue healing and regeneration.
Currently, most tissue engineering approaches involve isolating and expanding cells in vitro [1].
However, Cell source is an important parameter to consider when applying tissue engineering
strategies to restore lost tissue and function [1].

Primary cells for instance, also referred to as mature cells, are differentiated cells that are
committed to performing given cell type-specific functions. These cells are generally obtained
via primary cultures originating from small pieces of donor tissue. For example, a small skin
biopsy may be performed in order to isolate keratinocytes and dermal fibroblasts, the two main
cell types in skin, or bone biopsy in order to isolate osteoblasts, the main cell type responsible for
the synthesis of collagen type I in bone. Once isolated, these cells may be cultured and expanded
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in vitro to yield the desired number of cells required for creation of tissue-engineered skin or bone
[2].

One advantage of using mature cells in tissue engineering strategies is that it enables tissueorgan regeneration using the patient’s own cells, thus eliminating concerns of immunogenicity.
Additionally, many works have concentrated on characterizing many mature cell types and their
responses to various biological factors, thus facilitating the tissue engineer’s ability to predict and
control cell behavior and tissue formation. However, in situations where a tissue sample of
proliferative cells can be obtained using minimally invasive means, the use of primary cells as a
component of the tissue engineering platform represents a viable strategy. Hence, skin, ligament
and bone are examples of tissues that contain readily accessible mature cells that can grow
outside the body and remain capable of generating their corresponding tissue type [3].

4.1.1.1.Primary Dermal Fibroblasts
Dermal fibroblasts are resident mesenchymal cells that are found between the epidermis and the
hypodermis layer of the skin. Dermal fibroblasts are primarily responsible for synthesizing
collagen, glycosaminoglycan and some other protein molecules including laminin and fibronectin
[3,4]. These synthesized components by dermal fibroblasts support the structural and mechanical
integrity of the skin. In addition, dermal fibroblasts are responsible for creating long fibrous bands
of connective tissue which anchor the skin to the fascia of the body during skin. Therefore, without
dermal fibroblasts, the largest and heaviest organ would not tightly adhere to body's frame. Dermal
fibroblasts have been shown to play a vital role in supporting cutaneous wound healing and skin
repair [3]. More importantly, autologous dermal fibroblasts are believed to promote skin
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regeneration and rejuvenation, making them an ideal cell source for wound healing applications
[5]. The wound healing process undergoes four major phases: homeostasis, inflammation,
proliferation and remodeling [6]. During the third proliferative phase of the wound healing process,
dermal fibroblasts begin to proliferate and migrate into the wound bed to produce extracellular
matrix (ECM) proteins, which makes them critical during this phase. Extracellular matrix protein
serves as a scaffold for inflammatory cell migration and granulation tissue generation. The
generated granulation tissue act as a temporary substrate upon which re-epithelization by
keratinocytes takes place to start regenerating the epidermal layer. In addition to the vital role of
dermal fibroblasts in synthesizing the extracellular matrix through the production of ECM proteins
and supporting re-epithelization, they further differentiate into myofibroblasts that generate wound
contracture. Later, myofibroblasts-derived dermal fibroblasts undergo apoptosis resulting in a
decreased cellular density while the remaining dermal fibroblasts begin to produce collagen type
I. The unique plasticity of dermal fibroblasts as it transitions from producing ECM to promoting
wound contracture to the synthesis of Type I collagen makes it an attractive candidate for cellular
based therapies in wound healing [5, 6].

Dermal fibroblasts can be obtained through simple biopsy procedures where the skin is thoroughly
cleaned and a small injection of a local anesthetic to numb the skin is made. A sample of skin is
then taken by a biopsy from the numb area of the skin. The sample is then transferred under sterile
conditions to for dermal fibroblasts isolations. Once isolated, these cells may be cultured and
expanded in vitro to yield the desired number of cells required for creation of tissue-engineered
skin [7]
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4.1.1.2.Primary Ligament fibroblasts
Ligament fibroblasts are the main cell type of ligament, and are found entrapped with the collagen
matrix of the ligament tissue. Ligament fibroblasts are primarily responsible for synthesizing
collagen types I and III along with some other extracellular matrix proteins such as proteoglycans,
elastin, fibronectin and laminin [8, 9]. Proteoglycans and elastin provide the ligament with the
mechanical and structural support, whereas fibronectin and laminin serve as adhesive proteins [9].
These fibroblasts are also responsible for maintaining, repairing, and remolding of the ligament
[9]. Several studies have demonstrated the ability of ligament fibroblasts to enhance ACL
regeneration marking them as the most suitable cells for the further study and development of
tissue-engineered ligament [10]. In addition, pre-seeded grafts with mature ligament fibroblasts
and implanted in a rabbit ACL model were shown to result in extensive collagen type I and III
production as well as α-smooth muscle actin [11]. These findings demonstrate the potential of
primary ligament fibroblasts to serve as a candidate for ligament tissue engineering.

Ligament fibroblasts can be obtained through biopsy procedures, where the knee joint is extended,
and the area around the knee is deeply cleaned. A needle can be then inserted until it reached the
ACL, and the biopsy can be taken. The sample is then transferred under sterile conditions to for
ligament fibroblasts isolations. Once isolated, these cells may be cultured and expanded in vitro to
yield the desired number of cells required for creation of tissue-engineered ligament [12]

4.1.1.3.Primary Osteoblasts
Osteoblasts are single nucleated cells and one of the three cell types found in human bone. They
are specialized terminally differentiated products of mesenchymal stem cells that are responsible
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for synthesis the bone’s dense crosslinked collagen matrix including osteocalcin, osteopontin,
osteonectin, osteoprotegerin (OPG), bone morphogenetic proteins (BMPs), and glycoproteins
which compose the organic matrix of bone [13].

In organized and well-connected groups, osteoblasts participate in matrix mineralization through
the production and deposition of hydroxyapatite and calcium phosphate, which provide strength
to the bone. When an osteoblast is entrapped into the collagen matrix, it becomes an osteocyte, the
most abundant cell type in bone. Bone is a dynamic tissue that is constantly being remodeled by
osteoblasts, which produce and secrete matrix proteins and transport mineral into the matrix,
and osteoclasts, which break down the tissues. Bone remodeling is a continues process that lasts
during the human’s life maintaining the hemostasis of bone [13, 14]. Osteoblasts play a vital role
in bone formation, growth and repair, as they are solely responsible for formation of the bony
matrix [15]. Several studies have demonstrated the ability of osteoblasts to adapt with several
substrates during osteogenesis, owing their vital role in bone tissue engineering [16, 17, 18].

Bone osteoblasts can be easily obtained from individuals through a bone biopsy procedure, where
an incision through the skin is made to expose the area of the bone, followed by a needle insertion
and extraction of the bone. The bone is then taken under sterile condition, where it undergoes
digestion step to isolate the cells. Once isolated, these cells may be cultured and expanded in vitro
to yield the desired number of cells required for creation of tissue-engineered bone [19].
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4.1.1.4.Primary Cells Characterization
Primary cells are generally isolated from heterogeneous cellular environment, thus, characterizing
their phenotype is important to ensure the homogeneity of the isolated cellular population. The
phenotype of primary cells can be characterized either by their morphology, or based on the
expression of specific cellular markers such as proteins or gene expressions. Morphological
characterization is the simplest and the most direct way to characterize primary cells, and it is done
by observing the cell size, shape and structure. For example, fibroblasts can easily be identified by
their elongated flattened, oblong or triangular cytoplasm structure [20], and osteoblasts can be
identified by their round, flattened structure [21]. On the other hand, cells can also be identified
through the detection of specific markers such as proteins or genes that are only expressed by these
cells via a specific combination of antibodies and the target antigen. These bound antibodies can
then be detected using several different methods. For example, Immunocytochemistry (ICC) is
one common method that is extensively being used in order to evaluate whether or not cells in a
particular sample express the protein or gene in question. Briefly, an antibody is a secreted gene
or protein that is found at the surface of the cell or intracellularly and it acts as a receptor for
antigens. An antigen is a molecule that is produced to match a specific antibody intracellularly or
at the surface of the cell after it comes into contact with it. Once the antigen is specifically bound
to the antibody of interest, it can then be labeled with a secondary antibody for the detection of the
expression of certain genes or proteins in the sample. In case the antigen was not specific to the
antibody of interest (protein, gene), the secondary antibody will not find an antigen to bind into,
and therapy no response will be initiated. However, in cases where the antigen is bound to the
antibody if interest, the secondary antibody will find antigens to bind into resulting in the initiation
of a tailored response that can be seen as colors or a fluorescent tag. The samples can then be
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visualized using a fluorescence microscope to confirm the expression of the protein or the gene of
interest [22].

4.1.1.5.Morphological Characterization and Specific Markers of Primary Dermal
Fibroblasts
4.1.1.5.1. Morphological Characterization
Freshly isolated dermal fibroblasts can morphologically be identified by their well-known
elongated flattened form, oblong or triangular. Dermal fibroblasts exhibit thicker central parts of
the body and two narrow peripheral processes with smooth lateral edges. They may be 50 to 100
µm long, up to 30 µm at its broadest, and only about 3 µm at its thickest [20].

4.1.1.5.2. Dermal Fibroblasts Specific Marker
The lack of suitable dermal fibroblasts marker led to the poor understanding of the mechanisms
that control the growth and activation of fibroblasts in vivo [29]. Recently, the effort of biologist
led to the discovery of several markers that are believed to be specific for dermal fibroblasts and
are used to confirm their phenotype [29]. Two of the most commonly measured dermal fibroblastic
markers are Vimentin and TE-7.

4.1.1.5.2.1.Vimentin
Vimentin is an intracellular protein mainly located in the cytosol and it has been shown to be
involved in wound healing in that it coordinates fibroblast proliferation and keratinocyte
differentiation during healing process [24]. Vimentin is one of the most commonly used marker to
identify dermal fibroblasts, and it can also be expressed in cells of mesenchymal origin including
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mayofibroblasts [23]. Recent data showed that it plays a vital role in numerous cellular processes,
with functions in cell adhesion, migration and invasion, signaling, differentiation, cytoskeletal
rearrangements, and regulation of cell morphology and plasticity [24]. In relation to tissue repair,
vimentin has been also shown to be involved in mesenchymal repair cells during to regulate the
collective movement of the lens epithelium in response to an injury [25]. In wound healing,
vimentin has been shown to show high level of expression following injures to directly be involved
in regulating the cellular processes and interactions that are required for proper regeneration and
healing, confirming its vita role to serve as an integrator of the processes that occur during wound
healing [24]. The lack of vimentin can lead to a severe deficiency in fibroblast growth, and thus,
minimizing their vital regenerative capacity [24]. These data suggest that vimentin can be used as
a great candidate to identify dermal fibroblasts.

4.1.1.5.2.2.TE-7
TE-7 is a surface protein mainly located on the cell membrane of dermal fibroblasts [63]. Similarly,
to vimentin, TE-7 is another fibroblast-specific connective tissue protein marker that can be used
to identify dermal fibroblasts and distinguish them from other cell types such as human peripheral
blood monocyte-derived fibrocytes, endothelial cells, chondrocytes, macrophages [26]. TE-7
antibody has been shown to serve as useful tool for the assessment of thymic epithelial culture
contamination with dermal fibroblasts, and the identification of cells of mesodermal origin in the
fetus, indicating its specificity to dermal fibroblasts [30]. Although TE-7 has been shown to be
specific for dermal fibroblasts, it still can be expressed in other fibroblastic cells such as lung and
muscle fibroblasts in varying densities, with the highest expression in dermal fibroblasts [27, 29]
Minimal information is available regarding the protein.
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4.1.1.6.Morphological Characterization and Specific Markers of Primary Ligament
Fibroblasts
4.1.1.6.1. Morphological Characterization
Similarly, to dermal fibroblasts, ligament fibroblasts also display either elongated, oblong or
triangular cytoplasmic structure after they are freshly isolated. They also show a thicker central
part and two narrow peripheral processes with smooth lateral edges. Ligament fibroblasts are
known to make contact with their neighboring cells upon confluency. These contacts are adhesions
that distort the known elongated structure of the freshly isolated fibroblasts. Upon the complete
contact with the neighboring cells, they make a meshwork-like structure. This structure is one of
the unique ways to recognize fibroblasts. Cells at the boarder of the meshwork display a concavelike structure that helps other neighboring cells to get in contact and thereby be part of the
meshwork. It is believed that when fibroblasts display this smooth, slightly concave bordered
meshwork structure, this is an indication that they are under considerable tension between their
adhesions to neighboring cell. The tensions are very probably developed by an actin-myosin
system [20, 28].

4.1.1.6.2. Ligament Fibroblasts Specific Markers
Ligament fibroblasts produce certain specific proteins that can be used as markers to confirm their
phenotype. Two of the most commonly measured ligament fibroblastic markers used for ligament
fibroblast identifications are markers are Scleraxis and Tenomodulin.
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4.1.1.6.2.1 Scleraxis
The scleraxis protein is a member of the basic helix-loop-helix (bHLH) superfamily
of transcription factors, and it is the earliest marker known for ligament and tendon [31]. Currently
two genes (SCXA ) and (SCXB ) have been identified to code for identical scleraxis proteins
[31].It is believed that Scleraxis is expressed at the early stages of ligament and tendon formation,
and at the early stages of the formation of some muscle/tendon attachments [32]. Previous studies
revealed that scleraxis is a highly specific marker for all connective tissues mediating the
attachments of muscle to bone, and bone to bone, indicating their specificity to tendons and
ligament [32]. Scleraxis has shown to upregulate other genes that are strongly expressed in
ligament and tendon tissues, such as collagen I, collagen XIV, tenomodulin (Tnmd), and fibroblast
growth factor (FGF) [33, 34]. Both fibroblasts growth factor (FGF) and transforming growth factor
beta 1 have been shown to play a vital role in the induction scleraxix during the development stages
of ligaments and tendons [35]. Overexpression of Scleraxis was shown to induce ligamentouslineage differentiation of MSCs and improves ligament formation [36]. Further, it was shown that
cells expressing Scleraxis are necessary for the establishment of junctions between hyaline
cartilage and tendons/ligaments [37] These results suggest that SCX can be used as a suitable
marker to identify ligament fibroblasts.

4.1.1.6.2.2 Tenomodulin
Tenomodulin, also referred to as (tendin), (myodulin), (Tnmd) and (TeM) is a type II
transmembrane glycoprotein containing a C-terminal anti-angiogenic domain and is
predominantly expressed in dense connective tissues including tendons and ligaments [38, 39]
Tenomodulin is localized on the X chromosome and accounts for an approximately 1.4 kb
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transcript and a predicted protein consisting of 317 amino acids [40]. Although the exact function
and mechanism od TNMD is still unclear, it was shown to play a vital role in ligament and tendons
maturations [41, 42]. The lack of TNMD was shown to increase the deficiency of tenocytes
proliferation in newborn mice and disrupted adult collagen fibril structure [43]. The proliferation,
migration and tube formation of vascular endothelial cells were shown to be inhibited by the
soluble form of TNMD containing the C-terminal ChM-I like domain, in addition to blocking the
growth of malignant melanoma by inhibiting angiogenesis [44]. Therefore, marking it as a suitable
phenotypic marker for later events during ligaments and tendons development.

4.1.1.7. Morphological Characterization and Specific Markers of Primary Osteoblasts
4.1.1.7.1. Morphological Characterization
Freshly isolated bone osteoblasts are known to display a flattened and slightly slender structure.
During the first few days post isolation, these cells normally are sparse and display relatively short
cytoplasmic processes of 2-5 µm in length. Once reached confluency, osteoblasts no longer
maintain they slender shape and they become smaller and create a meshwork [21].

4.1.1.7.2. Osteoblasts Specific Markers
Certain molecular components are produced by osteoblasts that can be employed as specific
marker to confirm their phenotype. However, every marker is known to contribute in the bone
homeostasis and also known to have a specific location related to its function [45]. Two of the
most commonly measured osteoblastic markers are Alkaline Phosphate (ALP), and osteocalcin
(OCN).
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4.1.1.7.2.1.Alkaline Phosphate (ALP)
Alkaline Phosphate (ALP) is an enzyme that causes the phosphate Easter to be hydrolyzed from
different types of molecules such as nucleotides and proteins. ALP was named according to its
enhanced activities at high pH levels [45]. Although it can be found within all tissues of the human
body, it highly concentrates in number of tissues such as bone, liver, placenta, and kidney [45].
ALP is known to be found in three different isoenzymes forms which are, tissue non-specific,
intestinal, and placental. The tissue nonspecific isoenzyme is found in bone tissue, in an isoform
that can be differentiated from its two other isoforms (found in the liver and kidney) according to
their different carbohydrate moieties on the same polypeptide backbone [45, 46]. ALP has been
shown to participate in the bone mineralization process [47]. In bone, ALP is a glycoprotein that
is found on the cell membrane of osteoblasts, and is known to be one of the most commonly
measured phenotypic osteoblast marker [48]. In stem cells, ALP expressions are known to be at
their lowest comparing to already matured fully differentiated cells osteoblasts [48, 49]. These
finding indicate that ALP is a great candidate that can be used as an osteoblastic marker to identify
their phenotype.

4.1.1.7.2.2.Osteocalcin (OCN)
Osteocalcin (OCN) is the most abundant non-collagenous protein in bone tissue. OCN is a
calcium-binding protein that is extensively produced by fully differentiation osteoblast, and its
function is dependent on vitamin K [50]. Although the exact mechanism of how OCN functions is
not clear, it is known for its vital role in the bone mineralization process, as it supports the binding
of calcium phosphate CaP to the bone matrix. Only in the presence of ionic calcium, OCN can
contain gamma- carboxy-glutamic acid (Gla), which allows it to undergo a specific conformational
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change that permits the protein to bind to the bone mineral [50]. Since OCN largely supports the
bone mineralization process, it is primary synthesized at the early stages of the matrix
mineralization or may be synthesized during the matrix mineralization stages of osteoblastic
development [45]. Therefore, during these mineralization development stages, osteoblasts intend
to produce large amounts of OCN that some of it that can also be emitted into the blood. It is for
this reason that serum levels of OCN are considered to be indicative of new bone formation. These
findings suggest that OCN can be used as an indicative marker for matured primary osteoblasts.

4.1.2. Scaffolds
4.1.2.1.General Scaffold Requirements
Beside the vital role of cells in tissue engineering, scaffold is another essential component that act
as the framework for tissue regeneration. Scaffolds essentially act as a template for tissue
formation and usually seeded with healthy isolated cells or/and incorporated with growth factors,
depending on the application needs [51]. Ideally, a scaffold should provide cells with a variety of
physical, chemical, and biological cues that are naturally inherited by the native ECM to facilitate
cell growth and function [52]. In vivo, cells are found entrapped within an ECM, in which they are
provided with all the necessary physical and chemical cues that guide their development,
arrangement and regenerative abilities by molecular interactions between specific cell membrane
receptors and signaling cues from surrounding ECM material [52] To duplicate the in vivo
environment, the scaffold should exhibit controllable physical, chemical and mechanical
properties, cell adhesion properties and growth factor release kinetics [53]. Generally, an ideal
tissue engineering scaffold should be biocompatible that maintains cell viability in vitro and do
not elicit any immune response upon implantation in vivo. In addition, the scaffold should be
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biodegradable with a degradation rate compatible to the rate of the neotissue formation to fully be
replaced with newly formed tissue. The scaffold should also be highly porous to facilitate cell
migration, proliferation, nitration diffusion and waste removal, and should also exhibit biomimetic
mechanical and architectural properties resembling those found at the native tissue [54]. In
addition, the scaffold should serve as a reservoir for local, sustained, and controlled growth factors
delivery to regulate cellular activates in order help induce neovascularity and promote tissue
regeneration.

4.1.2.2.Scaffold Materials
Providing a proper niche for cell adhesion, migration, and proliferation is generally based on the
material choice. Biomaterials used for tissue engineering scaffold are mainly classified into two
categories, naturally derived and synthetic biomaterials. Natural biomaterials can be further
classified into proteins (silk, collagen, gelatin, fibrinogen, elastin, keratin, actin, and myosin),
polysaccharides (cellulose, amylose, dextran, chitin, and glycosaminoglycan), or polynucleotides
(DNA, RNA). Natural biomaterials are known for their excellent biocompatibility, bioactive
properties, and good interactions with cells, owing an enhanced cellular performance in biological
systems [55]. Despite all of their advantages, natural biomaterials possess poor physical and
mechanical properties, which limit their use for load-bearing applications. Synthetic biomaterials
on the other hand, are further characterized into degradable and non-degradable synthetic
polymers. Biodegradable synthetic polymers are preferred over the non-degradable polymers due
to their degradability nature, which in turn facilitate a faster neo-tissue ingrowth and better tissue
infiltration, in addition to minimizing the chance for a secondary surgery after implantation [55].
A wide range of synthesis biodegradable polymers such as, poly(lactic acid) (PLA), poly(glycolic
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acid) (PGA), poly(lactic-co-glycolic acid) (PLGA), poly-L-lactic acid (PLLA), and
polycaprolactone PCL, have been used for many musculoskeletal tissues and skin tissue
engineering due to their intrinsic tailored properties [55]. Although synthetic polymers have the
advantages of tailoring their properties such as, porosity, degradation rate, physical and mechanical
characteristics for specific applications and needs, they possess poor biocompatibility and lack all
the ligands required for cell attachments and proliferation, which can result in poor cell adaption
to the matrix and thus, poor tissue formation. Limitations associated with both natural and
synthetic biomaterials limit their use on their own in many tissue engineering applications where
both mechanical and biocompatibility are highly required. The native ECM resembles some
properties that are found in synthetic materials only or natural materials only, therefore, composite
scaffolds are the best solution to address the disadvantages of both natural and synthetic scaffolds,
as it helps in the mutual enhancement of the scaffold properties and thereby allowing controlled
degradation and mechanical properties as well as improving the biocompatibility, and providing
cells with all the necessary physical and chemical cues that are naturally inherited by the natural
ECM, to achieve the best possible biomimicry of the native ECM [56].

One great example of a composite biomaterials that is suggested to be used in skin, ligament and
bone tissue engineering is PLGA/Gelatin. PLGA is known for its tailored mechanical and
degradation properties in addition to the easy processability into a wide variety of different
structures; and gelatin is known to inherit all the necessary arginine-glycineaspartic acid (RGD)
sequences that allows for enhanced cell adhesion, and it is less immunogenic [57, 58]. However,
this elegant combination between PLGA/gelatin, in which PLGA provides the mechanical and
structural support to the scaffold, whereas gelatin influences cell adhesion and proliferation is
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expected to positively influence tissue regeneration. Norouzi et al. developed a PLGA/gelatin
coaxial electrospun nanofiber scaffold for skin regeneration. In this study, gelatin was coaxially
electrospun with PLGA where the core-shell was consisted of gelatin to increase biocompatibility
and cellular adhesion and the fiber sheath was consisted of PLGA for mechanical reinforcement.
The scaffold was pre-seeded with human dermal fibroblasts and the scaffold’s biocompatibility
along with the gene expression of collagen type I and III have been evaluated [81]. In vitro results
showed a significant increase in cell number over time along with extensive production of collagen
type I and III when comparted to the control, indicating the potential of PLGA/gelatin composite
to serve as a scaffold material for wound healing applications and suggesting that it can serve a
composite biomaterial for other tissue engineering application such as ligament TE. Additionally,
PLGA/gelatin as a biomaterial has been shown to enhance osteoblasts adhesion and proliferation
in vitro and bone regeneration in vivo [82]. Findings from these studies demonstrate the potential
of PLGA/gelatin to serve as a composite biomaterial for various tissue engineering applications.

4.1.3. Growth Factors Delivery
Growth factors are endogenously secreted in the body by cells themselves, but in very minimal
amounts that cannot aid in tissue regeneration in the case of large trauma, which necessitates the
sustained and controlled delivery of exogenous growth factors to aid in the regeneration process.
As discussed in section 3.1., several methods can be employed in order to achieve a sustained and
controllable release over growth factors for more effective tissue regeneration outcomes. It was
demonstrated that incorporation of growth factors in the core-shell of the fiber during
electrospinning will result in the production of a scaffold that can serve as a great candidate for
sustained and controlled with minimal burst release. In addition, gelatin hydrogel was
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demonstrated to be a good drug delivery vehicle for growth factors. Thus, providing the most
suitable growth factor delivery profiles is crucial for functional tissue regeneration. Growth factors
are soluble-secreted signaling polypeptides capable of instructing specific cellular responses in a
biological environment [59]. Cell producing Growth factors has the ability to elicit an effect from
either itself, or another targeted cell. According to their function, growth factors can be autocrine,
paracrine or endocrine [64]. Autocrine growth factors signal back to the cell from which they are
secreted, paracrine growth factors signal to neighboring cells, and endocrine growth factors are
secreted into the blood stream in order to travel to distant target cells [64]. Cells reside in
metabolically active tissues are more likely to continually respond to dynamic combinations of
factors that provide them with information about their surrounding environment.

According to their effect, growth factors can further be classified into cytokines or chemokines.
Cytokines are growth factors that stimulate proliferation or differentiation of the target cell, while
chemokines are growth factors that induce cellular migration [64]. Cells receive information from
growth factors through specific bindings of the growth factors to their corresponding cell receptors,
which are found integrated in the cell’s plasma membrane. Once the growth factor is bound to its
specific associated receptor, an intercellular response is stimulated [64]. The specific cellular
response trigged by growth factor signaling can result in a very wide range of cell actions,
including cell survival, and control over migration, differentiation or proliferation of a specific
subset of cells. Several growth factors have been extensively used for tissue engineering
applications such as BMP-2, for bone tissue regeneration [60], PDGF-BB and IGF-I for mostly
skin, and ligament tissue regeneration applications respectively [61, 62].
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4.1.3.1.Platelet-Derived Growth Factor-BB (PDGF-BB)
PDGF is a dimeric glycoprotein from a superfamily that include various forms of PDGF such as
PDGF-BB, AA, and AB, depending on the composition of the two molecular chains of the dimer.
It was originally isolated from platelets, but it is now known to be secreted by many cell types
[65]. PDGF is involved throughout all stages of normal wound healing and is known to stimulate
the chemotaxis of a variety of cell types including fibroblasts. It mainly stimulates the proliferation
of fibroblasts and other originating mesenchymal cell and is involved in macrophage activation
during wound healing [66]. In addition to its ability to promote tissue remodeling by stimulating
fibroblasts to produce both collagenase and collagen, PDGF-BB is responsible for the
differentiation of fibroblasts into their contractile phenotype, therapy resulting in accelerated
wound healing [67]. PDGF-BB was shown to decrease the wound volume dramatically after skin
injuries in humans [68]. Additionally, it was shown that wounds treated with PDGF-BB had higher
level of fibroblasts differentiation in vitro and neovascularization in vivo comparing to controls in
humans [69]. these findings suggest that PDGF-BB correlate in extensive collagen production and
reduced wound volume during wound healing, owing its vital role for wound healing application
and skin regeneration.

4.1.3.2.Insulin-Like Growth Factor-I (IGF-I)
IGF-I, also called somatomedin C, is a human protein encoded with IGF1 gene [70]. IGF-I is also
a hormone that plays an important role in childhood growth and continues to have anabolic effects
in adults, making it ideal for the treatment of growth failure [70]. IGF-I is produced throughout
the human’s life, with a highest rate of production during the pubertal growth spurt, and starts to
lower in production as the person ages [71]. IGF-I is primary produced by the liver as
an endocrine hormone as well as in target tissues in a paracrine/autocrine fashion [72]. In ligament
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tissue engineering, IGF-I was shown to increase the metabolic activates and proliferation of
ligament fibroblasts both in vitro and vivo in a rabbit MCL model, which resulted in enhanced
healing of the ruptured ligament [73]. In addition, IGF-I is believed to attribute to an antiinflammatory effect in vivo, therapy decreasing the recovery time after tendon and ligament injures
[74]. It was also reported that ligament treated with IGF-I in combination with PDGF had
increased rupture force, stiffness, and breaking energy in vivo [75]. Additionally, IGF-I was shown
to enhances the proliferation and osteogenic differentiation of human ligament fibroblasts,
resulting in enhanced ligament-bone osteointegration [76]. These promising findings
demonstrate the role of IGF-I in enhancing ligament healing and regeneration.

4.1.3.3 Bone Morphogenetic Protein 2 (BMP-2)
Bone Morphogenetic Proteins are part of the transforming growth factor- β (TGF-β) gene superfamily. Several reports have highlighted important role of BMPs in the development of bone and
cartilage [77]. Bone Morphogenetic proteins are known to regulate in the formation of new
cartilage and bone by binding to extracellular receptors that, like all TGF-β proteins, are
serine/threonine receptor kinases. This binding however, stimulates intracellular kinases to initiate
a cascade of events that ultimately leads to mRNA-directed production of proteins such as
osteocalcin and alkaline phosphatase, which are necessary for bone remodeling and mineralization
[77]. Although many types of BMPs have been extensively studied for their osteoinductive
capabilities, BMP-2, 4 and 7 are the most commonly used and studies members of the growth
factor family due to the fact that their receptors have been well identified [78] BMP-2 for instant,
is known to promote the differentiation of cells into the osteoblast lineage and upregulate the
calcification of bone defects, which can result in increased bone formation [79]. Additionally, it
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was shown that BMP-2 can enhance the proliferation of mature osteoblasts and promote their
production of collagen and other extracellular matrix proteins, which results in enhanced bone
formation [80].

In this aim, we sought to isolate and characterize three different primary cells, dermal fibroblasts,
ligament fibroblasts as well as osteoblasts. Post characterizations, the three different cell types will
be further used to investigate the capability of the three different phases with the integrated graft
system to support their viability and proliferation at different time points. In addition, the effect of
the different growth factors incorporation methods (coaxial Vs uniaxial, or gelatin incorporation
Vs. surface absorption) and releasing profiles (minimal burst release Vs. rapid burst release) on
the cell proliferation will be investigated.
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4.2. Materials and Methods:
85:15 Poly(lactide-co-glycolide) (PLAGA) (MW ~ 94,000 kDa) was purchased from (Absorbable
Polymers, Birmingham, AL, USA), Hexafluoro-2-propanol (HFIP) was purchased from (Acros
Organics, USA), Gelatin Type A from Pork (Porcine skin) was purchased from (MP Biomedical,
OH, USA), Microbial Transglutaminase (mTG) was Purchased from (Ajinomoto, Japan),
Dichloromethane (DCM) was purchased from (Fisher Scientific, USA), PDGF-BB, IGF-I and
BMP-2 growth factors were purchased from (Fisher Scientific, USA), Dulbecco’s PhosphateBuffered Saline (PBS) of pH 7.4, MEM Alpha (1X) Minimum Essential Medium, DMEM/F-12
(1:1) (Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12), Antibiotic-Antimycotic
(100X), Trypsin-EDTA (0.25%) phenol red, Fetal Bovine Serum, Qualified, PenicillinStreptomycin (10,000 U/mL), and Hank’s balanced salt solution (HBSS) were purchased from
Gibco (Grand Island, NY), collagenase type I powder was purchased from (ThermoFisher
Scientific, IL, USA), Liberase Blendzyme 3 was purchased from Sigma-Aldrich (Milwaukee, WI),
primary antibodies, IgG monoclonal unconjugated Anti-Alkaline Phosphatase (ab108337), IgG3
monoclonal unconjugated Anti-Osteocalcin antibody (ab13420), IgG monoclonal unconjugated
Anti-SCXA antibody (ab58655), IgG monoclonal unconjugated Anti-tenomodulin antibody
(ab203676), IgG monoclonal unconjugated Anti-TE-7 antibody (ab197896), IgG monoclonal
unconjugated Anti-Vimentin antibody (ab92547), and the compatible secondary antibodies, IgG
polyclonal Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077), and IgG polyclonal Goat
Anti-Mouse IgG H&L (Alexa Fluor® 488)(ab150113) were purchased from (Abcam, MA, USA),
DAPI (4',6-Diamidino-2-Phenylindole, Dihydrochloride), and anti-fade mounting medium,
LIVE/DEAD™ Viability/Cytotoxicity Kit were parched from (Invitrogen, USA), and CellTiter
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96® AQueous One Solution Cell Proliferation Assay (MTS) was purchased from (Promega Inc,
USA).

4.2.1 Fabrication of PLGA-Gelatin Coaxial Nanofiber Scaffolds
As described previously, PLGA (85:15) granules were dissolved in HFIP at 16 % wt and stirred
overnight at room temperature to prepare the (shell solution) of nanofibers. To prepare the core
solution, gelatin powder type A was dissolved in HFIP at 4% wt and stirred overnight at room
temperature. At the day of electrospinning, both growth factors were reconstituted at a
concentration of 1 mg/ml, and 81 µl of the reconstitution of either PDGF-BB and IGF-I were added
to 1.5 ml of gelatin solutions and stirred for 15 minutes to allow the growth factor to homogenize
with the gelatin solution. In the case of coaxial nanofibers with no growth factors, gelatin solution
was used alone in the core-shell. An electrospinning pump (NE 300 SYRINGE pumps, USA) was
used in order to fabricate the coaxial PLGA-Gelatin nanofibers. The setting to prepare the coaxial
scaffolds consisted of two coaxial syringe pumps with different flow rates. In this study, the PLGA
solution was used to form the outer shell and the gelatin-growth factors or free of growth factors
solutions were used to form the inner core. PLGA solution or either gelatin-growth factors or free
of growth factors solution were loaded into two separate 10 ml syringes and connected to the
coaxial needles, a 16 G (ID = 1.6 mm) outer needle and a 22 G (ID = 0.7 mm) inner needle,
respectively, and then concentrically placed. The electrospinning parameters were as follows:
(applied voltage: 10 kV; 1.5 mL/h for the sheath flow rate and 0.75 mL/h for the core flow rate).
The tip of the needle was placed 10 cm away from the collector. The electrospinning process lasted
for 1.5 h. Coaxial electrospun nanofibers were peeled from the collector and stored under
vacuumed desiccator for 24 hours to insure complete evaporation of solvent.
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4.2.2 Fabrication of PLGA Uniaxial Nanofiber Scaffolds
PLGA (85:18) granules were dissolved at 16% wt in HFIP with stirring to form clear,
homogeneous, and viscous solution. From the same patch used for the coaxial nanofibers
fabrication, 81 µl reconstitution of both PDGF-BB and IGF-I were directly added to 3.5 ml of
PLGA solution and stirred for 30 minutes to allow the growth factor to homogenize with the
polymer solution. In the case of uniaxial nanofibers with no growth factors, PLGA solution was
electrospun alone. PLGA-growth factors or PLGA solutions were loaded into 10 ml plastic syringe
and electrospun at flow rate of 0.75 mL/h through a 20-gauge blunt needle with the electrospinning
pump (NE 300 SYRINGE pumps, USA) at an applied voltage of 10 kv. The tip of the needle was
placed 10 cm away from the collector. The electrospinning process lasted for 3.5 h. Uniaxial
electrospun nanofibers were peeled from the collector and stored under vacuumed desiccator for
24 hours to insure complete evaporation of solvent.

4.2.3 Fabrication of PLGA Microspheres
As previously described, single emulsion solvent evaporation technique was used to fabricate
PLGA microspheres. PLGA granules were dissolved at 12.5% wt in Dichloromethane (DCM) in
glassy vials. Vials were vortexed for 1 h at a speed of 550 RPM until clear, homogeneous, and
viscous solution was obtained. Next, PLGA solution was added via a thin stream into 1% PVA
solution in a 1000 ml beaker and it was let to stir at (300 RPM) overnight to allow the solvent to
evaporate. After that, microspheres were collected, filtered, air dried and then they were stored in
-20 for 24 h to freeze any residual water particle inside of the microspheres. Next, microspheres
were freeze dried for 48 h and were then sieved to obtain the desired particle size range 300 – 600
µm.
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4.2.4 Incorporation of BMP-2 in Gelatin-mTG Hydrogel
Gelatin gel formation was initiated by mTG addition. For hydrogel preparation, 3% wt gelatin
powder type A was dissolved in preheated phosphate-buffered saline (PBS) at 50 °C and it was let
to stir on a stirrer plate for 15 minutes at 500 RPM to completely dissolve the powder. The mTG
solution was prepared by dissolving 10% wt mTG in preheated PBS at 50 °C, then it was let to stir
on a stirrer plate for 15 minutes at 500 RPM. As soon as both gelatin and mTG completely
dissolved in PBS, the temperature of the stirrer plate was adjusted to 37 °C and they were let to
stir for another 15 minutes to allow for the temperature drop. Next, to initiate the cross-linking
reaction between gelatin and mTG for the hydrogel preparation, mTG solution was mixed with the
3% wt gelatin solution at a ratio of 1:11.5 under stirrer speed of 500 RPM at 37 °C. The mixture
was let to stir for 5 minutes until a semi-viscus solution is fabricated and ready to by injected.
BMP-2 incorporation was done by adding 1 µg of BMP-2 in 100 ul of gelatin-mTG solution and
mix them gently.

4.2.5 Fabrications of PLGA Microspheres Scaffold Incorporated Gelatin-mTG/BMP-2
To fabricate the three-dimensional scaffolds and use it to either incorporate gelatin-mTG/BMP-2
or gelatin-mTG hydrogels within it, PLGA microspheres were poured into a 10 mm x 10 mm
stainless steel mold and heated for 90 °C for 90 minutes. These parameters allowed the
microspheres to fuse together forming the 3D scaffolds. After 90 minutes, the stainless-steel mold
was removed from the oven and allowed to cool to room temperature for 2 hours. Next, scaffolds
were removed and the semi-viscus gelatin-mTG/BMP-2 hydrogel was injected inside of the
microsphere scaffold using an insulin syringe until all porosity were filled and it was allowed to
gel at 37 °C for 1 hours. In the case of the physical adsorption, 1 µg of BMP-2 was physically
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poured on PLGA-Gelatin-mTG microsphere scaffolds and was let to dry out for 1 h to ensure
attachment of the protein.

4.2.6 Primary Cells Isolations
6-8 weeks old (150 – 200 g) Lewis rats were obtained from (Charles River Laboratories, CT, USA)
and used for all primary cell isolations. All the animal experiments were approved by the
Institutional Animal Care and Use Committee (IACUC) at the University of Connecticut Health
Center, CT, Farmington, USA.

4.2.6.1 Primary Dermal Fibroblasts Isolation and in Culture Maintenance
Animals were euthanized with CO2 for 10 minutes until they are ready to be handled. Next, cervical
dislocation technique was performed after euthanizing the animals with CO2 to confirm the death
of the animals. Animals were lightly sprayed with 70% ethanol, and more extensively around the
incision site to prevent any chance of having contamination. Skin from underarm was selected to
be dissected because skin in that particular site is usually thinner, contains less fat, and the fur is
less dense. The fur around the site of incision was completely shaved with a sharp scalpel.
Approximately 1 cm2 of skin fragment was collected by pinching the skin with a tissue forceps,
and carefully cutting with scissor with paying attention not to cut the fat layer with the skin.
Dissected tissue fragment was then placed in in 50 mL tubes containing sterile PBS with 1%
Antibiotic-Antimycotic. Under the hood, the tissue fragment was transferred into a 10-cm tissue
culture dish and it was cut into small pieces (~ 1 mm) using a scalpel. Using the same scalpels, the
small skin fragments were transferred into a sterile 30 mL beaker with a sterile stir bar containing
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30 mL DMEM/F12 medium with 0.14 Wunsch unites/ mL Liberase Blendzyme 3, and 1%
Antibiotic-Antimycotic. The beaker was covered with sterile alumni foil and incubated at 37 °C
stirring slowly for 120 minutes. Next, the solution with the tissue fragments were transferred into
a sterile 50 mL tube, and 20 mL of DMEM/F-12 medium supplemented with 15% FBS, and 1%
Antibiotic-Antimycotic was added to the solution to stop the Liberase digestion. The tube was then
placed for centrifugation and was centrifuged at 524 g for 5 minutes. Next, the supernatant was
removed and the pellet was re-suspended with 40 ml of warm of DMEM/F-12 medium
supplemented with 15% FBS, and 1% Antibiotic-Antimycotic and it was centrifuged again for 5
minutes. This process was repeated 2 times to insure the complete removal of the trace Liberase.
At the last centrifugation cycle, the supernatant was removed, and the pellet was resuspended with
10 mL of DMEM/F-12 medium supplemented with 15% FBS, and 1% Antibiotic-Antimycotic and
transferred into 10 cm tissue culture dish and placed in a tissue incubator at 37°C, 5%CO2, 3%O2.
The tissue culture plate was let for 7 days at the incubator without changing the medium to allow
all cells to exit the tissue fragments and to adhere on the TCP. At day 7, the medium was changed
and it was let for another 7 days to allow the cells to completely exit the tissue fragments and
adhere on the TCP. After 14 days, cells were trypsinized with 0.25 EDTA trypsin, harvested, and
plated on new T-75 flasks at a density of 5 x 105 cells/flask with EMEM supplemented with 15%
FBS, 1X Penicillin/Streptomycin, non-essential amino acids, and sodium pyruvate. EMEM media
will support growth of fibroblasts only and other cell types will die or stop proliferating. Cells
were never frozen and were used at the second passage for further experiments.

4.2.6.2 Primary Ligament Fibroblasts Isolation and in Culture Maintenance
All animals were euthanized following the same procedure as mentioned previously for ligament
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dissections and isolation. The area around the knee was extensively sprayed with 70 % ethanol
and scrubbed with betadine scrub solution to kill all bacteria around the incision site, then it was
draped. A straight midline longitudinal incision was made using a blade, extending from the distal
fourth of the femur to the tibial tuberosity. The skin and the subcutaneous fascia were retracted to
expose the patellar tendon, which was then excised by a parapatellar incision that runs the length
of the tendon from the tibial to the sartorius muscle. The tendon was then bisected, and the fat pad
and the patella were dissected from the tendon. A deeper incision into the joint capsule was made
to expose the femoral condyles and the tibial plateau. The ACL and MCL (anterior cruciate
ligament and medial collateral ligament) were transected from the bone insertion sites at either
ends to insure a dissection of a full ACL and MCL. The dissected ligaments were placed in sterile
50 mL tube containing PBS with 1% Penicillin/Streptomycin. Under a sterile tissue culture hood,
the ligament fragments were transferred into a 10 cm tissue culture dishes with 2 ml of PBS to
keep the tissue hydrated. Ligaments were diced into very small pieces of approximately 1 mm
using a sharp scalpel. Using the same scalpels, the small ligament fragments were transferred into
a sterile 30 mL beaker with a sterile stir bar containing 30 mL of filtered collagenase type I solution
in DMEM/F-12 medium with 1% Penicillin/Streptomycin. The beaker was covered with sterile
alumni foil and incubated at 37 C stirring slowly for 4 hours. Next, the solution was poured through
70 um nylon mesh to hold any undigested tissue fragments. 20 mL of fresh and warm DMEM/F12 supplemented with 10% FBS and 1% P/S was added to the solution to stop the collagenase
digestion, then it was centrifuged at 500g for 10 in a sterile 50 mL tube. Post centrifugation, the
supernatant was removed, and the pellet was resuspended with 1 mL of fresh warm DMEM/F-12
medium supplemented with 10% FBS and 1% P/S. cells were plated in 25 cm flask and 4-5 mL
medium was further added. Flask was placed in a tissue incubator at 37°C, 5%CO2, 3%O2. Medium
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was changed every 2 days, and 7 days post plating, when the flask reached ~ 90% confluence, cells
were trypsinized with 0.25 EDTA trypsin solution and harvested then plated into a new T-150
flask at a density of 6 X 105 cells/flask for further expansion. Cells were never frozen and were
used at the second passage for further experiments.

4.2.6.3 Primary Bone Osteoblasts Isolation and in Culture Maintenance
All animals were euthanized following the same procedure as mentioned previously for long bone
dissections and isolation. The area around the femur was extensively sprayed with 70 % ethanol
and scrubbed with betadine scrub solution to kill all bacteria around the incision site. A straight
midline longitudinal incision was made using a blade, extending from the distal end of the knee
joint to the hip joint. The skin and the subcutaneous fascia were retracted to expose the long femur
bone. Muscles covering the femur were removed with a sharp scalpel to clearly expose the bone.
The long femur bone was dislocated from the proximal hip joint and the distal knee joint by
transecting all ligament and tendons at both joints until it became mobilized. Bone was then
dissected and placed in a 50-mL tube containing sterile PBS with 1% Penicillin/Streptomycin.
Under a sterile tissue culture hood, bone was placed in a 10-cm tissue culture dish containing 10
mL of sterile PBS. The remaining muscles and connective tissues covering the long bone as well
as the periosteum were removed using a scalpel. After removing all residual tissues, bones were
further rinsed with PBS and placed in a new tissue culture plate containing fresh 10 mL PBS. The
bone epiphyses were cut off and the bone marrow was flushed out using a needle and a syringe.
Flushing step was repeated several times, each time with fresh PBS until all bone marrow has been
flushed out. Bones were then placed in a new tissue culture dish with fresh 10 mL PBS and it was
cut in half lengthwise and then cut into 1 – 2 mm long using a scalpel. After cutting bones into
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small pieces, they were placed in fresh PBS for a brief wash. Next, four digestion cycle have been
performed on the bone pieces to isolate osteoblasts as follows; (Digest 1) was done by incubating
the bone pieces in 8 ml of warmed collagenase solution (filtered 1% collagenase type I in PBS)
for 1 hour in the 37 °C room on a rocker set at 5 RPM. 1 hour after incubation, the entire solution
was aspirated and transferred in a new tube, bone pieces in the old tube were rinsed with 5 ml of
HBSS three times with aspirating the solution to the new tube in every time. Collagenase with the
HBSS aspirates in the new tube was centrifuged for 5 minutes at 500 g until a pellet was obtained,
then the pellet was resuspended with MEM Alpha (1X) Minimum Essential Medium supplemented
with 15% FBS and 1% Penicillin/Streptomycin, and then plated in a six-well tissue culture plate
with 5 ml medium. Another 8 mL of the collagenase solution were added to the bone pieces to
further digest them for 1 h to get to the second digest cycle. For digest cycle 2, 3, and 4 the same
procedure from digest cycle 1 was repeated. After completing digest cycle 4, bone pieces were
places in another six-well tissue culture plate with 5 ml of MEM Alpha (1X) Minimum Essential
Medium supplemented with 15% FBS and 1% Penicillin/Streptomycin per well and maintained in
a tissue culture incubator at 37°C, 5%CO2, 3%O2. Medium was changed every 3 days, and 7 days
post plating, when all the wells reached ~ 90% confluence, cells were trypsinized with 0.25 EDTA
trypsin solution and harvested then plated into a new T-150 flask at a density of 6 X 105 cells/flask
for further expansion. Cells were never frozen and were used at the second passage for further
experiments.

4.2.7 Morphological and Immunofluorescence Phenotypic Characterization of the
Isolated Primary Cells
Primary cells are usually isolated from a heterogeneous cellular population, however, there is a
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very high chance that these isolated primary cells are contaminated with other cellular populations.
To ensure the homogeneity within the isolated cellular population, these cells must undergo
phenotypic

characterizations

steps.

Morphology

and

Immunofluorescence

phenotypic

characterization are some of the most commonly used methods to characterize isolated primary
cells.

4.2.7.1 Morphological Characterization of the Isolated Primary Cells
For morphological characterization, the three different cell types in the culture dishes were fixed
in 2.5% glutaraldehyde in 0.1 M cacodylate for 20 min. They were then rinsed with PBS for 5 min,
then they were incubated in 1 % osmium tetroxide for 20 min, then dehydrated in a graded series
of alcohol (cold 30%, cold 70%, 95% and 100%), and subsequently samples were let to dry
overnight under a chemical hood. Cells were then visualized under a normal light microcopy, and
pictures at low (10 X) and high (40 X) magnifications were taken.

4.2.7.2 Immunofluorescence Phenotypic Characterization of the Isolated Primary Cells
For Immunofluorescence characterization, large coverslips were autoclaved for sterilization, and
then placed in sterile six-well tissue culture plates. The three different cell types were separately
cultured (each cell type in a separate plate) over the cover slips for 2 days at a density of 5 X 10 3
per well and maintained in a tissue culture incubator at 37°C, 5%CO2, 3%O2. Every cell type was
maintained in culture with 5 mL of the relevant medium type, MEM supplemented with 15% FBS,
1X Penicillin/Streptomycin, non-essential amino acids, and sodium pyruvate, DMEM/F-12
supplemented with 10% FBS and 1% P/S, and MEM Alpha (1X) Minimum Essential Medium
supplemented with 15% FBS and 1% Penicillin/Streptomycin, for primary dermal fibroblasts,
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ligament fibroblasts, and bone osteoblasts respectively. When cells reached 50 – 70 % confluent,
the culture medium was aspirated from every well and cells were gently rinsed twice with PBS at
room temperature. Cells were then fixed with 2 mL of 100X absolute methanol for 5 minutes,
followed by three washes with PBS. Cells were then Permeabilized with 1 mL of 0.1 % Triton X100 in PBS for 15 minutes, followed by three washes with PBS. Cells were then blocked with 10%
goat serum in PBS for 1 hour at room temperature, following by three washes with PBS. Every
cell type was incubated for 2 hours with two positive IgG monoclonal unconjugated primary
antibodies and one negative IgG monoclonal unconjugated primary antibody (negative control).
Dermal fibroblasts were incubated with IgG monoclonal unconjugated Anti-TE-7 antibody
(1:250), IgG monoclonal unconjugated Anti-Vimentin antibody (1:500) (the two positive
antibodies), and with IgG monoclonal unconjugated Anti-tenomodulin antibody (1:100) as a
negative control; ligament fibroblasts were incubated with IgG monoclonal unconjugated AntiSCXA antibody (1:1000), IgG monoclonal unconjugated Anti-tenomodulin antibody (1:100) (the
two positives antibodies), and IgG monoclonal unconjugated Anti-TE-7 antibody (1:250) as a
negative control; and bone osteoblast were incubated with IgG monoclonal unconjugated AntiAlkaline Phosphatase (1:100), IgG3 monoclonal unconjugated Anti-Osteocalcin antibody (1:100)
(the two positive antibodies), and IgG monoclonal unconjugated Anti-SCXA antibody (1:1000) as
a negative control. All antibodies were diluted using the same blocking solution of 10% goat serum
in PBS. Post incubation, cells were washed three times with PBS and incubated with the secondary
antibodies for another 2 hours at dark. All cells were incubated with the secondary antibody IgG
polyclonal Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (1:500), expect for the cells incubated
with Anti-Osteocalcin primary antibody, which were incubated with the secondary antibody IgG
polyclonal Goat Anti-Mouse IgG H&L (Alexa Fluor® 488) (1:500). After incubation with the
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secondary antibodies for 2 hours, cells were washed three times with PBS away from light, then
incubated with DAPI (4',6-Diamidino-2-Phenylindole, Dihydrochloride) at a concentration
(1:3000). Cells were then washed 1 time with PBS and coverslips were mounted on microscope
slides on anti-fade mounting medium. Nail polish was applied at the edge of every cover slip to
keep the samples hydrated. All samples were visualized using an inverted fluorescence microscope
(Zeiss LSM 880) using Zen Software. To quantify the fluorescence data, all images were processed
through Image J software. For every antibody, the intensity in six images were measured, averaged
and values were plotted as % of antibody expression.

4.2.8 LIVE/DEAD Viability Assay
All scaffolds were sterilized prior to cell seeding. To sterilize PLGA microsphere scaffolds, they
were submerged in 70% ethanol for 20 minutes followed by submerging in sterile PBS to remove
any ethanol residuals. Next, scaffolds were exposed to UV light for 30 minutes each side. To
sterilize both the uniaxial and uniaxial-growth factors as well as the coaxial and coaxial-growth
factors electrospun nanofiber scaffolds, they were placed inside of the cell culture hood and
exposed to UV light for 30 minutes each side. To incorporate BMP-2 in PLGA microsphere
scaffolds, scaffolds were either surface absorbed with 10 µl of BMP-2 (1 µg/ scaffold), or injected
with 100 µl of gelatin-mTG/BMP-2 (1 µg/ scaffold). Scaffolds injected with gelatin-mTG were
further incubated at 37°C to allow for complete gelation. Four different experimental groups were
included to assess the viability of every cell type as follows; dermal fibroblasts were seeded on
coaxial PLGA-Gelatin-PDGF-BB, PLGA-Gelatin, and uniaxial PLGA-PDGF-BB, PLGA
electrospun nanofiber scaffolds; ligament fibroblasts were seeded on coaxial PLGA-Gelatin-IGFI, PLGA-Gelatin, and uniaxial PLGA-IGF-I, PLGA electrospun nanofiber scaffolds; and primary
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osteoblasts were seeded on PLGA-gelatin-mTG/BMP-2, PLGA-gelatin-mTG, PLGA/BMP-2, and
PLGA microsphere scaffolds. All cells were seeded at a density of 1 X 105 cells/ scaffold and
scaffolds were placed in low binding 24-well plates in triplicate. Cells were allowed to attach for
1.5 h in the cell culture incubator at 37 °C prior to the addition of 2 ml of the relevant medium for
every cell type. All cells were maintained in a tissue culture incubator at 37°C, 5%CO2, 3%O2.
After 3 and 7 days, scaffolds were harvested, washed with PBS twice and assessed for
LIVE/DEAD assay, which was used to qualitatively determine cell viability based on a green
fluorescent probe that recognizes intracellular esterase activity, calcein AM, and a red fluorescent
probe that recognizes damaged plasma membranes, ethidium homodimer-1 (EthD-1). To perform
the assay, all scaffolds were incubated with 2 mL of the prepared EthD-1/calcein solution at a
concentration of 2 µl/ mL EthD-1, and 0.5 µl/ mL calcein AM in PBS for 1 hour. Next, scaffolds
were washed twice with PBS and visualized using an inverted fluorescence microscope (Zeiss
LSM 880) using Zen Software.

4.2.9 Proliferation Assay
The capability of all scaffolds to support the growth and proliferation of the different cell types
were assessed using the Cell Titer 96® AQueous One Solution Cell Proliferation Assay according
to the manufacturer’s instructions. All scaffolds underwent the same sterilization technique as
described in the previous experiment, and the same seeding density was applied to all scaffolds for
all cell types having the same experimental groups. After day 3 and 7, scaffolds were removed
from their wells and placed in new wells after two washes with PBS. Next, scaffolds were
incubated with a cocktail of the relevant medium type premixed with MTS solution at a ratio of
(1:5) for 3 hours at 37 °C. 500 μl of sodium dodecyl sulfate was added to each well to stop the
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reaction and the absorbance at 490 nm was measured with a spectrophotometric plate reader
(TECAN, Crailsheim, Germany).

4.2.10 Statistical Analysis
Data are presented as mean ± standard deviation (SD). All statistical analyses were performed
using the Statistical Software Prism GraphPad (Version 5) using two-way Analysis of Variance
(ANOVA) with a Tukey test for Post Hoc parameter comparisons. Statistical significance was set
at p < 0.05.

4.3.Results:
4.3.1. Morphological and Immunofluorescence Phenotypic of the Isolated Primary Cells
The three different cell types were morphologically characterized or by immunofluorescence to
ensure the homogeneity in our cellular population. To morphologically characterize them, all cells
were fixed and visualized under a normal light microscopy at two different magnifications high
(40 X) and low (10 X). Both cell types isolated from skin and ligament exhibited a spindle and
elongated cytoplasm structure with relatively long cytoplasmic processes of 3 - 7 µm and 5 – 11
µm in length for both dermal and ligament respectively as measured in Image J. These cells
displayed a thicker central part of the body and two narrow peripheral processes with smooth
lateral edges, which suggest their fibroblastic phenotype (Figure 4.1, 4.2). Cells isolated from long
bones appeared flattened and slightly slender in shape and displayed sparse and relatively-short
cytoplasmic processes (2-5 µm) in length when compared to the isolated fibroblasts (Figure 4.3).
These maintained their slenderer shape during culture but they became smaller and packed when
they reach confluence. These findings suggest that the isolated cells are the cells of interest, but
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further characterization of these cells is indeed required to ensure the exact phenotype of every
cell type.
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Next, cells were stained for specific markers that are known to be expressed by them. Dermal
fibroblasts were stained against tow positive markers TE-7 and Vimentin, and negatively stained
against Alkaline Phosphatase. Similarly, ligament fibroblasts were stained against two positive
markers that are known to be expressed by ligament fibroblast, SCXA and tenomodulin, and
negatively stained against TE-7. Primary osteoblasts are known to express Alkaline Phosphatase
and Osteocalcin, which were used as positive markers to stain osteoblasts, however, SCXA was
used as the negative control for this last cell type. Our data revealed that all the three different cell
types were specific to all markers and showed 100% positive expression for every specific marker
(Figure 4.4, 4.5, 4.6). All cell types were stained negative and showed no expression at all for all
the negative control markers, except for ligament fibroblasts, which showed a very slight
expression for the dermal fibroblastic specific marker TE-7, indicating that TE-7 is not 100%
specific for dermal fibroblasts. Our data indicate that all the isolated primary cells are specific to
their origin and can be used for further analysis.
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4.3.2. LIVE/DEAD Viability and Proliferation Assays
LIVE/DEAD and MTS proliferation assays were performed on the three different cell types
cultured in different scaffolds either with or without growth factor on day 3 and 7 to qualitatively
determine the capability of these substrate to support the viability of the different cells as well as
to quantitatively examine the effect of the growth factors incorporation methods (coaxial Vs
uniaxial, or gelation incorporation Vs. surface absorption) and releasing profiles (minimal burst
release Vs. rapid burst release) on the cell proliferation. As shown in (Figure 4.7, Figure 4.8, Figure
4.9), all scaffolds supported the viability and the proliferation of primary dermal fibroblasts and
dead cells were not evidence, as cells displayed a robust and healthy morphology. In general, cells
cultured on coaxial PLGA-Gelatin-PDGF-BB and uniaxial PLGA-PDGF-BB showed a significant
increase in cell viability and proliferation in both days 3 and 7 when compared to PLGA-Gelatin
and PLGA electrospun nanofiber scaffolds without PDGF-BB (Figure 4.8, Figure 4.9). When
cultured on PLGA-Gelatin and PLGA nanofiber scaffolds, dermal fibroblasts showed a significant
increase in cell viability and proliferation on the coaxial PLGA-Gelatin when compared to the
uniaxial PLGA nanofiber scaffolds at both days 3 and 7 (Figure 4.7). When cultured on coaxial
PLGA-Gelatin-PDGF-BB and uniaxial PLGA-PDGF-BB, dermal fibroblasts showed a relatively
similar viability and cell growth in both time points 3 and 7 days with no significant difference
(Figure 4.8 A, B, E, F, Figure 4.9).
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The behaviors of ligament fibroblasts cultured on the same scaffolds but with the presence of IGFI, was relatively similar to the behavior of dermal fibroblasts with no significant difference (Figure
4.10, Figure 4.11, Figure 12), where viability and proliferation have been supported by these
substrates, and cells showed significantly higher proliferation and viability with the presence of
IGF-I when compared to the scaffold that don’t contain IGF-I in the coaxial and uniaxial cases. As
shown in (Figure 4.13, Figure 4.14, Figure 15) Osteoblasts cultured on PLGA-Gelatin-mTG/BMP2 and PLGA/BMP-2 showed a significant increase in cell viability and proliferation in both days
3 and 7 when compared to PLGA-Gelatin-mTG and PLGA-Gelatin free. When cultured on the
PLGA-Gelatin-mTG and PLGA-Gelatin-mTG free, osteoblasts showed a significant increase in
cell viability and proliferation on PLGA-Gelatin-mTG when compared to the PLGA-Gelatin-mTG
free in both time points day 3 and 7 (Figure 4.13). When cultured on PLGA-Gelatin-mTG/BMP2 and PLGA/BMP-2, osteoblasts showed a significant increase in cell viability and proliferation
on the PLGA/BMP-2 group in day 3 when compared to the PLGA-Gelatin-mTG/BMP-2 group
(Figure 4.14 A, B, E, F, and Figure 4.15). In day 7, osteoblasts showed a significant increase in
cell viability and proliferation on PLGA-Gelatin-mTG/BMP-2 scaffolds when compared to
PLGA/BMP-2 scaffolds.
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4.4.Discussion:
The capability of the three different phases within the integrated graft system to support cellular
viability and proliferation as well as the effect of the different growth factors incorporation
methods have been evaluated on the three-different isolated primary cells; dermal fibroblast,
ligament fibroblasts, and osteoblasts.

The three different cells were successfully isolated and characterized by morphology and
immunofluorescence against specific markers in order to confirm their phenotype after they have
been isolated from a heterogeneous environment to ensure the homogeneity in our cellular
population. We initially morphologically characterized every cell type by observing the shape,
size, and structure of the cell. Both cell types isolated from skin and ligament exhibited a spindle
and elongated cytoplasm structure with relatively long cytoplasmic processes of 3 - 7 µm and 5 –
11 µm in length for both dermal and ligament respectively as measured in Image J. These cells
displayed a thicker central part of the body and two narrow peripheral processes with smooth
lateral edges, which suggest their fibroblastic phenotype. Cells isolated from long bones appeared
flattened and slightly slender in shape and displayed sparse and relatively short cytoplasmic
processes 2-5 µm in length when compared to the isolated fibroblasts (Figure 4.3). Osteoblasts
maintained their slender shape during culture, but they became smaller and packed when they
reach confluence. Our morphological observations to the three different cell types correspond with
previously conducted morphological studies that morphologically characterized both fibroblasts
and osteoblasts [20, 21].
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Further characterizations have been conducted with immunofluorescence in order to verify the
cells’ phenotype. Every cell type was stained against two positive markers that are known to be
expressed by them along with a negative marker as a control. Our data revealed that all the three
different cell types were specific to all markers and showed 100% positive expression for every
specific marker as indicated by Image J when conducting the image pixel analysis (Figure 4.4, 4.5,
4.6). All cell types were stained negative and showed no expression at all for all the negative
control markers, except for ligament fibroblasts, which showed a very slight expression for the
dermal fibroblastic specific marker TE-7. This corresponds with other several previous studies that
TE-7 could potentially be expressed in other fibroblasts from different anatomical locations such
as lung and muscle fibroblasts [27, 29]. Thus, our data suggest that ligament fibroblasts can be one
of the TE-7 expressing cells since it was slightly stained in its cytoplasm. Our cell characterization
results indicate that all the three different cell types are specific to the origin they were isolated
from and that they can be used to conduct further studies with confident.

LIVE/DEAD and MTS proliferation assays were performed on the three different cell types
cultured in different scaffolds either with or without growth factor on day 3 and 7 to qualitatively
determine the capability of these substrate to support the viability of the different cells as well as
to quantitatively examine the effect of the growth factors incorporation methods (coaxial Vs
uniaxial, or gelatin incorporation Vs. surface absorption) and releasing profiles (minimal burst
release Vs. rapid burst release) on the cell proliferation.

As shown in (Figure 4.7, Figure 4.8, Figure 9), all scaffolds supported the viability and the
proliferation of primary dermal fibroblasts, and dead cells were not evidence, as cells displayed a
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robust and healthy morphology. In general, cells cultured on PLGA-Gelatin-PDGF-BB and
PLGA-PDGF-BB showed a significant increase in cell viability and proliferation in both days 3
and 7 when compared to PLGA-Gelatin and PLGA electrospun nanofiber scaffolds without
PDGF-BB (Figure 4.8, Figure 4.9). This corresponds with a previously conducted study that
PDGF-BB has the ability to support dermal fibroblasts growth by stimulating them to rapidly
proliferate [64]. When cultured on PLGA-Gelatin and PLGA nanofiber scaffolds, dermal
fibroblasts showed a significant increase in cell viability and proliferation on the coaxial PLGAGelatin when compared to the uniaxial PLGA nanofiber scaffolds at both days 3 and 7 (Figure
4.7). This could have been due to the fact the coaxial nanofibers have less PLGA content than the
uniaxial, which might have caused the hydrophilicity in the coaxial nanofibers to increase,
resulting in enhanced cellular attachment and therapy, proliferation. In addition, the presence of
gelatin in the core-shell of the scaffold have been shown to enhance cell proliferation because
gelatin inherits all the necessary arginine-glycineaspartic acid (RGD) sequences that allows for
enhanced cell adhesion, which is the reason for the increase in the cell number in the PLGAGelatin group [81]. When cultured on coaxial PLGA-Gelatin-PDGF-BB and uniaxial PLGAPDGF-BB, dermal fibroblasts showed a relatively similar viability and cell proliferation in both
time points 3 and 7 days with no significant difference (Figure 4.8 A, B, E, F, Figure 4.9). This
does not seem to correlate with the data of PLGA-Gelatin and PLGA alone, where the viability
and proliferation were significantly higher in the coaxial PLGA-Gelatin scaffolds when compared
to uniaxial PLGA alone in both time points in the case of no growth factors. However, we believe
that having no significant difference in cell proliferation at the two-time points might have been
due to the effect of the burst release of the growth factor from the uniaxial nanofiber scaffolds,
which caused a rapid cell proliferation that could level up in a timely manner with the proliferation
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of the cells seeded on the coaxial fibers.

The behaviors of ligament fibroblasts cultured on coaxial PLGA-Gelatin and uniaxial PLGA with
or without IGF-I was relatively similar to the behavior of dermal fibroblasts (Figure 4.10, Figure
4.11, Figure 12), where viability and proliferation have been supported by these substrates, and
cells showed significantly higher proliferation and viability with the presence of IGF-I when
compared to the scaffolds that don’t contain IGF-I in the coaxial and uniaxial cases. Several groups
have previously demonstrated the positive effect of IGF-I in enhancing the metabolic activities of
ligament fibroblast, stimulating them to rapidly proliferate. This, however, explains the reason for
the rapid proliferation of ligament fibroblasts seeded on PLGA/IGF-I nanofingers scaffolds when
compared to PLGA nanofibers scaffold with no growth factors [73]. Although no significant
difference in cell growth was found between PLGA-Gelatin and PLGA alone, ligament fibroblasts
seeded on PLGA-Gelatin had a relatively higher proliferation when compared to PLGA, which
further confirms that the presence of gelatin in the core-shell enhances the cellular performance.
Data from both cell types indicate that the presence of gelatin in the core–shell of the fiber
enhanced cell viability and proliferation.

As shown in (Figure 4.13, Figure 4.14, Figure 4.15) Osteoblasts cultured on PLGA-GelatinmTG/BMP-2 and PLGA/BMP-2 showed a significant increase in cell viability and proliferation
in both days 3 and 7 when compared to PLGA-Gelatin-mTG and PLGA-Gelatin free. This implies
that BMP-2 has positive effects on primary osteoblasts, stimulating them to rapidly proliferate as
previously mentioned [79]. When cultured on the PLGA-Gelatin-mTG and PLGA-Gelatin-mTG
free, osteoblasts showed a significant increase in cell viability and proliferation on PLGA-Gelatin-
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mTG when compared to the PLGA-Gelatin-mTG free in both time points day 3 and 7 (Figure
4.13). This indicates that the presence of gelatin did not negatively affect cellular viability or
proliferation and thus, enhanced the overall cellular performance and increased the scaffold
biocompatibility.

When cultured on PLGA-Gelatin-mTG/BMP-2 and PLGA/BMP-2, osteoblasts showed a
significant increase in cell viability and proliferation on the PLGA/BMP-2 group in day 3 when
compared to the PLGA-Gelatin-mTG/BMP-2 group (Figure 4.14 A, B, E, F, and Figure 4.15). In
day 7, osteoblasts showed a significant increase in cell viability and proliferation on PLGAGelatin-mTG/BMP-2 scaffolds when compared to PLGA/BMP-2 scaffolds. Because of the high
burst release of the surface adsorbed BMP-2, osteoblasts showed a significantly higher
proliferation within the first three days in the surface adsorbed group when compared to the
retained BMP-2 group. Surface absorbed PLGA with BMP-2 is known to exhibit a high initial
burst release, followed by a complete release of the protein within the first 48 hours [83]. However,
it its believed that the complete release of BMP-2 in the growth medium stimulated osteoblasts to
rapidly proliferate, which correlates with the high cell growth of osteoblasts seeded on the surface
absorbed with BMP-2 group at day 3. During the experiment, mediums from all groups were
removed and replaced with freshly new medium after day 3. However, since all the BMP-2 in the
surface adsorbed groups was released to the medium within the first ~ 48 h, it was removed with
the medium change. This, however, caused osteoblasts cultured on the retained BMP-2 groups to
constantly maintain their proliferation over time, and osteoblasts cultured on the surface adsorbed
scaffold to decrease in proliferation due to the lack of BMP-2. This can be correlated with our ALP
findings from the previous chapter (Figure 3.3), where cultured MC3T3 cells had lower ALP
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activities when seeded on PLGA-Gelatin-mTG/BMP-2 group in comparison to the surface
absorbed PLGA with BMP-2 group on the 7th day of the experiment, but significantly higher ALP
activities on day 14 on PLGA-Gelatin-mTG/BMP-2 group when compared to the other groups,
indicating that the retention of BMP-2 in the gelatin hydrogel does not affect the osteoindctivity
of BMP-2. These findings demonstrate the gelatin-mTG/BMP-2 embedded PLGA microspheres
have the protentional to stimulate osteoblasts proliferation for longer times due to the
immobilization of BMP-2.

Based on the overall findings of the proliferation and viability studies performed on the three
differed cell types on the different relevant scaffolds, we decided to further continue conducting
the next set of experiments using the PLGA-Gelatin-Growth factors electrospun nanofiber
scaffolds for the support of dermal and ligament fibroblasts culture, and PLGA-GelatinmTG/BMP-2 for the support of osteoblasts culture.
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4.5.Conclusion:
In conclusion, the isolated primary cells, dermal fibroblasts, ligament fibroblasts and osteoblasts
were specific to all markers and showed 100% positive expression for every specific marker,
indicating that these cells are specific to the origin they were isolated from. Ligament fibroblasts
showed low expression of the specific dermal osteoblasts marker TE-7, indicating that this marker
is not completely specific to dermal fibroblasts. Viability and proliferation of both dermal and
ligament fibroblasts were shown to be enhanced on the coaxial elctrospun PLGA-Gelatin
nanofiber scaffolds when compared to the uniaxial PLGA alone at the two time points due to the
presence of gelatin at the core-shell of the fiber, which enhanced cell adhesion and therapy cell
proliferation. PDGF-BB and IGF-I were shown to enhance the proliferation of dermal and
ligament fibroblasts respectively. Cell proliferation was shown to be affected by the different
incorporation methods of growth factors within the scaffolds. In the case of no growth factors,
both cells showed significant increase in cell growth on PLGA-Gelatin scaffolds when compared
to the uniaxial PLGA alone. However, due to the effect of the burst release associated with the
uniaxial PLGA nanofiber scaffolds, no significant difference was noticed in cell growth of both
cell types seeded on PLGA-Gelatin or uniaxial PLGA alone, in the case of growth factors.
Osteoblasts proliferation and viability were enhanced on PLGA-Gelatin-mTG scaffold when
compared to PLGA-Gelatin-mTG free at both time points. Due to the burst release of BMP-2,
osteoblasts showed a significantly higher proliferation on the surface absorbed PLGA with BMP2 when compared to PLGA-Gelatin-mTG/BMP-2 at day 3, and significantly higher on PLGAGelatin-mTG/BMP-2 when compared to PLGA/BMP-2 at day 7. These findings indicate that
osteoblasts proliferation was affected by the different growth factors incorporation methods. Based
on these results, its anticipated that PLGA-Gelatin-mTG/BMP-2 microsphere scaffolds and PLGA
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coaxial electrospun nanofiber scaffold (w/growth factors) will have the potential to serve as
suitable substrates for further experiments.
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CHAPTER 5
DEVELOPMENT AND CHARACTERIZATION OF A TRI-CULTURE SYSTEM AND
EVALUATING THE CAPABILITY OF THE INTEGRATED GRAFT SYSTEM TO
SUPPORT HETEROGENIC CELLULAR INTERACTIONS
5.7.Introduction
The human body is known for its limited regenerative capacity [1]. Bone and skin, for instance,
can self-regenerate upon injury to a certain extent depending on how severe the damage is,
however, if self-repair mechanisms are overstrained, in case of non-unions or critical size defects,
these tissues loss the ability to repair themselves, leading to the existence of an empty defect or
the formation of a scar tissue that lacks all the necessary functional and biological properties [2, 3,
4].

One of the grand challenges in the modern medicine is the limited availability of subsequent
functional impairment to these lost or damaged tissues; for example, to address the current
challenges of restoring the function of damaged/injured organ or tissue, the use of biological grafts
such as autograft, defined as the transplantation of a tissue within an individual from a donor site
to the injury site, or allograft, defined as the transplantation of a tissue or a whole organ from
another individual or a cadaver, is considered as the only viable strategy [5]. Despite the fact that
the use of biological grafts led to improving the quality of lives to many individuals, serious
drawbacks such as the poor biocompatibility and integration of allografts to the host tissues, and
the limited availability along with the high price demand of autograft limit their clinical use, which
led to the necessity of finding alternatives that mostly focus on regenerating the damaged tissues
rather than repairing or replacing them [6].
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Tissue engineering, which has been defined as the application of biological, chemical, and
engineering principles toward the repair restoration, regeneration of tissues using biomaterial,
cells, and factors alone or in combination, evolved of this necessity. Significant efforts have been
made in the past few decades towards regenerating single tissues both in vitro and in vivo using
the tissue engineering approaches [7]. By utilizing the tissue engineering approaches, tissuespecific scaffolds for almost every single tissue within the lower and the upper extremities such as
bone [8-17], ligament [17-21], cartilage [22], muscle [23] and skin [22] have been created with
great potential. Despite the fact that tissue engineering demonstrated many approaches that led to
understanding the feasibility toward repairing or regenerating single targeted tissues, they do not
address the grand challenges associated with engineering complex tissues such as organ systems
or an entire limb.

Limitations of the current biological and engineering approaches towards complex tissue
regeneration made it clear that a paradigm shift is required to successfully create translational
technologies that can address the grand clinical challenges [24]. Developing a new
interdisciplinary approach that utilizes the most advanced technologies currently available in
different fields such as developmental biology, bioengineering, biomaterials science, stem cell
biology, and clinical medicine along with a full understanding of the human’s self-regenerative
capacity may hold the key toward complex tissue regeneration [24, 25]. The efforts of scientists
from these various fields led to the emergence of a new paradigm we term “Regenerative
Engineering,” which has been defined as “the Convergence of Advanced Materials Sciences, Stem
Cell Sciences, Physics, Developmental Biology and Clinical Translation for the regeneration of
complex tissues and organ systems.” Regenerative Engineering has elements of regenerative
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medicine, tissue engineering, and morphogenesis but is distinct from these individual disciplines
in that it is less applicable to spot the repair of injured tissues and elements and primarily focuses
on the integration and the subsequent response of stem cells to biomaterials and regeneration of
the interfaces between different tissue types [26]. This new field is proposed to regenerate damaged
complex tissues, with addressing grand challenges such as the regeneration of a total knee or a
whole limb through the utilization of the classical top-down tissue engineering approaches in
combination with bottom-up strategies used in regenerative biology in addition to the knowledge
from other discipline such as advanced materials science and engineering and developmental
biology [27].

The top-down approach is built on the integration of well-established elements of classical tissue
engineering such as biomaterials, cells with high regenerating ability, and biologically active
factors such as growth factors or small molecules [27]. The bottom-up approach calls on
developmental and regenerative biology, where intact tissues are self-assembled from highly
proliferative and differentiated cell layers, similarly to those cells found within the blastemal in
the urodele amphibians [27]. This opens the chance to discuss the unique ability of the urodele
amphibians in regenerating a totally amputated limb. Distance from humans, who don't possess
the ability to regenerate amputated limbs, urodele amphibians have a remarkably high regenerative
capability to regenerate a severely damaged or amputated limb any time during their life time
through a process known as “Epimorphic Regeneration” [28]. This unique ability to completely
regrow severed limb loss in urodele amphibians has established a field of intense study to
understand the characteristics of a regenerative limb [29]. Amphibians rely on their regeneration
on the formation of what is referred to as blastema (a cluster of highly proliferative differentiated
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cells) that plays a crucial role in establishing the regeneration process [29]. Briefly, following
amputation, a cascade of events sequentially takes place starting from the formation of the wound
epidermal, to the formation of blastema and the proliferation of the cells within the blastema
followed by patterning of the forming tissues until a newly intact limb is regenerated [29]. We
simply cannot use the same approach that the amphibians use due to the fact that our biology is
completely different from the biology of the amphibians, which adds up another translational
challenge; however, studying their regenerative capacity must be part of the arsenal we use to
achieve our grand challenge [29].

The Regenerative engineering strategy in overcoming the barriers to regeneration in vertebrates is
to harness the amphibians in humans through (1) the lessons learned from their regenerative
process, which has the potential to inform us and provide us with hints in what is required for a
regenerative limb to successfully regenerate, (2) in addition to developing novel engineering-based
translational strategies using the top-bottom and bottom-up approaches. One lesson that we can
learn from the regenerative process in the amphibian is that during limb regeneration, all tissues
within the limb, including the skin interact together to reform simultaneously until a newly intact
limb is regenerated. This lesson taken from the regenerative process in the amphibians has
provided us with insight, that tissue formation during limb regeneration is a simultaneous process
and is required for a regenerative limb to successfully regenerate. Knowing that limb regeneration
is a simultaneous process, the next horizon in the field of regenerative engineering resides in how
to simultaneously form these tissues and assemble them into intact multi-tissue units and facilitate
their integration to the host in vivo [27].
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A great deal of advances has been accomplished in the past few years to regenerate multi-tissue
units along with their interfaces through the utilization of the regenerative engineering approaches,
such as bone-to-ligament interface [30], bone-to-tendon interface [31], tendon-to-muscle interface
[32] as well as bone-to-cartilage interface [33]. However, these current advances in the field of
regenerative engineering, at the musculoskeletal level, would not have been accomplished without
the effort made in several very initial proof-of-concept studies that have been carried out
attempting to study the interactions between different tissue-relevant and/or interface-relevant
cells in three-dimensional heterogenic cellular environments. These preliminary studies led to
understanding the feasibility toward tissue/interface relevant cell-cell interactions and their role in
initiating interfaces between several musculoskeletal tissues. For example, Sapalazzi et al. was the
first who studied the interaction between primary osteoblasts and ligament fibroblast in a threedimensional substrate with location-specific topographies based on the hypothesis that coculturing both cells in a substrate with tissue-specific phases will result in the formation of a
fibrocartilage-like tissue at the contact site without modulating the phenotype of both cells at either
site [30]. This one initial novel preliminary study clarified many concepts and demonstrated the
feasibility towards multi-tissue regeneration and tissues interfaces. However, providing a wellengineered three-dimensional framework to study the interactions between the different
tissue/interface relevant cells, especially those found within the limb may hold the key towards
limb regeneration.

In this aim, a tri-culture system has been developed in order to determine a growth medium that
would best sustain the viability and proliferation of the three different cell types, dermal
fibroblasts, ligament fibroblasts and osteoblasts in a tri-culture environment. In addition, the
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capability of the integrated graft system to sustain the biological properties of the three different
cell types such as cell viability, proliferation, and phenotype in the heterogenic cellular
environment has been evaluated. Furthermore, cell localization in their respective phases, as well
as cell migration between the three different phases within the integrated graft system, have been
examined by immunofluorescence.
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5.2 Materials and Methods:
Poly(lactide-co-glycolide) PLGA 85:15 (PLAGA) (MW ~ 94,000 kDa) was purchased from
(Absorbable Polymers, Birmingham, AL, USA), Hexafluoro-2-propanol (HFIP) was purchased
from (Acros Organics, USA), Gelatin Type A from Pork (Porcine skin) was purchased from (MP
Biomedical, OH, USA), Microbial Transglutaminase (mTG) was Purchased from (Ajinomoto,
Japan), Dichloromethane (DCM) was purchased from (Fisher Scientific, USA), PDGF-BB, IGF-I
and BMP-2 growth factors were purchased from (Fisher Scientific, USA), Dulbecco’s PhosphateBuffered Saline (PBS) of pH 7.4, MEM Alpha (1X) Minimum Essential Medium, DMEM/F-12
(1:1) (Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12), Antibiotic-Antimycotic
(100X), Trypsin-EDTA (0.25%) phenol red, Fetal Bovine Serum, Qualified, PenicillinStreptomycin (10,000 U/mL), and Hank’s balanced salt solution (HBSS) were purchased from
Gibco (Grand Island, NY), primary antibodies, IgG monoclonal unconjugated Anti-Alkaline
Phosphatase (ab108337), IgG3 monoclonal unconjugated Anti-Osteocalcin antibody (ab13420),
IgG monoclonal unconjugated Anti-SCXA antibody (ab58655), IgG monoclonal unconjugated
Anti-tenomodulin antibody (ab203676), IgG monoclonal unconjugated Anti-TE-7 antibody
(ab197896), IgG monoclonal unconjugated Anti-Vimentin antibody (ab92547), and the
compatible secondary antibodies, IgG polyclonal Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488)
(ab150077), and IgG polyclonal Goat Anti-Mouse IgG H&L (Alexa Fluor® 488)(ab150113) were
purchased from (Abcam, MA, USA), DAPI (4',6-Diamidino-2-Phenylindole, Dihydrochloride),
and anti-fade mounting medium, LIVE/DEAD™ Viability/Cytotoxicity Kit were parched from
(Invitrogen, USA), and CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS) was
purchased from (Promega Inc, USA), Polydimethylsiloxane was purchased from (Fisher Scientific
Inc. , USA).
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5.2.1 Tri-Culture Design Concept
The capability of the integrated graft system to sustain the viability, proliferation and the
heterogeneity of the three different cell types was evaluated. However, this has been accomplished
by seeding the three different cell types within the integrated graft system, each in its relevant
phase and maintaining them in culture for predetermined time points and conducting the
appropriate set of experiment. Prior to this, knowing the suitable growth medium that would best
sustain the growth of the three different cell populations in a tri-culture environment was essential
in order to ensure maintaining the viability of the cell populations. In order to determine the best
suitable medium, a tri-culture model has been developed. The concept behind the idea was to
establish an appropriate environment that can be employed to culture three different cell
populations and have them share the same medium while they are physically separated under the
same symmetrical conditions. This was done by separating the well of a 24-well plate into three
different chambers, in which each chamber could be used to culture a different cell population.
This was accomplished by placing a prefabricated Polydimethylsiloxane (PDMS) segment that
separated the well into three different chambers. By separating the well into three different
chambers, every cell population could be cultured in a different chamber within the same well, in
which one cellular population could be seeded in one chamber, another cellular population could
be seeded in the other next chamber, and a third cellular population could be seeded in the next
third chamber within the same well. Culturing three different and physically separated cellular
populations within the same well while sharing the same medium is an optimal setup for initiating
cell-cell interactions in order to study the behavior of the single cell population in a tri culture
environment. The tri-culture model served as a suitable tool that could be utilized in order to study
the behavior of the single cell population in a tri-culture environment.
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5.2.2 Mold Design, Development and Three-Dimensional Printing
A mold was first designed and 3D printed in order to be used for fabricating the PDMS segment.
The mold consisted on two parts, a disc and a plate that served as a carrier for the disk. The two
parts were first 3D designed using the SolidWorks 3D CAD software. The disc had a diameter of
(17 mm) and a thickness of (5 mm) with an internal gap distance of (2 mm). The plate had a length
of (13 mm), and a width of (8 mm) and a height of (2 mm) with an internal hole diameter of (17
mm). For 3D printing, both parts were 3D printed using (MakerBot Replicator, Makerbot, USA).
Briefly, PLA filament plastic was loaded into the 3D printer syringe and it was heated to 50 °C to
melt the polymer. Both parts were 3D printed with a syringe nozzle of 200 um and printing velocity
of 5 mm/s within a laminar flow-cabinet. Parts were then harvest and stored.

5.2.3

Polydimethylsiloxane Segments Fabrication

To fabricate the polydimethylsiloxane (PDMS) segment, PDMS elastomer was mixed with a
curing agent at a ratio of (10:1) elastomer to curing agent. The solution was mixed thoroughly for
5 minutes to ensure homogeneity between the elastomer and the curing agent. The mixture was
then placed in a desiccator until almost all bubbles were removed. To fabricate the PDMS segment,
the 3D printed disc was inserted into the holes within the plate, followed by pouring the PDMS
elastomer into the mold. The mold containing PDMS elastomer was then placed at 37 °C for 24
hours for the PDMS elastomer to completely cure. After it is cured, the PDMS segments were
removed from the mold, and stored at the desiccator for later use

5.2.4 Testing the Functionality of the Tri-Culture System
Testing the functionality of the PDMS segments was compromised into two steps:
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5.2.4.1 Liquids Penetration
PDMS segments were placed into the well of a 24-well plate N=3/ time point. After placing the
segments, the well was separated into three different chambers. 150 µl of PBS was added to the
first chamber, 150 µl of a red dye was added to the second chamber, and 150 µl of a blue dye was
added to the third chamber within the same well. The plates were incubated at 37 °C. At
predetermined time points, 3 and 7 days, the penetration of the three liquids to the other chambers
was examined.

5.2.4.2 Cell Migration
PDMS segments were autoclaved and exposed to UV light for 30 minutes each side for
sterilization. The segments were then placed into the well of a 24-well plate N=3/ time points.
After placing the segments, the well was separated into three different chambers. For cell seeding,
the three different cell types were trypsinized with 0.25 trypsin EDTA and centrifuged to obtain a
pellet. After centrifugation, the pellet was disturbed and every chamber was seeded with a different
cell type at a concertation of 5 X 103 cells/chamber and 1 ml of MEM Alpha (1X) Minimum
Essential Medium supplemented with 15% FBS and 1% Penicillin/Streptomycin was added to
each well and plates were incubated in a tissue culture incubator at 37°C, 5%CO2, 3%O2. At
predetermined time points, 3 and 7 days, the plates were removed from the tissue culture incubator,
the PDMS segments were removed and cell migration was observed using a normal light
microcopy.

5.2.5 Fabrication of PLGA-Gelatin Coaxial Nanofiber Scaffolds
As described previously, PLGA (85:15) granules were dissolved in HFIP at 16 % wt and stirred
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overnight at room temperature to prepare the (shell solution) of nanofibers. To prepare the core
solution, gelatin powder type A was dissolved in HFIP at 4% wt and stirred overnight at room
temperature. At the day of electrospinning, both growth factors were reconstituted at a
concentration of 1 mg/ml, and 81 µl of the reconstitution of either PDGF-BB and IGF-I were added
to 1.5 ml of gelatin solutions and stirred for 15 minutes to allow the growth factor to homogenize
with the gelatin solution. In the case of coaxial nanofibers with no growth factors, gelatin solution
was used alone in the core-shell. An electrospinning pump (NE 300 SYRINGE pumps, USA) was
used in order to fabricate the coaxial PLGA-Gelatin nanofibers. The setting to prepare the coaxial
scaffolds consisted of two coaxial syringe pumps with different flow rates. In this study, the PLGA
solution was used to form the outer shell and the gelatin-growth factors or free of growth factors
solutions were used to form the inner core. PLGA solution and either gelatin-growth factors or
free of growth factors solution were loaded into two separate 10 ml syringes and connected to the
coaxial needles, a 16 G (ID = 1.6 mm) outer needle and a 22 G (ID = 0.7 mm) inner needle,
respectively, and then concentrically placed. The electrospinning parameters were as follows:
(applied voltage: 10 kV; 1.5 mL/h for the sheath flow rate and 0.75 mL/h for the core flow rate).
The tip of the needle was placed 10 cm away from the collector. The electrospinning process lasted
for 1.5 h. Coaxial electrospun nanofibers were peeled from the collector and stored under
vacuumed desiccator for 24 hours to insure complete evaporation of solvent.

5.2.6 Fabrication of PLGA Microspheres
As previously described, single emulsion solvent evaporation technique was used to fabricate
PLGA microspheres. PLGA granules were dissolved at 12.5% wt in Dichloromethane (DCM) in
glassy vials. Vials were vortexed for 1 h at a speed of 550 RPM until clear, homogeneous, and
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viscous solution was obtained. Next, PLGA solution was added via a thin stream into 1% PVA
solution in a 1000 ml beaker and it was let to stir at (300 RPM) overnight to allow the solvent to
evaporate. After that, microspheres were collected, filtered, air dried and then they were stored in
-20 °C for 24 h to freeze any residual water particle inside of the microspheres. Next, microspheres
were freeze dried for 48 h and were then sieved to obtain the desired particle size range 300 – 600
µm.

5.2.7 Incorporation of BMP-2 in Gelatin-mTG Hydrogel
Gelatin gel formation was initiated by mTG addition. For hydrogel preparation, 3% wt gelatin
powder type A was dissolved in preheated phosphate-buffered saline (PBS) at 50 °C and it was let
to stir on a stirrer plate for 15 minutes at 500 RPM to completely dissolve the powder. The mTG
solution was prepared by dissolving 10% wt mTG in preheated PBS at 50 °C, then it was let to stir
on a stirrer plate for 15 minutes at 500 RPM. As soon as both gelatin and mTG completely
dissolved in PBS, the temperature of the stirrer plate was adjusted to 37 °C and they were let to
stir for another 15 minutes to allow for the temperature drop. Next, to initiate the cross-linking
reaction between gelatin and mTG for the hydrogel preparation, mTG solution was mixed with the
3% wt gelatin solution at a ratio of 1:11.5 under stirrer speed of 500 RPM at 37 °C. The mixture
was let to stir for 5 minutes until a semi-viscus solution is fabricated and ready to by injected.
BMP-2 incorporation was done by adding 1 µlgof BMP-2 in 100 µl of gelatin-mTG solution and
mix them gently.
5.2.8 Fabrications of PLGA Microsphere Scaffolds Incorporated Gelatin-mTG/BMP-2
To fabricate the three-dimensional scaffolds and use it to either incorporate gelatin-mTG/BMP-2
or gelatin-mTG hydrogels within it, PLGA microspheres were poured into a 10mm x 10 mm and
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5 mm X 5 mm stainless steel molds and heated for 90 °C for 90 minutes. These parameters allowed
the microspheres to fuse together forming the 3D scaffolds. After 90 minutes, the stainless-steel
mold was removed from the oven and allowed to cool to room temperature for 2 hours. Next,
scaffolds were removed and the semi-viscus gelatin-mTG/BMP-2 hydrogel was injected inside of
the microsphere scaffold using an insulin syringe until all porosity were filled and it was allowed
to gel at 37 °C for 1 hours.

5.2.9 Primary Cells Isolations:
6-8 weeks old (150 – 200 g) Lewis rats were obtained from (Charles River Laboratories, CT,
USA) and used for all primary cell isolations. All the animal experiments were approved by the
Institutional Animal Care and Use Committee (IACUC) at the University of Connecticut Health
Center, CT, Farmington, USA.

5.2.9.1 Primary Dermal Fibroblasts Isolation and in Culture Maintenance:
Dermal fibroblasts were isolated and maintained in culture using the same method described in
section 4.2.6.1.

5.2.9.2 Primary Ligament Fibroblasts Isolation and in Culture Maintenance:
Ligament fibroblasts were isolated and maintained in culture using the same method described in
section 4.2.6.2.
5.2.9.3 Primary Bone Osteoblasts Isolation and in Culture Maintenance:
Bone osteoblasts were isolated and maintained in culture using the same method described in
section 4.2.6.3.
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5.2.10 In vitro Tri-culture study for the Determination of a Heterogenic Culture Medium:
The growth of the different cell types in the different mediums and medium composition in the
single and the tri-culture environment was assessed using the Cell Titer 96® AQueous One
Solution Cell Proliferation Assay according to the manufacturer’s instructions. All scaffolds were
sterilized prior to cell seeding. To sterilize PLGA microsphere scaffolds, they were submerged in
70% ethanol for 20 minutes followed by submerging in sterile PBS to remove any ethanol
residuals. Next, scaffolds were exposed to UV light for 30 minutes each side. To sterilize PLGAGelatin coaxial electrospun nanofiber scaffolds, they were placed inside of the cell culture hood
and exposed to UV light for 30 minutes each side. Finally, to sterilize the PDMS segments, they
were autoclaved and exposed to UV light for 30 minutes each side. The three different cell types
were trypsinized with 0.25 EDTA trypsin and centrifuged to get a pellet. After centrifugation, the
cell pellet was disturbed and used for cell seeding. Dermal and ligament fibroblasts were seeded
on 5 mm X 5 mm PLGA-Gelatin coaxial electrospun nanofiber scaffolds at a density of 5 X 10 4
cells/scaffold, and osteoblasts were seeded on 5 mm X 5 mm PLGA-Gelatin-mTG microsphere
scaffolds at a density of 5 X 10

4

cells/scaffold. For the single culture environment, pre-seeded

scaffolds were placed in low-binding 24-well plates and every scaffold was maintained in culture
in 1 ml of three different mediums, and four different medium composition as follows: (1) MEM
supplemented with 15% FBS, 1X Penicillin/Streptomycin, non-essential amino acids, and sodium
pyruvate, (2), DMEM/F-12 supplemented with 10% FBS and 1% P/S (3), MEM Alpha (1X)
Minimum Essential Medium supplemented with 15% FBS and 1% Penicillin/Streptomycin (4),
[2:1:1] (5), [1:2:1] (6), [1:1:2] and (7) [1:1:1] respectively with an N=3/ medium type for every
scaffold. For the tri-culture environment, PDMS segments were placed in low-binding 24-well
plates, in which every well was separated into three different chambers. Every chamber was
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occupied with a different scaffold pre-seeded with a different cell type. In every well, dermal
fibroblasts pre-seeded PLGA-Gelatin coaxial electrospun nanofiber scaffold was placed in the first
chamber, ligament fibroblasts pre-seeded PLGA-Gelatin coaxial electrospun nanofiber scaffold
was placed in the second chamber, and osteoblasts pre-seeded PLGA-Gelatin-mTG scaffold was
placed in the next third chamber of the same well with an N=3/ medium type for every scaffold.
All scaffolds were maintained in 1 ml of the same mediums and medium compositions of the single
culture environment. All scaffolds from the single and tri-culture envirnement were maintained in
a tissue culture incubator at at 37°C, 5%CO2, 3%O2. After day 3 and 7, scaffolds were removed
from their wells or chambers and placed in new wells after two washes with PBS. Next, scaffolds
were incubated with a cocktail of the relevant medium type premixed with MTS solution at a ratio
of (1:5) for 3 hours at 37 C. 500 μL of sodium dodecyl sulfate was added to each well to stop the
reaction and the absorbance at 490 nm was measured with a spectrophotometric plate reader
(TECAN, Crailsheim, Germany).

5.2.11 In Vitro Evaluations of the Integrated Graft System
5.2.11.1

LIVE/DEAD Assay

All scaffolds were sterilized prior to cell seeding. To sterilize PLGA microsphere scaffolds, they
were submerged in 70% ethanol for 20 minutes followed by submerging in sterile PBS to remove
any ethanol residuals. Next, scaffolds were exposed to UV light for 30 minutes each side. To
sterilize PLGA-Gelatin/growth factors coaxial electrospun nanofiber scaffolds, they were placed
inside of the cell culture hood and exposed to UV light for 30 minutes each side. To incorporate
BMP-2 in PLGA microsphere scaffolds, scaffolds were injected with 100 ul of gelatin-mTG/BMP2 (1ug/ scaffold). Scaffolds injected with gelatin-mTG/BMP-2 were further incubated at 37C to
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allow for complete gelation. Dermal and fibroblasts were seeded on 1 cm X 2 cm PLGA-GelatinPDGF-BB coaxial electrospun nanofiber scaffolds (Phase A), ligament fibroblasts were seeded on
1 cm X 1 cm PLGA-Gelatin-IGF-I coaxial electrospun nanofiber scaffolds (Phase B), and
osteoblasts were seeded on 10 mm X 10 mm PLGA-Gelatin-mTG/BMP-2 cylindrical microsphere
scaffolds (Phase C). All cells were seeded at a density of 1 X 105 cells/ scaffold and scaffolds were
placed in low binding 24-well plates in triplicate. Cells were allowed to attach for 1.5 h in the cell
culture incubator at 37 C prior to the addition of 2 ml of the relevant medium for every cell type.
All scaffolds were maintained in a tissue culture incubator at 37°C, 5%CO2, 3%O2 with an N=3/
scaffold. At day 2, all scaffolds were harvested, washed twice with PBS and assessed for
construction of the integrated graft system, in which Phase B was placed on top of Phase C and
both Phases C and B were wrapped up by Phase A. The grafts were then sutured to fix the phases
and placed in fresh low-binding 24-well plate with 2 ml of MEM Alpha (1X) Minimum Essential
Medium supplemented with 15% FBS and 1% Penicillin/Streptomycin for every well and were
maintained in a tissue culture incubator at 37°C, 5%CO2, 3%O2. After 3 and 7 days of the graft
construction, grafts were harvested, washed with PBS twice, the phases were then separated and
every phase was assessed for LIVE/DEAD assay, which was used to qualitatively determine cell
viability based on a green fluorescent probe that recognizes intracellular esterase activity, calcein
AM, and a red fluorescent probe that recognizes damaged plasma membranes, ethidium
homodimer-1 (EthD-1). To perform the assay, every separated phase was incubated with 2 mL of
the prepared EthD-1/calcein solution at a concentration of 2 ul/ mL EthD-1, and 0.5 ul/ mL calcein
AM in PBS for 1 hour. Next, phases were washed twice with PBS and visualized using an inverted
fluorescence microscope (Zeiss LSM 880) using Zen Software.
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5.2.11.2

Proliferation Assay

The capability of the integrated graft system to sustain the proliferation of the different cell types
in the tri-culture environment was assessed using the Cell Titer 96® AQueous One Solution Cell
Proliferation Assay according to the manufacturer’s instructions. All phases underwent the same
sterilization technique as described in the previous experiment, and the same seeding density was
applied to all phases for all cell types having the same experimental groups and conditions. At day
2, all phases were assembled as described previously, and after culturing the graft for 3 and 7 days
post graft construction, grafts were harvested, washed with PBS twice, the phases were then
separated and every phase was incubated separately with a cocktail of MEM Alpha (1X) Minimum
Essential Medium supplemented with 15% FBS and 1% Penicillin/Streptomycin premixed with
MTS solution at a ratio of (1:5) for 3 hours at 37 C. 500 μL of sodium dodecyl sulfate was added
to each well to stop the reaction and the absorbance at 490 nm was measured with a
spectrophotometric plate reader (TECAN, Crailsheim, Germany).

5.2.11.3

Cell Localization and Phenotypic Maintenance of the Three Different Cellular

Populations Within the Integrated Graft System:
To determine the localization and the phenotypic maintenance of three different cell types on the
relevant phases within the integrated graft system in the heterogenic cellular environment, all
phases were subjected to Immunofluorescence analysis. Briefly, all phases underwent the same
sterilization technique as described in the previous experiment, and the same seeding density was
applied to all phases for all cell types having the same experimental groups and conditions. At day
2, all phases were assembled as described previously, and after culturing the graft for 3 and 7 days
post graft construction, grafts were harvested, washed with PBS twice, and they were then
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separated. Post separation, the three different phases were subjected to Immunofluorescence
analysis at room temperature as follows: all phases were placed separately in different wells in
24-well plate and 2 mL of 100X absolute methanol was added to each well to fix cells cultured on
the phases for 5 minutes, followed by three washes with PBS. Cells within the phases were then
Permeabilized with 1 mL of 0.1 % Triton X-100 in PBS for 15 minutes, followed by three washes
with PBS. Cells were then blocked with 10% goat serum in PBS for 1 hour at room temperature,
followed by three washes with PBS. Next, Phase A was incubated with IgG monoclonal
unconjugated Anti-Vimentin antibody (1:500); Phase B was incubated with IgG monoclonal
unconjugated Anti-SCXA antibody (1:1000); and Phase C was incubated with IgG monoclonal
unconjugated Anti-Alkaline Phosphatase (1:100) for 2 hours. All antibodies were diluted using the
same blocking solution of 10% goat serum in PBS. Post incubation, cells were washed three times
with PBS and incubated with the secondary antibodies for another 2 hours at dark. All cells were
incubated with the secondary antibody IgG polyclonal Goat Anti-Rabbit IgG H&L (Alexa Fluor®
488) (1:500). After incubation with the secondary antibodies for 2 hours, cells were washed three
times with PBS away from light, then incubated with DAPI (4',6-Diamidino-2-Phenylindole,
Dihydrochloride) at a concentration (1:3000). Cells were then washed 1 time with PBS and all
phases were visualized using an inverted fluorescence microscope (Zeiss LSM 880) using Zen
Software.

5.2.11.4

Cell Migration within the Integrated Graft System:

To examine the cell migration within the different phases, all phases underwent the same
sterilization technique as described in the previous experiment, and the same seeding density was
applied to all phases for all cell types having the same experimental groups and conditions. At day
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2, all phases were assembled as described previously, and after culturing the graft for 3 and 7 days
post graft construction, grafts were harvested, washed with PBS twice, and they were then
separated. Post separation, the three different phases were subjected to the same
Immunofluorescence analysis described in the previous experiment with varying in the type of
antibodies used for incubations. Briefly, to examine the migration of ligament fibroblasts to Phase
A, Phase A was incubated with the IgG monoclonal unconjugated Anti-SCXA antibody (1:1000);
to examine the migration of dermal fibroblasts to Phase B, Phase B was incubated with IgG
monoclonal unconjugated Anti-Vimentin antibody (1:500); to examine the migration of
osteoblasts to Phase B, Phase B was incubated with IgG monoclonal unconjugated Anti-Alkaline
Phosphatase (1:100); and to examine the migration of ligament fibroblasts to Phase C, Phase C
was incubated with IgG monoclonal unconjugated Anti-SCXA antibody (1:1000). All phases
underwent the same incubation times and were subjected to incubation with the same secondary
antibody. After incubation with the secondary antibodies for 2 hours, cells were washed, incubated
with DAPI and visualized under fluorescence microscope following the same procedure as
described previously.

5.2.12 Statistical Analysis
Data are presented as mean ± standard deviation (SD). All statistical analyses were performed
using the Statistical Software Prism GraphPad (Version 5) using two-way Analysis of Variance
(ANOVA) with a Tukey test for Post Hoc parameter comparisons. Statistical significance was set
at p < 0.05.
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5.3 Results:
5.3.1 Development and Testing the Functionality of the Tri-Culture Model:
The mold was successfully designed and 3D printed as shown in (Figure 5.1 A, B). This mold was
essential in order to be able to fabricate the PDMS segments that were further used to establish our
tri-culture model. As shown in the (Figure 5.1 A, B), the mold consisted of two different parts, a
disc and a plate. The plate however, served as a platform that housed the disc in the provided holes
to prevent the PDMS from leaking from the sides of the disc during the pouring process of the
elastomer into the mold. When the PDMS was poured into the mold, no leakage was observed
indicating that the disc is well fitted into the holes. After pouring the PDMS into the mold, it was
incubated at 37 °C for 24 h for the PDMS to cure in order to allow for the formation of the PDMS
segments. After they cured, the PDMS segments were removed from the mold and placed inside
of the well of the 24-well plate and they perfectly fitted the well, indicating that the dimensions
used in the design were accurate. By placing the PDMS segment to the well, the well was separated
into three different chambers, in which each chamber could be used to culture a different cell
population (Figure 5.1 D).

To examine the liquids penetration, different water-based dyes were added to different chambers
after placing the PDMS segment into the well of the 24-well plate in which, a red dye was placed
in the first chamber, a blue dye was placed in the other chamber and PBS was placed in the next
third chamber and the liquid penetration was examined after 3 and 7 days of incubation at 37 °C.
No liquid penetration was observed at the two-time points, indicating that the PDMS segments are
well fitted into the wells and that they are acting as real physical barrier between the three different
chambers (Figure 5.4). To examine the cell migration between the chambers, different cell types
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were seeded in the three chambers and cultured for 3 and 7 days and the cell migration was
observed after every time point under a normal light microscopy. No evidence for cellular
migration between the chambers was seen after the removal of the PDMS segments from the wells
in the two different time points (Figure 5.5, 5.6).
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5.3.2. In vitro Tri-Culture Study for the Determination of a Heterogenic Culture Medium
To examine the most suitable growth medium that would best sustain the growth of the three
different cell types both in the single and triculture environment, cells were seeded in their relevant
phases and assayed for proliferation after 3 and 7 days post culture. Regardless of the medium
type, all the three different cell types had significantly higher proliferation rates in the tri-culture
environment in comparison to their proliferation rates when cultured alone in the single culture
environment (Figure 5.7, 5.8, 5.9, 5.10).

To make the comparison understandable and much easier, we calculated the increase in the fold
number between day 3 and day 7 for all cell types cultured in all different medium and medium
compositions in the single and tri-culture environment (Figure 5.7). In the single culture
environment, dermal fibroblasts had the highest fold number when cultured in the (LF) medium
(0.54 folds) when compared to all the other mediums, and in the tri-culture environment, dermal
fibroblasts had the highest fold number when cultured in the [1:2:1] medium composition (2.21
folds) in comparison to all the other mediums (Figure 5.7, 5.8). When comparing the behavior of
ligament fibroblasts and osteoblasts, both ligament fibroblasts and osteoblasts had the highest fold
number in the single and tri-culture environment when cultured in the (OB) medium when
compared to all the other mediums (Figure 5.7, 5.9, 5.10). However, the increase in fold numbers
of ligament fibroblasts cultured in (OB) medium in the single and tri-culture environment were
(0.5, 0.66 folds) respectively (Figure 5.7, 5.9), and the increase in fold numbers of osteoblasts
cultured in (OB) medium in the single and tri-culture environment were (1.14, 1.23 folds)
respectively (Figure 5.7, 5.10).
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5.3.3. LIVE/DEAD and Proliferation Assays
LIVE/DEAD and MTS proliferation assays were performed on the three different phases on day
3 and 7 to qualitatively and quantitatively determine capability of the integrated graft system to
sustain the viability and proliferation of the three different cell types seeded in their relevant
phases. Our integrated graft system supported the viability and the proliferation of primary dermal
fibroblasts, ligament fibroblasts and osteoblasts and dead cells were not evidence, as cells
displayed a robust and healthy morphology. At day 3, both dermal and ligament fibroblasts showed
more of a flattened morphology when compared to day 7, where they were intact and displayed
more of a selender shape cytoplasm (Figure 5.11). The three different cell types showed significant
increase in proliferation rates between the two different time points 3 and 7 (Figure 5.12). Although
the difference was not statistically significant, osteoblasts showed higher proliferation trend in
comparison to both dermal and ligament fibroblasts in day 3. This could have been due to the fact
that microsphere scaffolds possess higher surface area than the electrospun nanofiber scaffold,
which by its turn gave more space for osteoblasts to grow. In day 7, both dermal fibroblast and
osteoblasts showed higher proliferation tends when compared to ligament fibroblasts, but not
statistically significant.
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5.3.4. Localization, Migration and Phenotypic Maintenance:
The capability of the integrated graft system to sustain the localization and phenotypic
maintenance of the three different cell types in their respective phases have been evaluated by
immunofluorescence using cell-specific marker. In addition, cell migration within the phases has
been examined too with immunofluorescence. As shown in in (Figure 5.13), fluorescence
microscopy data revealed that the three different cell types, dermal fibroblasts, ligament fibroblasts
and osteoblasts were indeed localized primarily at their respective phases at the two-time points.
After 7 days of culture, the three different cell types were still localized and proliferated in their
respective phases. Cell migration was observed between all the phases, where both ligament
fibroblasts and osteoblasts migrated between Phases B and C in both days 3 and 7, with an increase
in the number of the migrated cells at day 7 as seen in (Figure 5.13). Migration of both ligament
and dermal fibroblasts between Phases A and B was evidenced too based on the
immunofluorescence data, however, migration of these two cell types within these phases was only
observed at day 7, with no migration observed at day 3.
The three different phases were immuno-stained with cell-specific markers, where Phase A was
stained with the IgG monoclonal unconjugated Anti-Vimentin, and Phase B was stained with the
IgG monoclonal unconjugated Anti-SCXA antibody, and Phase C was stained with the IgG
monoclonal unconjugated Anti-Alkaline Phosphatase antibody in order to examine the
maintenance of the phenotype of the three different cell types in the heterogenic cellular
population. As seen in (Figure 3.15) all cells within their respective phases have been positively
stained against all the specific markers used for immunostaining after culturing them in a
heterogenic cellular population for 3 and 7 days, indicating that the IGS supported the phenotypic
maintenance of these cells.
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5.4. Discussion:
The capability of the integrated graft system to sustain the viability, proliferation, localization and
phenotypic maintenance of the three different cell types in the heterogenic cellular population was
evaluated. However, this would not have been appropriately accomplished without optimizing
what growth medium would best support the growth of the three different cell types in the
heterogenic environment. It is very well known from the literature that cell growth can strongly be
influenced by the surrounding external environment [34]. For example, cells cultured in a coculture environment tend to behave differently than when they are cultured in a single culture
environment [34]. In a single culture environment, cells tend to normally proliferate if they are
provided with the appropriate growth medium. On the other hand, cells cultured with different
cellular populations tend to behave differently due to the cell-cell interactions initiated in the coculture environment, thus, resulting in either an increase or decrease in cell proliferation [34]. Yet
there is increasing evidence that the choice of growth media can contribute to the increase or
decrease in cell proliferation in the co-culture environment [34]. Therefore, an early optimization
of the most suitable growth medium is essential to ensure sustaining the best level of viability and
cell proliferation in the co-culture environment.

In this study, to determine the best suitable medium, a tri-culture model has been developed by
conducting very simple procedures that consisted of designing and three-dimensional printing of
a mold, that was further used to fabricate PDMS segments that were used for the establishment of
the tri-culture system. Three-dimensional (3D) printing has emerged as a unique technology that
can be employed by disparate fields to several different needs [35]. This technology is utilized to
produce a variety of complex and functional structures with complex geometries using less
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material than the traditional manufacturing methods in a timely manner. 3D printing
applications cover various sectors from education to industry and more recently in tissue
engineering for the production of biomimetic scaffolds with precise geometry [35]. In this study,
3D printing technology was employed to produce a mold that could be further utilized to fabricate
PDMS segments for the establishment of a tri-culture model. However, the mold was successfully
designed, and 3D printed as shown in (Figure 5.1 A, B). PDMS is an elastomer which through
very simple molding procedure can be shaped into a wide variety of different structures depending
on the applications needs [36]. It is transparent, biocompatible, and permeable to gas, which
explains the strong interest of the scientific community in using this material to fabricate
microfluidic devices for cell biological studies as well as to fabricate segments, boundaries or
monolayers for co-culturing studies [36].

As shown in the (Figure 5.1 A, B), the mold consisted of two different parts, a disc, and a plate.
The plate, however, served as a platform that housed the disc in the provided holes to prevent the
PDMS from leaking from the sides of the disc during the pouring process of the elastomer into the
mold. When the PDMS was poured into the mold, no leakage was observed indicating that the disc
is well fitted into the holes. After pouring the PDMS into the mold, it was incubated at 37 °C for
24 h for the PDMS to cure in order to allow for the formation of the PDMS segments. PDMS
elastomer has the ability to cure at various temperatures ranging from 25 °C to 150 °C. However;
the curing time largely depends on the incubation temperature, where the higher the temperature,
the faster it cures. For example, PDMS elastomers incubated at 150 °C take up to ~ 10 minutes to
cure, while elastomers incubated at 37 °C can take up to 24 h to completely cure. Due to the fact
that the mold was printed from a plastic material, we had to incubate it at 37 °C to prevent the
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mold from melting [37]. After they cured, the PDMS segments were removed from the mold and
placed inside of the well of the 24-well plate, and they perfectly fitted the well, indicating that the
dimensions used in the design were accurate. When designing the mold, dimensions were carefully
taken into considerations to ensure the perfect fit of the PDMS segments into the wells of the 24well plate. By placing the PDMS segment to the well, the well was separated into three different
chambers, in which each chamber could be used to culture a different cell population (Figure 5.1
D). During the design process, the height of the disc (5 mm) had to be quarter the total height of
the well of the 24-well plate (20 mm), and that is in order to facilitate the medium exchange
between the three different cell types when establishing the tri-culture after placing the PDMS
segments into the well (Figure 5.1 D). One elegant property inherited by PDMS is the stickiness
observed on its surface after it cures, this property, in particular, supported the integration of the
PDMS segments into the walls and the surface of the TCP when they were placed inside of the
well of the 24-well plate [36]. Since the PDMS segments are mobile and not physically fixed into
the wells of the 24- well plate, we needed to investigate two important factors that had to be met
in order to mark the success of the tri-culture model, (1) when culturing cells into the different
chambers, cells have to stay and only proliferate within the chamber they are seeded into and not
migrate to the other neighboring chambers, and (2) when adding different liquids into the different
chambers, they have to remain held within the chamber they are added into and not penetrate to
the other chambers. This second point, however, is very important in cases where different reagents
such as MTS, Picogreen, etc. need to be added into the different chambers for running assays to
study the behavior of the single cell population in the tri-culture environment.
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To examine the liquids penetration, different water-based dyes were added to different chambers
after placing the PDMS segment into the well of the 24-well plate in which, a red dye was placed
in the first chamber, a blue dye was placed in the other chamber, and PBS was placed in the next
third chamber, and the liquid penetration was examined after 3 and 7 days of incubation at 37 °C.
No liquid penetration was observed at the two-time points indicating that the PDMS segments are
well fitted into the wells and that they are acting as real physical barriers between the three different
chambers (Figure 5.4). Water molecules are very small, 0.27 nm in size, however, if these very
small water molecules could not penetrate from the sides nor underneath the PDMS segments,
cells which are ~ 10 um in diameter, should not migrate at all. Although this fact was stated, we
still needed to examine the cell migration between the chambers [38]. To do so, different cell types
were seeded in the three chambers and cultured for 3 and 7 days and the cell migration was
observed after every time point under a normal light microscopy. No evidence for cellular
migration between the chambers was seen after the removal of the PDMS segment from the wells
in the two different time points (Figure 5.5, 5.6). In a study by Yang et al. the migration speed of
cultured endothelial cells has been investigated by placing a PDMS monolayer blocker at the
middle of a cell culture dish that separated the dish into two different chambers. Both chambers
were seeded with the same endothelial cell population and were cultured for pretrimmed time
points [39]. However, after removing the PDMS blocker, no evidence of cell migration was found.
These observations suggest that PDMS have the potential to serve as a physical barrier for coculturing or/and tri-culturing purposes. Based on our findings, we could prove the functionality of
our tri-culture model and its ability to serve as a valuable system for studying the behavior of the
single cell population in a tri-culture environment. Our tri-culture model has emerged to be unique,
simple and functional.
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The tri-culture model was further used in order to examine the most suitable growth medium that
would best sustain the proliferation of the three different cell types both in the single and triculture
environment. To do so, cells were seeded in their relevant phases and assayed for proliferation
after 3 and 7 days post culture. Using our synthetic tri-culture model, we were able to study the
proliferative abilities of the three different cell types cultured alone, or in a tri-culture environment
by exposing them to different mediums and medium compositions.

Interestingly and regardless the medium type, all the three different cell types had significantly
higher proliferation rates in the tri-culture environment in comparison to their proliferation rates
when cultured alone in the single culture environment (Figure 5.7). The significant increase in cell
proliferation of the three different cell types in the tri-culture environment when compared to the
single culture environment could be attributed to the secretion of an array of different endogenous
growth factors and cytokines by the both fibroblasts and osteoblasts that could potentially
upregulated the proliferation of the three different cell types in the tri-culture environment.
Fibroblasts play an essential role in wound healing by endogenously producing an array of growth
factors and cytokines that are essential for collagen synthesis as well as maintaining cell viability
and growth [40]. Osteoblasts are also known to produce a number of growth factors and cytokines
that are known to encourage cellular proliferation and differentiation. A list of all the endogenous
growth factors secreted by both fibroblasts and osteoblasts stimulating cellular behaviors can be
seen in (Table 1). A number of studies have explained the biological responses of dermal
fibroblasts co-cultured with osteoblasts, and ligament fibroblasts co-cultured with osteoblasts, but
no study to date has evaluated the biological responses of the three cultured together [41,30].
Dermal fibroblasts have shown to enhance the biological responses of primary osteoblasts such as
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proliferation when co-cultured together [41], similarly to ligament fibroblasts which have been
proven to maintain the proliferation of osteoblasts in a co-culture environment. These findings
demonstrate the strong relationship of both fibroblasts to primary osteoblasts, and that their
presence in culture along with osteoblasts can positively influence the biological responses of
osteoblasts. In contrast, findings from our study indicate that not only the presence of fibroblasts
can enhance the biological responses of osteoblasts, but also the presence of osteoblasts can
potentially enhance the biological properties of fibroblasts, thus, implying the strong relationship
between fibroblasts and osteoblasts. However, further studies are indeed required in order to
validate these findings.

To make the comparison of our findings from the tri-culture experiment understandable and much
easier, we calculate the increase in the fold number between day 3 and day 7 for all cell types
cultured in all different mediums and medium compositions in the single and tri-culture
environment (Figure 5.7). In the single culture environment, dermal fibroblasts had the highest
fold number when cultured in the (LF) medium (0.54 folds) when compared to all the other
mediums, and in the tri-culture environment, dermal fibroblasts had the highest fold number when
cultured in the [1:2:1] medium composition (2.21 folds) in comparison to all the other mediums
(Figure 5.7, 5.8). When comparing the behavior of ligament fibroblasts and osteoblasts, both
ligament fibroblasts and osteoblasts had the highest fold number in the single and tri-culture
environment when cultured in the (OB) medium when compared to their proliferation in all the
other mediums (Figure 5.7, 5.9, 5.10). However, the increase in fold numbers of ligament
fibroblasts cultured in (OB) medium in the single and tri-culture environment were (0.5, 0.66 folds)
respectively (Figure 5.7, 5.9), and the increase in fold numbers of osteoblasts cultured in (OB)
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medium in the single and tri-culture environment were (1.14, 1.23 folds) respectively (Figure 5.7,
5.10). Since both ligament fibroblasts and osteoblasts showed the best cell proliferation in the (OB)
medium, and since dermal fibroblasts also showed a relatively good proliferation in (OB) medium
(1.42 folds), we suggest that (OB) medium would be the growth medium that can best sustain the
viability and proliferation of all the three different cell types when cultured in the heterogenic
cellular population within the integrated graft system.

The scaffold design for this study includes different phases with variation in morphology,
composition and cell type with a specific intention of supporting multiple cell types. The current
integrated graft system is based on the synthetic biodegradable polymer (PLGA 85:15) and the
naturally derived biomaterial (gelatin), where Phase A is fabricated from PLGA-Gelatin-PDGFBB coaxial electrospun nanofibers to support dermal fibroblasts culture, Phase B is fabricated from
PLGA-Gelatin-IGF-I coaxial electrospun nanofibers to support ligament fibroblasts culture, and
Phase C is fabricated from PLGA-Gelatin-mTG/ BMP-2 to support osteoblasts culture. However,
due to the morphological, compositional complexity found within the system, viability,
proliferation, localization and phenotypic maintenance of the three different cell types in the
heterogenic environment had to be evaluated over time in order to examine the capability of our
complex integrated graft system to sustain these cellular biological properties.

Based on our findings from the proliferation and viability assays conducted after 3 and 7 days, the
integrated graft system could sustain the viability and proliferation of the three different cell types,
each in its respective phase. In general, cellular proliferation of osteoblasts and dermal fibroblasts
were higher than ligament fibroblasts. Spalazzi et al. have reported that co-culturing ligament
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fibroblasts and osteoblasts result in an increase in cell proliferation of both cell types over time.
Although they both continuously proliferated over time, it was found that ligament fibroblasts had
higher proliferation rates in the co-culture environment when compared to osteoblast and this is
most likely due to the difference in proliferation rates between fibroblasts and osteoblasts [30]. In
our case the proliferation rate of osteoblast was higher in comparison to ligament fibroblasts, but
not statistically significant. Conclusions cannot be made that whether the presence of dermal
fibroblasts had influenced the proliferation of osteoblasts, resulting in an increase in osteoblasts
cell proliferation, therefore, further experiments are still needed in order to study the contributions
and the direct influence of dermal fibroblasts on osteoblasts. Although several studies have
reported the potential of dermal fibroblasts differentiation into the osteogenic tendency, very
limited number of studies has reported their influence on osteoblasts proliferation in a co-culture
environment [42].

Our immunofluorescence data revealed that the three different cellular populations were mainly
localized and continued to proliferate in their respective phases at both time points 3 and 7 days.
In addition, cell migration was observed between all the phases at both time points. However, cell
migration between Phases A and B was only observed at day 7, with no cell migration observed at
day 3 at all.

The three different phases were immuno-stained with cell-specific markers in order to examine the
phenotypic maintenance of the three different cell types in the three-dimensional heterogenic
cellular environment. As seen in (Figure 3.15) all cells within their respective phases have been
positively stained against all the specific markers used for immunostaining after culturing them in
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the heterogenic cellular environment for 3 and 7 days, indicating that the IGS could sustain the
phenotype of these cells for up to 7 days.

It has been reported that interaction of osteoblasts and ligament fibroblasts in a monolayer coculture model resulted in modulation in cellular phenotype along with decrease in osteoblasts
alkaline phosphate activity and expression of type II collagen as well as an increase in
mineralization potential of fibroblasts at the contact site, but resulted in phenotypic maintenance
of both cells at either site. In addition, it was shown that co-culture of fibroblasts with osteoblasts
resulted in an increase in cell proliferation, tissue-specific extracellular matrix production in
comparison to the monoculture of either cell [30]. These observations suggest that both osteoblasts
and ligament fibroblasts have the potential to maintain their phenotype, proliferation, and the
production of tissue-specific extracellular matrix proteins in a co-culture environment. While
ligament fibroblasts have the potential to maintain their phenotype in a co-culture system, dermal
fibroblasts find difficulties maintaining their phenotype in heterogenic cellular populations,
specifically when co-cultured with osteoblasts [42]. Dermal fibroblasts are mesenchymal stem
cells by nature; they can directly be converted or reprogrammed into another differentiated lineage
without passing an intermediate pluripotent Stage [42]. These conversions include direct
conversion of dermal fibroblasts into cardiomyocytes (43, 44), neurons (45–47), chondrocytes
(48), and hepatocytes (49, 50), as well as of human fibroblasts into cardiomyocytes (51,52),
neurons (46, 53), hematopoietic cells (52) and osteoblasts [42].

Although dermal fibroblasts do not typically express markers of osteoblastic differentiation, they
have previously been shown to undergo osteoinduction when stimulated with bone morphogenetic
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proteins (BMPs) [55]. These observations suggest that the surrounding external environment can
largely influence dermal fibroblasts by triggering them to modulate their phenotype and
differentiate into other tendencies. Although BMP-2 was incorporated within Phase C, which
could have been able to affect the phenotype of dermal fibroblast, dermal fibroblasts could
maintain their phenotype in the heterogenic environment for up to 7 days. These findings
demonstrate the capability of the IGS to sustain the phenotype of the three different cell types in
the heterogenic cellular environment. The ability of the IGS to sustain the phenotype of the three
different cell types in the heterogenic cellular environment can be attributed to many factors that
include but not limited to, (1) providing the appropriate 3D synthetic matrix for every cell type
that could potentially support the phenotypic maintenance, and (2) delivering growth factors that
are known to encourage cellular proliferation locally. These factors might have aided in the
maintenance of the phenotype of the three different cell types in the heterogenic cellular
environment.

To our knowledge, this is the first reported study that focuses on designing a single scaffold system
to study the heterogenic cellular interactions of dermal, ligament fibroblasts and osteoblasts as
well as their potential to form tissues simultaneously. This integrated graft system is designed to
provide structurally, compositionally and chemically suitable environment that could sustain the
viability, proliferation and heterogenic cellular interaction of dermal fibroblasts, ligament
fibroblast, and osteoblasts. Our promising results demonstrate the feasibility of heterogenic
cellular interactions on a single scaffold, and the potential of the integrated graft system to support
multiple tissue regeneration simultaneously in vivo.
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The capability of the integrated graft system to sustain the viability, proliferation, and phenotype
of the three different cell types in the heterogenic cellular environment can be further investigated
for a longer time to examine the graft’s capability to sustain the biological properties of the three
different cell types in a longer timeframe. In addition, the direct effect of dermal fibroblast on
osteoblasts and ligament fibroblasts shall be investigated.
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5.5. Conclusion:
In conclusion, a tri-culture model has been successfully designed, developed, evaluated and
utilized in order to determine the growth medium that would best support the viability and
proliferation of the three different cell types in the heterogenic cellular environment. The triculture experiment findings suggest that (OB) medium “MEM Alpha (1X) Minimum Essential
Medium supplemented with 15% FBS and 1% Penicillin/Streptomycin” would be a suitable
growth medium that can best sustain the viability and proliferation of all the three different cell
types when cultured in the heterogenic cellular environment within the integrated graft system.
The integrated graft system has been shown to support the viability, proliferation, localization, and
phenotypic maintenance of the distinct cellular population in the heterogenic environment for up
to 7 days. While additional studies are needed to further characterize the system to confirm its
efficacy, the presented work suggests the feasibility of heterogenic cellular interactions on a single
scaffold, and the potential of the integrated graft system to support multiple tissue regeneration
simultaneously in vivo.
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CHAPTER 6
FUTURE DIRECTION
6.1. Conclusion and Future work.
The present study demonstrated the feasibility of the integrated graft system to sustain heterogenic
cellular interactions for a short period of time. However, future work will focus on increasing the
culture duration of the integrated graft system for up to 35 days to facilitate evaluating the
production of the tissues-specific extracellular matrix proteins and the expression of cell-specific
genes within the distinct phases. In addition, cell localization in every phase as well as cells
migration within the different phases will be evaluated through cell tracking experiments by prelabeling the three different cells. Furthermore, the graft's capability to sustain cell viability,
proliferation, and phenotype of the three cell types will be examined for a prolonged period of
time. Interaction between ligament fibroblasts and osteoblasts, dermal fibroblasts and osteoblasts,
as well as between osteoblasts and both fibroblasts will be evaluated using the appropriate set of
experiments in a co-culture and tri-culture environment in order to further understand their
capabilities, interactions and biological responses in respect of each other. All the aforementioned
experiments will be conducted with or without the presence of growth factor to examine whether
the presence of growth factor have a significant impact on sustaining the phenotype of the cells in
the heterogenic cellular environment. Lastly, the in vivo response to the integrated graft system
will be examined after optimizing the optimal in vitro condition in order to investigate the potential
of skin, ligament and bone to in vivo form simultaneously.
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